$sny 2023 Q4 20-F

Concept	2023 Q4	2023
Revenue	$24.90B	$46.44B
YoY Change	1.24%	2.32%
Cost Of Revenue	$7.889B	$14.24B
YoY Change	4.28%	3.95%
Gross Profit	$17.01B	€32.21B
YoY Change	-0.11%	1.62%
Gross Profit Margin	68.32%	69.35%
Selling, General & Admin	$5.510B	€10.69B
YoY Change	-0.52%	1.91%
% of Gross Profit	32.39%	33.2%
Research & Development	$3.535B	€6.728B
YoY Change	-0.67%	0.33%
% of Gross Profit	20.78%	20.89%
Depreciation & Amortization	$2.954B	$2.172B
YoY Change	84.63%	-36.49%
% of Gross Profit	17.37%	6.74%
Operating Expenses	$11.60B	€17.42B
YoY Change	15.84%	1.29%
Operating Profit	$5.409B	€14.79B
YoY Change	-22.88%	2.01%
Interest Expense	-$132.0M	-$815.0M
YoY Change	633.33%	482.14%
% of Operating Profit	-2.44%	-5.51%
Other Income/Expense, Net	-$573.0M
YoY Change	3270.59%
Pretax Income	$2.915B	$7.153B
YoY Change	-56.8%	-31.37%
Income Tax	$872.0M	$1.602B
% Of Pretax Income	29.91%	22.4%
Net Earnings	$1.970B	€5.436B
YoY Change	-62.02%	-35.93%
Net Earnings / Revenue	7.91%	11.7%
Basic Earnings Per Share
Diluted Earnings Per Share	$1.57	$4.31
COMMON SHARES
Basic Shares Outstanding	1.265B shares
Diluted Shares Outstanding

Concept	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.710B	$8.710B
YoY Change	-31.61%	-35.0%
Cash & Equivalents	$8.710B	$8.710B
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory	$21.55B	$21.55B
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$30.66B	$30.66B
YoY Change	-9.91%	-9.91%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.81B	$11.81B
YoY Change	1.11%	1.11%
Goodwill	€49.40B
YoY Change	-0.98%
Intangibles
YoY Change
Long-Term Investments	$10.07B	$10.07B
YoY Change	264.16%	264.16%
Other Assets	$203.0M	$203.0M
YoY Change	-96.76%	-96.76%
Total Long-Term Assets	€95.81B	$95.66B
YoY Change	3.36%	3.2%
TOTAL ASSETS
Total Short-Term Assets	$30.66B	$30.66B
Total Long-Term Assets	€95.81B	$95.66B
Total Assets	€126.5B	$126.3B
YoY Change	-0.2%	-0.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$20.88B	$20.88B
YoY Change	206.5%	206.5%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due	$2.320B	$2.320B
YoY Change	-45.88%	-45.88%
Total Short-Term Liabilities	$24.01B	$24.01B
YoY Change	0.18%	0.18%
LONG-TERM LIABILITIES
Long-Term Debt	$16.10B	$16.10B
YoY Change	-5.54%	-5.54%
Other Long-Term Liabilities	$9.995B	$9.995B
YoY Change	14.65%	14.65%
Total Long-Term Liabilities	$26.10B	$26.10B
YoY Change	1.29%	1.29%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.01B	$24.01B
Total Long-Term Liabilities	$26.10B	$26.10B
Total Liabilities	$52.27B	$52.27B
YoY Change	0.65%	0.65%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$74.04B	$74.04B
YoY Change
Total Liabilities & Shareholders Equity	$126.3B	$126.3B
YoY Change	-0.32%	-0.32%

Concept	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	$1.970B	€5.436B
YoY Change	-62.02%	-35.93%
Depreciation, Depletion And Amortization	$2.954B	$2.172B
YoY Change	84.63%	-36.49%
Cash From Operating Activities	$6.695B	$10.26B
YoY Change	-0.09%	-2.55%
INVESTING ACTIVITIES
Capital Expenditures	$2.094B	$3.024B
YoY Change	70.66%	37.39%
Acquisitions
YoY Change
Other Investing Activities	-$1.033B	-$3.176B
YoY Change	-269.07%	-2620.63%
Cash From Investing Activities	-$3.127B	-$6.200B
YoY Change	407.63%	198.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-2.838B	-8.052B
YoY Change	1213.89%	38.33%
NET CHANGE
Cash From Operating Activities	6.695B	10.26B
Cash From Investing Activities	-3.127B	-6.200B
Cash From Financing Activities	-2.838B	-8.052B
Net Change In Cash	730.0M	-3.994B
YoY Change	-87.56%	-251.86%
FREE CASH FLOW
Cash From Operating Activities	$6.695B	$10.26B
Capital Expenditures	$2.094B	$3.024B
Free Cash Flow	$4.601B	$7.234B
YoY Change	-15.95%	-13.11%

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001121404
CY2023	dei	Document Type DocumentType	20-F
CY2023	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q4	ifrs-full	Current Trade Receivables CurrentTradeReceivables	8433000000	eur
CY2022Q4	ifrs-full	Current Trade Receivables CurrentTradeReceivables	8424000000	eur
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-31368
CY2023	dei	Entity Registrant Name EntityRegistrantName	Sanofi
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	I0
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	46, avenue de la Grande Armée
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	75017
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Paris
CY2023	dei	Entity Address Country EntityAddressCountry	FR
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1264799969	shares
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Document Accounting Standard DocumentAccountingStandard	International Financial Reporting Standards
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Auditor Firm AuditorFirmId	1347
CY2023	dei	Auditor Name AuditorName	PricewaterhouseCoopers Audit
CY2023	dei	Auditor Location AuditorLocation	Neuilly-sur-Seine
CY2023Q4	ifrs-full	Property Plant And Equipment PropertyPlantAndEquipment	10160000000	eur
CY2022Q4	ifrs-full	Property Plant And Equipment PropertyPlantAndEquipment	9869000000	eur
CY2021Q4	ifrs-full	Property Plant And Equipment PropertyPlantAndEquipment	10028000000	eur
CY2023Q4	ifrs-full	Rightofuse Assets RightofuseAssets	1654000000	eur
CY2022Q4	ifrs-full	Rightofuse Assets RightofuseAssets	1815000000	eur
CY2021Q4	ifrs-full	Rightofuse Assets RightofuseAssets	1948000000	eur
CY2023Q4	ifrs-full	Goodwill Goodwill	49404000000	eur
CY2022Q4	ifrs-full	Goodwill Goodwill	49892000000	eur
CY2021Q4	ifrs-full	Goodwill Goodwill	48056000000	eur
CY2023Q4	ifrs-full	Intangible Assets Other Than Goodwill IntangibleAssetsOtherThanGoodwill	24319000000	eur
CY2022Q4	ifrs-full	Intangible Assets Other Than Goodwill IntangibleAssetsOtherThanGoodwill	21640000000	eur
CY2021Q4	ifrs-full	Intangible Assets Other Than Goodwill IntangibleAssetsOtherThanGoodwill	21407000000	eur
CY2023Q4	ifrs-full	Investment Accounted For Using Equity Method InvestmentAccountedForUsingEquityMethod	424000000	eur
CY2022Q4	ifrs-full	Investment Accounted For Using Equity Method InvestmentAccountedForUsingEquityMethod	677000000	eur
CY2021Q4	ifrs-full	Investment Accounted For Using Equity Method InvestmentAccountedForUsingEquityMethod	250000000	eur
CY2023Q4	ifrs-full	Other Noncurrent Assets OtherNoncurrentAssets	3218000000	eur
CY2022Q4	ifrs-full	Other Noncurrent Assets OtherNoncurrentAssets	3095000000	eur
CY2021Q4	ifrs-full	Other Noncurrent Assets OtherNoncurrentAssets	3127000000	eur
CY2023Q4	ifrs-full	Current Tax Assets Noncurrent CurrentTaxAssetsNoncurrent	188000000	eur
CY2022Q4	ifrs-full	Current Tax Assets Noncurrent CurrentTaxAssetsNoncurrent	242000000	eur
CY2021Q4	ifrs-full	Current Tax Assets Noncurrent CurrentTaxAssetsNoncurrent	175000000	eur
CY2023Q4	ifrs-full	Deferred Tax Assets DeferredTaxAssets	6427000000	eur
CY2022Q4	ifrs-full	Deferred Tax Assets DeferredTaxAssets	5381000000	eur
CY2021Q4	ifrs-full	Deferred Tax Assets DeferredTaxAssets	4598000000	eur
CY2023Q4	ifrs-full	Noncurrent Assets NoncurrentAssets	95794000000	eur
CY2022Q4	ifrs-full	Noncurrent Assets NoncurrentAssets	92611000000	eur
CY2021Q4	ifrs-full	Noncurrent Assets NoncurrentAssets	89589000000	eur
CY2023Q4	ifrs-full	Inventories Inventories	9666000000	eur
CY2022Q4	ifrs-full	Inventories Inventories	8960000000	eur
CY2021Q4	ifrs-full	Inventories Inventories	8715000000	eur
CY2021Q4	ifrs-full	Current Trade Receivables CurrentTradeReceivables	7568000000	eur
CY2023Q4	ifrs-full	Other Current Assets OtherCurrentAssets	3455000000	eur
CY2022Q4	ifrs-full	Other Current Assets OtherCurrentAssets	3532000000	eur
CY2021Q4	ifrs-full	Other Current Assets OtherCurrentAssets	3571000000	eur
CY2023Q4	ifrs-full	Current Tax Assets Current CurrentTaxAssetsCurrent	391000000	eur
CY2022Q4	ifrs-full	Current Tax Assets Current CurrentTaxAssetsCurrent	374000000	eur
CY2021Q4	ifrs-full	Current Tax Assets Current CurrentTaxAssetsCurrent	612000000	eur
CY2023Q4	ifrs-full	Cash And Cash Equivalents CashAndCashEquivalents	8710000000	eur
CY2022Q4	ifrs-full	Cash And Cash Equivalents CashAndCashEquivalents	12736000000	eur
CY2021Q4	ifrs-full	Cash And Cash Equivalents CashAndCashEquivalents	10098000000	eur
CY2023Q4	ifrs-full	Current Assets Other Than Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners	30655000000	eur
CY2022Q4	ifrs-full	Current Assets Other Than Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners	34026000000	eur
CY2021Q4	ifrs-full	Current Assets Other Than Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners	30564000000	eur
CY2023Q4	ifrs-full	Noncurrent Assets Or Disposal Groups Classified As Held For Sale NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale	15000000	eur
CY2022Q4	ifrs-full	Noncurrent Assets Or Disposal Groups Classified As Held For Sale NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale	85000000	eur
CY2021Q4	ifrs-full	Noncurrent Assets Or Disposal Groups Classified As Held For Sale NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale	89000000	eur
CY2023Q4	ifrs-full	Assets Assets	126464000000	eur
CY2022Q4	ifrs-full	Assets Assets	126722000000	eur
CY2021Q4	ifrs-full	Assets Assets	120242000000	eur
CY2023Q4	ifrs-full	Equity Attributable To Owners Of Parent EquityAttributableToOwnersOfParent	74040000000	eur
CY2022Q4	ifrs-full	Equity Attributable To Owners Of Parent EquityAttributableToOwnersOfParent	74784000000	eur
CY2021Q4	ifrs-full	Equity Attributable To Owners Of Parent EquityAttributableToOwnersOfParent	68681000000	eur
CY2023Q4	ifrs-full	Noncontrolling Interests NoncontrollingInterests	313000000	eur
CY2022Q4	ifrs-full	Noncontrolling Interests NoncontrollingInterests	368000000	eur
CY2021Q4	ifrs-full	Noncontrolling Interests NoncontrollingInterests	350000000	eur
CY2023Q4	ifrs-full	Equity Equity	74353000000	eur
CY2022Q4	ifrs-full	Equity Equity	75152000000	eur
CY2021Q4	ifrs-full	Equity Equity	69031000000	eur
CY2023Q4	ifrs-full	Longterm Borrowings LongtermBorrowings	14347000000	eur
CY2022Q4	ifrs-full	Longterm Borrowings LongtermBorrowings	14857000000	eur
CY2021Q4	ifrs-full	Longterm Borrowings LongtermBorrowings	17123000000	eur
CY2023Q4	ifrs-full	Noncurrent Lease Liabilities NoncurrentLeaseLiabilities	1755000000	eur
CY2022Q4	ifrs-full	Noncurrent Lease Liabilities NoncurrentLeaseLiabilities	1904000000	eur
CY2021Q4	ifrs-full	Noncurrent Lease Liabilities NoncurrentLeaseLiabilities	1839000000	eur
CY2023Q4	sny	Non Current Liabilities Related To Business Combinations And To Non Controlling Interests NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests	501000000	eur
CY2022Q4	sny	Non Current Liabilities Related To Business Combinations And To Non Controlling Interests NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests	674000000	eur
CY2021Q4	sny	Non Current Liabilities Related To Business Combinations And To Non Controlling Interests NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests	577000000	eur
CY2023Q4	sny	Non Current Provisions And Other Non Current Liabilities NonCurrentProvisionsAndOtherNonCurrentLiabilities	7602000000	eur
CY2022Q4	sny	Non Current Provisions And Other Non Current Liabilities NonCurrentProvisionsAndOtherNonCurrentLiabilities	6341000000	eur
CY2021Q4	sny	Non Current Provisions And Other Non Current Liabilities NonCurrentProvisionsAndOtherNonCurrentLiabilities	6721000000	eur
CY2023Q4	ifrs-full	Current Tax Liabilities Noncurrent CurrentTaxLiabilitiesNoncurrent	1842000000	eur
CY2022Q4	ifrs-full	Current Tax Liabilities Noncurrent CurrentTaxLiabilitiesNoncurrent	1979000000	eur
CY2021Q4	ifrs-full	Current Tax Liabilities Noncurrent CurrentTaxLiabilitiesNoncurrent	2039000000	eur
CY2023Q4	ifrs-full	Deferred Tax Liabilities DeferredTaxLiabilities	1857000000	eur
CY2022Q4	ifrs-full	Deferred Tax Liabilities DeferredTaxLiabilities	1841000000	eur
CY2021Q4	ifrs-full	Deferred Tax Liabilities DeferredTaxLiabilities	1617000000	eur
CY2023Q4	ifrs-full	Noncurrent Liabilities NoncurrentLiabilities	27904000000	eur
CY2022Q4	ifrs-full	Noncurrent Liabilities NoncurrentLiabilities	27596000000	eur
CY2021Q4	ifrs-full	Noncurrent Liabilities NoncurrentLiabilities	29916000000	eur
CY2023Q4	ifrs-full	Trade And Other Current Payables To Trade Suppliers TradeAndOtherCurrentPayablesToTradeSuppliers	7328000000	eur
CY2022Q4	ifrs-full	Trade And Other Current Payables To Trade Suppliers TradeAndOtherCurrentPayablesToTradeSuppliers	6813000000	eur
CY2021Q4	ifrs-full	Trade And Other Current Payables To Trade Suppliers TradeAndOtherCurrentPayablesToTradeSuppliers	6180000000	eur
CY2023Q4	sny	Current Liabilities Related To Business Combinations And To Non Controlling Interests CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests	208000000	eur
CY2022Q4	sny	Current Liabilities Related To Business Combinations And To Non Controlling Interests CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests	105000000	eur
CY2021Q4	sny	Current Liabilities Related To Business Combinations And To Non Controlling Interests CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests	137000000	eur
CY2023Q4	sny	Current Provisions And Other Current Liabilities CurrentProvisionsAndOtherCurrentLiabilities	13741000000	eur
CY2022Q4	sny	Current Provisions And Other Current Liabilities CurrentProvisionsAndOtherCurrentLiabilities	12021000000	eur
CY2021Q4	sny	Current Provisions And Other Current Liabilities CurrentProvisionsAndOtherCurrentLiabilities	11217000000	eur
CY2023Q4	ifrs-full	Current Tax Liabilities Current CurrentTaxLiabilitiesCurrent	597000000	eur
CY2022Q4	ifrs-full	Current Tax Liabilities Current CurrentTaxLiabilitiesCurrent	574000000	eur
CY2021Q4	ifrs-full	Current Tax Liabilities Current CurrentTaxLiabilitiesCurrent	309000000	eur
CY2023Q4	ifrs-full	Current Lease Liabilities CurrentLeaseLiabilities	275000000	eur
CY2022Q4	ifrs-full	Current Lease Liabilities CurrentLeaseLiabilities	277000000	eur
CY2021Q4	ifrs-full	Current Lease Liabilities CurrentLeaseLiabilities	269000000	eur
CY2023Q4	ifrs-full	Current Borrowings And Current Portion Of Noncurrent Borrowings CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings	2045000000	eur
CY2022Q4	ifrs-full	Current Borrowings And Current Portion Of Noncurrent Borrowings CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings	4174000000	eur
CY2021Q4	ifrs-full	Current Borrowings And Current Portion Of Noncurrent Borrowings CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings	3183000000	eur
CY2023Q4	ifrs-full	Current Liabilities Other Than Liabilities Included In Disposal Groups Classified As Held For Sale CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale	24194000000	eur
CY2022Q4	ifrs-full	Current Liabilities Other Than Liabilities Included In Disposal Groups Classified As Held For Sale CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale	23964000000	eur
CY2021Q4	ifrs-full	Current Liabilities Other Than Liabilities Included In Disposal Groups Classified As Held For Sale CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale	21295000000	eur
CY2023Q4	ifrs-full	Liabilities Included In Disposal Groups Classified As Held For Sale LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale	13000000	eur
CY2022Q4	ifrs-full	Liabilities Included In Disposal Groups Classified As Held For Sale LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale	10000000	eur
CY2021Q4	ifrs-full	Liabilities Included In Disposal Groups Classified As Held For Sale LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale	0	eur
CY2023Q4	ifrs-full	Equity And Liabilities EquityAndLiabilities	126464000000	eur
CY2022Q4	ifrs-full	Equity And Liabilities EquityAndLiabilities	126722000000	eur
CY2021Q4	ifrs-full	Equity And Liabilities EquityAndLiabilities	120242000000	eur
CY2023	ifrs-full	Revenue From Sale Of Goods RevenueFromSaleOfGoods	43070000000	eur
CY2022	ifrs-full	Revenue From Sale Of Goods RevenueFromSaleOfGoods	42997000000	eur
CY2021	ifrs-full	Revenue From Sale Of Goods RevenueFromSaleOfGoods	37761000000	eur
CY2023	ifrs-full	Other Revenue OtherRevenue	3374000000	eur
CY2022	ifrs-full	Other Revenue OtherRevenue	2392000000	eur
CY2021	ifrs-full	Other Revenue OtherRevenue	1414000000	eur
CY2023	ifrs-full	Cost Of Sales CostOfSales	14236000000	eur
CY2022	ifrs-full	Cost Of Sales CostOfSales	13695000000	eur
CY2021	ifrs-full	Cost Of Sales CostOfSales	12255000000	eur
CY2023	ifrs-full	Gross Profit GrossProfit	32208000000	eur
CY2022	ifrs-full	Gross Profit GrossProfit	31694000000	eur
CY2021	ifrs-full	Gross Profit GrossProfit	26920000000	eur
CY2023	ifrs-full	Research And Development Expense ResearchAndDevelopmentExpense	6728000000	eur
CY2022	ifrs-full	Research And Development Expense ResearchAndDevelopmentExpense	6706000000	eur
CY2021	ifrs-full	Research And Development Expense ResearchAndDevelopmentExpense	5692000000	eur
CY2023	ifrs-full	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10692000000	eur
CY2022	ifrs-full	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10492000000	eur
CY2021	ifrs-full	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9555000000	eur
CY2023	ifrs-full	Miscellaneous Other Operating Income MiscellaneousOtherOperatingIncome	1292000000	eur
CY2022	ifrs-full	Miscellaneous Other Operating Income MiscellaneousOtherOperatingIncome	1969000000	eur
CY2021	ifrs-full	Miscellaneous Other Operating Income MiscellaneousOtherOperatingIncome	859000000	eur
CY2023	ifrs-full	Miscellaneous Other Operating Expense MiscellaneousOtherOperatingExpense	3516000000	eur
CY2022	ifrs-full	Miscellaneous Other Operating Expense MiscellaneousOtherOperatingExpense	2531000000	eur
CY2021	ifrs-full	Miscellaneous Other Operating Expense MiscellaneousOtherOperatingExpense	1805000000	eur
CY2023	ifrs-full	Amortisation Intangible Assets Other Than Goodwill AmortisationIntangibleAssetsOtherThanGoodwill	2172000000	eur
CY2022	ifrs-full	Amortisation Intangible Assets Other Than Goodwill AmortisationIntangibleAssetsOtherThanGoodwill	2053000000	eur
CY2021	ifrs-full	Amortisation Intangible Assets Other Than Goodwill AmortisationIntangibleAssetsOtherThanGoodwill	1580000000	eur
CY2023	ifrs-full	Impairment Loss Recognised In Profit Or Loss Intangible Assets Other Than Goodwill ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill	896000000	eur
CY2022	ifrs-full	Impairment Loss Recognised In Profit Or Loss Intangible Assets Other Than Goodwill ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill	-454000000	eur
CY2021	ifrs-full	Impairment Loss Recognised In Profit Or Loss Intangible Assets Other Than Goodwill ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill	192000000	eur
CY2023	ifrs-full	Increase Decrease In Contingent Consideration Asset Liability IncreaseDecreaseInContingentConsiderationAssetLiability	93000000	eur
CY2022	ifrs-full	Increase Decrease In Contingent Consideration Asset Liability IncreaseDecreaseInContingentConsiderationAssetLiability	-27000000	eur
CY2021	ifrs-full	Increase Decrease In Contingent Consideration Asset Liability IncreaseDecreaseInContingentConsiderationAssetLiability	4000000	eur
CY2023	ifrs-full	Expense Of Restructuring Activities ExpenseOfRestructuringActivities	1490000000	eur
CY2022	ifrs-full	Expense Of Restructuring Activities ExpenseOfRestructuringActivities	1336000000	eur
CY2021	ifrs-full	Expense Of Restructuring Activities ExpenseOfRestructuringActivities	820000000	eur
CY2023	sny	Other Gains Losses And Litigation OtherGainsLossesAndLitigation	-38000000	eur
CY2022	sny	Other Gains Losses And Litigation OtherGainsLossesAndLitigation	-370000000	eur
CY2021	sny	Other Gains Losses And Litigation OtherGainsLossesAndLitigation	-5000000	eur
CY2023	ifrs-full	Profit Loss From Operating Activities ProfitLossFromOperatingActivities	7875000000	eur
CY2022	ifrs-full	Profit Loss From Operating Activities ProfitLossFromOperatingActivities	10656000000	eur
CY2021	ifrs-full	Profit Loss From Operating Activities ProfitLossFromOperatingActivities	8126000000	eur
CY2023	ifrs-full	Finance Costs FinanceCosts	1313000000	eur
CY2022	ifrs-full	Finance Costs FinanceCosts	440000000	eur
CY2021	ifrs-full	Finance Costs FinanceCosts	368000000	eur
CY2023	ifrs-full	Finance Income FinanceIncome	591000000	eur
CY2022	ifrs-full	Finance Income FinanceIncome	206000000	eur
CY2021	ifrs-full	Finance Income FinanceIncome	40000000	eur
CY2023	sny	Income Before Tax And Investments Accounted For Equity Method Investments IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments	7153000000	eur
CY2022	sny	Income Before Tax And Investments Accounted For Equity Method Investments IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments	10422000000	eur
CY2021	sny	Income Before Tax And Investments Accounted For Equity Method Investments IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments	7798000000	eur
CY2023	ifrs-full	Income Tax Expense Continuing Operations IncomeTaxExpenseContinuingOperations	1602000000	eur
CY2022	ifrs-full	Income Tax Expense Continuing Operations IncomeTaxExpenseContinuingOperations	2006000000	eur
CY2021	ifrs-full	Income Tax Expense Continuing Operations IncomeTaxExpenseContinuingOperations	1558000000	eur
CY2023	ifrs-full	Share Of Profit Loss Of Associates Accounted For Using Equity Method ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod	-115000000	eur
CY2022	ifrs-full	Share Of Profit Loss Of Associates Accounted For Using Equity Method ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod	68000000	eur
CY2021	ifrs-full	Share Of Profit Loss Of Associates Accounted For Using Equity Method ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod	39000000	eur
CY2023	ifrs-full	Profit Loss ProfitLoss	5436000000	eur
CY2022	ifrs-full	Profit Loss ProfitLoss	8484000000	eur
CY2021	ifrs-full	Profit Loss ProfitLoss	6279000000	eur
CY2023	ifrs-full	Profit Loss Attributable To Noncontrolling Interests ProfitLossAttributableToNoncontrollingInterests	36000000	eur
CY2022	ifrs-full	Profit Loss Attributable To Noncontrolling Interests ProfitLossAttributableToNoncontrollingInterests	113000000	eur
CY2021	ifrs-full	Profit Loss Attributable To Noncontrolling Interests ProfitLossAttributableToNoncontrollingInterests	56000000	eur
CY2023	ifrs-full	Profit Loss Attributable To Owners Of Parent ProfitLossAttributableToOwnersOfParent	5400000000	eur
CY2022	ifrs-full	Profit Loss Attributable To Owners Of Parent ProfitLossAttributableToOwnersOfParent	8371000000	eur
CY2021	ifrs-full	Profit Loss Attributable To Owners Of Parent ProfitLossAttributableToOwnersOfParent	6223000000	eur
CY2023	ifrs-full	Weighted Average Shares WeightedAverageShares	1251700000	shares
CY2022	ifrs-full	Weighted Average Shares WeightedAverageShares	1251900000	shares
CY2021	ifrs-full	Weighted Average Shares WeightedAverageShares	1252500000	shares
CY2023	ifrs-full	Adjusted Weighted Average Shares AdjustedWeightedAverageShares	1256400000	shares
CY2022	ifrs-full	Adjusted Weighted Average Shares AdjustedWeightedAverageShares	1256900000	shares
CY2021	ifrs-full	Adjusted Weighted Average Shares AdjustedWeightedAverageShares	1257900000	shares
CY2023	sny	Basic Earnings Loss Per Share Attributable To Owners Of Parent BasicEarningsLossPerShareAttributableToOwnersOfParent	4.31
CY2022	sny	Basic Earnings Loss Per Share Attributable To Owners Of Parent BasicEarningsLossPerShareAttributableToOwnersOfParent	6.69
CY2021	sny	Basic Earnings Loss Per Share Attributable To Owners Of Parent BasicEarningsLossPerShareAttributableToOwnersOfParent	4.97
CY2023	sny	Diluted Earnings Loss Per Share Attributable To Owners Of Parent DilutedEarningsLossPerShareAttributableToOwnersOfParent	4.30
CY2022	sny	Diluted Earnings Loss Per Share Attributable To Owners Of Parent DilutedEarningsLossPerShareAttributableToOwnersOfParent	6.66
CY2021	sny	Diluted Earnings Loss Per Share Attributable To Owners Of Parent DilutedEarningsLossPerShareAttributableToOwnersOfParent	4.95
CY2023	ifrs-full	Profit Loss ProfitLoss	5436000000	eur
CY2022	ifrs-full	Profit Loss ProfitLoss	8484000000	eur
CY2021	ifrs-full	Profit Loss ProfitLoss	6279000000	eur
CY2023	ifrs-full	Profit Loss Attributable To Owners Of Parent ProfitLossAttributableToOwnersOfParent	5400000000	eur
CY2022	ifrs-full	Profit Loss Attributable To Owners Of Parent ProfitLossAttributableToOwnersOfParent	8371000000	eur
CY2021	ifrs-full	Profit Loss Attributable To Owners Of Parent ProfitLossAttributableToOwnersOfParent	6223000000	eur
CY2023	ifrs-full	Profit Loss Attributable To Noncontrolling Interests ProfitLossAttributableToNoncontrollingInterests	36000000	eur
CY2022	ifrs-full	Profit Loss Attributable To Noncontrolling Interests ProfitLossAttributableToNoncontrollingInterests	113000000	eur
CY2021	ifrs-full	Profit Loss Attributable To Noncontrolling Interests ProfitLossAttributableToNoncontrollingInterests	56000000	eur
CY2023	ifrs-full	Actuarial Gains Losses Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset	171000000	eur
CY2022	ifrs-full	Actuarial Gains Losses Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset	-654000000	eur
CY2021	ifrs-full	Actuarial Gains Losses Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset	-686000000	eur
CY2023	ifrs-full	Gains Losses Recognised In Other Comprehensive Income Fair Value Measurement Entitys Own Equity Instruments GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments	97000000	eur
CY2022	ifrs-full	Gains Losses Recognised In Other Comprehensive Income Fair Value Measurement Entitys Own Equity Instruments GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments	13000000	eur
CY2021	ifrs-full	Gains Losses Recognised In Other Comprehensive Income Fair Value Measurement Entitys Own Equity Instruments GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments	165000000	eur
CY2023	ifrs-full	Income Tax Relating To Components Of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss	3000000	eur
CY2022	ifrs-full	Income Tax Relating To Components Of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss	216000000	eur
CY2021	ifrs-full	Income Tax Relating To Components Of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss	54000000	eur
CY2023	ifrs-full	Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net Of Tax OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax	-77000000	eur
CY2022	ifrs-full	Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net Of Tax OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax	451000000	eur
CY2021	ifrs-full	Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net Of Tax OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax	797000000	eur
CY2023	sny	Gains Losses On Remeasuring Debt Instruments Before Tax GainsLossesOnRemeasuringDebtInstrumentsBeforeTax	21000000	eur
CY2022	sny	Gains Losses On Remeasuring Debt Instruments Before Tax GainsLossesOnRemeasuringDebtInstrumentsBeforeTax	-77000000	eur
CY2021	sny	Gains Losses On Remeasuring Debt Instruments Before Tax GainsLossesOnRemeasuringDebtInstrumentsBeforeTax	-21000000	eur
CY2023	ifrs-full	Gains Losses On Cash Flow Hedges Before Tax GainsLossesOnCashFlowHedgesBeforeTax	-1000000	eur
CY2022	ifrs-full	Gains Losses On Cash Flow Hedges Before Tax GainsLossesOnCashFlowHedgesBeforeTax	7000000	eur
CY2021	ifrs-full	Gains Losses On Cash Flow Hedges Before Tax GainsLossesOnCashFlowHedgesBeforeTax	-6000000	eur
CY2023	ifrs-full	Gains Losses On Exchange Differences On Translation Before Tax GainsLossesOnExchangeDifferencesOnTranslationBeforeTax	-1540000000	eur
CY2022	ifrs-full	Gains Losses On Exchange Differences On Translation Before Tax GainsLossesOnExchangeDifferencesOnTranslationBeforeTax	2278000000	eur
CY2021	ifrs-full	Gains Losses On Exchange Differences On Translation Before Tax GainsLossesOnExchangeDifferencesOnTranslationBeforeTax	2459000000	eur
CY2023	ifrs-full	Income Tax Relating To Components Of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss	6000000	eur
CY2022	ifrs-full	Income Tax Relating To Components Of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss	-105000000	eur
CY2021	ifrs-full	Income Tax Relating To Components Of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss	-78000000	eur
CY2023	ifrs-full	Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net Of Tax OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax	-1526000000	eur
CY2022	ifrs-full	Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net Of Tax OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax	2313000000	eur
CY2021	ifrs-full	Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net Of Tax OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax	2510000000	eur
CY2023	ifrs-full	Other Comprehensive Income OtherComprehensiveIncome	-1603000000	eur
CY2022	ifrs-full	Other Comprehensive Income OtherComprehensiveIncome	2764000000	eur
CY2021	ifrs-full	Other Comprehensive Income OtherComprehensiveIncome	3307000000	eur
CY2023	ifrs-full	Comprehensive Income ComprehensiveIncome	3833000000	eur
CY2022	ifrs-full	Comprehensive Income ComprehensiveIncome	11248000000	eur
CY2021	ifrs-full	Comprehensive Income ComprehensiveIncome	9586000000	eur
CY2023	ifrs-full	Comprehensive Income Attributable To Owners Of Parent ComprehensiveIncomeAttributableToOwnersOfParent	3810000000	eur
CY2022	ifrs-full	Comprehensive Income Attributable To Owners Of Parent ComprehensiveIncomeAttributableToOwnersOfParent	11130000000	eur
CY2021	ifrs-full	Comprehensive Income Attributable To Owners Of Parent ComprehensiveIncomeAttributableToOwnersOfParent	9519000000	eur
CY2023	ifrs-full	Comprehensive Income Attributable To Noncontrolling Interests ComprehensiveIncomeAttributableToNoncontrollingInterests	23000000	eur
CY2022	ifrs-full	Comprehensive Income Attributable To Noncontrolling Interests ComprehensiveIncomeAttributableToNoncontrollingInterests	118000000	eur
CY2021	ifrs-full	Comprehensive Income Attributable To Noncontrolling Interests ComprehensiveIncomeAttributableToNoncontrollingInterests	67000000	eur
CY2020Q4	ifrs-full	Equity Equity	63252000000	eur
CY2021	ifrs-full	Other Comprehensive Income OtherComprehensiveIncome	3307000000	eur
CY2021	ifrs-full	Profit Loss ProfitLoss	6279000000	eur
CY2021	ifrs-full	Comprehensive Income ComprehensiveIncome	9586000000	eur
CY2021	ifrs-full	Dividends Paid Ordinary Shares Per Share DividendsPaidOrdinarySharesPerShare	3.20
CY2021	ifrs-full	Dividends Recognised As Distributions To Owners Of Parent DividendsRecognisedAsDistributionsToOwnersOfParent	4008000000	eur
CY2021	ifrs-full	Dividends Recognised As Distributions To Noncontrolling Interests DividendsRecognisedAsDistributionsToNoncontrollingInterests	49000000	eur
CY2021	ifrs-full	Purchase Of Treasury Shares PurchaseOfTreasuryShares	382000000	eur
CY2021	ifrs-full	Increase Decrease Through Exercise Of Options IncreaseDecreaseThroughExerciseOfOptions	11000000	eur
CY2021	sny	Increase Decrease Through Share Based Payment Plans Issuance Of Restricted Shares And Vesting Of Existing Restricted Shares IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares	0	eur
CY2021	sny	Increase Decrease Through Share Based Payment Plans Employee Share Ownership Plans IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans	168000000	eur
CY2021	sny	Increase Decrease Through Share Based Payment Plans Value Of Services Obtained From Employees IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees	244000000	eur
CY2021	sny	Increase Decrease Through Share Based Payment Plans Tax Effects Of The Exercise Of Stock Options IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions	23000000	eur
CY2021	sny	Increase Decrease Through Changes In Non Controlling Interests Arising From Divestment IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment	186000000	eur
CY2021Q4	ifrs-full	Equity Equity	69031000000	eur
CY2021Q4	ifrs-full	Equity Equity	69031000000	eur
CY2022	ifrs-full	Other Comprehensive Income OtherComprehensiveIncome	2764000000	eur
CY2022	ifrs-full	Profit Loss ProfitLoss	8484000000	eur
CY2022	ifrs-full	Comprehensive Income ComprehensiveIncome	11248000000	eur
CY2022	ifrs-full	Dividends Paid Ordinary Shares Per Share DividendsPaidOrdinarySharesPerShare	3.33
CY2022	ifrs-full	Dividends Recognised As Distributions To Owners Of Parent DividendsRecognisedAsDistributionsToOwnersOfParent	4168000000	eur
CY2022	sny	Exceptional Supplementary Dividends Recognised As Distributions To Owners Of Parent ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent	793000000	eur
CY2022	ifrs-full	Dividends Recognised As Distributions To Noncontrolling Interests DividendsRecognisedAsDistributionsToNoncontrollingInterests	100000000	eur
CY2022	ifrs-full	Purchase Of Treasury Shares PurchaseOfTreasuryShares	497000000	eur
CY2022	ifrs-full	Reduction Of Issued Capital ReductionOfIssuedCapital	0	eur
CY2022	ifrs-full	Increase Decrease Through Exercise Of Options IncreaseDecreaseThroughExerciseOfOptions	35000000	eur
CY2022	sny	Increase Decrease Through Share Based Payment Plans Issuance Of Restricted Shares And Vesting Of Existing Restricted Shares IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares	0	eur
CY2022	sny	Increase Decrease Through Share Based Payment Plans Employee Share Ownership Plans IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans	153000000	eur
CY2022	sny	Increase Decrease Through Share Based Payment Plans Value Of Services Obtained From Employees IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees	245000000	eur
CY2022	sny	Increase Decrease Through Share Based Payment Plans Tax Effects Of The Exercise Of Stock Options IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions	8000000	eur
CY2022	ifrs-full	Increase Decrease Through Transfers And Other Changes Equity IncreaseDecreaseThroughTransfersAndOtherChangesEquity	-10000000	eur
CY2022Q4	ifrs-full	Equity Equity	75152000000	eur
CY2022Q4	ifrs-full	Equity Equity	75152000000	eur
CY2023	ifrs-full	Other Comprehensive Income OtherComprehensiveIncome	-1603000000	eur
CY2023	ifrs-full	Profit Loss ProfitLoss	5436000000	eur
CY2023	ifrs-full	Comprehensive Income ComprehensiveIncome	3833000000	eur
CY2023	ifrs-full	Dividends Paid Ordinary Shares Per Share DividendsPaidOrdinarySharesPerShare	3.56
CY2023	ifrs-full	Dividends Recognised As Distributions To Owners Of Parent DividendsRecognisedAsDistributionsToOwnersOfParent	4454000000	eur
CY2023	ifrs-full	Dividends Recognised As Distributions To Noncontrolling Interests DividendsRecognisedAsDistributionsToNoncontrollingInterests	59000000	eur
CY2023	ifrs-full	Purchase Of Treasury Shares PurchaseOfTreasuryShares	593000000	eur
CY2023	ifrs-full	Increase Decrease Through Exercise Of Options IncreaseDecreaseThroughExerciseOfOptions	37000000	eur
CY2023	sny	Increase Decrease Through Share Based Payment Plans Issuance Of Restricted Shares And Vesting Of Existing Restricted Shares IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares	0	eur
CY2023	sny	Increase Decrease Through Share Based Payment Plans Employee Share Ownership Plans IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans	159000000	eur
CY2023	sny	Increase Decrease Through Share Based Payment Plans Value Of Services Obtained From Employees IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees	283000000	eur
CY2023	sny	Increase Decrease Through Share Based Payment Plans Tax Effects Of The Exercise Of Stock Options IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions	3000000	eur
CY2023	sny	Increase Decrease Through Issuance Of Restricted Shares Equity IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity	2000000	eur
CY2023	sny	Increase Decrease Through Changes In Non Controlling Interests Arising From Divestment IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment	-10000000	eur
CY2023Q4	ifrs-full	Equity Equity	74353000000	eur
CY2023	ifrs-full	Profit Loss Attributable To Ordinary Equity Holders Of Parent Entity ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity	5400000000	eur
CY2022	ifrs-full	Profit Loss Attributable To Ordinary Equity Holders Of Parent Entity ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity	8371000000	eur
CY2021	ifrs-full	Profit Loss Attributable To Ordinary Equity Holders Of Parent Entity ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity	6223000000	eur
CY2023	ifrs-full	Profit Loss Attributable To Noncontrolling Interests ProfitLossAttributableToNoncontrollingInterests	36000000	eur
CY2022	ifrs-full	Profit Loss Attributable To Noncontrolling Interests ProfitLossAttributableToNoncontrollingInterests	113000000	eur
CY2021	ifrs-full	Profit Loss Attributable To Noncontrolling Interests ProfitLossAttributableToNoncontrollingInterests	56000000	eur
CY2023	ifrs-full	Adjustments For Undistributed Profits Of Investments Accounted For Using Equity Method AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod	-295000000	eur
CY2022	ifrs-full	Adjustments For Undistributed Profits Of Investments Accounted For Using Equity Method AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod	48000000	eur
CY2021	ifrs-full	Adjustments For Undistributed Profits Of Investments Accounted For Using Equity Method AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod	15000000	eur
CY2023	sny	Adjustments For Depreciation And Amortisation Expense And Impairment Loss Reversal Of Impairment Loss Of Property Plant And Equipment Right Of Use Assets And Intangible Asset AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset	4792000000	eur
CY2022	sny	Adjustments For Depreciation And Amortisation Expense And Impairment Loss Reversal Of Impairment Loss Of Property Plant And Equipment Right Of Use Assets And Intangible Asset AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset	3420000000	eur
CY2021	sny	Adjustments For Depreciation And Amortisation Expense And Impairment Loss Reversal Of Impairment Loss Of Property Plant And Equipment Right Of Use Assets And Intangible Asset AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset	3351000000	eur
CY2023	ifrs-full	Adjustments For Losses Gains On Disposal Of Noncurrent Assets AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets	-509000000	eur
CY2022	ifrs-full	Adjustments For Losses Gains On Disposal Of Noncurrent Assets AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets	-711000000	eur
CY2021	ifrs-full	Adjustments For Losses Gains On Disposal Of Noncurrent Assets AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets	-300000000	eur
CY2023	ifrs-full	Adjustments For Deferred Tax Expense AdjustmentsForDeferredTaxExpense	-970000000	eur
CY2022	ifrs-full	Adjustments For Deferred Tax Expense AdjustmentsForDeferredTaxExpense	-578000000	eur
CY2021	ifrs-full	Adjustments For Deferred Tax Expense AdjustmentsForDeferredTaxExpense	-356000000	eur
CY2023	sny	Adjustments For Non Current Provisions And Other Non Current Liabilities AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities	-136000000	eur
CY2022	sny	Adjustments For Non Current Provisions And Other Non Current Liabilities AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities	280000000	eur
CY2021	sny	Adjustments For Non Current Provisions And Other Non Current Liabilities AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities	-37000000	eur
CY2023	ifrs-full	Adjustments For Sharebased Payments AdjustmentsForSharebasedPayments	283000000	eur
CY2022	ifrs-full	Adjustments For Sharebased Payments AdjustmentsForSharebasedPayments	245000000	eur
CY2021	ifrs-full	Adjustments For Sharebased Payments AdjustmentsForSharebasedPayments	244000000	eur
CY2023	sny	Impact Of The Workdown Of Acquired Inventories Remeasured At Fair Value ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue	20000000	eur
CY2022	sny	Impact Of The Workdown Of Acquired Inventories Remeasured At Fair Value ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue	3000000	eur
CY2021	sny	Impact Of The Workdown Of Acquired Inventories Remeasured At Fair Value ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue	4000000	eur
CY2023	ifrs-full	Other Adjustments To Reconcile Profit Loss OtherAdjustmentsToReconcileProfitLoss	283000000	eur
CY2022	ifrs-full	Other Adjustments To Reconcile Profit Loss OtherAdjustmentsToReconcileProfitLoss	138000000	eur
CY2021	ifrs-full	Other Adjustments To Reconcile Profit Loss OtherAdjustmentsToReconcileProfitLoss	-57000000	eur
CY2023	ifrs-full	Cash Flows From Used In Operations Before Changes In Working Capital CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital	9494000000	eur
CY2022	ifrs-full	Cash Flows From Used In Operations Before Changes In Working Capital CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital	11233000000	eur
CY2021	ifrs-full	Cash Flows From Used In Operations Before Changes In Working Capital CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital	9113000000	eur
CY2023	ifrs-full	Adjustments For Decrease Increase In Inventories AdjustmentsForDecreaseIncreaseInInventories	-840000000	eur
CY2022	ifrs-full	Adjustments For Decrease Increase In Inventories AdjustmentsForDecreaseIncreaseInInventories	-927000000	eur
CY2021	ifrs-full	Adjustments For Decrease Increase In Inventories AdjustmentsForDecreaseIncreaseInInventories	-357000000	eur
CY2023	ifrs-full	Adjustments For Decrease Increase In Trade Account Receivable AdjustmentsForDecreaseIncreaseInTradeAccountReceivable	-397000000	eur
CY2022	ifrs-full	Adjustments For Decrease Increase In Trade Account Receivable AdjustmentsForDecreaseIncreaseInTradeAccountReceivable	-777000000	eur
CY2021	ifrs-full	Adjustments For Decrease Increase In Trade Account Receivable AdjustmentsForDecreaseIncreaseInTradeAccountReceivable	185000000	eur
CY2023	ifrs-full	Adjustments For Increase Decrease In Trade Account Payable AdjustmentsForIncreaseDecreaseInTradeAccountPayable	402000000	eur
CY2022	ifrs-full	Adjustments For Increase Decrease In Trade Account Payable AdjustmentsForIncreaseDecreaseInTradeAccountPayable	452000000	eur
CY2021	ifrs-full	Adjustments For Increase Decrease In Trade Account Payable AdjustmentsForIncreaseDecreaseInTradeAccountPayable	451000000	eur
CY2023	sny	Net Change In Other Current Assets And Other Current Liabilities NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities	1599000000	eur
CY2022	sny	Net Change In Other Current Assets And Other Current Liabilities NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities	545000000	eur
CY2021	sny	Net Change In Other Current Assets And Other Current Liabilities NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities	1130000000	eur
CY2023	ifrs-full	Cash Flows From Used In Operating Activities CashFlowsFromUsedInOperatingActivities	10258000000	eur
CY2022	ifrs-full	Cash Flows From Used In Operating Activities CashFlowsFromUsedInOperatingActivities	10526000000	eur
CY2021	ifrs-full	Cash Flows From Used In Operating Activities CashFlowsFromUsedInOperatingActivities	10522000000	eur
CY2023	ifrs-full	Purchase Of Property Plant And Equipment Intangible Assets Other Than Goodwill Investment Property And Other Noncurrent Assets PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets	3024000000	eur
CY2022	ifrs-full	Purchase Of Property Plant And Equipment Intangible Assets Other Than Goodwill Investment Property And Other Noncurrent Assets PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets	2201000000	eur
CY2021	ifrs-full	Purchase Of Property Plant And Equipment Intangible Assets Other Than Goodwill Investment Property And Other Noncurrent Assets PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets	2043000000	eur
CY2023	ifrs-full	Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities	3870000000	eur
CY2022	ifrs-full	Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities	992000000	eur
CY2021	ifrs-full	Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities	5594000000	eur
CY2023	ifrs-full	Purchase Of Financial Instruments Classified As Investing Activities PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities	134000000	eur
CY2022	ifrs-full	Purchase Of Financial Instruments Classified As Investing Activities PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities	488000000	eur
CY2021	ifrs-full	Purchase Of Financial Instruments Classified As Investing Activities PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities	311000000	eur
CY2023	ifrs-full	Proceeds From Disposals Of Property Plant And Equipment Intangible Assets Other Than Goodwill Investment Property And Other Noncurrent Assets ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets	1015000000	eur
CY2022	ifrs-full	Proceeds From Disposals Of Property Plant And Equipment Intangible Assets Other Than Goodwill Investment Property And Other Noncurrent Assets ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets	1488000000	eur
CY2021	ifrs-full	Proceeds From Disposals Of Property Plant And Equipment Intangible Assets Other Than Goodwill Investment Property And Other Noncurrent Assets ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets	676000000	eur
CY2023	ifrs-full	Cash Flows From Losing Control Of Subsidiaries Or Other Businesses Classified As Investing Activities CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities	42000000	eur
CY2022	ifrs-full	Cash Flows From Losing Control Of Subsidiaries Or Other Businesses Classified As Investing Activities CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities	134000000	eur
CY2021	ifrs-full	Cash Flows From Losing Control Of Subsidiaries Or Other Businesses Classified As Investing Activities CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities	42000000	eur
CY2023	sny	Net Change In Other Non Current Assets NetChangeInOtherNonCurrentAssets	-229000000	eur
CY2022	sny	Net Change In Other Non Current Assets NetChangeInOtherNonCurrentAssets	-16000000	eur
CY2021	sny	Net Change In Other Non Current Assets NetChangeInOtherNonCurrentAssets	-68000000	eur
CY2023	ifrs-full	Cash Flows From Used In Investing Activities CashFlowsFromUsedInInvestingActivities	-6200000000	eur
CY2022	ifrs-full	Cash Flows From Used In Investing Activities CashFlowsFromUsedInInvestingActivities	-2075000000	eur
CY2021	ifrs-full	Cash Flows From Used In Investing Activities CashFlowsFromUsedInInvestingActivities	-7298000000	eur
CY2023	ifrs-full	Proceeds From Issuing Shares ProceedsFromIssuingShares	195000000	eur
CY2022	ifrs-full	Proceeds From Issuing Shares ProceedsFromIssuingShares	188000000	eur
CY2021	ifrs-full	Proceeds From Issuing Shares ProceedsFromIssuingShares	186000000	eur
CY2023	ifrs-full	Dividends Paid To Equity Holders Of Parent Classified As Financing Activities DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities	4454000000	eur
CY2022	ifrs-full	Dividends Paid To Equity Holders Of Parent Classified As Financing Activities DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities	4168000000	eur
CY2021	ifrs-full	Dividends Paid To Equity Holders Of Parent Classified As Financing Activities DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities	4008000000	eur
CY2023	ifrs-full	Dividends Paid To Noncontrolling Interests Classified As Financing Activities DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities	61000000	eur
CY2022	ifrs-full	Dividends Paid To Noncontrolling Interests Classified As Financing Activities DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities	99000000	eur
CY2021	ifrs-full	Dividends Paid To Noncontrolling Interests Classified As Financing Activities DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities	48000000	eur
CY2023	ifrs-full	Payments From Changes In Ownership Interests In Subsidiaries PaymentsFromChangesInOwnershipInterestsInSubsidiaries	3000000	eur
CY2022	ifrs-full	Payments From Changes In Ownership Interests In Subsidiaries PaymentsFromChangesInOwnershipInterestsInSubsidiaries	0	eur
CY2021	ifrs-full	Payments From Changes In Ownership Interests In Subsidiaries PaymentsFromChangesInOwnershipInterestsInSubsidiaries	0	eur
CY2023	ifrs-full	Proceeds From Noncurrent Borrowings ProceedsFromNoncurrentBorrowings	48000000	eur
CY2022	ifrs-full	Proceeds From Noncurrent Borrowings ProceedsFromNoncurrentBorrowings	1549000000	eur
CY2021	ifrs-full	Proceeds From Noncurrent Borrowings ProceedsFromNoncurrentBorrowings	0	eur
CY2023	ifrs-full	Repayments Of Noncurrent Borrowings RepaymentsOfNoncurrentBorrowings	3684000000	eur
CY2022	ifrs-full	Repayments Of Noncurrent Borrowings RepaymentsOfNoncurrentBorrowings	2718000000	eur
CY2021	ifrs-full	Repayments Of Noncurrent Borrowings RepaymentsOfNoncurrentBorrowings	2241000000	eur
CY2023	ifrs-full	Payments Of Lease Liabilities Classified As Financing Activities PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities	265000000	eur
CY2022	ifrs-full	Payments Of Lease Liabilities Classified As Financing Activities PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities	291000000	eur
CY2021	ifrs-full	Payments Of Lease Liabilities Classified As Financing Activities PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities	149000000	eur
CY2023	sny	Cash Flows From Used In Increase Decrease In Current Borrowings And Other Financial Instruments CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments	765000000	eur
CY2022	sny	Cash Flows From Used In Increase Decrease In Current Borrowings And Other Financial Instruments CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments	215000000	eur
CY2021	sny	Cash Flows From Used In Increase Decrease In Current Borrowings And Other Financial Instruments CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments	-414000000	eur
CY2023	ifrs-full	Payments To Acquire Or Redeem Entitys Shares PaymentsToAcquireOrRedeemEntitysShares	593000000	eur
CY2022	ifrs-full	Payments To Acquire Or Redeem Entitys Shares PaymentsToAcquireOrRedeemEntitysShares	497000000	eur
CY2021	ifrs-full	Payments To Acquire Or Redeem Entitys Shares PaymentsToAcquireOrRedeemEntitysShares	382000000	eur
CY2023	ifrs-full	Cash Flows From Used In Financing Activities CashFlowsFromUsedInFinancingActivities	-8052000000	eur
CY2022	ifrs-full	Cash Flows From Used In Financing Activities CashFlowsFromUsedInFinancingActivities	-5821000000	eur
CY2021	ifrs-full	Cash Flows From Used In Financing Activities CashFlowsFromUsedInFinancingActivities	-7056000000	eur
CY2023	ifrs-full	Effect Of Exchange Rate Changes On Cash And Cash Equivalents EffectOfExchangeRateChangesOnCashAndCashEquivalents	-32000000	eur
CY2022	ifrs-full	Effect Of Exchange Rate Changes On Cash And Cash Equivalents EffectOfExchangeRateChangesOnCashAndCashEquivalents	8000000	eur
CY2021	ifrs-full	Effect Of Exchange Rate Changes On Cash And Cash Equivalents EffectOfExchangeRateChangesOnCashAndCashEquivalents	15000000	eur
CY2023	ifrs-full	Increase Decrease In Cash And Cash Equivalents IncreaseDecreaseInCashAndCashEquivalents	-4026000000	eur
CY2022	ifrs-full	Increase Decrease In Cash And Cash Equivalents IncreaseDecreaseInCashAndCashEquivalents	2638000000	eur
CY2021	ifrs-full	Increase Decrease In Cash And Cash Equivalents IncreaseDecreaseInCashAndCashEquivalents	-3817000000	eur
CY2022Q4	ifrs-full	Cash And Cash Equivalents CashAndCashEquivalents	12736000000	eur
CY2021Q4	ifrs-full	Cash And Cash Equivalents CashAndCashEquivalents	10098000000	eur
CY2020Q4	ifrs-full	Cash And Cash Equivalents CashAndCashEquivalents	13915000000	eur
CY2023Q4	ifrs-full	Cash And Cash Equivalents CashAndCashEquivalents	8710000000	eur
CY2022Q4	ifrs-full	Cash And Cash Equivalents CashAndCashEquivalents	12736000000	eur
CY2021Q4	ifrs-full	Cash And Cash Equivalents CashAndCashEquivalents	10098000000	eur
CY2023	ifrs-full	Income Taxes Paid Refund Classified As Operating Activities IncomeTaxesPaidRefundClassifiedAsOperatingActivities	2623000000	eur
CY2022	ifrs-full	Income Taxes Paid Refund Classified As Operating Activities IncomeTaxesPaidRefundClassifiedAsOperatingActivities	2452000000	eur
CY2021	ifrs-full	Income Taxes Paid Refund Classified As Operating Activities IncomeTaxesPaidRefundClassifiedAsOperatingActivities	1280000000	eur
CY2023	ifrs-full	Interest Paid Classified As Operating Activities InterestPaidClassifiedAsOperatingActivities	559000000	eur
CY2022	ifrs-full	Interest Paid Classified As Operating Activities InterestPaidClassifiedAsOperatingActivities	380000000	eur
CY2021	ifrs-full	Interest Paid Classified As Operating Activities InterestPaidClassifiedAsOperatingActivities	334000000	eur
CY2023	ifrs-full	Interest Received Classified As Operating Activities InterestReceivedClassifiedAsOperatingActivities	547000000	eur
CY2022	ifrs-full	Interest Received Classified As Operating Activities InterestReceivedClassifiedAsOperatingActivities	173000000	eur
CY2021	ifrs-full	Interest Received Classified As Operating Activities InterestReceivedClassifiedAsOperatingActivities	3000000	eur
CY2023	sny	Dividends Received From Non Consolidated Entities Classified As Operating Activities DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities	17000000	eur
CY2022	sny	Dividends Received From Non Consolidated Entities Classified As Operating Activities DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities	1000000	eur
CY2021	sny	Dividends Received From Non Consolidated Entities Classified As Operating Activities DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities	2000000	eur
CY2023	ifrs-full	Disclosure Of General Information About Financial Statements Explanatory DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory	<div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Introduction</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi, together with its subsidiaries (collectively “Sanofi”, “the Group” or “the Company”), is a global healthcare leader engaged in the research, development and marketing of therapeutic solutions focused on patient needs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is listed in Paris (Euronext: SAN) and New York (Nasdaq: SNY).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The consolidated financial statements for the year ended December 31, 2023, and the notes thereto, were signed off by the Sanofi Board of Directors on</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> January 31, 2024.</span></div>
CY2023	ifrs-full	Disclosure Of Basis Of Preparation Of Financial Statements Explanatory DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory	Basis of preparation<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.1. International financial reporting standards (IFRS)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The consolidated financial statements cover the twelve-month periods ended December 31, 2023, 2022 and 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with Regulation No. 1606/2002 of the European Parliament and Council of July 19, 2002 on the application of international accounting standards, Sanofi has presented its consolidated financial statements in accordance with IFRS since January 1, 2005. The term “IFRS” refers collectively to international accounting and financial reporting standards (IASs and IFRSs) and to interpretations of the interpretations committees (SIC and IFRIC) with mandatory application as of December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The consolidated financial statements of Sanofi as of December 31, 2023 have been prepared in compliance with IFRS as issued by the International Accounting Standards Board (IASB) and with IFRS as endorsed by the European Union as of December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">IFRS as endorsed by the European Union as of December 31, 2023 are available under the heading “IFRS Financial Statements” via the following web link:</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">https://www.efrag.org/Endorsement</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in accordance with the IFRS general principles of fair presentation, going concern, accrual basis of accounting, consistency of presentation, materiality, and aggregation.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.2. New standards, amendments and interpretations</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.2.1. New standards applicable from January 1, 2023</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following amendments are applicable from January 1, 2023, and have had no material impact: “Disclosure of Accounting Policies” (amendment to IAS 1); “Definition of Accounting Estimates” (amendment to IAS 8); and “Deferred Tax Assets and Liabilities Arising from a Single Transaction” (amendment to IAS 12).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 23, 2023, the IASB issued “International Tax Reform—Pillar Two Model Rules”, an immediately applicable amendment to IAS 12 that was endorsed on November 9, 2023. The amendment relates to the effects of the global minimum corporate income tax rate of 15% that will come into force in 2024, in accordance with the model framework of OECD Pillar Two.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The French Finance Bill for 2024 imposes a global minimum corporate income tax rate of 15% and introduces (i) a supplementary multinational tax and (ii) a supplementary national tax for annual accounting periods commencing on or after December 31, 2023. Given that the legislation had not come into force as of December 31, 2023, Sanofi is not liable for any current taxes in that respect. In addition, Sanofi has not recognized any deferred taxes associated with the minimum tax, in accordance with the temporary exemption available under the May 2023 amendment to IAS 12. At this stage, a material impact is expected in respect of Sanofi's operations in France and Singapore, because Sanofi’s average effective tax rate in those countries was less than 15% at the end of 2023. Other things being equal, applying the Pillar 2 rules in 2023 would have led to an increase of approximately 1.5 percentage points in the effective tax rate based on the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income before tax and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">IFRS 17 (Insurance Contracts), issued on May 18, 2017 and applicable on or after January 1, 2023, does not apply to the Sanofi consolidated financial statements because the insurance activities carried on by Sanofi’s captive insurance companies are internal within the Sanofi group (the sole policyholders being subsidiaries of Sanofi), and hence are eliminated on consolidation.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.2.2. New pronouncements issued by the IASB and applicable from 2024 or later</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This note describes standards, amendments and interpretations issued by the IASB that will have mandatory application in 2024 or subsequent years, and Sanofi’s position regarding future application.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On September 22, 2022, the IASB issued an amendment to IFRS 16 (Leases), relating to lease liabilities in a sale-and-leaseback arrangement, which is applicable at the earliest from January 1, 2024;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> it will not have a material impact on the Sanofi financial statements, and </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has not early adopted it.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On January 23, 2020, the IASB issued “Classification of Liabilities as Current or Non-current”, an amendment to IAS 1, and then on October 31, 2022 issued “Non-current Liabilities with Covenants”, a further amendment to IAS 1. The amendments are applicable at the earliest from January 1, 2024; they will not have a material impact on the Sanofi financial statements, and Sanofi has not early adopted them.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 25, 2023, the IASB issued "Supplier Finance Arrangements", an amendment to IAS 7 and IFRS 7, which is applicable at the earliest from January 1, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (subject to endorsement by the European Union) and which relates to disclosures of information about such arrangements. The amendment does not </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">have a material impact on the Sanofi financial statements, and Sanofi will not early adopt it</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On August 15, 2023, the IASB issued "Lack of Exchangeability", an amendment to IAS 21 (The Effect of Changes in Foreign Exchange Rates), relating to how to determine the exchange rate when a currency is not exchangeable. The amendment is applicable at the earliest from January 1, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (subject to endorsement by the European Union); it</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> will not have a material impact on the Sanofi financial statements, and Sanofi will not early adopt it</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.3. Use of estimates and judgments</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date of the finalization of the financial statements. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions (see Notes B.13. and D.23.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">impairment of property, plant and equipment and intangible assets (see Notes B.6. and D.5.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the valuation of goodwill and the valuation and estimated useful life of acquired intangible assets (see Notes B.3.2., B.4., D.4. and D.5.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the measurement of contingent consideration receivable in connection with asset divestments (see Notes B.8.5. and D.12.) and of contingent consideration payable (see Notes B.3. and D.18.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the measurement of financial assets and liabilities at amortized cost (see Note B.8.5.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of post-employment benefit obligations (see Notes B.23. and D.19.1.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of liabilities or provisions for restructuring, litigation, tax risks relating to corporate income taxes, and environmental risks (see Notes B.12., B.19., B.20., D.19. and D.22.); and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of deferred tax assets resulting from tax losses available for carry-forward and deductible temporary differences (see Notes B.22. and D.14.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actual results could differ from these estimates.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In preparing the consolidated financial statements, Sanofi has also taken account of risks related to the effects of climate change and energy transition.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As part of its Planet Care program, Sanofi has committed to move towards carbon neutrality by 2030 and net zero emissions by 2045 for its Scope 1, 2 and 3 emissions. That involves:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">aiming for a 55% reduction in greenhouse gas (GHG) emissions from Sanofi’s own activities (Scopes 1 & 2) and a 30% reduction in Scope 3 GHG emissions by 2030 (versus a 2019 baseline), and a 90% reduction in GHG emissions (all scopes) by 2045. These objectives have been validated by the Science Based Target initiative (STBi);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">supplying all our sites with 100% renewably-sourced electricity by 2030;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">promoting an eco-friendly vehicle fleet by 2030; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">engaging the Sanofi supply chain in reducing Scope 3 emissions.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The analysis of climate-related physical and transition risks facing Sanofi was updated in 2023 on the basis of three global warming scenarios out to 2030 and 2050. A number of assumptions – on issues such as carbon costs, natural disasters, water stress, raw material scarcity and logistics disruption – were built into this analysis, which also takes account of certain capital expenditures on mitigations derived from the Planet Care roadmap.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In preparing the consolidated financial statements, that analysis was taken into account as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the value of intangible assets and property, plant and equipment was subject to impairment testing conducted at CGU level, as described in Note D.5. Certain climate-related assumptions, such as the evolution of energy costs, transitioning to sustainable agriculture, and waste management, are already built into the forecast used for impairment testing purposes. For those assumptions not yet built into budgets, sensitivity analyses can be performed as needed;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the periodic reviews conducted on the useful lives of property, plant and equipment take account of environmental regulatory constraints, including not only GHG emissions but also physical risks;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">environmental risks are covered by provisions on the basis described in Note D.19.3.; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the credit facilities available to Sanofi as of December 31, 2023 incorporate performance objectives, including objectives related to cutting Sanofi’s carbon footprint, which could reduce the cost of debt if they are attained (see Note D.17.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is important to bear in mind that estimating climate change related risks involves an element of unpredictability. Uncertainties may arise from factors such as changes in government policy, rapid technological change, and varied responses from stakeholders. That high level of uncertainty adds complexity to assessment of the potential impacts on our operations, and to how those impacts are reflected in our budgets. Actual impacts on Sanofi’s profits and financial position could therefore differ from initial estimates.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, in line with its environmental protection objectives, Sanofi has initiated projects to build eco-design into its products so as to limit their environmental impacts over their entire life cycle. Those projects will require Sanofi to redefine all of its production methods, and as such have also been built into definitions of the useful lives of Sanofi production facilities.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.4. Hyperinflation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, Sanofi continued to account for subsidiaries based in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS 10 (Consolidated Financial Statements) are still met. The contribution of the Venezuelan subsidiaries to the consolidated financial statements is immaterial.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Argentina, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since July 1, 2018 treated Argentina as a hyperinflationary economy and has applied IAS 29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Turkey, the cumulative rate of inflation over the last three years is in excess of 100% based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since January 1, 2022 treated Turkey as a hyperinflationary economy and has applied IAS 29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.5. Agreements relating to the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On February 18, 2020, Sanofi and the US Department of Health and Human Services extended their research and development partnership to leverage Sanofi’s previous development work on a SARS vaccine to attempt to unlock a fast path forward for developing a COVID-19 vaccine. Under the terms of the collaboration, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the US Department of Health and Human Services, is helping to fund the research and development undertaken by Sanofi.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 14, 2020, Sanofi and GlaxoSmithKline (GSK) entered into a collaboration agreement to develop a recombinant COVID-19 vaccine candidate, with Sanofi contributing its S‑protein COVID-19 antigen (based on recombinant DNA technology) and GSK contributing its pandemic adjuvant technology. Sanofi is leading clinical development and the registration process for the vaccine.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July 31, 2020, the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK was selected by the US government’s Operation Warp Speed (OWS) program. Under the OWS, the US government is providing funds to support further development of the vaccine, including clinical trials and scaling-up of manufacturing capacity. Initially, the agreement also provided for the supply of 100 million doses of the vaccine. In light of the evolving context of the pandemic (including variants of the virus) and the availability of vaccines on the market, the parties decided to review the initial supply contract. At the end of 2023, the agreement was amended in respect of the supply clause, confirming that Sanofi had fulfilled its contractual obligations and setting the amount of compensation paid to Sanofi. On the basis of that signed amendment, Sanofi recognized an amount of €411 million within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">; that amount was paid to Sanofi in December 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has recognized the funding received from the US government as a deduction from the development expenses incurred, in accordance with IAS 20 (Accounting for Government Grants and Disclosure of Government Assistance).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The amount of government aid received from the US federal government and BARDA and recognized </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">as a deduction from development expenses</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and other operating expenses was €59 million in 2023, compared with €265 million in 2022 and €147 million in 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In September 2020, Sanofi and GSK signed pre-order contracts with the Canadian and UK governments and with the European Union for doses of the vaccine candidate. During 2021, Sanofi and GSK contractualized with the Canadian and UK governments and with the European Union on the number of doses ordered.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On December 15, 2021, Sanofi and GSK announced positive preliminary data on their COVID-19 booster vaccine candidate and indicated that their Phase 3 trial was to continue, based on recommendations from an independent monitoring board.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On November 10, 2022, in line with the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, the European Commission approved VIDPREVTYN Beta vaccine as booster for the prevention of COVID-19 in adults aged 18 years and older. Designed to provide broad protection against multiple variants, this protein-based COVID-19 booster vaccine is based on the Beta variant antigen and includes GSK’s pandemic adjuvant. VIDPREVTYN</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Beta is indicated as a booster for active immunization against SARS-CoV-2 in adults who have previously received an mRNA or adenoviral COVID-19 vaccine.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On December 21, 2022, following the European Commission approval, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved VIDPREVTYN Beta vaccine for the prevention of COVID-19 in adults aged 18 and over within the UK.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 15 (see Note B.13.1.), Sanofi recognizes revenue when control over the product is transferred to the customer (for vaccines, transfer of control is determined by reference to the terms of release and acceptance of batches of vaccine). Payments received subsequent to signature of vaccine pre-order contracts relating to doses not yet delivered are customer contract liabilities (i.e. an obligation for the entity to supply goods to a customer, for which consideration has been received from the customer). They are presented within “Customer contract liabilities” in the balance sheet (see Note D.19.5.), and within “Net change in other current assets and other current liabilities” in the statement of cash flows.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The pre-order contracts for Canada, the United Kingdom and the European Union expired in 2023. The customer contract liabilities, which amounted to €269 million as of December 31, 2022 and €319 million as of December 31, 2021 (see Note D.19.5., “</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Current provisions and other current liabilities”</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) were released to profit or loss in 2023, including an amount of €94 million classified in</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other revenue</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in respect of doses which there was no longer an obligation to deliver as of December 31, 2023.</span></div>
CY2023	ifrs-full	Statement Of Ifrs Compliance StatementOfIFRSCompliance	International financial reporting standards (IFRS)<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The consolidated financial statements cover the twelve-month periods ended December 31, 2023, 2022 and 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with Regulation No. 1606/2002 of the European Parliament and Council of July 19, 2002 on the application of international accounting standards, Sanofi has presented its consolidated financial statements in accordance with IFRS since January 1, 2005. The term “IFRS” refers collectively to international accounting and financial reporting standards (IASs and IFRSs) and to interpretations of the interpretations committees (SIC and IFRIC) with mandatory application as of December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The consolidated financial statements of Sanofi as of December 31, 2023 have been prepared in compliance with IFRS as issued by the International Accounting Standards Board (IASB) and with IFRS as endorsed by the European Union as of December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">IFRS as endorsed by the European Union as of December 31, 2023 are available under the heading “IFRS Financial Statements” via the following web link:</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">https://www.efrag.org/Endorsement</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in accordance with the IFRS general principles of fair presentation, going concern, accrual basis of accounting, consistency of presentation, materiality, and aggregation.</span></div>
CY2023	ifrs-full	Description Of Initial Application Of Standards Or Interpretations DescriptionOfInitialApplicationOfStandardsOrInterpretations	New standards, amendments and interpretations<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.2.1. New standards applicable from January 1, 2023</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following amendments are applicable from January 1, 2023, and have had no material impact: “Disclosure of Accounting Policies” (amendment to IAS 1); “Definition of Accounting Estimates” (amendment to IAS 8); and “Deferred Tax Assets and Liabilities Arising from a Single Transaction” (amendment to IAS 12).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 23, 2023, the IASB issued “International Tax Reform—Pillar Two Model Rules”, an immediately applicable amendment to IAS 12 that was endorsed on November 9, 2023. The amendment relates to the effects of the global minimum corporate income tax rate of 15% that will come into force in 2024, in accordance with the model framework of OECD Pillar Two.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The French Finance Bill for 2024 imposes a global minimum corporate income tax rate of 15% and introduces (i) a supplementary multinational tax and (ii) a supplementary national tax for annual accounting periods commencing on or after December 31, 2023. Given that the legislation had not come into force as of December 31, 2023, Sanofi is not liable for any current taxes in that respect. In addition, Sanofi has not recognized any deferred taxes associated with the minimum tax, in accordance with the temporary exemption available under the May 2023 amendment to IAS 12. At this stage, a material impact is expected in respect of Sanofi's operations in France and Singapore, because Sanofi’s average effective tax rate in those countries was less than 15% at the end of 2023. Other things being equal, applying the Pillar 2 rules in 2023 would have led to an increase of approximately 1.5 percentage points in the effective tax rate based on the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income before tax and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">IFRS 17 (Insurance Contracts), issued on May 18, 2017 and applicable on or after January 1, 2023, does not apply to the Sanofi consolidated financial statements because the insurance activities carried on by Sanofi’s captive insurance companies are internal within the Sanofi group (the sole policyholders being subsidiaries of Sanofi), and hence are eliminated on consolidation.</span></div>
CY2023	sny	Increase Decrease In Effective Tax Rate IncreaseDecreaseInEffectiveTaxRate	0.015
CY2023	ifrs-full	Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations	New pronouncements issued by the IASB and applicable from 2024 or later<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This note describes standards, amendments and interpretations issued by the IASB that will have mandatory application in 2024 or subsequent years, and Sanofi’s position regarding future application.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On September 22, 2022, the IASB issued an amendment to IFRS 16 (Leases), relating to lease liabilities in a sale-and-leaseback arrangement, which is applicable at the earliest from January 1, 2024;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> it will not have a material impact on the Sanofi financial statements, and </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has not early adopted it.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On January 23, 2020, the IASB issued “Classification of Liabilities as Current or Non-current”, an amendment to IAS 1, and then on October 31, 2022 issued “Non-current Liabilities with Covenants”, a further amendment to IAS 1. The amendments are applicable at the earliest from January 1, 2024; they will not have a material impact on the Sanofi financial statements, and Sanofi has not early adopted them.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 25, 2023, the IASB issued "Supplier Finance Arrangements", an amendment to IAS 7 and IFRS 7, which is applicable at the earliest from January 1, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (subject to endorsement by the European Union) and which relates to disclosures of information about such arrangements. The amendment does not </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">have a material impact on the Sanofi financial statements, and Sanofi will not early adopt it</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On August 15, 2023, the IASB issued "Lack of Exchangeability", an amendment to IAS 21 (The Effect of Changes in Foreign Exchange Rates), relating to how to determine the exchange rate when a currency is not exchangeable. The amendment is applicable at the earliest from January 1, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (subject to endorsement by the European Union); it</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> will not have a material impact on the Sanofi financial statements, and Sanofi will not early adopt it</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div>
CY2023	ifrs-full	Disclosure Of Accounting Judgements And Estimates Explanatory DisclosureOfAccountingJudgementsAndEstimatesExplanatory	Use of estimates and judgments<div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date of the finalization of the financial statements. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions (see Notes B.13. and D.23.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">impairment of property, plant and equipment and intangible assets (see Notes B.6. and D.5.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the valuation of goodwill and the valuation and estimated useful life of acquired intangible assets (see Notes B.3.2., B.4., D.4. and D.5.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the measurement of contingent consideration receivable in connection with asset divestments (see Notes B.8.5. and D.12.) and of contingent consideration payable (see Notes B.3. and D.18.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the measurement of financial assets and liabilities at amortized cost (see Note B.8.5.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of post-employment benefit obligations (see Notes B.23. and D.19.1.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of liabilities or provisions for restructuring, litigation, tax risks relating to corporate income taxes, and environmental risks (see Notes B.12., B.19., B.20., D.19. and D.22.); and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of deferred tax assets resulting from tax losses available for carry-forward and deductible temporary differences (see Notes B.22. and D.14.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actual results could differ from these estimates.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In preparing the consolidated financial statements, Sanofi has also taken account of risks related to the effects of climate change and energy transition.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As part of its Planet Care program, Sanofi has committed to move towards carbon neutrality by 2030 and net zero emissions by 2045 for its Scope 1, 2 and 3 emissions. That involves:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">aiming for a 55% reduction in greenhouse gas (GHG) emissions from Sanofi’s own activities (Scopes 1 & 2) and a 30% reduction in Scope 3 GHG emissions by 2030 (versus a 2019 baseline), and a 90% reduction in GHG emissions (all scopes) by 2045. These objectives have been validated by the Science Based Target initiative (STBi);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">supplying all our sites with 100% renewably-sourced electricity by 2030;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">promoting an eco-friendly vehicle fleet by 2030; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">engaging the Sanofi supply chain in reducing Scope 3 emissions.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The analysis of climate-related physical and transition risks facing Sanofi was updated in 2023 on the basis of three global warming scenarios out to 2030 and 2050. A number of assumptions – on issues such as carbon costs, natural disasters, water stress, raw material scarcity and logistics disruption – were built into this analysis, which also takes account of certain capital expenditures on mitigations derived from the Planet Care roadmap.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In preparing the consolidated financial statements, that analysis was taken into account as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the value of intangible assets and property, plant and equipment was subject to impairment testing conducted at CGU level, as described in Note D.5. Certain climate-related assumptions, such as the evolution of energy costs, transitioning to sustainable agriculture, and waste management, are already built into the forecast used for impairment testing purposes. For those assumptions not yet built into budgets, sensitivity analyses can be performed as needed;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the periodic reviews conducted on the useful lives of property, plant and equipment take account of environmental regulatory constraints, including not only GHG emissions but also physical risks;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">environmental risks are covered by provisions on the basis described in Note D.19.3.; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the credit facilities available to Sanofi as of December 31, 2023 incorporate performance objectives, including objectives related to cutting Sanofi’s carbon footprint, which could reduce the cost of debt if they are attained (see Note D.17.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is important to bear in mind that estimating climate change related risks involves an element of unpredictability. Uncertainties may arise from factors such as changes in government policy, rapid technological change, and varied responses from stakeholders. That high level of uncertainty adds complexity to assessment of the potential impacts on our operations, and to how those impacts are reflected in our budgets. Actual impacts on Sanofi’s profits and financial position could therefore differ from initial estimates.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, in line with its environmental protection objectives, Sanofi has initiated projects to build eco-design into its products so as to limit their environmental impacts over their entire life cycle. Those projects will require Sanofi to redefine all of its production methods, and as such have also been built into definitions of the useful lives of Sanofi production facilities.</span></div>
CY2023	sny	Planet Care Program Objectives Net Emissions By2045 PlanetCareProgramObjectivesNetEmissionsBy2045	0	emission
CY2023	sny	Planet Care Program Objectives Percentage Of Reduction In Scope1 And2 Greenhouse Gas By2030 PlanetCareProgramObjectivesPercentageOfReductionInScope1And2GreenhouseGasBy2030	0.55
CY2023	sny	Planet Care Program Objectives Percentage Of Reduction In Scope3 Greenhouse Gas By2030 PlanetCareProgramObjectivesPercentageOfReductionInScope3GreenhouseGasBy2030	0.30
CY2023	sny	Planet Care Program Objectives Percentage Of Reduction In All Scopes Greenhouse Gas By2030 PlanetCareProgramObjectivesPercentageOfReductionInAllScopesGreenhouseGasBy2030	0.90
CY2023	sny	Planet Care Program Objectives Percentage Of Renewably Sourced Energy In All Sites By2030 PlanetCareProgramObjectivesPercentageOfRenewablySourcedEnergyInAllSitesBy2030	1
CY2023	sny	Planet Care Program Objectives Number Of Global Warming Scenarios PlanetCareProgramObjectivesNumberOfGlobalWarmingScenarios	3	scenario
CY2023	ifrs-full	Description Of Accounting Policy For Treasury Shares Explanatory DescriptionOfAccountingPolicyForTreasurySharesExplanatory	Treasury shares<div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS 32, Sanofi treasury shares are deducted from equity, irrespective of the purpose for which they are held. No gain or loss is recognized in the income statement on the purchase, sale, impairment or cancellation of treasury shares.</span></div>
CY2023	ifrs-full	Disclosure Of Hyperinflationary Reporting Explanatory DisclosureOfHyperinflationaryReportingExplanatory	Hyperinflation<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, Sanofi continued to account for subsidiaries based in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS 10 (Consolidated Financial Statements) are still met. The contribution of the Venezuelan subsidiaries to the consolidated financial statements is immaterial.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Argentina, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since July 1, 2018 treated Argentina as a hyperinflationary economy and has applied IAS 29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Turkey, the cumulative rate of inflation over the last three years is in excess of 100% based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since January 1, 2022 treated Turkey as a hyperinflationary economy and has applied IAS 29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div>
CY2023	ifrs-full	Disclosure Of Material Accounting Policy Information Explanatory DisclosureOfMaterialAccountingPolicyInformationExplanatory	Summary of significant accounting policiesBasis of consolidation<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 10 (Consolidated Financial Statements), the consolidated financial statements of Sanofi include the financial statements of entities that Sanofi controls directly or indirectly, regardless of the level of the equity interest in those entities. An entity is controlled when Sanofi has power over the entity, exposure or rights to variable returns from its involvement with the entity, and the ability to affect those returns through its power over the entity. In determining whether control exists, potential voting rights must be taken into account if those rights are substantive, in other words they can be exercised on a timely basis when decisions about the relevant activities of the entity are to be taken.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Entities consolidated by Sanofi are referred to as “subsidiaries”. Entities that Sanofi controls by means other than voting rights are referred to as “consolidated structured entities”.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 11 (Joint Arrangements), Sanofi classifies its joint arrangements (i.e. arrangements in which Sanofi exercises joint control with one or more other parties) either as a joint operation (in which case, Sanofi recognizes the assets and liabilities of the operation in proportion to its rights and obligations relating to those assets and liabilities) or as a joint venture.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi exercises joint control over a joint arrangement when decisions relating to the relevant activities of the arrangement require the unanimous consent of Sanofi and the other parties with whom control is shared.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi exercises significant influence over an entity when it has the power to participate in the financial and operating policy decisions of that entity, but does not have the power to exercise control or joint control over those policies.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS 28 (Investments in Associates and Joint Ventures), the equity method is used to account for joint ventures (i.e. entities over which Sanofi exercises joint control) and for associates (i.e. entities over which Sanofi exercises significant influence).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the equity method, the investment is initially recognized at cost, and subsequently adjusted to reflect changes in the net assets of the associate or joint venture. IAS 28 does not specify the treatment to be adopted on first-time application of the equity method to an investee following a step acquisition. Consequently, by reference to paragraph 10 of IAS 28, Sanofi has opted to apply the cost method, whereby the carrying amount of the investment represents the sum of the historical cost amounts for each step in the acquisition. As of the date on which the equity method is first applied, goodwill (which is included in the carrying amount of the investment) is determined for each acquisition step. The same applies to subsequent increases in the percentage interest in the equity-accounted investment.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When the criteria of IFRS 5 are met, Sanofi recognizes the equity interest within the balance sheet line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. The equity method is not applied to equity interests that are classified as held-for-sale assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Transactions between consolidated companies are eliminated, as are intragroup profits.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A list of the principal companies included in the consolidation in 2023 is presented in Note F.</span></div>Foreign currency translation<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.2.1. Accounting for foreign currency transactions in the financial statements of consolidated entities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Non-current assets (other than receivables) and inventories acquired in foreign currencies are translated into the functional currency using the exchange rate prevailing at the acquisition date.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the end of the reporting period. The gains and losses resulting from foreign currency translation are recorded in the income statement. However, foreign exchange gains and losses arising from the translation of advances between consolidated subsidiaries for which settlement is neither planned nor likely to occur in the foreseeable future are recognized in equity, in the line item</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Change in currency translation differences.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.2.2. Foreign currency translation of the financial statements of foreign entities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi presents its consolidated financial statements in euros (€). In accordance with IAS 21 (The Effects of Changes in Foreign Exchange Rates), each subsidiary accounts for its transactions in the currency that is most representative of its economic environment (the functional currency).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">All assets and liabilities are translated into euros using the exchange rate of the subsidiary’s functional currency prevailing at the end of the reporting period. Income statements are translated using a weighted average exchange rate for the period, except in the case of foreign subsidiaries in a hyperinflationary economy. The resulting currency translation difference is recognized as a separate component of equity in the consolidated statement of comprehensive income, and is recognized in the income statement only when the subsidiary is sold or is wholly or partially liquidated.</span></div>Business combinations and transactions with non-controlling interests<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.3.1. Accounting for business combinations, transactions with non-controlling interests and loss of control</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Business combinations are accounted for in accordance with IFRS 3 (Business Combinations) and IFRS 10 (Consolidated Financial Statements).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Business combinations are accounted for using the acquisition method. Under this method, the acquiree’s identifiable assets and liabilities that satisfy the recognition criteria of IFRS 3 (Business Combinations) are measured initially at their fair values at the date of acquisition, except for (i) non-current assets classified as held for sale (which are measured at fair value less costs to sell) and (ii) assets and liabilities that fall within the scope of IAS 12 (Income Taxes) and IAS 19 (Employee Benefits). Restructuring liabilities are recognized as a liability of the acquiree only if the acquiree has an obligation as of the acquisition date to carry out the restructuring.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal accounting rules applicable to business combinations and transactions with non-controlling interests include:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">acquisition-related costs are recognized as an expense, as a component of </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">contingent consideration is recognized in equity if the contingent payment is settled by delivery of a fixed number of the acquirer’s equity instruments; otherwise, it is recognized in liabilities related to business combinations. Contingent consideration is recognized at fair value at the acquisition date irrespective of the probability of payment. If the contingent consideration was originally recognized as a financial liability, subsequent adjustments to the liability are recognized in profit or loss in the line item</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Fair value remeasurement of contingent consideration</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, unless the adjustment is made within the 12 months following the acquisition date and relates to facts and circumstances existing as of that date;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">goodwill may be calculated on the basis of either (i) the entire fair value of the acquiree, or (ii) a share of the fair value of the acquiree proportionate to the interest acquired. This option is elected for each acquisition individually.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Purchase price allocations are performed under the responsibility of management, with assistance from an independent valuer in the case of major acquisitions. IFRS 3 does not specify an accounting treatment for contingent consideration arising from a business combination made by an entity prior to the acquisition of control in that entity and carried as a liability in the acquired entity’s balance sheet. The accounting treatment applied by Sanofi to such a liability is to measure it at fair value as of the acquisition date and to report it in the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, with subsequent remeasurements recognized in profit or loss. This treatment is consistent with the accounting applied to contingent consideration in the books of the acquirer.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, management may where it deems fit elect to apply the optional test to identify concentration of fair value permitted under IFRS 3 in order to determine whether a transaction is a business combination within the meaning of IFRS 3, or merely the acquisition of an asset or of a group of similar assets.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.3.2. Goodwill</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The excess of the cost of an acquisition over Sanofi’s interest in the fair value of the identifiable assets and liabilities of the acquiree is recognized as goodwill at the date of the business combination. Goodwill arising on the acquisition of subsidiaries is shown in a separate balance sheet line item, whereas goodwill arising on the acquisition of investments accounted for using the equity method is recorded in</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Investments accounted for using the equity method.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill arising on foreign operations is expressed in the functional currency of the country concerned and translated into euros using the exchange rate prevailing at the end of the reporting period.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS 36 (Impairment of Assets), goodwill is carried at cost less accumulated impairment (see Note B.6.).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill is tested for impairment annually and whenever events or circumstances indicate that impairment might exist. Such events or circumstances include significant changes more likely than not to have an other-than-temporary impact on the substance of the original investment.</span></div>Other intangible assets<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other intangible assets are initially measured at acquisition cost or production cost, including any directly attributable costs of preparing the asset for its intended use, or (in the case of assets acquired in a business combination) at fair value as of the date of the business combination. Intangible assets are amortized on a straight line basis over their useful lives.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The useful lives of other intangible assets are reviewed at the end of each reporting period. The effect of any adjustment to useful lives is recognized prospectively as a change in accounting estimate.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amortization of other intangible assets is recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Amortization of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> except for amortization charged against (i) acquired or internally-developed software and (ii) other rights of an industrial or operational nature, which is recognized in the relevant classification of expense by function.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi does not own any intangible assets with an indefinite useful life, other than goodwill.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Intangible assets (other than goodwill) are carried at cost less accumulated amortization and accumulated impairment, if any, in accordance with IAS 36 (see Note B.6.).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.4.1. Research and development not acquired in a business combination</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Internally generated research and development</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IAS 38, research expenses are recognized in profit or loss when incurred.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Internally generated development expenses are recognized as an intangible asset if, and only if, all the following six criteria can be demonstrated: (a) the technical feasibility of completing the development project; (b) Sanofi’s intention to complete the project; (c) Sanofi’s ability to use the project; (d) the probability that the project will generate future economic benefits; (e) the availability of adequate technical, financial and other resources to complete the project; and (f) the ability to measure the development expenditure reliably.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Due to the risks and uncertainties relating to regulatory approval and to the research and development process, the six criteria for capitalization are usually considered not to have been met until the product has obtained marketing approval from the regulatory authorities. Consequently, internally generated development expenses arising before marketing approval has been obtained, mainly the cost of clinical trials, are generally expensed as incurred within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Some industrial development expenses (such as those incurred in developing a second-generation synthesis process) are incurred after marketing approval has been obtained, in order to improve the industrial process for an active ingredient. To the extent that the six IAS 38 criteria are considered as having been met, such expenses are recognized as an asset in the balance sheet within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> as incurred. Similarly, some clinical trials, for example those undertaken to obtain a geographical extension for a molecule that has already obtained marketing approval in a major market, may in certain circumstances meet the six capitalization criteria under IAS 38, in which case the related expenses are recognized as an asset in the balance sheet within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separately acquired research and development</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Payments for separately acquired research and development are capitalized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> provided that they meet the definition of an intangible asset: a resource that is (i) controlled by Sanofi, (ii) expected to provide future economic benefits for Sanofi, and (iii) identifiable (i.e. it is either separable or arises from contractual or legal rights). Under paragraph 25 of IAS 38, the first condition for capitalization (the probability that the expected future economic benefits from the asset will flow to the entity) is considered to be satisfied for separately acquired research and development. Consequently, upfront and milestone payments to third parties related to pharmaceutical products for which marketing approval has not yet been obtained are recognized as intangible assets, and amortized on a straight line basis over their useful lives beginning when marketing approval is obtained.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Payments under research and development arrangements relating to access to technology or to databases, and payments made to purchase generics dossiers, are also capitalized, and amortized over the useful life of the intangible asset.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subcontracting arrangements, payments for research and development services, and continuous payments under research and development collaborations which are unrelated to the outcome of that collaboration, are expensed over the service term.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.4.2. Other intangible assets not acquired in a business combination</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Licenses other than those related to pharmaceutical products and research projects, in particular software licenses, are capitalized at acquisition cost, including any directly attributable cost of preparing the software for its intended use. Software licenses are amortized on a straight line basis over their useful lives for Sanofi (<span style="-sec-ix-hidden:f-646">three</span> to five years).</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Internally generated costs incurred to develop or upgrade software are capitalized if the IAS 38 recognition criteria are satisfied, and amortized on a straight line basis over the useful life of the software from the date on which the software is ready for use.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.4.3. Other intangible assets acquired in a business combination</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other intangible assets acquired in a business combination (in-process research and development, technology platforms, and currently marketed products) that are reliably measurable are identified separately from goodwill, measured at fair value, and capitalized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with IFRS 3 (Business Combinations) and IAS 38 (Intangible Assets). The related deferred tax liability is also recognized if a deductible or taxable temporary difference exists.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In-process research and development acquired in a business combination is amortized on a straight line basis over its useful life from the date of receipt of marketing approval.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Rights to technology platforms and to products currently marketed by Sanofi are amortized on a straight line basis over their useful lives, determined (in particular for marketed products) on the basis of cash flow forecasts which take into account the patent protection period of the marketed product.</span></div>Property, plant and equipment owned and leased<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.5.1. Property, plant and equipment owned</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Property, plant and equipment is initially measured and recognized at acquisition cost, including any directly attributable cost of preparing the asset for its intended use, or (in the case of assets acquired in a business combination) at fair value as of the date of the business combination. The component-based approach to accounting for property, plant and equipment is applied. Under this approach, each component of an item of property, plant and equipment with a cost which is significant in relation to the total cost of the item and which has a different useful life from the other components must be depreciated separately.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">After initial measurement, property, plant and equipment is carried at cost less accumulated depreciation and impairment, except for land which is carried at cost less impairment.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subsequent costs are not recognized as assets unless (i) it is probable that future economic benefits associated with those costs will flow to Sanofi and (ii) the costs can be measured reliably.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Borrowing costs attributable to the financing of items of property, plant and equipment, and incurred during the construction period, are capitalized as part of the acquisition cost of the item.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Government grants relating to property, plant and equipment are deducted from the acquisition cost of the asset to which they relate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The depreciable amount of items of property, plant and equipment, net of any residual value, is depreciated on a straight line basis over the useful life of the asset. The useful life of an asset is usually equivalent to its economic life.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The customary useful lives of property, plant and equipment are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:49.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.671%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15 to 40 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 to 20 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 to 15 years</span></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 to 15 years</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Useful lives and residual values of property, plant and equipment are reviewed annually. The effect of any adjustment to useful lives or residual values is recognized prospectively as a change in accounting estimate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Depreciation of property, plant and equipment is recognized as an expense in the income statement, in the relevant classification of expense by function.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.5.2. Property, plant and equipment leased</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Effective from January 1, 2019 leases contracted by Sanofi have been accounted for in accordance with IFRS 16 (Leases). Sanofi recognizes a right-of-use asset and a lease liability for all of its lease contracts, except for (i) leases relating to low-value assets and (ii) short-term leases (12 months or less). Payments made in respect of leases not recognized on the balance sheet are recognized as an operating expense on a straight line basis over the lease term.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On commencement of a lease, the liability for future lease payments is discounted at the incremental borrowing rate, which is a risk-free rate adjusted to reflect the specific risk profile of each Sanofi entity. Because lease payments are spread over the lease term, Sanofi applies a discount rate based on the duration of those payments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The payments used to determine the liability for future lease payments exclude non-lease components, but include fixed payments that Sanofi expects to make to the lessor over the estimated lease term.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">After commencement of the lease, the liability for future lease payments is reduced by the amount of the lease payments made, and increased to reflect interest on the liability. In the event of a reassessment or modification of future lease payments, the lease liability is remeasured. The right-of-use asset – which is initially measured at cost including direct costs of the lessee, prepayments made at or prior to the commencement date, less lease incentives received and restoration costs – is depreciated on a straight line basis over the lease term, and tested for impairment as required.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi recognizes deferred taxes in respect of right-of-use assets and lease liabilities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Leasehold improvements are depreciated over their economic life, which is capped at the lease term as determined under IFRS 16.</span></div>Impairment of property, plant and equipment, intangible assets, and investments accounted for using the equity method<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.6.1. Impairment of property, plant and equipment and intangible assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS 36 (Impairment of Assets), assets that generate separate cash flows and assets included in cash-generating units (CGUs) are assessed for impairment when events or changes in circumstances indicate that the asset or CGU may be impaired. A CGU is the smallest identifiable group of assets that generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IAS 36, each CGU or group of CGUs to which goodwill is allocated must (i) represent the lowest level within the entity at which the goodwill is monitored for internal management purposes, and (ii) not be larger than an operating segment determined in accordance with IFRS 8 (Operating Segments), before application of the IFRS 8 aggregation criteria (see Note B.26.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Quantitative and qualitative indications of impairment (primarily relating to the status of the research and development portfolio, pharmacovigilance, patent litigation, and the launch of competing products) are reviewed at the end of each reporting period. If there is any internal or external indication of impairment, Sanofi estimates the recoverable amount of the asset or CGU.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other intangible assets not yet available for use (such as capitalized in-process research and development), and CGUs or groups of CGUs that include goodwill, are tested for impairment annually whether or not there is any indication of impairment, and more frequently if any event or circumstance indicates that they might be impaired. Such assets are not amortized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When there is an internal or external indication of impairment, Sanofi estimates the recoverable amount of the asset and recognizes an impairment loss if the carrying amount of the asset exceeds its recoverable amount. The recoverable amount of the asset is the higher of its fair value less costs to sell or its value in use. To determine value in use, Sanofi uses estimates of future cash flows generated by the asset or CGU, prepared using the same methods as those used in the initial measurement of the asset or CGU on the basis of medium-term strategic plans.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of goodwill, estimates of future cash flows are based on a six-year strategic plan and a terminal value. In the case of other intrangible assets, the period used is based on the economic life of the asset.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Estimated cash flows are discounted at long-term market interest rates that reflect the best estimate by Sanofi of the time value of money, the risks specific to the asset or CGU, and economic conditions in the geographical regions in which the business activity associated with the asset or CGU is located.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Certain assets and liabilities that are not directly attributable to a specific CGU are allocated between CGUs on a basis that is reasonable, and consistent with the allocation of the corresponding goodwill.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Impairment losses arising on property, plant and equipment, software and certain rights, are recognized within the appropriate income statement line item according to the origin of the impairment.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Impairment losses arising on other intangible assets (products, trademarks, technology platforms, acquired R&D) are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Impairment of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.6.2. Impairment of investments accounted for using the equity method</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS 28 (Investments in Associates and Joint Ventures), Sanofi determines whether investments accounted for using the equity method may be impaired based on indicators such as default in contractual payments, significant financial difficulties, probability of bankruptcy, or a prolonged or significant decline in quoted market price. If an investment is impaired, the amount of the impairment loss is determined by applying IAS 36 (see Note B.6.1.) and recognized in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Share of profit/(loss) from investments accounted for using the equity method.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.6.3. Reversals of impairment losses charged against property, plant and equipment, intangible assets, and investments accounted for using the equity method</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">At the end of each reporting period, Sanofi assesses whether events or changes in circumstances indicate that an impairment loss recognized in a prior period in respect of an asset (other than goodwill) or an investment accounted for using the equity method can be reversed. If this is the case, and the recoverable amount as determined based on the revised estimates exceeds the carrying amount of the asset, Sanofi reverses the impairment loss only to the extent of the carrying amount that would have been determined had no impairment loss been recognized for the asset.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Reversals of impairment losses in respect of other intangible assets are recognized within the income statement line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Impairment of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, while reversals of impairment losses in respect of investments accounted for using the equity method are recognized within the income statement line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Share of profit/(loss) from investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Impairment losses taken against goodwill are never reversed, unless the goodwill is part of the carrying amount of an investment accounted for using the equity method.</span></div>Assets held for sale or exchange and liabilities related to assets held for sale or exchange<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations), non-current assets and groups of assets are classified as held for sale in the balance sheet if their carrying amount will be recovered principally through a sale transaction rather than through continuing use. Within the meaning of IFRS 5, the term “sale” also includes exchanges for other assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Non-current assets or asset groups held for sale must be available for immediate sale in their present condition, subject only to terms that are usual and customary for sales of such assets, and a sale must be highly probable. Criteria used to determine whether a sale is highly probable include:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the appropriate level of management must be committed to a plan to sell;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">an active program to locate a buyer and complete the plan must have been initiated;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the asset must be actively marketed for sale at a price that is reasonable in relation to its current fair value;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">completion of the sale should be foreseeable within the 12 months following the date of reclassification to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">actions required to complete the plan should indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Before initial reclassification of the non-current asset (or asset group) to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, the carrying amounts of the asset (or of all the assets and liabilities in the asset group) must be measured in accordance with the applicable standards.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subsequent to reclassification to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, the non-current asset (or asset group) is measured at the lower of carrying amount or fair value less costs to sell, with any write-down recognized by means of an impairment loss. Once a non-current asset has been reclassified as held for sale or exchange, it is no longer depreciated or amortized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In a disposal of an equity interest leading to loss of control, all the assets and liabilities of the entity involved are classified as held-for-sale assets or liabilities within the balance sheet line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">or</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Liabilities related to assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, provided that the disposal satisfies the IFRS 5 classification criteria.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The profit or loss generated by a held-for-sale asset group is reported in a separate line item in the income statement for the current period and for the comparative periods presented, provided that the asset group:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">represents a separate major line of business or geographical area of operations; or</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">is part of a single coordinated plan to dispose of a separate major line of business or geographical area of operations; or</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">is a subsidiary acquired exclusively with a view to resale.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 10, transactions between companies that are held for sale or treated as discontinued operations and other consolidated companies are eliminated.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Events or circumstances beyond Sanofi’s control may extend the period to complete the sale or exchange beyond one year without precluding classification of the asset (or disposal group) in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> provided that there is sufficient evidence that Sanofi remains committed to the planned sale or exchange. Finally, in the event of changes to a plan of sale that requires an asset no longer to be classified as held for sale, IFRS 5 specifies the following treatment:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the assets and liabilities previously classified as held for sale are reclassified to the appropriate balance sheet line items, with no restatement of comparative periods;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">each asset is measured at the lower of (a) its carrying amount before the asset was reclassified as held for sale, adjusted for any depreciation, amortization or revaluation that would have been recognized if the asset had not been reclassified as held for sale, or (b) its recoverable amount at the date of reclassification;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the backlog of depreciation, amortization and impairment not recognized while non-current assets were classified as held for sale must be reported in the same income statement line item that was used to report impairment losses arising on initial reclassification of assets as held for sale and gains or losses arising on the sale of such assets. In the consolidated income statement, those impacts are reported within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the net income of a business previously classified as discontinued or as held for sale or exchange and reported on a separate line in the income statement must be reclassified and included in net income from continuing operations, for all periods presented;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">in addition, segment information relating to the income statement and the statement of cash flows (acquisitions of non-current assets) must be disclosed in the notes to the financial statements in accordance with IFRS 8 (Operating Segments), and must also be restated for all prior periods presented.</span></div>Financial instruments<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.1. Non-derivative financial assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 9 (Financial Instruments) and IAS 32 (Financial Instruments: Presentation), Sanofi has adopted the classification of non-derivative financial assets described below. The classification used depends on (i) the characteristics of the contractual cash flows (i.e. whether they represent interest or principal) and (ii) the business model for managing the asset applied at the time of initial recognition.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial assets at fair value through other comprehensive income</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These mainly comprise:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">quoted and unquoted equity investments that Sanofi does not hold for trading purposes and that management has designated at “fair value through other comprehensive income” on initial recognition. Gains and losses arising from changes in fair value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such instruments are derecognized, the previously-recognized changes in fair value remain within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, as does the gain or loss on divestment. Dividends received are recognized in profit or loss for the period, within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">debt instruments whose contractual cash flows represent payments of interest or repayments of principal, and which are managed with a view to collecting cash flows and selling the asset. Gains and losses arising from changes in fair value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such assets are derecognized, the cumulative gains and losses previously recognized in equity are reclassified to profit or loss for the period within the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial assets at fair value through profit or loss</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These mainly comprise:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">contingent consideration already carried in the books of an acquired entity or granted in connection with a business combination;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">instruments whose contractual cash flows represent payments of interest and repayments of principal, which are managed with a view to selling the asset;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">instruments that management has designated at “fair value through profit or loss” on initial recognition; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">quoted and unquoted equity investments: equity instruments that are not held for trading and which management did not designate at “fair value through other comprehensive income” on initial recognition, and instruments that do not meet the IFRS definition of “equity instruments”.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Gains and losses arising from changes in fair value are recognized in profit or loss within the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Dividends received are recognized in profit or loss for the period, within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of equity investments in unquoted entities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On initial recognition of an equity investment in an entity not quoted in an active market, the fair value of the investment is the acquisition cost. Cost ceases to be a representative measure of the fair value of an unquoted equity investment when Sanofi identifies significant changes in the investee, or in the environment in which it operates. In such cases, an internal valuation is carried out, based mainly on growth forecasts or by reference to similar transactions contracted with third parties.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial assets measured at amortized cost</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Financial assets at amortized cost comprise instruments whose contractual cash flows represent payments of interest and repayments of principal and which are managed with a view to collecting cash flows. The main assets in this category are loans and receivables. They are presented within the line items</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other non-current assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Accounts receivable </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Cash and cash equivalents</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Loans with a maturity of more than 12 months are presented in “Long-term loans and advances” within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other non-current assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. These financial assets are measured at amortized cost using the effective interest method.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of financial assets measured at amortized cost</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The main assets involved are accounts receivable. Accounts receivable are initially recognized at the amount invoiced to the customer. Impairment losses on trade accounts receivable are estimated using the expected loss method, in order to take account of the risk of payment default throughout the lifetime of the receivables. The expected credit loss is estimated collectively for all accounts receivable at each reporting date using an average expected loss rate, determined primarily on the basis of historical credit loss rates. However, that average expected loss rate may be adjusted if there are indications of a likely significant increase in credit risk. If a receivable is subject to a known credit risk, a specific impairment loss is recognized for that receivable. The amount of expected losses is recognized in the balance sheet as a reduction in the gross amount of accounts receivable. Impairment losses on accounts receivable are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Selling and general expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.2. Derivative instruments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Derivative instruments that do not qualify for hedge accounting are initially and subsequently measured at fair value, with changes in fair value recognized in the income statement in</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, depending on the nature of the underlying economic item which is hedged.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Derivative instruments that qualify for hedge accounting are measured using the policies described in Note B.8.3. below.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">IFRS 13 (Fair Value Measurement) requires counterparty credit risk to be taken into account when measuring the fair value of financial instruments. That risk is estimated on the basis of observable, publicly-available statistical data.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Policy on offsetting</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In order for a financial asset and a financial liability to be presented as a net amount in the balance sheet under IAS 32, there must be:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(a) a legally enforceable right to offset; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(b) the intention either to settle on a net basis, or to realize the asset and settle the liability simultaneously.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.3. Hedging</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As part of its overall market risk management policy, Sanofi enters into various hedging transactions involving derivative or non-derivative instruments; these may include forward contracts, currency swaps or options, interest rate swaps or options, cross-currency swaps, and debt placings or issues.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Such financial instruments are designated as hedging instruments and recognized using the hedge accounting principles of IFRS 9 when (a) there is formal designation and documentation of the hedging relationship, of how the effectiveness of the hedging relationship will be assessed, and of the underlying market risk management objective and strategy; (b) the hedged item and the hedging instrument are eligible for hedge accounting; and (c) there is an economic relationship between the hedged item and the hedging instrument, defined on the basis of a hedge ratio that is consistent with the underlying market risk management strategy, and the residual credit risk does not dominate the value changes that result from that economic relationship.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value hedge</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A fair value hedge is a hedge of the exposure to changes in fair value of an asset, liability or firm commitment that is attributable to one or more risk components and could affect profit or loss.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in fair value of the hedging instrument and changes in fair value of the hedged item attributable to the hedged risk components are generally recognized in the income statement, within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to operating activities, or within</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to investing or financing activities.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash flow hedge</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A cash flow hedge is a hedge of the exposure to variability in cash flows from an asset, liability or highly probable forecast transaction that is attributable to one or more risk components and could affect profit or loss.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in fair value of the hedging instrument attributable to the effective portion of the hedge are recognized directly in equity in the consolidated statement of comprehensive income. Changes in fair value attributable to the ineffective portion of the hedge are recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">for hedges related to operating activities, and within</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to investing or financing activities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Cumulative changes in fair value of the hedging instrument previously recognized in equity are reclassified to the income statement when the hedged transaction affects profit or loss. Those reclassified gains and losses are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to operating activities, and within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to investing or financing activities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When a forecast transaction results in the recognition of a non-financial asset or liability, cumulative changes in the fair value of the hedging instrument previously recognized in equity are incorporated in the initial carrying amount of that asset or liability.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When the hedging instrument expires or is sold, terminated or exercised, the cumulative gain or loss previously recognized in equity remains separately recognized in equity and is not reclassified to the income statement, or recognized as an adjustment to the initial cost of the related non-financial asset or liability, until the forecast transaction occurs. However, if Sanofi no longer expects the forecast transaction to occur, the cumulative gain or loss previously recognized in equity is recognized immediately in profit or loss.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hedge of a net investment in a foreign operation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In a hedge of a net investment in a foreign operation, changes in the fair value of the hedging instrument attributable to the effective portion of the hedge are recognized directly in equity in the consolidated statement of comprehensive income. Changes in fair value attributable to the ineffective portion of the hedge are recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. When the investment in the foreign operation is sold, the changes in the fair value of the hedging instrument previously recognized in equity are reclassified to the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of hedging</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As part of its market risk management policy, Sanofi may designate currency options or interest rate options as hedging instruments, the effectiveness of which is measured on the basis of changes in intrinsic value. In such cases, the time value of the option is treated as a hedging cost and accounted for as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">if the option includes a component that is not aligned on the critical features of the hedged item, the corresponding change in the time value is taken to profit or loss;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">otherwise, the change in the time value is taken to equity within the statement of comprehensive income, and then:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">if the hedged item is linked to a transaction that results in the recognition of a financial asset or liability, the change in the time value is reclassified to profit or loss symmetrically with the hedged item, or</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">if the hedged item is linked to a transaction that results in the recognition of a non-financial asset or liability, the change in the time value is incorporated in the initial carrying amount of that asset or liability, or</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">if the hedged item is linked to a period of time, the change in time value is reclassified to profit or loss on a straight line basis over the life of the hedging relationship.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of forward contracts and foreign exchange swaps, and of cross-currency swaps that qualify for hedge accounting on the basis of changes in spot rates, Sanofi may elect for each transaction to use the option whereby the premium/discount or foreign currency basis spread are treated in the same way as the time value of an option.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discontinuation of hedge accounting</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Hedge accounting is discontinued when the eligibility criteria are no longer met (in particular, when the hedging instrument expires or is sold, terminated or exercised), or if there is a change in the market risk management objective of the hedging relationship.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.4. Non-derivative financial liabilities</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Borrowings and debt</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Bank borrowings and debt instruments are initially measured at fair value of the consideration received, net of directly attributable transaction costs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subsequently, they are measured at amortized cost using the effective interest method. All costs related to the issuance of borrowings or debt instruments, and all differences between the issue proceeds net of transaction costs and the value on redemption, are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement over the term of the debt using the effective interest method.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These line items record the fair value of (i) contingent consideration payable in connection with business combinations and (ii) commitments to buy out equity holders of subsidiaries, including put options granted to non-controlling interests.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Adjustments to the fair value of commitments to buy out equity holders of subsidiaries, including put options granted to non-controlling interests, are recognized in equity.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other non-derivative financial liabilities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other non-derivative financial liabilities include trade accounts payable, which are measured at fair value (which in most cases equates to face value) on initial recognition, and subsequently at amortized cost.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.5. Fair value of financial instruments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IFRS 13 (Fair Value Measurement) and IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.69pt">level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.08pt">level 2: quoted prices in active markets for similar assets and liabilities, or valuation techniques in which all important inputs are derived from observable market data; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.61pt">level 3: valuation techniques in which not all important inputs are derived from observable market data.</span></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:5.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.362%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Type of financial instrument</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Measurement<br/>principle</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in<br/>fair value<br/>hierarchy</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation<br/>technique</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Method used to determine fair value</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation<br/>model</span></td><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market data</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exchange rate</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest<br/>rate</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted equity instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted debt instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (unquoted equity instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cost/Approach based on comparables</span></div></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">If cost ceases to be a representative measure of fair value, an internal valuation is carried out, based mainly on comparables.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (contingent consideration receivable)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value held to meet obligations under <br/>post-employment benefit plans</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets designated at fair value held to meet obligations under deferred compensation plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.13.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Investments in mutual funds</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Net asset value</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.13.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Negotiable debt instruments, commercial paper, instant access deposits and term deposits</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Because these instruments have a maturity of less than three months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.17.1., D.19.</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">In the case of debt with a maturity of less than three months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">For debt with a maturity of more than three months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.17.2.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The liability for future lease payments is discounted using the incremental borrowing rate.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">< 1 year:</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Money Market</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">> 1 year: </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Zero Coupon</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market<br/>Spot</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">< 1 year:</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Money Market and LIFFE interest rate futures</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">> 1 year: </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Zero Coupon</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market<br/>Spot</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">< 1 year:<br/>Mid Money Market and LIFFE interest rate futures<br/>> 1 year: <br/>Mid Zero Coupon</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.18.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests (CVRs)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.18.</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests (other than CVRs)</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3 </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.8.4.</span></div></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.6. Derecognition of financial instruments</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Financial assets are derecognized when the contractual rights to cash flows from the asset have ended or have been transferred and when Sanofi has transferred substantially all the risks and rewards of ownership of the asset. If Sanofi has neither transferred nor retained substantially all the risks and rewards of ownership of a financial asset, it is derecognized if Sanofi does not retain control of the asset.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A financial liability is derecognized when Sanofi’s contractual obligations in respect of the liability are discharged, cancelled or extinguished.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.7. Risks relating to financial instruments</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Market risks in respect of non-current financial assets, cash equivalents, derivative instruments and debt are described in the discussions of risk factors presented in Item 3.D. and Item 11. of Sanofi’s annual report on Form 20-F for 2023.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Credit risk is the risk that customers may fail to pay their debts. For a description of credit risk, refer to “We are subject to the risk of non-payment by our customers” within Item 3.D. and Item 11. of Sanofi’s annual report on Form 20-F for 2023.</span></div>Inventories<div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Inventories are measured at the lower of cost or net realizable value. Cost is calculated using the weighted average cost method or the first-in, first-out method, depending on the nature of the inventory.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The cost of finished goods inventories includes costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the launch phase of a new product, any inventories of that product are written down to zero pending regulatory approval, other than in specific circumstances which make it possible to estimate that there is a high probability at the end of the reporting period that the carrying amount of the inventories will be recoverable. The write-down is reversed once it becomes highly probable that marketing approval will be obtained.</span></div>Cash and cash equivalents<div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Cash and cash equivalents as shown in the consolidated balance sheet and statement of cash flows comprise cash, plus liquid short-term investments that are readily convertible into cash and are subject to an insignificant risk of changes in value in the event of movements in interest rates.</span></div>Treasury shares<div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS 32, Sanofi treasury shares are deducted from equity, irrespective of the purpose for which they are held. No gain or loss is recognized in the income statement on the purchase, sale, impairment or cancellation of treasury shares.</span></div>Provisions for risks<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS 37 (Provisions, Contingent Liabilities and Contingent Assets), Sanofi records a provision when it has a present obligation, whether legal or constructive, as a result of a past event; it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and a reliable estimate can be made of the amount of the outflow of resources.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If the obligation is expected to be settled more than 12 months after the end of the reporting period, or has no definite settlement date, the provision is recorded within Non-current provisions and other non-current liabilities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Provisions relating to the insurance programs in which Sanofi’s captive insurance company participates are based on risk exposure estimates calculated by management, with assistance from independent actuaries, using IBNR (Incurred But Not Reported) techniques. Those techniques use past claims experience, within Sanofi and in the market, to estimate future trends in the cost of claims.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Contingent liabilities are not recognized, but are disclosed in the notes to the financial statements unless the possibility of an outflow of economic resources is remote.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi estimates provisions on the basis of events and circumstances related to present obligations at the end of the reporting period and of past experience, and to the best of management’s knowledge at the date of preparation of the financial statements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Reimbursements offsetting the probable outflow of resources are recognized as assets only if it is virtually certain that they will be received. Contingent assets are not recognized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restructuring provisions are recognized if Sanofi has a detailed, formal restructuring plan at the end of the reporting period and has announced its intention to implement this plan to those affected by it.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No provisions are recorded for future operating losses.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi records non-current provisions for certain obligations, such as legal or constructive obligations, where an outflow of resources is probable and the amount of the outflow can be reliably estimated.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of environmental risks, including at sites where operations are ongoing, Sanofi recognizes a provision where there is a violation of integrity in respect of human health or the environment resulting from past contamination at a site that requires remediation. The amount of the provision is a best estimate of the future expenditures to be incurred on the remediation plan.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Where the effect of the time value of money is material, those provisions are measured at the present value of the expenditures expected to be required to settle the obligation, calculated using a discount rate that reflects an estimate of the time value of money and the risks specific to the obligation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Increases in provisions to reflect the effects of the passage of time are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div>Revenue recognition<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.13.1. Net sales</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Revenue arising from the sale of goods is presented in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net sales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Net sales comprise revenue from sales of pharmaceutical products, consumer healthcare products, active ingredients and vaccines, net of sales returns, of customer incentives and discounts, and of certain sales-based payments paid or payable to the healthcare authorities. Analyses of net sales are provided in Note D.35.1. “Segment Information”.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 15 (Revenue from Contracts with Customers), such revenue is recognized when Sanofi transfers control over the product to the customer; control of an asset refers to the ability to direct the use of, and obtain substantially all of the remaining benefits from that asset. For the vast majority of contracts, revenue is recognized when the product is physically transferred, in accordance with the delivery and acceptance terms agreed with the customer.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For contracts entered into by Sanofi Pasteur, transfer of control is usually determined by reference to the terms of release (immediate or deferred) and acceptance of batches of vaccine.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of contracts with distributors, Sanofi does not recognize revenue when the product is physically transferred to the distributor if the products are sold on consignment, or if the distributor acts as agent. In such cases, revenue is recognized when control is transferred to the end customer, and the distributor’s commission is presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Selling and general expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The amount of revenue recognized reflects the various types of price reductions or rights of return offered by Sanofi to its customers on certain products. Such price reductions and rights of return qualify as variable consideration under IFRS 15.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In particular, products sold in the United States are covered by various Government and State programs (such as Medicare and Medicaid) under which products are sold at a discount. Rebates are granted to healthcare authorities, and under contractual arrangements with certain customers. Some wholesalers are entitled to chargeback incentives based on the selling price to the end customer, under specific contractual arrangements. Cash discounts may also be granted for prompt payment. Returns, discounts, incentives and rebates, as described above, are recognized in the period in which the underlying sales are recognized as a reduction of gross sales.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These amounts are calculated as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of chargeback incentives is estimated on the basis of the relevant subsidiary’s standard sales terms and conditions, and in certain cases on the basis of specific contractual arrangements with the customer;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of rebates based on attainment of sales targets is estimated and accrued as each of the underlying sales transactions is recognized;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of price reductions under Government and State programs, largely in the United States, is estimated on the basis of the specific terms of the relevant regulations or agreements, and accrued as each of the underlying sales transactions is recognized;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of sales returns is calculated on the basis of management’s best estimate of the amount of product that will ultimately be returned by customers. In countries where product returns are possible, Sanofi operates a returns policy that allows the customer to return products within a certain period either side of the expiry date (usually 12 months after the expiry date). The amount recognized for returns is estimated on the basis of past experience of sales returns. Sanofi also takes into account factors such as levels of inventory in its various distribution channels, product expiry dates, information about potential discontinuation of products, the entry of competing generics into the market, and the launch of over-the-counter medicines. Most product return clauses relate solely to date-expired products, which cannot be resold and are destroyed. Sanofi does not recognize a right of return asset in the balance sheet for contracts that allow for the return of time-expired products, since those products have no value.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The estimated amounts described above are recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net sales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">as a reduction of gross sales, and within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the balance sheet. They are subject to regular review and adjustment as appropriate based on the most recent data available to management. Sanofi believes that it has the ability to measure each of the above amounts reliably, using the following factors in developing its estimates:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the nature and patient profile of the underlying product;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the applicable regulations or the specific terms and conditions of contracts with governmental authorities, wholesalers and other customers;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">historical data relating to similar contracts, in the case of qualitative and quantitative rebates and chargeback incentives;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">past experience and sales growth trends for the same or similar products;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">actual inventory levels in distribution channels, monitored by Sanofi using internal sales data and externally provided data;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the shelf life of Sanofi products; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">market trends including competition, pricing and demand.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of provisions for discounts, rebates and sales returns is provided in Note D.23.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.13.2. Other revenues</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is used to recognize all revenue that falls within the scope of IFRS 15 but does not relate to sales of Sanofi products.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It mainly comprises (i) royalties received from licensing intellectual property rights to third parties; (ii) VaxServe sales of products sourced from third-party manufacturers; and (iii) revenue received under agreements for Sanofi to provide manufacturing services to third parties.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Royalties received under licensing arrangements are recognized over the period during which the underlying sales are recognized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">VaxServe is a Vaccines segment entity whose operations include the distribution within the United States of vaccines and other products manufactured by third parties. VaxServe sales of products sourced from third-party manufacturers are presented within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div>Cost of sales<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> consists primarily of the industrial cost of goods sold, payments made under licensing agreements, and distribution costs. The industrial cost of goods sold includes the cost of materials, depreciation of property, plant and equipment, amortization of software, personnel costs, and other expenses attributable to production.</span></div>Research and development<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Note B.4.1. “Research and development not acquired in a business combination” and Note B.4.3. “Other intangible assets acquired in a business combination” describe the principles applied to the recognition of research and development costs.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Contributions or reimbursements received from alliance partners are recorded as a reduction of </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div>Other operating income and expenses<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.16.1. Other operating income</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> includes the share of profits that Sanofi is entitled to receive from alliance partners in respect of product marketing agreements. It also includes revenues generated under certain agreements, which may include partnership, co-promotion arrangements and licenses not included in Other revenues.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This line item also includes realized and unrealized foreign exchange gains and losses on operating activities (see Note B.8.3.), and operating gains on disposals not regarded as major disposals (see Note B.20.).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.16.2. Other operating expenses</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> mainly comprise the share of profits that alliance partners are entitled to receive from Sanofi under product marketing agreements.</span></div>Amortization and impairment of intangible assets<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.17.1. Amortization of intangible assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The expenses recorded in this line item comprise amortization charged against intangible assets (products, trademarks and technology platforms, see Note D.4.) whose contribution to Sanofi’s commercial, industrial and development functions cannot be separately identified.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amortization of software, and of other rights of an industrial or operational nature, is recognized as an expense in the income statement, in the relevant line items of expense by function.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.17.2. Impairment of intangible assets</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This line item records impairment losses taken against intangible assets (products, trademarks, technology platforms and acquired research), and any reversals of such impairment losses.</span></div>Fair value remeasurement of contingent consideration<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in the fair value of contingent consideration that was (i) already carried in the books of an acquired entity, or (ii) granted in connection with a business combination and initially recognized as a liability in accordance with IFRS 3, are reported in profit or loss. Such adjustments are reported separately in the income statement, in the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Fair value remeasurement of contingent consideration</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This line item also includes changes in the fair value of contingent consideration receivable in connection with a divestment and classified as a financial asset at fair value through profit or loss.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, it includes the effect of the unwinding of discount, and of exchange rate movements where the asset or liability is expressed in a currency other than the functional currency of the reporting entity.</span></div>Restructuring costs and similar items<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restructuring costs are expenses incurred in connection with the transformation or reorganization of Sanofi’s operations or support functions. Such costs include collective redundancy plans, compensation to third parties for early termination of contracts, and commitments made in connection with transformation or reorganization decisions. They also include accelerated depreciation charges arising from site closures (including closures of leased sites), and losses on asset disposals resulting from such decisions.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, this line item includes expenses incurred in connection with programs implemented as part of the transformation strategy announced in December 2019 (and previously in November 2015), and intended primarily (i) to deliver a global information systems solution, further supported by the implementation from 2021 of Sanofi’s new digital strategy; and (ii) to create a standalone CHC entity and proceed to the proposed separation of the CHC business as announced when the new chapter in the Play to Win strategy was presented in October 2023.</span></div>Other gains and losses, and litigation<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> includes the impact of material transactions of an unusual nature or amount which Sanofi believes it necessary to report separately in the income statement in order to improve the relevance of the financial statements, such as:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">gains and losses on major disposals of property, plant and equipment, of intangible assets, of assets (or groups of assets and liabilities) held for sale, or of a business within the meaning of IFRS 3, other than those considered to be restructuring costs;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">impairment losses and reversals of impairment losses on assets (or groups of assets and liabilities) held for sale, other than those considered to be restructuring costs;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">gains on bargain purchases;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">costs relating to major litigation; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">pre-tax separation costs associated with the process of disinvesting from operations in the event of a major divestment.</span></div>Financial expenses and income<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.21.1. Financial expenses</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> mainly comprise interest charges on debt financing; negative changes in the fair value of certain financial instruments (where changes in fair value are recognized in profit or loss); realized and unrealized foreign exchange losses on financing and investing activities; impairment losses on financial instruments; and any reversals of impairment losses on financial instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> also include expenses arising from the unwinding of discount on long-term provisions, and the net interest cost related to employee benefits. This line item does not include commercial cash discounts, which are deducted from net sales.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.21.2. Financial income</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> includes interest and dividend income; positive changes in the fair value of certain financial instruments (where changes in fair value are recognized in profit or loss); realized and unrealized foreign exchange gains on financing and investing activities; and gains on disposals of financial assets at fair value through profit or loss.</span></div>Income tax expense<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income tax expense </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">includes all current and deferred taxes of consolidated companies.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi accounts for deferred taxes in accordance with IAS 12 (Income Taxes), using the methods described below:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">deferred tax assets and liabilities are recognized on taxable and deductible temporary differences, and on tax loss carry-forwards. Temporary differences are differences between the carrying amount of an asset or liability in the balance sheet and its tax base;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">French business taxes include a value added based component: “CVAE” </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Cotisation sur la Valeur Ajoutée des Entreprises)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Given that CVAE is (i) calculated as the amount by which certain revenues exceed certain expenses and (ii) borne primarily by companies that own intellectual property rights on income derived from those rights (royalties, and margin on sales to third parties and to Sanofi entities), it is regarded as meeting the definition of income taxes specified in IAS 12, paragraph 2 (“taxes which are based on taxable profits”);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">deferred tax assets and liabilities are calculated using the tax rate expected to apply in the period when the corresponding temporary differences are expected to reverse, based on tax rates enacted or substantively enacted at the end of the reporting period;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">deferred tax assets are recognized in respect of deductible temporary differences, tax losses available for carry-forward and unused tax credits to the extent that future recovery is regarded as probable. The recoverability of deferred tax assets is assessed on a case-by-case basis, taking into account the profit forecasts contained in Sanofi’s medium-term business plan;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a deferred tax liability is recognized for temporary differences relating to interests in subsidiaries, associates and joint ventures, except in cases where Sanofi is able to control the timing of the reversal of the temporary differences. This applies in particular when Sanofi is able to control dividend policy and it is probable that the temporary differences will not reverse in the foreseeable future;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">no deferred tax is recognized on eliminations of intragroup transfers of interests in subsidiaries, associates or joint ventures;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">each tax entity calculates its own net deferred tax position. All net deferred tax asset and liability positions are then aggregated and shown in separate line items on the relevant side of the consolidated balance sheet. Deferred tax assets and liabilities are offset only if (i) Sanofi has a legally enforceable right to offset current tax assets and current tax liabilities, and (ii) the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same taxation authority;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">deferred taxes are not discounted, except implicitly in the case of deferred taxes on assets and liabilities which are already impacted by discounting. In addition, Sanofi has elected not to discount current taxes payable or receivable where the amounts in question are payable or receivable in the long term;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">withholding taxes on intragroup royalties and dividends, and on royalties and dividends collected from third parties, are accounted for as current income taxes.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accounting for business combinations, Sanofi complies with IFRS 3 as regards the recognition of deferred tax assets after the initial accounting period. Consequently, any deferred tax assets recognized by the acquiree after the end of that period in respect of temporary differences or tax loss carry-forwards existing at the acquisition date are recognized in profit or loss.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The positions adopted by Sanofi in tax matters are based on its interpretation of tax laws and regulations. Some of those positions may be subject to uncertainty. In such cases, Sanofi assesses the amount of the tax liability on the basis of the following assumptions: that its position will be examined by one or more tax authorities on the basis of all relevant information; that a technical assessment is carried out with reference to legislation, case law, regulations, and established practice; and that each position is assessed individually (or collectively where appropriate), with no offset or aggregation between positions. Those assumptions are assessed on the basis of facts and circumstances existing at the end of the reporting period. When an uncertain tax liability is regarded as probable, it is measured on the basis of Sanofi’s best estimate and recognized as a liability; uncertain tax assets are not recognized. The amount of the liability includes any penalties and late payment interest. The line item</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Income tax expense</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> includes the effects of tax reassessments and tax disputes, and any penalties and late payment interest arising from such disputes that have the characteristics of income taxes within the meaning of paragraph 2 of IAS 12 (“taxes which are based on taxable profits”). Tax exposures relating to corporate income taxes are presented separately within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Non-current income tax liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (see Note D.19.4.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No deferred taxation is recognized on temporary differences that are liable to be subject to US global intangible low taxed income (GILTI) provisions. The related tax expense is recognized in the year in which it is declared in the tax return to the extent that it arises from the existence of non-US profits that exceed the theoretical return on investment specified in the GILTI provisions and are taxed at a rate lower than the applicable US tax rate.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS 1 (Presentation of Financial Statements), current income tax assets and liabilities are presented as separate line items in the consolidated balance sheet.</span></div>Employee benefit obligations<div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi offers retirement benefits to employees and retirees. Such benefits are accounted for in accordance with IAS 19 (Employee Benefits).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Benefits are provided in the form of either defined contribution plans or defined benefit plans. In the case of defined contribution plans, the cost is recognized immediately in the period in which it is incurred, and equates to the amount of the contributions paid by Sanofi. For defined benefit plans, Sanofi generally recognizes its obligations to pay pensions and similar benefits to employees as a liability, based on an actuarial estimate of the rights vested or currently vesting in employees and retirees, using the projected unit credit method. Estimates are performed at least once a year, and rely on financial assumptions (such as discount </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">rates) and demographic assumptions (such as life expectancy, retirement age, employee turnover, and the rate of salary increases).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Obligations relating to other post-employment benefits (healthcare and life insurance) offered by Sanofi companies to employees are also recognized as a liability based on an actuarial estimate of the rights vested or currently vesting in employees and retirees at the end of the reporting period.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Such liabilities are recognized net of the fair value of plan assets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of multi-employer defined benefit plans where plan assets cannot be allocated to each participating employer with sufficient reliability, the plan is accounted for as a defined contribution plan, in accordance with paragraph 34 of IAS 19.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The benefit cost for the period consists primarily of current service cost, past service cost, net interest cost, gains or losses arising from plan settlements not specified in the terms of the plan, and actuarial gains or losses arising from plan curtailments. Net interest cost for the period is determined by applying the discount rate specified in IAS 19 to the net liability (i.e. the amount of the obligation, net of plan assets) recognized in respect of defined benefit plans. Past service cost is recognized immediately in profit or loss in the period in which it is incurred, regardless of whether or not the rights have vested at the time of adoption (in the case of a new plan) or of amendment (in the case of an existing plan).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actuarial gains and losses on defined benefit plans (pensions and other post-employment benefits), also referred to as “Remeasurements of the net defined benefit liability (asset)”</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> arise as a result of changes in financial and demographic assumptions, experience adjustments, and the difference between the actual return and interest cost on plan assets. The impacts of those remeasurements are recognized in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, net of deferred taxes; they are not subsequently reclassifiable to profit or loss.</span></div>Share-based payment<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Share-based payment expense is recognized as a component of operating income, in the relevant classification of expense by function. In measuring the expense, the level of attainment of any performance conditions is taken into account.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.24.1. Stock option plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has granted a number of equity-settled share-based payment plans (stock option plans) to some of its employees. The terms of those plans may make the award contingent on the attainment of performance criteria for some of the grantees.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 2 (Share-Based Payment), services received from employees as consideration for stock options are recognized as an expense in the income statement, with the opposite entry recognized in equity. The expense corresponds to the fair value of the stock option plans, and is charged to income on a straight-line basis over the four-year vesting period of the plan.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The fair value of stock option plans is measured at the date of grant using the Black-Scholes valuation model, taking into account the expected life of the options. The resulting expense also takes into account the expected cancellation rate of the options. The expense is adjusted over the vesting period to reflect actual cancellation rates resulting from option-holders ceasing to be employed by Sanofi.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.24.2. Employee share ownership plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi may offer its employees the opportunity to subscribe to reserved share issues at a discount to the reference market price. Shares awarded to employees under such plans fall within the scope of IFRS 2. Consequently, an expense is recognized at the subscription date, based on the value of the discount offered to employees.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.24.3. Restricted share plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi may award restricted share plans to certain of its employees. The terms of those plans may make the award contingent on the attainment of performance criteria for some of the grantees.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 2, an expense equivalent to the fair value of such plans is recognized in profit or loss on a straight line basis over the vesting period of the plan, with the opposite entry recognized in equity. The vesting period is three years.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The fair value of restricted share plans is based on the quoted market price of Sanofi shares at the date of grant, adjusted for expected dividends during the vesting period; it also takes account of any vesting conditions contingent on stock market performance, measured using the Monte-Carlo valuation model. Other vesting conditions are taken into account in the estimate of the number of shares awarded during the vesting period; that number is then definitively adjusted based on the actual number of shares awarded on the vesting date.</span></div>Earnings per share<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Basic earnings per share is calculated using the weighted average number of shares outstanding during the reporting period, adjusted on a time-weighted basis from the acquisition date to reflect the number of own shares held by Sanofi. Diluted earnings per share is calculated on the basis of the weighted average number of ordinary shares, computed using the treasury stock method.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This method assumes that (i) all outstanding dilutive options and warrants are exercised, and (ii) Sanofi acquires its own shares at the quoted market price for an amount equivalent to the cash received as consideration for the exercise of the options or warrants, plus the expense arising on unamortized stock options.</span></div>Segment information<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 8 (Operating Segments), the segment information reported by Sanofi is prepared on the basis of internal management data provided to our Chief Executive Officer, who is the chief operating decision maker of Sanofi. The performance of those segments is monitored individually using internal reports and common indicators.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2022, Sanofi reported three operating segments (Pharmaceuticals, Vaccines and Consumer Healthcare). The costs of the global support functions (Corporate Affairs, Finance, People & Culture, Legal, Ethics, Business Integrity & Global Security, Information Solutions & Technology, Sanofi Business Services, etc.), which are mainly managed centrally at group-wide level, were presented within the “Other” category. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, Sanofi reviewed the presentation of its segment information following adjustments to its internal reporting systems in order to reflect (i) progress on the “Play to Win” strategy leading to the creation of the standalone Consumer Healthcare Global Business Unit (GBU) which, in addition to integrated research, development and production functions now also has its own dedicated global support functions (including Finance, People & Culture, Legal, Ethics, Business Integrity & Global Security, Information Solutions & Technology, Global Business Services, etc.); and (ii) organizational changes to Sanofi’s Manufacturing & Supply global function (previously known as Industrial Affairs). </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Consequently, with effect from January 1, 2023, Sanofi reports two operating segments: Biopharma and Consumer Healthcare.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Biopharma operating segment comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines and Vaccines franchises, for all geographical territories. The segment’s results include the costs of global support functions that are not within the managerial responsibility of the Consumer Healthcare GBU.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Consumer Healthcare operating segment comprises commercial operations relating to Consumer Healthcare products, and research, development and production activities and global support functions (as listed above) dedicated to the segment, for all geographical territories. The Consumer Healthcare GBU segment’s results reflect all incurred costs of global support functions attributable to its business.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The “Other” category comprises reconciling items, primarily but not limited to (i) gains and losses on centralized foreign exchange risk hedging transactions that cannot be allocated to the operating segments and (ii) gains and losses on retained commitments in respect of previously divested operations.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Information about operating segments for the years ended December 31, 2023, 2022 and 2021 is presented in Note D.35</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">., </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">“Segment information”.</span></div>Management of capital<div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In order to maintain or adjust the capital structure, Sanofi can adjust the amount of dividends paid to shareholders, repurchase its own shares, issue new shares, or issue securities giving access to its capital.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following objectives are defined under the terms of Sanofi’s share repurchase programs:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the implementation of any stock option plan giving entitlement to purchase shares in the Sanofi parent company;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the allotment or sale of shares to employees under statutory profit sharing schemes and employee savings plans;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the consideration-free allotment of shares (i.e. restricted share plans);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the cancellation of some or all of the repurchased shares;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">market-making in the secondary market by an investment services provider under a liquidity contract in compliance with the ethical code recognized by the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Autorité des marchés financiers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (AMF);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the delivery of shares on the exercise of rights attached to securities giving access to the capital by redemption, conversion, exchange, presentation of a warrant or any other means;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the delivery of shares (in exchange, as payment, or otherwise) in connection with mergers and acquisitions;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the execution by an investment services provider of purchases, sales or transfers by any means, in particular via off-market trading; or</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.1pt">any other purpose that is or may in the future be authorized under the applicable laws and regulations.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is not subject to any constraints on equity capital imposed by third parties.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total equity includes </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Equity attributable to equity holders of Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Equity attributable to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, as shown in the consolidated balance sheet.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi defines “Net debt” as (i) the sum of short-term debt, long-term debt and interest rate derivatives and currency derivatives used to hedge debt, minus (ii) the sum of cash and cash equivalents and interest rate derivatives and currency derivatives used to hedge cash and cash equivalents.</span></div>
CY2023	ifrs-full	Description Of Accounting Policy For Foreign Currency Translation Explanatory DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory	Foreign currency translation<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.2.1. Accounting for foreign currency transactions in the financial statements of consolidated entities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Non-current assets (other than receivables) and inventories acquired in foreign currencies are translated into the functional currency using the exchange rate prevailing at the acquisition date.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the end of the reporting period. The gains and losses resulting from foreign currency translation are recorded in the income statement. However, foreign exchange gains and losses arising from the translation of advances between consolidated subsidiaries for which settlement is neither planned nor likely to occur in the foreseeable future are recognized in equity, in the line item</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Change in currency translation differences.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.2.2. Foreign currency translation of the financial statements of foreign entities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi presents its consolidated financial statements in euros (€). In accordance with IAS 21 (The Effects of Changes in Foreign Exchange Rates), each subsidiary accounts for its transactions in the currency that is most representative of its economic environment (the functional currency).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">All assets and liabilities are translated into euros using the exchange rate of the subsidiary’s functional currency prevailing at the end of the reporting period. Income statements are translated using a weighted average exchange rate for the period, except in the case of foreign subsidiaries in a hyperinflationary economy. The resulting currency translation difference is recognized as a separate component of equity in the consolidated statement of comprehensive income, and is recognized in the income statement only when the subsidiary is sold or is wholly or partially liquidated.</span></div>
CY2023	ifrs-full	Description Of Accounting Policy For Business Combinations And Goodwill Explanatory DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory	Business combinations and transactions with non-controlling interests<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.3.1. Accounting for business combinations, transactions with non-controlling interests and loss of control</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Business combinations are accounted for in accordance with IFRS 3 (Business Combinations) and IFRS 10 (Consolidated Financial Statements).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Business combinations are accounted for using the acquisition method. Under this method, the acquiree’s identifiable assets and liabilities that satisfy the recognition criteria of IFRS 3 (Business Combinations) are measured initially at their fair values at the date of acquisition, except for (i) non-current assets classified as held for sale (which are measured at fair value less costs to sell) and (ii) assets and liabilities that fall within the scope of IAS 12 (Income Taxes) and IAS 19 (Employee Benefits). Restructuring liabilities are recognized as a liability of the acquiree only if the acquiree has an obligation as of the acquisition date to carry out the restructuring.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal accounting rules applicable to business combinations and transactions with non-controlling interests include:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">acquisition-related costs are recognized as an expense, as a component of </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">contingent consideration is recognized in equity if the contingent payment is settled by delivery of a fixed number of the acquirer’s equity instruments; otherwise, it is recognized in liabilities related to business combinations. Contingent consideration is recognized at fair value at the acquisition date irrespective of the probability of payment. If the contingent consideration was originally recognized as a financial liability, subsequent adjustments to the liability are recognized in profit or loss in the line item</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Fair value remeasurement of contingent consideration</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, unless the adjustment is made within the 12 months following the acquisition date and relates to facts and circumstances existing as of that date;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">goodwill may be calculated on the basis of either (i) the entire fair value of the acquiree, or (ii) a share of the fair value of the acquiree proportionate to the interest acquired. This option is elected for each acquisition individually.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Purchase price allocations are performed under the responsibility of management, with assistance from an independent valuer in the case of major acquisitions. IFRS 3 does not specify an accounting treatment for contingent consideration arising from a business combination made by an entity prior to the acquisition of control in that entity and carried as a liability in the acquired entity’s balance sheet. The accounting treatment applied by Sanofi to such a liability is to measure it at fair value as of the acquisition date and to report it in the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, with subsequent remeasurements recognized in profit or loss. This treatment is consistent with the accounting applied to contingent consideration in the books of the acquirer.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, management may where it deems fit elect to apply the optional test to identify concentration of fair value permitted under IFRS 3 in order to determine whether a transaction is a business combination within the meaning of IFRS 3, or merely the acquisition of an asset or of a group of similar assets.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.3.2. Goodwill</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The excess of the cost of an acquisition over Sanofi’s interest in the fair value of the identifiable assets and liabilities of the acquiree is recognized as goodwill at the date of the business combination. Goodwill arising on the acquisition of subsidiaries is shown in a separate balance sheet line item, whereas goodwill arising on the acquisition of investments accounted for using the equity method is recorded in</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Investments accounted for using the equity method.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill arising on foreign operations is expressed in the functional currency of the country concerned and translated into euros using the exchange rate prevailing at the end of the reporting period.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS 36 (Impairment of Assets), goodwill is carried at cost less accumulated impairment (see Note B.6.).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill is tested for impairment annually and whenever events or circumstances indicate that impairment might exist. Such events or circumstances include significant changes more likely than not to have an other-than-temporary impact on the substance of the original investment.</span></div>
CY2023	ifrs-full	Description Of Accounting Policy For Intangible Assets Other Than Goodwill Explanatory DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory	Other intangible assets<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other intangible assets are initially measured at acquisition cost or production cost, including any directly attributable costs of preparing the asset for its intended use, or (in the case of assets acquired in a business combination) at fair value as of the date of the business combination. Intangible assets are amortized on a straight line basis over their useful lives.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The useful lives of other intangible assets are reviewed at the end of each reporting period. The effect of any adjustment to useful lives is recognized prospectively as a change in accounting estimate.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amortization of other intangible assets is recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Amortization of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> except for amortization charged against (i) acquired or internally-developed software and (ii) other rights of an industrial or operational nature, which is recognized in the relevant classification of expense by function.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi does not own any intangible assets with an indefinite useful life, other than goodwill.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Intangible assets (other than goodwill) are carried at cost less accumulated amortization and accumulated impairment, if any, in accordance with IAS 36 (see Note B.6.).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.4.1. Research and development not acquired in a business combination</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Internally generated research and development</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IAS 38, research expenses are recognized in profit or loss when incurred.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Internally generated development expenses are recognized as an intangible asset if, and only if, all the following six criteria can be demonstrated: (a) the technical feasibility of completing the development project; (b) Sanofi’s intention to complete the project; (c) Sanofi’s ability to use the project; (d) the probability that the project will generate future economic benefits; (e) the availability of adequate technical, financial and other resources to complete the project; and (f) the ability to measure the development expenditure reliably.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Due to the risks and uncertainties relating to regulatory approval and to the research and development process, the six criteria for capitalization are usually considered not to have been met until the product has obtained marketing approval from the regulatory authorities. Consequently, internally generated development expenses arising before marketing approval has been obtained, mainly the cost of clinical trials, are generally expensed as incurred within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Some industrial development expenses (such as those incurred in developing a second-generation synthesis process) are incurred after marketing approval has been obtained, in order to improve the industrial process for an active ingredient. To the extent that the six IAS 38 criteria are considered as having been met, such expenses are recognized as an asset in the balance sheet within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> as incurred. Similarly, some clinical trials, for example those undertaken to obtain a geographical extension for a molecule that has already obtained marketing approval in a major market, may in certain circumstances meet the six capitalization criteria under IAS 38, in which case the related expenses are recognized as an asset in the balance sheet within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separately acquired research and development</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Payments for separately acquired research and development are capitalized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> provided that they meet the definition of an intangible asset: a resource that is (i) controlled by Sanofi, (ii) expected to provide future economic benefits for Sanofi, and (iii) identifiable (i.e. it is either separable or arises from contractual or legal rights). Under paragraph 25 of IAS 38, the first condition for capitalization (the probability that the expected future economic benefits from the asset will flow to the entity) is considered to be satisfied for separately acquired research and development. Consequently, upfront and milestone payments to third parties related to pharmaceutical products for which marketing approval has not yet been obtained are recognized as intangible assets, and amortized on a straight line basis over their useful lives beginning when marketing approval is obtained.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Payments under research and development arrangements relating to access to technology or to databases, and payments made to purchase generics dossiers, are also capitalized, and amortized over the useful life of the intangible asset.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subcontracting arrangements, payments for research and development services, and continuous payments under research and development collaborations which are unrelated to the outcome of that collaboration, are expensed over the service term.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.4.2. Other intangible assets not acquired in a business combination</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Licenses other than those related to pharmaceutical products and research projects, in particular software licenses, are capitalized at acquisition cost, including any directly attributable cost of preparing the software for its intended use. Software licenses are amortized on a straight line basis over their useful lives for Sanofi (<span style="-sec-ix-hidden:f-646">three</span> to five years).</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Internally generated costs incurred to develop or upgrade software are capitalized if the IAS 38 recognition criteria are satisfied, and amortized on a straight line basis over the useful life of the software from the date on which the software is ready for use.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.4.3. Other intangible assets acquired in a business combination</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other intangible assets acquired in a business combination (in-process research and development, technology platforms, and currently marketed products) that are reliably measurable are identified separately from goodwill, measured at fair value, and capitalized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with IFRS 3 (Business Combinations) and IAS 38 (Intangible Assets). The related deferred tax liability is also recognized if a deductible or taxable temporary difference exists.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In-process research and development acquired in a business combination is amortized on a straight line basis over its useful life from the date of receipt of marketing approval.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Rights to technology platforms and to products currently marketed by Sanofi are amortized on a straight line basis over their useful lives, determined (in particular for marketed products) on the basis of cash flow forecasts which take into account the patent protection period of the marketed product.</span></div>
CY2023	ifrs-full	Description Of Accounting Policy For Property Plant And Equipment Explanatory DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory	Property, plant and equipment owned and leased<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.5.1. Property, plant and equipment owned</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Property, plant and equipment is initially measured and recognized at acquisition cost, including any directly attributable cost of preparing the asset for its intended use, or (in the case of assets acquired in a business combination) at fair value as of the date of the business combination. The component-based approach to accounting for property, plant and equipment is applied. Under this approach, each component of an item of property, plant and equipment with a cost which is significant in relation to the total cost of the item and which has a different useful life from the other components must be depreciated separately.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">After initial measurement, property, plant and equipment is carried at cost less accumulated depreciation and impairment, except for land which is carried at cost less impairment.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subsequent costs are not recognized as assets unless (i) it is probable that future economic benefits associated with those costs will flow to Sanofi and (ii) the costs can be measured reliably.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Borrowing costs attributable to the financing of items of property, plant and equipment, and incurred during the construction period, are capitalized as part of the acquisition cost of the item.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Government grants relating to property, plant and equipment are deducted from the acquisition cost of the asset to which they relate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The depreciable amount of items of property, plant and equipment, net of any residual value, is depreciated on a straight line basis over the useful life of the asset. The useful life of an asset is usually equivalent to its economic life.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The customary useful lives of property, plant and equipment are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:49.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.671%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15 to 40 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 to 20 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 to 15 years</span></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 to 15 years</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Useful lives and residual values of property, plant and equipment are reviewed annually. The effect of any adjustment to useful lives or residual values is recognized prospectively as a change in accounting estimate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Depreciation of property, plant and equipment is recognized as an expense in the income statement, in the relevant classification of expense by function.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.5.2. Property, plant and equipment leased</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Effective from January 1, 2019 leases contracted by Sanofi have been accounted for in accordance with IFRS 16 (Leases). Sanofi recognizes a right-of-use asset and a lease liability for all of its lease contracts, except for (i) leases relating to low-value assets and (ii) short-term leases (12 months or less). Payments made in respect of leases not recognized on the balance sheet are recognized as an operating expense on a straight line basis over the lease term.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On commencement of a lease, the liability for future lease payments is discounted at the incremental borrowing rate, which is a risk-free rate adjusted to reflect the specific risk profile of each Sanofi entity. Because lease payments are spread over the lease term, Sanofi applies a discount rate based on the duration of those payments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The payments used to determine the liability for future lease payments exclude non-lease components, but include fixed payments that Sanofi expects to make to the lessor over the estimated lease term.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">After commencement of the lease, the liability for future lease payments is reduced by the amount of the lease payments made, and increased to reflect interest on the liability. In the event of a reassessment or modification of future lease payments, the lease liability is remeasured. The right-of-use asset – which is initially measured at cost including direct costs of the lessee, prepayments made at or prior to the commencement date, less lease incentives received and restoration costs – is depreciated on a straight line basis over the lease term, and tested for impairment as required.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi recognizes deferred taxes in respect of right-of-use assets and lease liabilities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Leasehold improvements are depreciated over their economic life, which is capped at the lease term as determined under IFRS 16.</span></div>
CY2023	ifrs-full	Description Of Accounting Policy For Impairment Of Assets Explanatory DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory	Impairment of property, plant and equipment, intangible assets, and investments accounted for using the equity method<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.6.1. Impairment of property, plant and equipment and intangible assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS 36 (Impairment of Assets), assets that generate separate cash flows and assets included in cash-generating units (CGUs) are assessed for impairment when events or changes in circumstances indicate that the asset or CGU may be impaired. A CGU is the smallest identifiable group of assets that generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IAS 36, each CGU or group of CGUs to which goodwill is allocated must (i) represent the lowest level within the entity at which the goodwill is monitored for internal management purposes, and (ii) not be larger than an operating segment determined in accordance with IFRS 8 (Operating Segments), before application of the IFRS 8 aggregation criteria (see Note B.26.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Quantitative and qualitative indications of impairment (primarily relating to the status of the research and development portfolio, pharmacovigilance, patent litigation, and the launch of competing products) are reviewed at the end of each reporting period. If there is any internal or external indication of impairment, Sanofi estimates the recoverable amount of the asset or CGU.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other intangible assets not yet available for use (such as capitalized in-process research and development), and CGUs or groups of CGUs that include goodwill, are tested for impairment annually whether or not there is any indication of impairment, and more frequently if any event or circumstance indicates that they might be impaired. Such assets are not amortized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When there is an internal or external indication of impairment, Sanofi estimates the recoverable amount of the asset and recognizes an impairment loss if the carrying amount of the asset exceeds its recoverable amount. The recoverable amount of the asset is the higher of its fair value less costs to sell or its value in use. To determine value in use, Sanofi uses estimates of future cash flows generated by the asset or CGU, prepared using the same methods as those used in the initial measurement of the asset or CGU on the basis of medium-term strategic plans.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of goodwill, estimates of future cash flows are based on a six-year strategic plan and a terminal value. In the case of other intrangible assets, the period used is based on the economic life of the asset.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Estimated cash flows are discounted at long-term market interest rates that reflect the best estimate by Sanofi of the time value of money, the risks specific to the asset or CGU, and economic conditions in the geographical regions in which the business activity associated with the asset or CGU is located.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Certain assets and liabilities that are not directly attributable to a specific CGU are allocated between CGUs on a basis that is reasonable, and consistent with the allocation of the corresponding goodwill.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Impairment losses arising on property, plant and equipment, software and certain rights, are recognized within the appropriate income statement line item according to the origin of the impairment.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Impairment losses arising on other intangible assets (products, trademarks, technology platforms, acquired R&D) are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Impairment of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.6.2. Impairment of investments accounted for using the equity method</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS 28 (Investments in Associates and Joint Ventures), Sanofi determines whether investments accounted for using the equity method may be impaired based on indicators such as default in contractual payments, significant financial difficulties, probability of bankruptcy, or a prolonged or significant decline in quoted market price. If an investment is impaired, the amount of the impairment loss is determined by applying IAS 36 (see Note B.6.1.) and recognized in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Share of profit/(loss) from investments accounted for using the equity method.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.6.3. Reversals of impairment losses charged against property, plant and equipment, intangible assets, and investments accounted for using the equity method</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">At the end of each reporting period, Sanofi assesses whether events or changes in circumstances indicate that an impairment loss recognized in a prior period in respect of an asset (other than goodwill) or an investment accounted for using the equity method can be reversed. If this is the case, and the recoverable amount as determined based on the revised estimates exceeds the carrying amount of the asset, Sanofi reverses the impairment loss only to the extent of the carrying amount that would have been determined had no impairment loss been recognized for the asset.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Reversals of impairment losses in respect of other intangible assets are recognized within the income statement line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Impairment of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, while reversals of impairment losses in respect of investments accounted for using the equity method are recognized within the income statement line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Share of profit/(loss) from investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Impairment losses taken against goodwill are never reversed, unless the goodwill is part of the carrying amount of an investment accounted for using the equity method.</span></div>
CY2023	ifrs-full	Description Of Accounting Policy For Noncurrent Assets Or Disposal Groups Classified As Held For Sale And Discontinued Operations Explanatory DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory	Assets held for sale or exchange and liabilities related to assets held for sale or exchange<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations), non-current assets and groups of assets are classified as held for sale in the balance sheet if their carrying amount will be recovered principally through a sale transaction rather than through continuing use. Within the meaning of IFRS 5, the term “sale” also includes exchanges for other assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Non-current assets or asset groups held for sale must be available for immediate sale in their present condition, subject only to terms that are usual and customary for sales of such assets, and a sale must be highly probable. Criteria used to determine whether a sale is highly probable include:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the appropriate level of management must be committed to a plan to sell;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">an active program to locate a buyer and complete the plan must have been initiated;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the asset must be actively marketed for sale at a price that is reasonable in relation to its current fair value;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">completion of the sale should be foreseeable within the 12 months following the date of reclassification to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">actions required to complete the plan should indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Before initial reclassification of the non-current asset (or asset group) to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, the carrying amounts of the asset (or of all the assets and liabilities in the asset group) must be measured in accordance with the applicable standards.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subsequent to reclassification to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, the non-current asset (or asset group) is measured at the lower of carrying amount or fair value less costs to sell, with any write-down recognized by means of an impairment loss. Once a non-current asset has been reclassified as held for sale or exchange, it is no longer depreciated or amortized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In a disposal of an equity interest leading to loss of control, all the assets and liabilities of the entity involved are classified as held-for-sale assets or liabilities within the balance sheet line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">or</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Liabilities related to assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, provided that the disposal satisfies the IFRS 5 classification criteria.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The profit or loss generated by a held-for-sale asset group is reported in a separate line item in the income statement for the current period and for the comparative periods presented, provided that the asset group:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">represents a separate major line of business or geographical area of operations; or</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">is part of a single coordinated plan to dispose of a separate major line of business or geographical area of operations; or</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">is a subsidiary acquired exclusively with a view to resale.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 10, transactions between companies that are held for sale or treated as discontinued operations and other consolidated companies are eliminated.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Events or circumstances beyond Sanofi’s control may extend the period to complete the sale or exchange beyond one year without precluding classification of the asset (or disposal group) in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> provided that there is sufficient evidence that Sanofi remains committed to the planned sale or exchange. Finally, in the event of changes to a plan of sale that requires an asset no longer to be classified as held for sale, IFRS 5 specifies the following treatment:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the assets and liabilities previously classified as held for sale are reclassified to the appropriate balance sheet line items, with no restatement of comparative periods;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">each asset is measured at the lower of (a) its carrying amount before the asset was reclassified as held for sale, adjusted for any depreciation, amortization or revaluation that would have been recognized if the asset had not been reclassified as held for sale, or (b) its recoverable amount at the date of reclassification;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the backlog of depreciation, amortization and impairment not recognized while non-current assets were classified as held for sale must be reported in the same income statement line item that was used to report impairment losses arising on initial reclassification of assets as held for sale and gains or losses arising on the sale of such assets. In the consolidated income statement, those impacts are reported within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the net income of a business previously classified as discontinued or as held for sale or exchange and reported on a separate line in the income statement must be reclassified and included in net income from continuing operations, for all periods presented;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">in addition, segment information relating to the income statement and the statement of cash flows (acquisitions of non-current assets) must be disclosed in the notes to the financial statements in accordance with IFRS 8 (Operating Segments), and must also be restated for all prior periods presented.</span></div>
CY2023	ifrs-full	Description Of Accounting Policy For Financial Instruments Explanatory DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory	Financial instruments<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.1. Non-derivative financial assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 9 (Financial Instruments) and IAS 32 (Financial Instruments: Presentation), Sanofi has adopted the classification of non-derivative financial assets described below. The classification used depends on (i) the characteristics of the contractual cash flows (i.e. whether they represent interest or principal) and (ii) the business model for managing the asset applied at the time of initial recognition.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial assets at fair value through other comprehensive income</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These mainly comprise:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">quoted and unquoted equity investments that Sanofi does not hold for trading purposes and that management has designated at “fair value through other comprehensive income” on initial recognition. Gains and losses arising from changes in fair value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such instruments are derecognized, the previously-recognized changes in fair value remain within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, as does the gain or loss on divestment. Dividends received are recognized in profit or loss for the period, within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">debt instruments whose contractual cash flows represent payments of interest or repayments of principal, and which are managed with a view to collecting cash flows and selling the asset. Gains and losses arising from changes in fair value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such assets are derecognized, the cumulative gains and losses previously recognized in equity are reclassified to profit or loss for the period within the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial assets at fair value through profit or loss</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These mainly comprise:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">contingent consideration already carried in the books of an acquired entity or granted in connection with a business combination;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">instruments whose contractual cash flows represent payments of interest and repayments of principal, which are managed with a view to selling the asset;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">instruments that management has designated at “fair value through profit or loss” on initial recognition; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">quoted and unquoted equity investments: equity instruments that are not held for trading and which management did not designate at “fair value through other comprehensive income” on initial recognition, and instruments that do not meet the IFRS definition of “equity instruments”.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Gains and losses arising from changes in fair value are recognized in profit or loss within the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Dividends received are recognized in profit or loss for the period, within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of equity investments in unquoted entities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On initial recognition of an equity investment in an entity not quoted in an active market, the fair value of the investment is the acquisition cost. Cost ceases to be a representative measure of the fair value of an unquoted equity investment when Sanofi identifies significant changes in the investee, or in the environment in which it operates. In such cases, an internal valuation is carried out, based mainly on growth forecasts or by reference to similar transactions contracted with third parties.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial assets measured at amortized cost</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Financial assets at amortized cost comprise instruments whose contractual cash flows represent payments of interest and repayments of principal and which are managed with a view to collecting cash flows. The main assets in this category are loans and receivables. They are presented within the line items</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other non-current assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Accounts receivable </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Cash and cash equivalents</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Loans with a maturity of more than 12 months are presented in “Long-term loans and advances” within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other non-current assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. These financial assets are measured at amortized cost using the effective interest method.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of financial assets measured at amortized cost</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The main assets involved are accounts receivable. Accounts receivable are initially recognized at the amount invoiced to the customer. Impairment losses on trade accounts receivable are estimated using the expected loss method, in order to take account of the risk of payment default throughout the lifetime of the receivables. The expected credit loss is estimated collectively for all accounts receivable at each reporting date using an average expected loss rate, determined primarily on the basis of historical credit loss rates. However, that average expected loss rate may be adjusted if there are indications of a likely significant increase in credit risk. If a receivable is subject to a known credit risk, a specific impairment loss is recognized for that receivable. The amount of expected losses is recognized in the balance sheet as a reduction in the gross amount of accounts receivable. Impairment losses on accounts receivable are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Selling and general expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.2. Derivative instruments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Derivative instruments that do not qualify for hedge accounting are initially and subsequently measured at fair value, with changes in fair value recognized in the income statement in</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, depending on the nature of the underlying economic item which is hedged.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Derivative instruments that qualify for hedge accounting are measured using the policies described in Note B.8.3. below.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">IFRS 13 (Fair Value Measurement) requires counterparty credit risk to be taken into account when measuring the fair value of financial instruments. That risk is estimated on the basis of observable, publicly-available statistical data.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Policy on offsetting</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In order for a financial asset and a financial liability to be presented as a net amount in the balance sheet under IAS 32, there must be:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(a) a legally enforceable right to offset; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(b) the intention either to settle on a net basis, or to realize the asset and settle the liability simultaneously.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.3. Hedging</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As part of its overall market risk management policy, Sanofi enters into various hedging transactions involving derivative or non-derivative instruments; these may include forward contracts, currency swaps or options, interest rate swaps or options, cross-currency swaps, and debt placings or issues.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Such financial instruments are designated as hedging instruments and recognized using the hedge accounting principles of IFRS 9 when (a) there is formal designation and documentation of the hedging relationship, of how the effectiveness of the hedging relationship will be assessed, and of the underlying market risk management objective and strategy; (b) the hedged item and the hedging instrument are eligible for hedge accounting; and (c) there is an economic relationship between the hedged item and the hedging instrument, defined on the basis of a hedge ratio that is consistent with the underlying market risk management strategy, and the residual credit risk does not dominate the value changes that result from that economic relationship.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value hedge</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A fair value hedge is a hedge of the exposure to changes in fair value of an asset, liability or firm commitment that is attributable to one or more risk components and could affect profit or loss.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in fair value of the hedging instrument and changes in fair value of the hedged item attributable to the hedged risk components are generally recognized in the income statement, within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to operating activities, or within</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to investing or financing activities.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash flow hedge</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A cash flow hedge is a hedge of the exposure to variability in cash flows from an asset, liability or highly probable forecast transaction that is attributable to one or more risk components and could affect profit or loss.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in fair value of the hedging instrument attributable to the effective portion of the hedge are recognized directly in equity in the consolidated statement of comprehensive income. Changes in fair value attributable to the ineffective portion of the hedge are recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">for hedges related to operating activities, and within</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to investing or financing activities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Cumulative changes in fair value of the hedging instrument previously recognized in equity are reclassified to the income statement when the hedged transaction affects profit or loss. Those reclassified gains and losses are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to operating activities, and within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to investing or financing activities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When a forecast transaction results in the recognition of a non-financial asset or liability, cumulative changes in the fair value of the hedging instrument previously recognized in equity are incorporated in the initial carrying amount of that asset or liability.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When the hedging instrument expires or is sold, terminated or exercised, the cumulative gain or loss previously recognized in equity remains separately recognized in equity and is not reclassified to the income statement, or recognized as an adjustment to the initial cost of the related non-financial asset or liability, until the forecast transaction occurs. However, if Sanofi no longer expects the forecast transaction to occur, the cumulative gain or loss previously recognized in equity is recognized immediately in profit or loss.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hedge of a net investment in a foreign operation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In a hedge of a net investment in a foreign operation, changes in the fair value of the hedging instrument attributable to the effective portion of the hedge are recognized directly in equity in the consolidated statement of comprehensive income. Changes in fair value attributable to the ineffective portion of the hedge are recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. When the investment in the foreign operation is sold, the changes in the fair value of the hedging instrument previously recognized in equity are reclassified to the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of hedging</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As part of its market risk management policy, Sanofi may designate currency options or interest rate options as hedging instruments, the effectiveness of which is measured on the basis of changes in intrinsic value. In such cases, the time value of the option is treated as a hedging cost and accounted for as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">if the option includes a component that is not aligned on the critical features of the hedged item, the corresponding change in the time value is taken to profit or loss;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">otherwise, the change in the time value is taken to equity within the statement of comprehensive income, and then:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">if the hedged item is linked to a transaction that results in the recognition of a financial asset or liability, the change in the time value is reclassified to profit or loss symmetrically with the hedged item, or</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">if the hedged item is linked to a transaction that results in the recognition of a non-financial asset or liability, the change in the time value is incorporated in the initial carrying amount of that asset or liability, or</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">if the hedged item is linked to a period of time, the change in time value is reclassified to profit or loss on a straight line basis over the life of the hedging relationship.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of forward contracts and foreign exchange swaps, and of cross-currency swaps that qualify for hedge accounting on the basis of changes in spot rates, Sanofi may elect for each transaction to use the option whereby the premium/discount or foreign currency basis spread are treated in the same way as the time value of an option.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discontinuation of hedge accounting</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Hedge accounting is discontinued when the eligibility criteria are no longer met (in particular, when the hedging instrument expires or is sold, terminated or exercised), or if there is a change in the market risk management objective of the hedging relationship.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.4. Non-derivative financial liabilities</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Borrowings and debt</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Bank borrowings and debt instruments are initially measured at fair value of the consideration received, net of directly attributable transaction costs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subsequently, they are measured at amortized cost using the effective interest method. All costs related to the issuance of borrowings or debt instruments, and all differences between the issue proceeds net of transaction costs and the value on redemption, are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement over the term of the debt using the effective interest method.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These line items record the fair value of (i) contingent consideration payable in connection with business combinations and (ii) commitments to buy out equity holders of subsidiaries, including put options granted to non-controlling interests.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Adjustments to the fair value of commitments to buy out equity holders of subsidiaries, including put options granted to non-controlling interests, are recognized in equity.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other non-derivative financial liabilities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other non-derivative financial liabilities include trade accounts payable, which are measured at fair value (which in most cases equates to face value) on initial recognition, and subsequently at amortized cost.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.5. Fair value of financial instruments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IFRS 13 (Fair Value Measurement) and IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.69pt">level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.08pt">level 2: quoted prices in active markets for similar assets and liabilities, or valuation techniques in which all important inputs are derived from observable market data; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.61pt">level 3: valuation techniques in which not all important inputs are derived from observable market data.</span></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:5.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.362%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Type of financial instrument</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Measurement<br/>principle</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in<br/>fair value<br/>hierarchy</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation<br/>technique</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Method used to determine fair value</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation<br/>model</span></td><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market data</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exchange rate</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest<br/>rate</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted equity instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted debt instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (unquoted equity instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cost/Approach based on comparables</span></div></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">If cost ceases to be a representative measure of fair value, an internal valuation is carried out, based mainly on comparables.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (contingent consideration receivable)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value held to meet obligations under <br/>post-employment benefit plans</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets designated at fair value held to meet obligations under deferred compensation plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.13.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Investments in mutual funds</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Net asset value</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.13.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Negotiable debt instruments, commercial paper, instant access deposits and term deposits</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Because these instruments have a maturity of less than three months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.17.1., D.19.</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">In the case of debt with a maturity of less than three months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">For debt with a maturity of more than three months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.17.2.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The liability for future lease payments is discounted using the incremental borrowing rate.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">< 1 year:</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Money Market</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">> 1 year: </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Zero Coupon</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market<br/>Spot</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">< 1 year:</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Money Market and LIFFE interest rate futures</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">> 1 year: </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Zero Coupon</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market<br/>Spot</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">< 1 year:<br/>Mid Money Market and LIFFE interest rate futures<br/>> 1 year: <br/>Mid Zero Coupon</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.18.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests (CVRs)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.18.</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests (other than CVRs)</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3 </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.8.4.</span></div></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.6. Derecognition of financial instruments</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Financial assets are derecognized when the contractual rights to cash flows from the asset have ended or have been transferred and when Sanofi has transferred substantially all the risks and rewards of ownership of the asset. If Sanofi has neither transferred nor retained substantially all the risks and rewards of ownership of a financial asset, it is derecognized if Sanofi does not retain control of the asset.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A financial liability is derecognized when Sanofi’s contractual obligations in respect of the liability are discharged, cancelled or extinguished.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.7. Risks relating to financial instruments</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Market risks in respect of non-current financial assets, cash equivalents, derivative instruments and debt are described in the discussions of risk factors presented in Item 3.D. and Item 11. of Sanofi’s annual report on Form 20-F for 2023.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Credit risk is the risk that customers may fail to pay their debts. For a description of credit risk, refer to “We are subject to the risk of non-payment by our customers” within Item 3.D. and Item 11. of Sanofi’s annual report on Form 20-F for 2023.</span></div>
CY2023	ifrs-full	Disclosure Of Detailed Information About Financial Instruments Explanatory DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory	<div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:5.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.362%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Type of financial instrument</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Measurement<br/>principle</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in<br/>fair value<br/>hierarchy</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation<br/>technique</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Method used to determine fair value</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation<br/>model</span></td><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market data</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exchange rate</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest<br/>rate</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted equity instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted debt instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (unquoted equity instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cost/Approach based on comparables</span></div></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">If cost ceases to be a representative measure of fair value, an internal valuation is carried out, based mainly on comparables.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (contingent consideration receivable)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value held to meet obligations under <br/>post-employment benefit plans</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets designated at fair value held to meet obligations under deferred compensation plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.13.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Investments in mutual funds</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Net asset value</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.13.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Negotiable debt instruments, commercial paper, instant access deposits and term deposits</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Because these instruments have a maturity of less than three months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.17.1., D.19.</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">In the case of debt with a maturity of less than three months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">For debt with a maturity of more than three months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.17.2.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The liability for future lease payments is discounted using the incremental borrowing rate.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">< 1 year:</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Money Market</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">> 1 year: </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Zero Coupon</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market<br/>Spot</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">< 1 year:</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Money Market and LIFFE interest rate futures</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">> 1 year: </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Zero Coupon</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market<br/>Spot</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">< 1 year:<br/>Mid Money Market and LIFFE interest rate futures<br/>> 1 year: <br/>Mid Zero Coupon</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.18.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests (CVRs)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.18.</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests (other than CVRs)</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3 </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.8.4.</span></div></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).</span></div>
CY2023	ifrs-full	Description Of Accounting Policy For Measuring Inventories DescriptionOfAccountingPolicyForMeasuringInventories	Inventories<div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Inventories are measured at the lower of cost or net realizable value. Cost is calculated using the weighted average cost method or the first-in, first-out method, depending on the nature of the inventory.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The cost of finished goods inventories includes costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the launch phase of a new product, any inventories of that product are written down to zero pending regulatory approval, other than in specific circumstances which make it possible to estimate that there is a high probability at the end of the reporting period that the carrying amount of the inventories will be recoverable. The write-down is reversed once it becomes highly probable that marketing approval will be obtained.</span></div>
CY2023	ifrs-full	Description Of Accounting Policy To Determine Components Of Cash And Cash Equivalents DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents	Cash and cash equivalents<div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Cash and cash equivalents as shown in the consolidated balance sheet and statement of cash flows comprise cash, plus liquid short-term investments that are readily convertible into cash and are subject to an insignificant risk of changes in value in the event of movements in interest rates.</span></div>
CY2023	sny	Gain Loss On Impairment Of Treasury Shares GainLossOnImpairmentOfTreasuryShares	0	eur
CY2023	sny	Gain Loss On Purchase Of Treasury Shares GainLossOnPurchaseOfTreasuryShares	0	eur
CY2023	sny	Gain Loss On Cancellation Of Treasury Shares GainLossOnCancellationOfTreasuryShares	0	eur
CY2023	sny	Gain Loss On Sale Of Treasury Shares GainLossOnSaleOfTreasuryShares	0	eur
CY2023	ifrs-full	Description Of Accounting Policy For Provisions Explanatory DescriptionOfAccountingPolicyForProvisionsExplanatory	Provisions for risks<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS 37 (Provisions, Contingent Liabilities and Contingent Assets), Sanofi records a provision when it has a present obligation, whether legal or constructive, as a result of a past event; it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and a reliable estimate can be made of the amount of the outflow of resources.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If the obligation is expected to be settled more than 12 months after the end of the reporting period, or has no definite settlement date, the provision is recorded within Non-current provisions and other non-current liabilities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Provisions relating to the insurance programs in which Sanofi’s captive insurance company participates are based on risk exposure estimates calculated by management, with assistance from independent actuaries, using IBNR (Incurred But Not Reported) techniques. Those techniques use past claims experience, within Sanofi and in the market, to estimate future trends in the cost of claims.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Contingent liabilities are not recognized, but are disclosed in the notes to the financial statements unless the possibility of an outflow of economic resources is remote.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi estimates provisions on the basis of events and circumstances related to present obligations at the end of the reporting period and of past experience, and to the best of management’s knowledge at the date of preparation of the financial statements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Reimbursements offsetting the probable outflow of resources are recognized as assets only if it is virtually certain that they will be received. Contingent assets are not recognized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restructuring provisions are recognized if Sanofi has a detailed, formal restructuring plan at the end of the reporting period and has announced its intention to implement this plan to those affected by it.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No provisions are recorded for future operating losses.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi records non-current provisions for certain obligations, such as legal or constructive obligations, where an outflow of resources is probable and the amount of the outflow can be reliably estimated.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of environmental risks, including at sites where operations are ongoing, Sanofi recognizes a provision where there is a violation of integrity in respect of human health or the environment resulting from past contamination at a site that requires remediation. The amount of the provision is a best estimate of the future expenditures to be incurred on the remediation plan.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Where the effect of the time value of money is material, those provisions are measured at the present value of the expenditures expected to be required to settle the obligation, calculated using a discount rate that reflects an estimate of the time value of money and the risks specific to the obligation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Increases in provisions to reflect the effects of the passage of time are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div>
CY2023	sny	Provisions Recorded For Future Operating Losses ProvisionsRecordedForFutureOperatingLosses	0	eur
CY2023	ifrs-full	Description Of Accounting Policy For Recognition Of Revenue DescriptionOfAccountingPolicyForRecognitionOfRevenue	Revenue recognition<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.13.1. Net sales</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Revenue arising from the sale of goods is presented in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net sales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Net sales comprise revenue from sales of pharmaceutical products, consumer healthcare products, active ingredients and vaccines, net of sales returns, of customer incentives and discounts, and of certain sales-based payments paid or payable to the healthcare authorities. Analyses of net sales are provided in Note D.35.1. “Segment Information”.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 15 (Revenue from Contracts with Customers), such revenue is recognized when Sanofi transfers control over the product to the customer; control of an asset refers to the ability to direct the use of, and obtain substantially all of the remaining benefits from that asset. For the vast majority of contracts, revenue is recognized when the product is physically transferred, in accordance with the delivery and acceptance terms agreed with the customer.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For contracts entered into by Sanofi Pasteur, transfer of control is usually determined by reference to the terms of release (immediate or deferred) and acceptance of batches of vaccine.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of contracts with distributors, Sanofi does not recognize revenue when the product is physically transferred to the distributor if the products are sold on consignment, or if the distributor acts as agent. In such cases, revenue is recognized when control is transferred to the end customer, and the distributor’s commission is presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Selling and general expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The amount of revenue recognized reflects the various types of price reductions or rights of return offered by Sanofi to its customers on certain products. Such price reductions and rights of return qualify as variable consideration under IFRS 15.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In particular, products sold in the United States are covered by various Government and State programs (such as Medicare and Medicaid) under which products are sold at a discount. Rebates are granted to healthcare authorities, and under contractual arrangements with certain customers. Some wholesalers are entitled to chargeback incentives based on the selling price to the end customer, under specific contractual arrangements. Cash discounts may also be granted for prompt payment. Returns, discounts, incentives and rebates, as described above, are recognized in the period in which the underlying sales are recognized as a reduction of gross sales.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These amounts are calculated as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of chargeback incentives is estimated on the basis of the relevant subsidiary’s standard sales terms and conditions, and in certain cases on the basis of specific contractual arrangements with the customer;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of rebates based on attainment of sales targets is estimated and accrued as each of the underlying sales transactions is recognized;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of price reductions under Government and State programs, largely in the United States, is estimated on the basis of the specific terms of the relevant regulations or agreements, and accrued as each of the underlying sales transactions is recognized;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of sales returns is calculated on the basis of management’s best estimate of the amount of product that will ultimately be returned by customers. In countries where product returns are possible, Sanofi operates a returns policy that allows the customer to return products within a certain period either side of the expiry date (usually 12 months after the expiry date). The amount recognized for returns is estimated on the basis of past experience of sales returns. Sanofi also takes into account factors such as levels of inventory in its various distribution channels, product expiry dates, information about potential discontinuation of products, the entry of competing generics into the market, and the launch of over-the-counter medicines. Most product return clauses relate solely to date-expired products, which cannot be resold and are destroyed. Sanofi does not recognize a right of return asset in the balance sheet for contracts that allow for the return of time-expired products, since those products have no value.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The estimated amounts described above are recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net sales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">as a reduction of gross sales, and within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the balance sheet. They are subject to regular review and adjustment as appropriate based on the most recent data available to management. Sanofi believes that it has the ability to measure each of the above amounts reliably, using the following factors in developing its estimates:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the nature and patient profile of the underlying product;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the applicable regulations or the specific terms and conditions of contracts with governmental authorities, wholesalers and other customers;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">historical data relating to similar contracts, in the case of qualitative and quantitative rebates and chargeback incentives;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">past experience and sales growth trends for the same or similar products;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">actual inventory levels in distribution channels, monitored by Sanofi using internal sales data and externally provided data;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the shelf life of Sanofi products; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">market trends including competition, pricing and demand.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of provisions for discounts, rebates and sales returns is provided in Note D.23.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.13.2. Other revenues</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is used to recognize all revenue that falls within the scope of IFRS 15 but does not relate to sales of Sanofi products.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It mainly comprises (i) royalties received from licensing intellectual property rights to third parties; (ii) VaxServe sales of products sourced from third-party manufacturers; and (iii) revenue received under agreements for Sanofi to provide manufacturing services to third parties.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Royalties received under licensing arrangements are recognized over the period during which the underlying sales are recognized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">VaxServe is a Vaccines segment entity whose operations include the distribution within the United States of vaccines and other products manufactured by third parties. VaxServe sales of products sourced from third-party manufacturers are presented within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div>
CY2023	sny	Description Of Accounting Policy For Cost Of Sales Explanatory DescriptionOfAccountingPolicyForCostOfSalesExplanatory	Cost of sales<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> consists primarily of the industrial cost of goods sold, payments made under licensing agreements, and distribution costs. The industrial cost of goods sold includes the cost of materials, depreciation of property, plant and equipment, amortization of software, personnel costs, and other expenses attributable to production.</span></div>
CY2023	ifrs-full	Description Of Accounting Policy For Research And Development Expense Explanatory DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory	Research and development<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Note B.4.1. “Research and development not acquired in a business combination” and Note B.4.3. “Other intangible assets acquired in a business combination” describe the principles applied to the recognition of research and development costs.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Contributions or reimbursements received from alliance partners are recorded as a reduction of </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div>
CY2023	ifrs-full	Description Of Accounting Policy For Intangible Assets And Goodwill Explanatory DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory	Amortization and impairment of intangible assets<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.17.1. Amortization of intangible assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The expenses recorded in this line item comprise amortization charged against intangible assets (products, trademarks and technology platforms, see Note D.4.) whose contribution to Sanofi’s commercial, industrial and development functions cannot be separately identified.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amortization of software, and of other rights of an industrial or operational nature, is recognized as an expense in the income statement, in the relevant line items of expense by function.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.17.2. Impairment of intangible assets</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This line item records impairment losses taken against intangible assets (products, trademarks, technology platforms and acquired research), and any reversals of such impairment losses.</span></div>
CY2022Q4	ifrs-full	Property Plant And Equipment PropertyPlantAndEquipment	9869000000	eur
CY2023Q4	ifrs-full	Property Plant And Equipment PropertyPlantAndEquipment	10160000000	eur
CY2023	ifrs-full	Description Of Accounting Policy For Finance Income And Costs Explanatory DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory	Financial expenses and income<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.21.1. Financial expenses</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> mainly comprise interest charges on debt financing; negative changes in the fair value of certain financial instruments (where changes in fair value are recognized in profit or loss); realized and unrealized foreign exchange losses on financing and investing activities; impairment losses on financial instruments; and any reversals of impairment losses on financial instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> also include expenses arising from the unwinding of discount on long-term provisions, and the net interest cost related to employee benefits. This line item does not include commercial cash discounts, which are deducted from net sales.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.21.2. Financial income</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> includes interest and dividend income; positive changes in the fair value of certain financial instruments (where changes in fair value are recognized in profit or loss); realized and unrealized foreign exchange gains on financing and investing activities; and gains on disposals of financial assets at fair value through profit or loss.</span></div>
CY2023	ifrs-full	Description Of Accounting Policy For Income Tax Explanatory DescriptionOfAccountingPolicyForIncomeTaxExplanatory	Income tax expense<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income tax expense </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">includes all current and deferred taxes of consolidated companies.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi accounts for deferred taxes in accordance with IAS 12 (Income Taxes), using the methods described below:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">deferred tax assets and liabilities are recognized on taxable and deductible temporary differences, and on tax loss carry-forwards. Temporary differences are differences between the carrying amount of an asset or liability in the balance sheet and its tax base;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">French business taxes include a value added based component: “CVAE” </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Cotisation sur la Valeur Ajoutée des Entreprises)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Given that CVAE is (i) calculated as the amount by which certain revenues exceed certain expenses and (ii) borne primarily by companies that own intellectual property rights on income derived from those rights (royalties, and margin on sales to third parties and to Sanofi entities), it is regarded as meeting the definition of income taxes specified in IAS 12, paragraph 2 (“taxes which are based on taxable profits”);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">deferred tax assets and liabilities are calculated using the tax rate expected to apply in the period when the corresponding temporary differences are expected to reverse, based on tax rates enacted or substantively enacted at the end of the reporting period;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">deferred tax assets are recognized in respect of deductible temporary differences, tax losses available for carry-forward and unused tax credits to the extent that future recovery is regarded as probable. The recoverability of deferred tax assets is assessed on a case-by-case basis, taking into account the profit forecasts contained in Sanofi’s medium-term business plan;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a deferred tax liability is recognized for temporary differences relating to interests in subsidiaries, associates and joint ventures, except in cases where Sanofi is able to control the timing of the reversal of the temporary differences. This applies in particular when Sanofi is able to control dividend policy and it is probable that the temporary differences will not reverse in the foreseeable future;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">no deferred tax is recognized on eliminations of intragroup transfers of interests in subsidiaries, associates or joint ventures;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">each tax entity calculates its own net deferred tax position. All net deferred tax asset and liability positions are then aggregated and shown in separate line items on the relevant side of the consolidated balance sheet. Deferred tax assets and liabilities are offset only if (i) Sanofi has a legally enforceable right to offset current tax assets and current tax liabilities, and (ii) the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same taxation authority;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">deferred taxes are not discounted, except implicitly in the case of deferred taxes on assets and liabilities which are already impacted by discounting. In addition, Sanofi has elected not to discount current taxes payable or receivable where the amounts in question are payable or receivable in the long term;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">withholding taxes on intragroup royalties and dividends, and on royalties and dividends collected from third parties, are accounted for as current income taxes.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accounting for business combinations, Sanofi complies with IFRS 3 as regards the recognition of deferred tax assets after the initial accounting period. Consequently, any deferred tax assets recognized by the acquiree after the end of that period in respect of temporary differences or tax loss carry-forwards existing at the acquisition date are recognized in profit or loss.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The positions adopted by Sanofi in tax matters are based on its interpretation of tax laws and regulations. Some of those positions may be subject to uncertainty. In such cases, Sanofi assesses the amount of the tax liability on the basis of the following assumptions: that its position will be examined by one or more tax authorities on the basis of all relevant information; that a technical assessment is carried out with reference to legislation, case law, regulations, and established practice; and that each position is assessed individually (or collectively where appropriate), with no offset or aggregation between positions. Those assumptions are assessed on the basis of facts and circumstances existing at the end of the reporting period. When an uncertain tax liability is regarded as probable, it is measured on the basis of Sanofi’s best estimate and recognized as a liability; uncertain tax assets are not recognized. The amount of the liability includes any penalties and late payment interest. The line item</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Income tax expense</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> includes the effects of tax reassessments and tax disputes, and any penalties and late payment interest arising from such disputes that have the characteristics of income taxes within the meaning of paragraph 2 of IAS 12 (“taxes which are based on taxable profits”). Tax exposures relating to corporate income taxes are presented separately within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Non-current income tax liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (see Note D.19.4.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No deferred taxation is recognized on temporary differences that are liable to be subject to US global intangible low taxed income (GILTI) provisions. The related tax expense is recognized in the year in which it is declared in the tax return to the extent that it arises from the existence of non-US profits that exceed the theoretical return on investment specified in the GILTI provisions and are taxed at a rate lower than the applicable US tax rate.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS 1 (Presentation of Financial Statements), current income tax assets and liabilities are presented as separate line items in the consolidated balance sheet.</span></div>
CY2023	ifrs-full	Description Of Accounting Policy For Employee Benefits Explanatory DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory	Employee benefit obligations<div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi offers retirement benefits to employees and retirees. Such benefits are accounted for in accordance with IAS 19 (Employee Benefits).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Benefits are provided in the form of either defined contribution plans or defined benefit plans. In the case of defined contribution plans, the cost is recognized immediately in the period in which it is incurred, and equates to the amount of the contributions paid by Sanofi. For defined benefit plans, Sanofi generally recognizes its obligations to pay pensions and similar benefits to employees as a liability, based on an actuarial estimate of the rights vested or currently vesting in employees and retirees, using the projected unit credit method. Estimates are performed at least once a year, and rely on financial assumptions (such as discount </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">rates) and demographic assumptions (such as life expectancy, retirement age, employee turnover, and the rate of salary increases).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Obligations relating to other post-employment benefits (healthcare and life insurance) offered by Sanofi companies to employees are also recognized as a liability based on an actuarial estimate of the rights vested or currently vesting in employees and retirees at the end of the reporting period.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Such liabilities are recognized net of the fair value of plan assets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of multi-employer defined benefit plans where plan assets cannot be allocated to each participating employer with sufficient reliability, the plan is accounted for as a defined contribution plan, in accordance with paragraph 34 of IAS 19.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The benefit cost for the period consists primarily of current service cost, past service cost, net interest cost, gains or losses arising from plan settlements not specified in the terms of the plan, and actuarial gains or losses arising from plan curtailments. Net interest cost for the period is determined by applying the discount rate specified in IAS 19 to the net liability (i.e. the amount of the obligation, net of plan assets) recognized in respect of defined benefit plans. Past service cost is recognized immediately in profit or loss in the period in which it is incurred, regardless of whether or not the rights have vested at the time of adoption (in the case of a new plan) or of amendment (in the case of an existing plan).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actuarial gains and losses on defined benefit plans (pensions and other post-employment benefits), also referred to as “Remeasurements of the net defined benefit liability (asset)”</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> arise as a result of changes in financial and demographic assumptions, experience adjustments, and the difference between the actual return and interest cost on plan assets. The impacts of those remeasurements are recognized in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, net of deferred taxes; they are not subsequently reclassifiable to profit or loss.</span></div>
CY2023	ifrs-full	Description Of Accounting Policy For Sharebased Payment Transactions Explanatory DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory	Share-based payment<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Share-based payment expense is recognized as a component of operating income, in the relevant classification of expense by function. In measuring the expense, the level of attainment of any performance conditions is taken into account.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.24.1. Stock option plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has granted a number of equity-settled share-based payment plans (stock option plans) to some of its employees. The terms of those plans may make the award contingent on the attainment of performance criteria for some of the grantees.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 2 (Share-Based Payment), services received from employees as consideration for stock options are recognized as an expense in the income statement, with the opposite entry recognized in equity. The expense corresponds to the fair value of the stock option plans, and is charged to income on a straight-line basis over the four-year vesting period of the plan.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The fair value of stock option plans is measured at the date of grant using the Black-Scholes valuation model, taking into account the expected life of the options. The resulting expense also takes into account the expected cancellation rate of the options. The expense is adjusted over the vesting period to reflect actual cancellation rates resulting from option-holders ceasing to be employed by Sanofi.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.24.2. Employee share ownership plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi may offer its employees the opportunity to subscribe to reserved share issues at a discount to the reference market price. Shares awarded to employees under such plans fall within the scope of IFRS 2. Consequently, an expense is recognized at the subscription date, based on the value of the discount offered to employees.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.24.3. Restricted share plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi may award restricted share plans to certain of its employees. The terms of those plans may make the award contingent on the attainment of performance criteria for some of the grantees.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 2, an expense equivalent to the fair value of such plans is recognized in profit or loss on a straight line basis over the vesting period of the plan, with the opposite entry recognized in equity. The vesting period is three years.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The fair value of restricted share plans is based on the quoted market price of Sanofi shares at the date of grant, adjusted for expected dividends during the vesting period; it also takes account of any vesting conditions contingent on stock market performance, measured using the Monte-Carlo valuation model. Other vesting conditions are taken into account in the estimate of the number of shares awarded during the vesting period; that number is then definitively adjusted based on the actual number of shares awarded on the vesting date.</span></div>
CY2023	ifrs-full	Description Of Accounting Policy For Earnings Per Share Explanatory DescriptionOfAccountingPolicyForEarningsPerShareExplanatory	Earnings per share<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Basic earnings per share is calculated using the weighted average number of shares outstanding during the reporting period, adjusted on a time-weighted basis from the acquisition date to reflect the number of own shares held by Sanofi. Diluted earnings per share is calculated on the basis of the weighted average number of ordinary shares, computed using the treasury stock method.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This method assumes that (i) all outstanding dilutive options and warrants are exercised, and (ii) Sanofi acquires its own shares at the quoted market price for an amount equivalent to the cash received as consideration for the exercise of the options or warrants, plus the expense arising on unamortized stock options.</span></div>
CY2023	ifrs-full	Description Of Accounting Policy For Segment Reporting Explanatory DescriptionOfAccountingPolicyForSegmentReportingExplanatory	Segment information<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 8 (Operating Segments), the segment information reported by Sanofi is prepared on the basis of internal management data provided to our Chief Executive Officer, who is the chief operating decision maker of Sanofi. The performance of those segments is monitored individually using internal reports and common indicators.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2022, Sanofi reported three operating segments (Pharmaceuticals, Vaccines and Consumer Healthcare). The costs of the global support functions (Corporate Affairs, Finance, People & Culture, Legal, Ethics, Business Integrity & Global Security, Information Solutions & Technology, Sanofi Business Services, etc.), which are mainly managed centrally at group-wide level, were presented within the “Other” category. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, Sanofi reviewed the presentation of its segment information following adjustments to its internal reporting systems in order to reflect (i) progress on the “Play to Win” strategy leading to the creation of the standalone Consumer Healthcare Global Business Unit (GBU) which, in addition to integrated research, development and production functions now also has its own dedicated global support functions (including Finance, People & Culture, Legal, Ethics, Business Integrity & Global Security, Information Solutions & Technology, Global Business Services, etc.); and (ii) organizational changes to Sanofi’s Manufacturing & Supply global function (previously known as Industrial Affairs). </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Consequently, with effect from January 1, 2023, Sanofi reports two operating segments: Biopharma and Consumer Healthcare.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Biopharma operating segment comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines and Vaccines franchises, for all geographical territories. The segment’s results include the costs of global support functions that are not within the managerial responsibility of the Consumer Healthcare GBU.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Consumer Healthcare operating segment comprises commercial operations relating to Consumer Healthcare products, and research, development and production activities and global support functions (as listed above) dedicated to the segment, for all geographical territories. The Consumer Healthcare GBU segment’s results reflect all incurred costs of global support functions attributable to its business.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The “Other” category comprises reconciling items, primarily but not limited to (i) gains and losses on centralized foreign exchange risk hedging transactions that cannot be allocated to the operating segments and (ii) gains and losses on retained commitments in respect of previously divested operations.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Information about operating segments for the years ended December 31, 2023, 2022 and 2021 is presented in Note D.35</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">., </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">“Segment information”.</span></div>
CY2022	sny	Number Of Operating Segments1 NumberOfOperatingSegments1	3	segment
CY2023	sny	Number Of Operating Segments1 NumberOfOperatingSegments1	2	segment
CY2023	ifrs-full	Description Of Accounting Policy For Issued Capital Explanatory DescriptionOfAccountingPolicyForIssuedCapitalExplanatory	Management of capital<div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In order to maintain or adjust the capital structure, Sanofi can adjust the amount of dividends paid to shareholders, repurchase its own shares, issue new shares, or issue securities giving access to its capital.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following objectives are defined under the terms of Sanofi’s share repurchase programs:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the implementation of any stock option plan giving entitlement to purchase shares in the Sanofi parent company;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the allotment or sale of shares to employees under statutory profit sharing schemes and employee savings plans;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the consideration-free allotment of shares (i.e. restricted share plans);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the cancellation of some or all of the repurchased shares;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">market-making in the secondary market by an investment services provider under a liquidity contract in compliance with the ethical code recognized by the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Autorité des marchés financiers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (AMF);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the delivery of shares on the exercise of rights attached to securities giving access to the capital by redemption, conversion, exchange, presentation of a warrant or any other means;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the delivery of shares (in exchange, as payment, or otherwise) in connection with mergers and acquisitions;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the execution by an investment services provider of purchases, sales or transfers by any means, in particular via off-market trading; or</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.1pt">any other purpose that is or may in the future be authorized under the applicable laws and regulations.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is not subject to any constraints on equity capital imposed by third parties.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total equity includes </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Equity attributable to equity holders of Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Equity attributable to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, as shown in the consolidated balance sheet.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi defines “Net debt” as (i) the sum of short-term debt, long-term debt and interest rate derivatives and currency derivatives used to hedge debt, minus (ii) the sum of cash and cash equivalents and interest rate derivatives and currency derivatives used to hedge cash and cash equivalents.</span></div>
CY2023	ifrs-full	Disclosure Of Detailed Information About Business Combinations Explanatory DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory	<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The provisional purchase price allocation led to the recognition of goodwill of €475 million, determined as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:66.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value at acquisition date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">774</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current and non-current assets and liabilities</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes, net</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net assets of QRIB Intermediate Holdings, LLC</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">867</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">475</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Purchase price</span></div></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,342</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The final purchase price allocation led to the recognition of €609 million of goodwill, determined as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:72.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value at acquisition date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">493</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current and non-current assets and liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net assets of Amunix</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">517</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">609</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Purchase price</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,126</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The final purchase price allocation, as presented in the table below, led to the recognition of goodwill of €2,118 million:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:72.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value at acquisition date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">396</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(93)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current and non-current assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">235</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shire contingent consideration liability (see Note D.18.)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(323)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net assets of Translate Bio</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">462</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,118</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Purchase price</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,580</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div>
CY2023	sny	Goodwill Tax Deductible Period GoodwillTaxDeductiblePeriod	P15Y
CY2023	ifrs-full	Disclosure Of Property Plant And Equipment Explanatory DisclosureOfPropertyPlantAndEquipmentExplanatory	Property, plant and equipment<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.3.1. Property, plant and equipment owned</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Property, plant and equipment owned by Sanofi is comprised of the following items:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:28.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Buildings</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Machinery<br/>and<br/>equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fixtures,<br/>fittings and<br/>other</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Property, plant<br/>and equipment<br/>in process</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">236</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,828</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,127</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,524</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,454</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">23,169</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,404 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,504 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(75)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(153)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(80)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(314)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">169 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">155 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">443 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">453 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(839)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">240</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,170</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,648</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,655</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,097</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24,810</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(294)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,480)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(163)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(150)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,104)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,642 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,748 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(161)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(240)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(155)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(559)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">122 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">144 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">347 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">480 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">722 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">108 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,626)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(318)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">237</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,328</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,848</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,515</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,996</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">23,924</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,583 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,693 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(340)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(502)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">481 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">457 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,071)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">228</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,681</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,912</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,500</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,449</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24,770</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation & impairment at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(10)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3,898)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(7,792)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,981)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(123)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(13,804)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(306)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(592)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(167)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,065)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">149 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">299 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(80)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(99)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(208)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation & impairment at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(9)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(4,190)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8,340)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,115)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(128)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(14,782)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,202 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">130 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,533 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(356)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(622)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(164)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,142)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(50)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(58)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(75)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(186)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">153 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">518 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(52)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(69)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(138)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation & impairment at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(10)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(4,225)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(7,637)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,015)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(168)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(14,055)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(321)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(620)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,080)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(130)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">488 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation & impairment at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(4,500)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(7,873)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,037)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(192)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(14,610)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carrying amount at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">231 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,980 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,308 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">540 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,969 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,028 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carrying amount at December 31, 2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,103 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,211 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">500 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,828 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,869 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">220</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,181</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,039</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">463</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,257</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,160</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) This line includes in particular property, plant and equipment in process brought into service during the period, but also the effect of the reclassification of assets to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth acquisitions and capitalized interest by operating segment for the years ended December 31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"></td><td style="width:57.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.188%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.188%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,693</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,748</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,504</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biopharma</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,592 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,678 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">of which Manufacturing & Supply</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,188 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,129 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceuticals</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,010 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vaccines</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">421 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consumer Healthcare</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">70 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">of which Manufacturing & Supply</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">63</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Of which capitalized interest</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) 2022 figures have been adjusted to take into account of the two new operating segments, Biopharma and Consumer Healthcare, effective January 1, 2023.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Off balance sheet commitments relating to property, plant and equipment as of December 31, 2023, 2022 and 2021 are set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Firm orders of property, plant and equipment</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">638 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">861 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">769 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Property, plant and equipment pledged as security for liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth the net impairment losses recognized in each of the last three financial periods:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net impairment losses on property, plant and equipment</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">130</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">186</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">39</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) These amounts mainly comprise impairment losses recognized as a result of decisions taken during the periods presented, relating primarily to shutdowns or changes in use of industrial sites.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.3.2. Property, plant and equipment leased – right-of-use assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Right-of-use assets relating to property, plant and equipment leased by Sanofi are analyzed in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:82.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Right-of-use assets</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,711</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">93 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">963 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(91)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,745</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(26)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">292 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(232)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,872</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,672</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation & impairment at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(513)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation and impairment charged in the period</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(315)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation & impairment at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(797)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation and impairment charged in the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(341)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation & impairment at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,057)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation and impairment charged in the period</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation & impairment at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,018)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,948</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,815</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,654</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) This line also includes the effect of the reclassification of assets to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) In December 2018, Sanofi signed two leases on real estate assets in the United States (at Cambridge, Massachusetts) for an initial lease term of 15 years. The first lease, relating to office space, began in April 2021; Sanofi recognized a right-of-use asset of €320 million, as well as the lease liability. The second lease, relating to laboratory facilities, began on July 1, 2021; Sanofi recognized a right-of-use asset of €424 million, as well as the lease liability.</span></div><div style="margin-top:1pt;padding-left:18pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Leased assets comprised offices and industrial premises (90%) and the vehicle fleet (10%) as of December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Annual lease costs on short term leases and low value asset leases amounted to €19 million in the year ended December 31, 2023, €26 million in the year ended December 31, 2022, and €25 million in the year ended December 31, 2021. Variable lease payments, sub-leasing activities, and sale-and-leaseback transactions were immaterial.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total cash outflows on leases (excluding annual lease costs on short term leases and low value asset leases) were €315 million in the year ended December 31, 2023, €389 million in the year ended December 31, 2022, and €302 million in the year ended December 31, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A maturity analysis of the lease liability is disclosed in Note D.17.2.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Commitments related to short-term leases and low value asset leases, including future payments for lease contracts committed but not yet commenced, are disclosed in Note D.21.</span></div>
CY2021Q4	ifrs-full	Property Plant And Equipment PropertyPlantAndEquipment	10028000000	eur
CY2023	ifrs-full	Additions Other Than Through Business Combinations Property Plant And Equipment AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment	1693000000	eur
CY2022	ifrs-full	Additions Other Than Through Business Combinations Property Plant And Equipment AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment	1748000000	eur
CY2021	ifrs-full	Additions Other Than Through Business Combinations Property Plant And Equipment AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment	1504000000	eur
CY2023	ifrs-full	Interest Costs Capitalised InterestCostsCapitalised	26000000	eur
CY2022	ifrs-full	Interest Costs Capitalised InterestCostsCapitalised	17000000	eur
CY2021	ifrs-full	Interest Costs Capitalised InterestCostsCapitalised	14000000	eur
CY2023	sny	Firm Orders Of Property Plant And Equipment FirmOrdersOfPropertyPlantAndEquipment	638000000	eur
CY2022	sny	Firm Orders Of Property Plant And Equipment FirmOrdersOfPropertyPlantAndEquipment	861000000	eur
CY2021	sny	Firm Orders Of Property Plant And Equipment FirmOrdersOfPropertyPlantAndEquipment	769000000	eur
CY2023Q4	ifrs-full	Property Plant And Equipment Pledged As Security PropertyPlantAndEquipmentPledgedAsSecurity	16000000	eur
CY2022Q4	ifrs-full	Property Plant And Equipment Pledged As Security PropertyPlantAndEquipmentPledgedAsSecurity	0	eur
CY2021Q4	ifrs-full	Property Plant And Equipment Pledged As Security PropertyPlantAndEquipmentPledgedAsSecurity	9000000	eur

CY2023

dei

Amendment Flag

AmendmentFlag

false

CY2023

dei

Document Fiscal Year Focus

DocumentFiscalYearFocus

2023

CY2023

dei

Document Fiscal Period Focus

DocumentFiscalPeriodFocus

FY

CY2023

dei

Entity Central Index Key

EntityCentralIndexKey

0001121404

CY2023

dei

Document Type

DocumentType

20-F

CY2023

dei

Document Registration Statement

DocumentRegistrationStatement

false

CY2023

dei

Document Annual Report

DocumentAnnualReport

true

CY2023

dei

Document Period End Date

DocumentPeriodEndDate

2023-12-31

CY2023

dei

Current Fiscal Year End Date

CurrentFiscalYearEndDate

--12-31

CY2023Q4

ifrs-full

Current Trade Receivables

CurrentTradeReceivables

8433000000

eur

CY2022Q4

ifrs-full

Current Trade Receivables

CurrentTradeReceivables

8424000000

eur

CY2023

dei

Document Transition Report

DocumentTransitionReport

false

CY2023

dei

Document Shell Company Report

DocumentShellCompanyReport

false

CY2023

dei

Entity File Number

EntityFileNumber

001-31368

CY2023

dei

Entity Registrant Name

EntityRegistrantName

Sanofi

CY2023

dei

Entity Incorporation State Country Code

EntityIncorporationStateCountryCode

I0

CY2023

dei

Entity Address Address Line1

EntityAddressAddressLine1

46, avenue de la Grande Armée

CY2023

dei

Entity Address Postal Zip Code

EntityAddressPostalZipCode

75017

CY2023

dei

Entity Address City Or Town

EntityAddressCityOrTown

Paris

CY2023

dei

Entity Address Country

EntityAddressCountry

FR

CY2023Q4

dei

Entity Common Stock Shares Outstanding

EntityCommonStockSharesOutstanding

1264799969

shares

CY2023

dei

Entity Well Known Seasoned Issuer

EntityWellKnownSeasonedIssuer

Yes

CY2023

dei

Entity Voluntary Filers

EntityVoluntaryFilers

No

CY2023

dei

Entity Current Reporting Status

EntityCurrentReportingStatus

Yes

CY2023

dei

Entity Interactive Data Current

EntityInteractiveDataCurrent

Yes

CY2023

dei

Entity Filer Category

EntityFilerCategory

Large Accelerated Filer

CY2023

dei

Entity Emerging Growth Company

EntityEmergingGrowthCompany

false

CY2023

dei

Icfr Auditor Attestation Flag

IcfrAuditorAttestationFlag

true

CY2023

dei

Document Fin Stmt Error Correction Flag

DocumentFinStmtErrorCorrectionFlag

false

CY2023

dei

Document Accounting Standard

DocumentAccountingStandard

International Financial Reporting Standards

CY2023

dei

Entity Shell Company

EntityShellCompany

false

CY2023

dei

Auditor Firm

AuditorFirmId

1347

CY2023

dei

Auditor Name

AuditorName

PricewaterhouseCoopers Audit

CY2023

dei

Auditor Location

AuditorLocation

Neuilly-sur-Seine

CY2023Q4

ifrs-full

Property Plant And Equipment

PropertyPlantAndEquipment

10160000000

eur

CY2022Q4

ifrs-full

Property Plant And Equipment

PropertyPlantAndEquipment

9869000000

eur

CY2021Q4

ifrs-full

Property Plant And Equipment

PropertyPlantAndEquipment

10028000000

eur

CY2023Q4

ifrs-full

Rightofuse Assets

RightofuseAssets

1654000000

eur

CY2022Q4

ifrs-full

Rightofuse Assets

RightofuseAssets

1815000000

eur

CY2021Q4

ifrs-full

Rightofuse Assets

RightofuseAssets

1948000000

eur

CY2023Q4

ifrs-full

Goodwill

49404000000

eur

CY2022Q4

ifrs-full

Goodwill

49892000000

eur

CY2021Q4

ifrs-full

Goodwill

48056000000

eur

CY2023Q4

ifrs-full

Intangible Assets Other Than Goodwill

IntangibleAssetsOtherThanGoodwill

24319000000

eur

CY2022Q4

ifrs-full

Intangible Assets Other Than Goodwill

IntangibleAssetsOtherThanGoodwill

21640000000

eur

CY2021Q4

ifrs-full

Intangible Assets Other Than Goodwill

IntangibleAssetsOtherThanGoodwill

21407000000

eur

CY2023Q4

ifrs-full

Investment Accounted For Using Equity Method

InvestmentAccountedForUsingEquityMethod

424000000

eur

CY2022Q4

ifrs-full

Investment Accounted For Using Equity Method

InvestmentAccountedForUsingEquityMethod

677000000

eur

CY2021Q4

ifrs-full

Investment Accounted For Using Equity Method

InvestmentAccountedForUsingEquityMethod

250000000

eur

CY2023Q4

ifrs-full

Other Noncurrent Assets

OtherNoncurrentAssets

3218000000

eur

CY2022Q4

ifrs-full

Other Noncurrent Assets

OtherNoncurrentAssets

3095000000

eur

CY2021Q4

ifrs-full

Other Noncurrent Assets

OtherNoncurrentAssets

3127000000

eur

CY2023Q4

ifrs-full

Current Tax Assets Noncurrent

CurrentTaxAssetsNoncurrent

188000000

eur

CY2022Q4

ifrs-full

Current Tax Assets Noncurrent

CurrentTaxAssetsNoncurrent

242000000

eur

CY2021Q4

ifrs-full

Current Tax Assets Noncurrent

CurrentTaxAssetsNoncurrent

175000000

eur

CY2023Q4

ifrs-full

Deferred Tax Assets

DeferredTaxAssets

6427000000

eur

CY2022Q4

ifrs-full

Deferred Tax Assets

DeferredTaxAssets

5381000000

eur

CY2021Q4

ifrs-full

Deferred Tax Assets

DeferredTaxAssets

4598000000

eur

CY2023Q4

ifrs-full

Noncurrent Assets

NoncurrentAssets

95794000000

eur

CY2022Q4

ifrs-full

Noncurrent Assets

NoncurrentAssets

92611000000

eur

CY2021Q4

ifrs-full

Noncurrent Assets

NoncurrentAssets

89589000000

eur

CY2023Q4

ifrs-full

Inventories

9666000000

eur

CY2022Q4

ifrs-full

Inventories

8960000000

eur

CY2021Q4

ifrs-full

Inventories

8715000000

eur

CY2021Q4

ifrs-full

Current Trade Receivables

CurrentTradeReceivables

7568000000

eur

CY2023Q4

ifrs-full

Other Current Assets

OtherCurrentAssets

3455000000

eur

CY2022Q4

ifrs-full

Other Current Assets

OtherCurrentAssets

3532000000

eur

CY2021Q4

ifrs-full

Other Current Assets

OtherCurrentAssets

3571000000

eur

CY2023Q4

ifrs-full

Current Tax Assets Current

CurrentTaxAssetsCurrent

391000000

eur

CY2022Q4

ifrs-full

Current Tax Assets Current

CurrentTaxAssetsCurrent

374000000

eur

CY2021Q4

ifrs-full

Current Tax Assets Current

CurrentTaxAssetsCurrent

612000000

eur

CY2023Q4

ifrs-full

Cash And Cash Equivalents

CashAndCashEquivalents

8710000000

eur

CY2022Q4

ifrs-full

Cash And Cash Equivalents

CashAndCashEquivalents

12736000000

eur

CY2021Q4

ifrs-full

Cash And Cash Equivalents

CashAndCashEquivalents

10098000000

eur

CY2023Q4

ifrs-full

Current Assets Other Than Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners

CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners

30655000000

eur

CY2022Q4

ifrs-full

Current Assets Other Than Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners

CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners

34026000000

eur

CY2021Q4

ifrs-full

Current Assets Other Than Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners

CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners

30564000000

eur

CY2023Q4

ifrs-full

Noncurrent Assets Or Disposal Groups Classified As Held For Sale

NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale

15000000

eur

CY2022Q4

ifrs-full

Noncurrent Assets Or Disposal Groups Classified As Held For Sale

NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale

85000000

eur

CY2021Q4

ifrs-full

Noncurrent Assets Or Disposal Groups Classified As Held For Sale

NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale

89000000

eur

CY2023Q4

ifrs-full

Assets

126464000000

eur

CY2022Q4

ifrs-full

Assets

126722000000

eur

CY2021Q4

ifrs-full

Assets

120242000000

eur

CY2023Q4

ifrs-full

Equity Attributable To Owners Of Parent

EquityAttributableToOwnersOfParent

74040000000

eur

CY2022Q4

ifrs-full

Equity Attributable To Owners Of Parent

EquityAttributableToOwnersOfParent

74784000000

eur

CY2021Q4

ifrs-full

Equity Attributable To Owners Of Parent

EquityAttributableToOwnersOfParent

68681000000

eur

CY2023Q4

ifrs-full

Noncontrolling Interests

NoncontrollingInterests

313000000

eur

CY2022Q4

ifrs-full

Noncontrolling Interests

NoncontrollingInterests

368000000

eur

CY2021Q4

ifrs-full

Noncontrolling Interests

NoncontrollingInterests

350000000

eur

CY2023Q4

ifrs-full

Equity

74353000000

eur

CY2022Q4

ifrs-full

Equity

75152000000

eur

CY2021Q4

ifrs-full

Equity

69031000000

eur

CY2023Q4

ifrs-full

Longterm Borrowings

LongtermBorrowings

14347000000

eur

CY2022Q4

ifrs-full

Longterm Borrowings

LongtermBorrowings

14857000000

eur

CY2021Q4

ifrs-full

Longterm Borrowings

LongtermBorrowings

17123000000

eur

CY2023Q4

ifrs-full

Noncurrent Lease Liabilities

NoncurrentLeaseLiabilities

1755000000

eur

CY2022Q4

ifrs-full

Noncurrent Lease Liabilities

NoncurrentLeaseLiabilities

1904000000

eur

CY2021Q4

ifrs-full

Noncurrent Lease Liabilities

NoncurrentLeaseLiabilities

1839000000

eur

CY2023Q4

sny

Non Current Liabilities Related To Business Combinations And To Non Controlling Interests

NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests

501000000

eur

CY2022Q4

sny

Non Current Liabilities Related To Business Combinations And To Non Controlling Interests

NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests

674000000

eur

CY2021Q4

sny

Non Current Liabilities Related To Business Combinations And To Non Controlling Interests

NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests

577000000

eur

CY2023Q4

sny

Non Current Provisions And Other Non Current Liabilities

NonCurrentProvisionsAndOtherNonCurrentLiabilities

7602000000

eur

CY2022Q4

sny

Non Current Provisions And Other Non Current Liabilities

NonCurrentProvisionsAndOtherNonCurrentLiabilities

6341000000

eur

CY2021Q4

sny

Non Current Provisions And Other Non Current Liabilities

NonCurrentProvisionsAndOtherNonCurrentLiabilities

6721000000

eur

CY2023Q4

ifrs-full

Current Tax Liabilities Noncurrent

CurrentTaxLiabilitiesNoncurrent

1842000000

eur

CY2022Q4

ifrs-full

Current Tax Liabilities Noncurrent

CurrentTaxLiabilitiesNoncurrent

1979000000

eur

CY2021Q4

ifrs-full

Current Tax Liabilities Noncurrent

CurrentTaxLiabilitiesNoncurrent

2039000000

eur

CY2023Q4

ifrs-full

Deferred Tax Liabilities

DeferredTaxLiabilities

1857000000

eur

CY2022Q4

ifrs-full

Deferred Tax Liabilities

DeferredTaxLiabilities

1841000000

eur

CY2021Q4

ifrs-full

Deferred Tax Liabilities

DeferredTaxLiabilities

1617000000

eur

CY2023Q4

ifrs-full

Noncurrent Liabilities

NoncurrentLiabilities

27904000000

eur

CY2022Q4

ifrs-full

Noncurrent Liabilities

NoncurrentLiabilities

27596000000

eur

CY2021Q4

ifrs-full

Noncurrent Liabilities

NoncurrentLiabilities

29916000000

eur

CY2023Q4

ifrs-full

Trade And Other Current Payables To Trade Suppliers

TradeAndOtherCurrentPayablesToTradeSuppliers

7328000000

eur

CY2022Q4

ifrs-full

Trade And Other Current Payables To Trade Suppliers

TradeAndOtherCurrentPayablesToTradeSuppliers

6813000000

eur

CY2021Q4

ifrs-full

Trade And Other Current Payables To Trade Suppliers

TradeAndOtherCurrentPayablesToTradeSuppliers

6180000000

eur

CY2023Q4

sny

Current Liabilities Related To Business Combinations And To Non Controlling Interests

CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests

208000000

eur

CY2022Q4

sny

Current Liabilities Related To Business Combinations And To Non Controlling Interests

CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests

105000000

eur

CY2021Q4

sny

Current Liabilities Related To Business Combinations And To Non Controlling Interests

CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests

137000000

eur

CY2023Q4

sny

Current Provisions And Other Current Liabilities

CurrentProvisionsAndOtherCurrentLiabilities

13741000000

eur

CY2022Q4

sny

Current Provisions And Other Current Liabilities

CurrentProvisionsAndOtherCurrentLiabilities

12021000000

eur

CY2021Q4

sny

Current Provisions And Other Current Liabilities

CurrentProvisionsAndOtherCurrentLiabilities

11217000000

eur

CY2023Q4

ifrs-full

Current Tax Liabilities Current

CurrentTaxLiabilitiesCurrent

597000000

eur

CY2022Q4

ifrs-full

Current Tax Liabilities Current

CurrentTaxLiabilitiesCurrent

574000000

eur

CY2021Q4

ifrs-full

Current Tax Liabilities Current

CurrentTaxLiabilitiesCurrent

309000000

eur

CY2023Q4

ifrs-full

Current Lease Liabilities

CurrentLeaseLiabilities

275000000

eur

CY2022Q4

ifrs-full

Current Lease Liabilities

CurrentLeaseLiabilities

277000000

eur

CY2021Q4

ifrs-full

Current Lease Liabilities

CurrentLeaseLiabilities

269000000

eur

CY2023Q4

ifrs-full

Current Borrowings And Current Portion Of Noncurrent Borrowings

CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings

2045000000

eur

CY2022Q4

ifrs-full

Current Borrowings And Current Portion Of Noncurrent Borrowings

CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings

4174000000

eur

CY2021Q4

ifrs-full

Current Borrowings And Current Portion Of Noncurrent Borrowings

CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings

3183000000

eur

CY2023Q4

ifrs-full

Current Liabilities Other Than Liabilities Included In Disposal Groups Classified As Held For Sale

CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale

24194000000

eur

CY2022Q4

ifrs-full

Current Liabilities Other Than Liabilities Included In Disposal Groups Classified As Held For Sale

CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale

23964000000

eur

CY2021Q4

ifrs-full

Current Liabilities Other Than Liabilities Included In Disposal Groups Classified As Held For Sale

CurrentLiabilitiesOtherThanLiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale

21295000000

eur

CY2023Q4

ifrs-full

Liabilities Included In Disposal Groups Classified As Held For Sale

LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale

13000000

eur

CY2022Q4

ifrs-full

Liabilities Included In Disposal Groups Classified As Held For Sale

LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale

10000000

eur

CY2021Q4

ifrs-full

Liabilities Included In Disposal Groups Classified As Held For Sale

LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale

0

eur

CY2023Q4

ifrs-full

Equity And Liabilities

EquityAndLiabilities

126464000000

eur

CY2022Q4

ifrs-full

Equity And Liabilities

EquityAndLiabilities

126722000000

eur

CY2021Q4

ifrs-full

Equity And Liabilities

EquityAndLiabilities

120242000000

eur

CY2023

ifrs-full

Revenue From Sale Of Goods

RevenueFromSaleOfGoods

43070000000

eur

CY2022

ifrs-full

Revenue From Sale Of Goods

RevenueFromSaleOfGoods

42997000000

eur

CY2021

ifrs-full

Revenue From Sale Of Goods

RevenueFromSaleOfGoods

37761000000

eur

CY2023

ifrs-full

Other Revenue

OtherRevenue

3374000000

eur

CY2022

ifrs-full

Other Revenue

OtherRevenue

2392000000

eur

CY2021

ifrs-full

Other Revenue

OtherRevenue

1414000000

eur

CY2023

ifrs-full

Cost Of Sales

CostOfSales

14236000000

eur

CY2022

ifrs-full

Cost Of Sales

CostOfSales

13695000000

eur

CY2021

ifrs-full

Cost Of Sales

CostOfSales

12255000000

eur

CY2023

ifrs-full

Gross Profit

GrossProfit

32208000000

eur

CY2022

ifrs-full

Gross Profit

GrossProfit

31694000000

eur

CY2021

ifrs-full

Gross Profit

GrossProfit

26920000000

eur

CY2023

ifrs-full

Research And Development Expense

ResearchAndDevelopmentExpense

6728000000

eur

CY2022

ifrs-full

Research And Development Expense

ResearchAndDevelopmentExpense

6706000000

eur

CY2021

ifrs-full

Research And Development Expense

ResearchAndDevelopmentExpense

5692000000

eur

CY2023

ifrs-full

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

10692000000

eur

CY2022

ifrs-full

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

10492000000

eur

CY2021

ifrs-full

Selling General And Administrative Expense

SellingGeneralAndAdministrativeExpense

9555000000

eur

CY2023

ifrs-full

Miscellaneous Other Operating Income

MiscellaneousOtherOperatingIncome

1292000000

eur

CY2022

ifrs-full

Miscellaneous Other Operating Income

MiscellaneousOtherOperatingIncome

1969000000

eur

CY2021

ifrs-full

Miscellaneous Other Operating Income

MiscellaneousOtherOperatingIncome

859000000

eur

CY2023

ifrs-full

Miscellaneous Other Operating Expense

MiscellaneousOtherOperatingExpense

3516000000

eur

CY2022

ifrs-full

Miscellaneous Other Operating Expense

MiscellaneousOtherOperatingExpense

2531000000

eur

CY2021

ifrs-full

Miscellaneous Other Operating Expense

MiscellaneousOtherOperatingExpense

1805000000

eur

CY2023

ifrs-full

Amortisation Intangible Assets Other Than Goodwill

AmortisationIntangibleAssetsOtherThanGoodwill

2172000000

eur

CY2022

ifrs-full

Amortisation Intangible Assets Other Than Goodwill

AmortisationIntangibleAssetsOtherThanGoodwill

2053000000

eur

CY2021

ifrs-full

Amortisation Intangible Assets Other Than Goodwill

AmortisationIntangibleAssetsOtherThanGoodwill

1580000000

eur

CY2023

ifrs-full

Impairment Loss Recognised In Profit Or Loss Intangible Assets Other Than Goodwill

ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill

896000000

eur

CY2022

ifrs-full

Impairment Loss Recognised In Profit Or Loss Intangible Assets Other Than Goodwill

ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill

-454000000

eur

CY2021

ifrs-full

Impairment Loss Recognised In Profit Or Loss Intangible Assets Other Than Goodwill

ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill

192000000

eur

CY2023

ifrs-full

Increase Decrease In Contingent Consideration Asset Liability

IncreaseDecreaseInContingentConsiderationAssetLiability

93000000

eur

CY2022

ifrs-full

Increase Decrease In Contingent Consideration Asset Liability

IncreaseDecreaseInContingentConsiderationAssetLiability

-27000000

eur

CY2021

ifrs-full

Increase Decrease In Contingent Consideration Asset Liability

IncreaseDecreaseInContingentConsiderationAssetLiability

4000000

eur

CY2023

ifrs-full

Expense Of Restructuring Activities

ExpenseOfRestructuringActivities

1490000000

eur

CY2022

ifrs-full

Expense Of Restructuring Activities

ExpenseOfRestructuringActivities

1336000000

eur

CY2021

ifrs-full

Expense Of Restructuring Activities

ExpenseOfRestructuringActivities

820000000

eur

CY2023

sny

Other Gains Losses And Litigation

OtherGainsLossesAndLitigation

-38000000

eur

CY2022

sny

Other Gains Losses And Litigation

OtherGainsLossesAndLitigation

-370000000

eur

CY2021

sny

Other Gains Losses And Litigation

OtherGainsLossesAndLitigation

-5000000

eur

CY2023

ifrs-full

Profit Loss From Operating Activities

ProfitLossFromOperatingActivities

7875000000

eur

CY2022

ifrs-full

Profit Loss From Operating Activities

ProfitLossFromOperatingActivities

10656000000

eur

CY2021

ifrs-full

Profit Loss From Operating Activities

ProfitLossFromOperatingActivities

8126000000

eur

CY2023

ifrs-full

Finance Costs

FinanceCosts

1313000000

eur

CY2022

ifrs-full

Finance Costs

FinanceCosts

440000000

eur

CY2021

ifrs-full

Finance Costs

FinanceCosts

368000000

eur

CY2023

ifrs-full

Finance Income

FinanceIncome

591000000

eur

CY2022

ifrs-full

Finance Income

FinanceIncome

206000000

eur

CY2021

ifrs-full

Finance Income

FinanceIncome

40000000

eur

CY2023

sny

Income Before Tax And Investments Accounted For Equity Method Investments

IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments

7153000000

eur

CY2022

sny

Income Before Tax And Investments Accounted For Equity Method Investments

IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments

10422000000

eur

CY2021

sny

Income Before Tax And Investments Accounted For Equity Method Investments

IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments

7798000000

eur

CY2023

ifrs-full

Income Tax Expense Continuing Operations

IncomeTaxExpenseContinuingOperations

1602000000

eur

CY2022

ifrs-full

Income Tax Expense Continuing Operations

IncomeTaxExpenseContinuingOperations

2006000000

eur

CY2021

ifrs-full

Income Tax Expense Continuing Operations

IncomeTaxExpenseContinuingOperations

1558000000

eur

CY2023

ifrs-full

Share Of Profit Loss Of Associates Accounted For Using Equity Method

ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod

-115000000

eur

CY2022

ifrs-full

Share Of Profit Loss Of Associates Accounted For Using Equity Method

ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod

68000000

eur

CY2021

ifrs-full

Share Of Profit Loss Of Associates Accounted For Using Equity Method

ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod

39000000

eur

CY2023

ifrs-full

Profit Loss

ProfitLoss

5436000000

eur

CY2022

ifrs-full

Profit Loss

ProfitLoss

8484000000

eur

CY2021

ifrs-full

Profit Loss

ProfitLoss

6279000000

eur

CY2023

ifrs-full

Profit Loss Attributable To Noncontrolling Interests

ProfitLossAttributableToNoncontrollingInterests

36000000

eur

CY2022

ifrs-full

Profit Loss Attributable To Noncontrolling Interests

ProfitLossAttributableToNoncontrollingInterests

113000000

eur

CY2021

ifrs-full

Profit Loss Attributable To Noncontrolling Interests

ProfitLossAttributableToNoncontrollingInterests

56000000

eur

CY2023

ifrs-full

Profit Loss Attributable To Owners Of Parent

ProfitLossAttributableToOwnersOfParent

5400000000

eur

CY2022

ifrs-full

Profit Loss Attributable To Owners Of Parent

ProfitLossAttributableToOwnersOfParent

8371000000

eur

CY2021

ifrs-full

Profit Loss Attributable To Owners Of Parent

ProfitLossAttributableToOwnersOfParent

6223000000

eur

CY2023

ifrs-full

Weighted Average Shares

WeightedAverageShares

1251700000

shares

CY2022

ifrs-full

Weighted Average Shares

WeightedAverageShares

1251900000

shares

CY2021

ifrs-full

Weighted Average Shares

WeightedAverageShares

1252500000

shares

CY2023

ifrs-full

Adjusted Weighted Average Shares

AdjustedWeightedAverageShares

1256400000

shares

CY2022

ifrs-full

Adjusted Weighted Average Shares

AdjustedWeightedAverageShares

1256900000

shares

CY2021

ifrs-full

Adjusted Weighted Average Shares

AdjustedWeightedAverageShares

1257900000

shares

CY2023

sny

Basic Earnings Loss Per Share Attributable To Owners Of Parent

BasicEarningsLossPerShareAttributableToOwnersOfParent

4.31

CY2022

sny

Basic Earnings Loss Per Share Attributable To Owners Of Parent

BasicEarningsLossPerShareAttributableToOwnersOfParent

6.69

CY2021

sny

Basic Earnings Loss Per Share Attributable To Owners Of Parent

BasicEarningsLossPerShareAttributableToOwnersOfParent

4.97

CY2023

sny

Diluted Earnings Loss Per Share Attributable To Owners Of Parent

DilutedEarningsLossPerShareAttributableToOwnersOfParent

4.30

CY2022

sny

Diluted Earnings Loss Per Share Attributable To Owners Of Parent

DilutedEarningsLossPerShareAttributableToOwnersOfParent

6.66

CY2021

sny

Diluted Earnings Loss Per Share Attributable To Owners Of Parent

DilutedEarningsLossPerShareAttributableToOwnersOfParent

4.95

CY2023

ifrs-full

Profit Loss

ProfitLoss

5436000000

eur

CY2022

ifrs-full

Profit Loss

ProfitLoss

8484000000

eur

CY2021

ifrs-full

Profit Loss

ProfitLoss

6279000000

eur

CY2023

ifrs-full

Profit Loss Attributable To Owners Of Parent

ProfitLossAttributableToOwnersOfParent

5400000000

eur

CY2022

ifrs-full

Profit Loss Attributable To Owners Of Parent

ProfitLossAttributableToOwnersOfParent

8371000000

eur

CY2021

ifrs-full

Profit Loss Attributable To Owners Of Parent

ProfitLossAttributableToOwnersOfParent

6223000000

eur

CY2023

ifrs-full

Profit Loss Attributable To Noncontrolling Interests

ProfitLossAttributableToNoncontrollingInterests

36000000

eur

CY2022

ifrs-full

Profit Loss Attributable To Noncontrolling Interests

ProfitLossAttributableToNoncontrollingInterests

113000000

eur

CY2021

ifrs-full

Profit Loss Attributable To Noncontrolling Interests

ProfitLossAttributableToNoncontrollingInterests

56000000

eur

CY2023

ifrs-full

Actuarial Gains Losses Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset

ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset

171000000

eur

CY2022

ifrs-full

Actuarial Gains Losses Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset

ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset

-654000000

eur

CY2021

ifrs-full

Actuarial Gains Losses Arising From Changes In Financial Assumptions Net Defined Benefit Liability Asset

ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset

-686000000

eur

CY2023

ifrs-full

Gains Losses Recognised In Other Comprehensive Income Fair Value Measurement Entitys Own Equity Instruments

GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments

97000000

eur

CY2022

ifrs-full

Gains Losses Recognised In Other Comprehensive Income Fair Value Measurement Entitys Own Equity Instruments

GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments

13000000

eur

CY2021

ifrs-full

Gains Losses Recognised In Other Comprehensive Income Fair Value Measurement Entitys Own Equity Instruments

GainsLossesRecognisedInOtherComprehensiveIncomeFairValueMeasurementEntitysOwnEquityInstruments

165000000

eur

CY2023

ifrs-full

Income Tax Relating To Components Of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss

IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss

3000000

eur

CY2022

ifrs-full

Income Tax Relating To Components Of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss

IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss

216000000

eur

CY2021

ifrs-full

Income Tax Relating To Components Of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss

IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss

54000000

eur

CY2023

ifrs-full

Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net Of Tax

OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax

-77000000

eur

CY2022

ifrs-full

Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net Of Tax

OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax

451000000

eur

CY2021

ifrs-full

Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net Of Tax

OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax

797000000

eur

CY2023

sny

Gains Losses On Remeasuring Debt Instruments Before Tax

GainsLossesOnRemeasuringDebtInstrumentsBeforeTax

21000000

eur

CY2022

sny

Gains Losses On Remeasuring Debt Instruments Before Tax

GainsLossesOnRemeasuringDebtInstrumentsBeforeTax

-77000000

eur

CY2021

sny

Gains Losses On Remeasuring Debt Instruments Before Tax

GainsLossesOnRemeasuringDebtInstrumentsBeforeTax

-21000000

eur

CY2023

ifrs-full

Gains Losses On Cash Flow Hedges Before Tax

GainsLossesOnCashFlowHedgesBeforeTax

-1000000

eur

CY2022

ifrs-full

Gains Losses On Cash Flow Hedges Before Tax

GainsLossesOnCashFlowHedgesBeforeTax

7000000

eur

CY2021

ifrs-full

Gains Losses On Cash Flow Hedges Before Tax

GainsLossesOnCashFlowHedgesBeforeTax

-6000000

eur

CY2023

ifrs-full

Gains Losses On Exchange Differences On Translation Before Tax

GainsLossesOnExchangeDifferencesOnTranslationBeforeTax

-1540000000

eur

CY2022

ifrs-full

Gains Losses On Exchange Differences On Translation Before Tax

GainsLossesOnExchangeDifferencesOnTranslationBeforeTax

2278000000

eur

CY2021

ifrs-full

Gains Losses On Exchange Differences On Translation Before Tax

GainsLossesOnExchangeDifferencesOnTranslationBeforeTax

2459000000

eur

CY2023

ifrs-full

Income Tax Relating To Components Of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss

IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss

6000000

eur

CY2022

ifrs-full

Income Tax Relating To Components Of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss

IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss

-105000000

eur

CY2021

ifrs-full

Income Tax Relating To Components Of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss

IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss

-78000000

eur

CY2023

ifrs-full

Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net Of Tax

OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax

-1526000000

eur

CY2022

ifrs-full

Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net Of Tax

OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax

2313000000

eur

CY2021

ifrs-full

Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net Of Tax

OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax

2510000000

eur

CY2023

ifrs-full

Other Comprehensive Income

OtherComprehensiveIncome

-1603000000

eur

CY2022

ifrs-full

Other Comprehensive Income

OtherComprehensiveIncome

2764000000

eur

CY2021

ifrs-full

Other Comprehensive Income

OtherComprehensiveIncome

3307000000

eur

CY2023

ifrs-full

Comprehensive Income

ComprehensiveIncome

3833000000

eur

CY2022

ifrs-full

Comprehensive Income

ComprehensiveIncome

11248000000

eur

CY2021

ifrs-full

Comprehensive Income

ComprehensiveIncome

9586000000

eur

CY2023

ifrs-full

Comprehensive Income Attributable To Owners Of Parent

ComprehensiveIncomeAttributableToOwnersOfParent

3810000000

eur

CY2022

ifrs-full

Comprehensive Income Attributable To Owners Of Parent

ComprehensiveIncomeAttributableToOwnersOfParent

11130000000

eur

CY2021

ifrs-full

Comprehensive Income Attributable To Owners Of Parent

ComprehensiveIncomeAttributableToOwnersOfParent

9519000000

eur

CY2023

ifrs-full

Comprehensive Income Attributable To Noncontrolling Interests

ComprehensiveIncomeAttributableToNoncontrollingInterests

23000000

eur

CY2022

ifrs-full

Comprehensive Income Attributable To Noncontrolling Interests

ComprehensiveIncomeAttributableToNoncontrollingInterests

118000000

eur

CY2021

ifrs-full

Comprehensive Income Attributable To Noncontrolling Interests

ComprehensiveIncomeAttributableToNoncontrollingInterests

67000000

eur

CY2020Q4

ifrs-full

Equity

63252000000

eur

CY2021

ifrs-full

Other Comprehensive Income

OtherComprehensiveIncome

3307000000

eur

CY2021

ifrs-full

Profit Loss

ProfitLoss

6279000000

eur

CY2021

ifrs-full

Comprehensive Income

ComprehensiveIncome

9586000000

eur

CY2021

ifrs-full

Dividends Paid Ordinary Shares Per Share

DividendsPaidOrdinarySharesPerShare

3.20

CY2021

ifrs-full

Dividends Recognised As Distributions To Owners Of Parent

DividendsRecognisedAsDistributionsToOwnersOfParent

4008000000

eur

CY2021

ifrs-full

Dividends Recognised As Distributions To Noncontrolling Interests

DividendsRecognisedAsDistributionsToNoncontrollingInterests

49000000

eur

CY2021

ifrs-full

Purchase Of Treasury Shares

PurchaseOfTreasuryShares

382000000

eur

CY2021

ifrs-full

Increase Decrease Through Exercise Of Options

IncreaseDecreaseThroughExerciseOfOptions

11000000

eur

CY2021

sny

Increase Decrease Through Share Based Payment Plans Issuance Of Restricted Shares And Vesting Of Existing Restricted Shares

IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares

0

eur

CY2021

sny

Increase Decrease Through Share Based Payment Plans Employee Share Ownership Plans

IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans

168000000

eur

CY2021

sny

Increase Decrease Through Share Based Payment Plans Value Of Services Obtained From Employees

IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees

244000000

eur

CY2021

sny

Increase Decrease Through Share Based Payment Plans Tax Effects Of The Exercise Of Stock Options

IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions

23000000

eur

CY2021

sny

Increase Decrease Through Changes In Non Controlling Interests Arising From Divestment

IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment

186000000

eur

CY2021Q4

ifrs-full

Equity

69031000000

eur

CY2021Q4

ifrs-full

Equity

69031000000

eur

CY2022

ifrs-full

Other Comprehensive Income

OtherComprehensiveIncome

2764000000

eur

CY2022

ifrs-full

Profit Loss

ProfitLoss

8484000000

eur

CY2022

ifrs-full

Comprehensive Income

ComprehensiveIncome

11248000000

eur

CY2022

ifrs-full

Dividends Paid Ordinary Shares Per Share

DividendsPaidOrdinarySharesPerShare

3.33

CY2022

ifrs-full

Dividends Recognised As Distributions To Owners Of Parent

DividendsRecognisedAsDistributionsToOwnersOfParent

4168000000

eur

CY2022

sny

Exceptional Supplementary Dividends Recognised As Distributions To Owners Of Parent

ExceptionalSupplementaryDividendsRecognisedAsDistributionsToOwnersOfParent

793000000

eur

CY2022

ifrs-full

Dividends Recognised As Distributions To Noncontrolling Interests

DividendsRecognisedAsDistributionsToNoncontrollingInterests

100000000

eur

CY2022

ifrs-full

Purchase Of Treasury Shares

PurchaseOfTreasuryShares

497000000

eur

CY2022

ifrs-full

Reduction Of Issued Capital

ReductionOfIssuedCapital

0

eur

CY2022

ifrs-full

Increase Decrease Through Exercise Of Options

IncreaseDecreaseThroughExerciseOfOptions

35000000

eur

CY2022

sny

Increase Decrease Through Share Based Payment Plans Issuance Of Restricted Shares And Vesting Of Existing Restricted Shares

IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares

0

eur

CY2022

sny

Increase Decrease Through Share Based Payment Plans Employee Share Ownership Plans

IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans

153000000

eur

CY2022

sny

Increase Decrease Through Share Based Payment Plans Value Of Services Obtained From Employees

IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees

245000000

eur

CY2022

sny

Increase Decrease Through Share Based Payment Plans Tax Effects Of The Exercise Of Stock Options

IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions

8000000

eur

CY2022

ifrs-full

Increase Decrease Through Transfers And Other Changes Equity

IncreaseDecreaseThroughTransfersAndOtherChangesEquity

-10000000

eur

CY2022Q4

ifrs-full

Equity

75152000000

eur

CY2022Q4

ifrs-full

Equity

75152000000

eur

CY2023

ifrs-full

Other Comprehensive Income

OtherComprehensiveIncome

-1603000000

eur

CY2023

ifrs-full

Profit Loss

ProfitLoss

5436000000

eur

CY2023

ifrs-full

Comprehensive Income

ComprehensiveIncome

3833000000

eur

CY2023

ifrs-full

Dividends Paid Ordinary Shares Per Share

DividendsPaidOrdinarySharesPerShare

3.56

CY2023

ifrs-full

Dividends Recognised As Distributions To Owners Of Parent

DividendsRecognisedAsDistributionsToOwnersOfParent

4454000000

eur

CY2023

ifrs-full

Dividends Recognised As Distributions To Noncontrolling Interests

DividendsRecognisedAsDistributionsToNoncontrollingInterests

59000000

eur

CY2023

ifrs-full

Purchase Of Treasury Shares

PurchaseOfTreasuryShares

593000000

eur

CY2023

ifrs-full

Increase Decrease Through Exercise Of Options

IncreaseDecreaseThroughExerciseOfOptions

37000000

eur

CY2023

sny

Increase Decrease Through Share Based Payment Plans Issuance Of Restricted Shares And Vesting Of Existing Restricted Shares

IncreaseDecreaseThroughShareBasedPaymentPlansIssuanceOfRestrictedSharesAndVestingOfExistingRestrictedShares

0

eur

CY2023

sny

Increase Decrease Through Share Based Payment Plans Employee Share Ownership Plans

IncreaseDecreaseThroughShareBasedPaymentPlansEmployeeShareOwnershipPlans

159000000

eur

CY2023

sny

Increase Decrease Through Share Based Payment Plans Value Of Services Obtained From Employees

IncreaseDecreaseThroughShareBasedPaymentPlansValueOfServicesObtainedFromEmployees

283000000

eur

CY2023

sny

Increase Decrease Through Share Based Payment Plans Tax Effects Of The Exercise Of Stock Options

IncreaseDecreaseThroughShareBasedPaymentPlansTaxEffectsOfTheExerciseOfStockOptions

3000000

eur

CY2023

sny

Increase Decrease Through Issuance Of Restricted Shares Equity

IncreaseDecreaseThroughIssuanceOfRestrictedSharesEquity

2000000

eur

CY2023

sny

Increase Decrease Through Changes In Non Controlling Interests Arising From Divestment

IncreaseDecreaseThroughChangesInNonControllingInterestsArisingFromDivestment

-10000000

eur

CY2023Q4

ifrs-full

Equity

74353000000

eur

CY2023

ifrs-full

Profit Loss Attributable To Ordinary Equity Holders Of Parent Entity

ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity

5400000000

eur

CY2022

ifrs-full

Profit Loss Attributable To Ordinary Equity Holders Of Parent Entity

ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity

8371000000

eur

CY2021

ifrs-full

Profit Loss Attributable To Ordinary Equity Holders Of Parent Entity

ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity

6223000000

eur

CY2023

ifrs-full

Profit Loss Attributable To Noncontrolling Interests

ProfitLossAttributableToNoncontrollingInterests

36000000

eur

CY2022

ifrs-full

Profit Loss Attributable To Noncontrolling Interests

ProfitLossAttributableToNoncontrollingInterests

113000000

eur

CY2021

ifrs-full

Profit Loss Attributable To Noncontrolling Interests

ProfitLossAttributableToNoncontrollingInterests

56000000

eur

CY2023

ifrs-full

Adjustments For Undistributed Profits Of Investments Accounted For Using Equity Method

AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod

-295000000

eur

CY2022

ifrs-full

Adjustments For Undistributed Profits Of Investments Accounted For Using Equity Method

AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod

48000000

eur

CY2021

ifrs-full

Adjustments For Undistributed Profits Of Investments Accounted For Using Equity Method

AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod

15000000

eur

CY2023

sny

Adjustments For Depreciation And Amortisation Expense And Impairment Loss Reversal Of Impairment Loss Of Property Plant And Equipment Right Of Use Assets And Intangible Asset

AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset

4792000000

eur

CY2022

sny

Adjustments For Depreciation And Amortisation Expense And Impairment Loss Reversal Of Impairment Loss Of Property Plant And Equipment Right Of Use Assets And Intangible Asset

AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset

3420000000

eur

CY2021

sny

Adjustments For Depreciation And Amortisation Expense And Impairment Loss Reversal Of Impairment Loss Of Property Plant And Equipment Right Of Use Assets And Intangible Asset

AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossOfPropertyPlantAndEquipmentRightOfUseAssetsAndIntangibleAsset

3351000000

eur

CY2023

ifrs-full

Adjustments For Losses Gains On Disposal Of Noncurrent Assets

AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets

-509000000

eur

CY2022

ifrs-full

Adjustments For Losses Gains On Disposal Of Noncurrent Assets

AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets

-711000000

eur

CY2021

ifrs-full

Adjustments For Losses Gains On Disposal Of Noncurrent Assets

AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets

-300000000

eur

CY2023

ifrs-full

Adjustments For Deferred Tax Expense

AdjustmentsForDeferredTaxExpense

-970000000

eur

CY2022

ifrs-full

Adjustments For Deferred Tax Expense

AdjustmentsForDeferredTaxExpense

-578000000

eur

CY2021

ifrs-full

Adjustments For Deferred Tax Expense

AdjustmentsForDeferredTaxExpense

-356000000

eur

CY2023

sny

Adjustments For Non Current Provisions And Other Non Current Liabilities

AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities

-136000000

eur

CY2022

sny

Adjustments For Non Current Provisions And Other Non Current Liabilities

AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities

280000000

eur

CY2021

sny

Adjustments For Non Current Provisions And Other Non Current Liabilities

AdjustmentsForNonCurrentProvisionsAndOtherNonCurrentLiabilities

-37000000

eur

CY2023

ifrs-full

Adjustments For Sharebased Payments

AdjustmentsForSharebasedPayments

283000000

eur

CY2022

ifrs-full

Adjustments For Sharebased Payments

AdjustmentsForSharebasedPayments

245000000

eur

CY2021

ifrs-full

Adjustments For Sharebased Payments

AdjustmentsForSharebasedPayments

244000000

eur

CY2023

sny

Impact Of The Workdown Of Acquired Inventories Remeasured At Fair Value

ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue

20000000

eur

CY2022

sny

Impact Of The Workdown Of Acquired Inventories Remeasured At Fair Value

ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue

3000000

eur

CY2021

sny

Impact Of The Workdown Of Acquired Inventories Remeasured At Fair Value

ImpactOfTheWorkdownOfAcquiredInventoriesRemeasuredAtFairValue

4000000

eur

CY2023

ifrs-full

Other Adjustments To Reconcile Profit Loss

OtherAdjustmentsToReconcileProfitLoss

283000000

eur

CY2022

ifrs-full

Other Adjustments To Reconcile Profit Loss

OtherAdjustmentsToReconcileProfitLoss

138000000

eur

CY2021

ifrs-full

Other Adjustments To Reconcile Profit Loss

OtherAdjustmentsToReconcileProfitLoss

-57000000

eur

CY2023

ifrs-full

Cash Flows From Used In Operations Before Changes In Working Capital

CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital

9494000000

eur

CY2022

ifrs-full

Cash Flows From Used In Operations Before Changes In Working Capital

CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital

11233000000

eur

CY2021

ifrs-full

Cash Flows From Used In Operations Before Changes In Working Capital

CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital

9113000000

eur

CY2023

ifrs-full

Adjustments For Decrease Increase In Inventories

AdjustmentsForDecreaseIncreaseInInventories

-840000000

eur

CY2022

ifrs-full

Adjustments For Decrease Increase In Inventories

AdjustmentsForDecreaseIncreaseInInventories

-927000000

eur

CY2021

ifrs-full

Adjustments For Decrease Increase In Inventories

AdjustmentsForDecreaseIncreaseInInventories

-357000000

eur

CY2023

ifrs-full

Adjustments For Decrease Increase In Trade Account Receivable

AdjustmentsForDecreaseIncreaseInTradeAccountReceivable

-397000000

eur

CY2022

ifrs-full

Adjustments For Decrease Increase In Trade Account Receivable

AdjustmentsForDecreaseIncreaseInTradeAccountReceivable

-777000000

eur

CY2021

ifrs-full

Adjustments For Decrease Increase In Trade Account Receivable

AdjustmentsForDecreaseIncreaseInTradeAccountReceivable

185000000

eur

CY2023

ifrs-full

Adjustments For Increase Decrease In Trade Account Payable

AdjustmentsForIncreaseDecreaseInTradeAccountPayable

402000000

eur

CY2022

ifrs-full

Adjustments For Increase Decrease In Trade Account Payable

AdjustmentsForIncreaseDecreaseInTradeAccountPayable

452000000

eur

CY2021

ifrs-full

Adjustments For Increase Decrease In Trade Account Payable

AdjustmentsForIncreaseDecreaseInTradeAccountPayable

451000000

eur

CY2023

sny

Net Change In Other Current Assets And Other Current Liabilities

NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities

1599000000

eur

CY2022

sny

Net Change In Other Current Assets And Other Current Liabilities

NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities

545000000

eur

CY2021

sny

Net Change In Other Current Assets And Other Current Liabilities

NetChangeInOtherCurrentAssetsAndOtherCurrentLiabilities

1130000000

eur

CY2023

ifrs-full

Cash Flows From Used In Operating Activities

CashFlowsFromUsedInOperatingActivities

10258000000

eur

CY2022

ifrs-full

Cash Flows From Used In Operating Activities

CashFlowsFromUsedInOperatingActivities

10526000000

eur

CY2021

ifrs-full

Cash Flows From Used In Operating Activities

CashFlowsFromUsedInOperatingActivities

10522000000

eur

CY2023

ifrs-full

Purchase Of Property Plant And Equipment Intangible Assets Other Than Goodwill Investment Property And Other Noncurrent Assets

PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets

3024000000

eur

CY2022

ifrs-full

Purchase Of Property Plant And Equipment Intangible Assets Other Than Goodwill Investment Property And Other Noncurrent Assets

PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets

2201000000

eur

CY2021

ifrs-full

Purchase Of Property Plant And Equipment Intangible Assets Other Than Goodwill Investment Property And Other Noncurrent Assets

PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets

2043000000

eur

CY2023

ifrs-full

Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities

CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities

3870000000

eur

CY2022

ifrs-full

Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities

CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities

992000000

eur

CY2021

ifrs-full

Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities

CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities

5594000000

eur

CY2023

ifrs-full

Purchase Of Financial Instruments Classified As Investing Activities

PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities

134000000

eur

CY2022

ifrs-full

Purchase Of Financial Instruments Classified As Investing Activities

PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities

488000000

eur

CY2021

ifrs-full

Purchase Of Financial Instruments Classified As Investing Activities

PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities

311000000

eur

CY2023

ifrs-full

Proceeds From Disposals Of Property Plant And Equipment Intangible Assets Other Than Goodwill Investment Property And Other Noncurrent Assets

ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets

1015000000

eur

CY2022

ifrs-full

Proceeds From Disposals Of Property Plant And Equipment Intangible Assets Other Than Goodwill Investment Property And Other Noncurrent Assets

ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets

1488000000

eur

CY2021

ifrs-full

Proceeds From Disposals Of Property Plant And Equipment Intangible Assets Other Than Goodwill Investment Property And Other Noncurrent Assets

ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets

676000000

eur

CY2023

ifrs-full

Cash Flows From Losing Control Of Subsidiaries Or Other Businesses Classified As Investing Activities

CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities

42000000

eur

CY2022

ifrs-full

Cash Flows From Losing Control Of Subsidiaries Or Other Businesses Classified As Investing Activities

CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities

134000000

eur

CY2021

ifrs-full

Cash Flows From Losing Control Of Subsidiaries Or Other Businesses Classified As Investing Activities

CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities

42000000

eur

CY2023

sny

Net Change In Other Non Current Assets

NetChangeInOtherNonCurrentAssets

-229000000

eur

CY2022

sny

Net Change In Other Non Current Assets

NetChangeInOtherNonCurrentAssets

-16000000

eur

CY2021

sny

Net Change In Other Non Current Assets

NetChangeInOtherNonCurrentAssets

-68000000

eur

CY2023

ifrs-full

Cash Flows From Used In Investing Activities

CashFlowsFromUsedInInvestingActivities

-6200000000

eur

CY2022

ifrs-full

Cash Flows From Used In Investing Activities

CashFlowsFromUsedInInvestingActivities

-2075000000

eur

CY2021

ifrs-full

Cash Flows From Used In Investing Activities

CashFlowsFromUsedInInvestingActivities

-7298000000

eur

CY2023

ifrs-full

Proceeds From Issuing Shares

ProceedsFromIssuingShares

195000000

eur

CY2022

ifrs-full

Proceeds From Issuing Shares

ProceedsFromIssuingShares

188000000

eur

CY2021

ifrs-full

Proceeds From Issuing Shares

ProceedsFromIssuingShares

186000000

eur

CY2023

ifrs-full

Dividends Paid To Equity Holders Of Parent Classified As Financing Activities

DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities

4454000000

eur

CY2022

ifrs-full

Dividends Paid To Equity Holders Of Parent Classified As Financing Activities

DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities

4168000000

eur

CY2021

ifrs-full

Dividends Paid To Equity Holders Of Parent Classified As Financing Activities

DividendsPaidToEquityHoldersOfParentClassifiedAsFinancingActivities

4008000000

eur

CY2023

ifrs-full

Dividends Paid To Noncontrolling Interests Classified As Financing Activities

DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities

61000000

eur

CY2022

ifrs-full

Dividends Paid To Noncontrolling Interests Classified As Financing Activities

DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities

99000000

eur

CY2021

ifrs-full

Dividends Paid To Noncontrolling Interests Classified As Financing Activities

DividendsPaidToNoncontrollingInterestsClassifiedAsFinancingActivities

48000000

eur

CY2023

ifrs-full

Payments From Changes In Ownership Interests In Subsidiaries

PaymentsFromChangesInOwnershipInterestsInSubsidiaries

3000000

eur

CY2022

ifrs-full

Payments From Changes In Ownership Interests In Subsidiaries

PaymentsFromChangesInOwnershipInterestsInSubsidiaries

0

eur

CY2021

ifrs-full

Payments From Changes In Ownership Interests In Subsidiaries

PaymentsFromChangesInOwnershipInterestsInSubsidiaries

0

eur

CY2023

ifrs-full

Proceeds From Noncurrent Borrowings

ProceedsFromNoncurrentBorrowings

48000000

eur

CY2022

ifrs-full

Proceeds From Noncurrent Borrowings

ProceedsFromNoncurrentBorrowings

1549000000

eur

CY2021

ifrs-full

Proceeds From Noncurrent Borrowings

ProceedsFromNoncurrentBorrowings

0

eur

CY2023

ifrs-full

Repayments Of Noncurrent Borrowings

RepaymentsOfNoncurrentBorrowings

3684000000

eur

CY2022

ifrs-full

Repayments Of Noncurrent Borrowings

RepaymentsOfNoncurrentBorrowings

2718000000

eur

CY2021

ifrs-full

Repayments Of Noncurrent Borrowings

RepaymentsOfNoncurrentBorrowings

2241000000

eur

CY2023

ifrs-full

Payments Of Lease Liabilities Classified As Financing Activities

PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities

265000000

eur

CY2022

ifrs-full

Payments Of Lease Liabilities Classified As Financing Activities

PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities

291000000

eur

CY2021

ifrs-full

Payments Of Lease Liabilities Classified As Financing Activities

PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities

149000000

eur

CY2023

sny

Cash Flows From Used In Increase Decrease In Current Borrowings And Other Financial Instruments

CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments

765000000

eur

CY2022

sny

Cash Flows From Used In Increase Decrease In Current Borrowings And Other Financial Instruments

CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments

215000000

eur

CY2021

sny

Cash Flows From Used In Increase Decrease In Current Borrowings And Other Financial Instruments

CashFlowsFromUsedInIncreaseDecreaseInCurrentBorrowingsAndOtherFinancialInstruments

-414000000

eur

CY2023

ifrs-full

Payments To Acquire Or Redeem Entitys Shares

PaymentsToAcquireOrRedeemEntitysShares

593000000

eur

CY2022

ifrs-full

Payments To Acquire Or Redeem Entitys Shares

PaymentsToAcquireOrRedeemEntitysShares

497000000

eur

CY2021

ifrs-full

Payments To Acquire Or Redeem Entitys Shares

PaymentsToAcquireOrRedeemEntitysShares

382000000

eur

CY2023

ifrs-full

Cash Flows From Used In Financing Activities

CashFlowsFromUsedInFinancingActivities

-8052000000

eur

CY2022

ifrs-full

Cash Flows From Used In Financing Activities

CashFlowsFromUsedInFinancingActivities

-5821000000

eur

CY2021

ifrs-full

Cash Flows From Used In Financing Activities

CashFlowsFromUsedInFinancingActivities

-7056000000

eur

CY2023

ifrs-full

Effect Of Exchange Rate Changes On Cash And Cash Equivalents

EffectOfExchangeRateChangesOnCashAndCashEquivalents

-32000000

eur

CY2022

ifrs-full

Effect Of Exchange Rate Changes On Cash And Cash Equivalents

EffectOfExchangeRateChangesOnCashAndCashEquivalents

8000000

eur

CY2021

ifrs-full

Effect Of Exchange Rate Changes On Cash And Cash Equivalents

EffectOfExchangeRateChangesOnCashAndCashEquivalents

15000000

eur

CY2023

ifrs-full

Increase Decrease In Cash And Cash Equivalents

IncreaseDecreaseInCashAndCashEquivalents

-4026000000

eur

CY2022

ifrs-full

Increase Decrease In Cash And Cash Equivalents

IncreaseDecreaseInCashAndCashEquivalents

2638000000

eur

CY2021

ifrs-full

Increase Decrease In Cash And Cash Equivalents

IncreaseDecreaseInCashAndCashEquivalents

-3817000000

eur

CY2022Q4

ifrs-full

Cash And Cash Equivalents

CashAndCashEquivalents

12736000000

eur

CY2021Q4

ifrs-full

Cash And Cash Equivalents

CashAndCashEquivalents

10098000000

eur

CY2020Q4

ifrs-full

Cash And Cash Equivalents

CashAndCashEquivalents

13915000000

eur

CY2023Q4

ifrs-full

Cash And Cash Equivalents

CashAndCashEquivalents

8710000000

eur

CY2022Q4

ifrs-full

Cash And Cash Equivalents

CashAndCashEquivalents

12736000000

eur

CY2021Q4

ifrs-full

Cash And Cash Equivalents

CashAndCashEquivalents

10098000000

eur

CY2023

ifrs-full

Income Taxes Paid Refund Classified As Operating Activities

IncomeTaxesPaidRefundClassifiedAsOperatingActivities

2623000000

eur

CY2022

ifrs-full

Income Taxes Paid Refund Classified As Operating Activities

IncomeTaxesPaidRefundClassifiedAsOperatingActivities

2452000000

eur

CY2021

ifrs-full

Income Taxes Paid Refund Classified As Operating Activities

IncomeTaxesPaidRefundClassifiedAsOperatingActivities

1280000000

eur

CY2023

ifrs-full

Interest Paid Classified As Operating Activities

InterestPaidClassifiedAsOperatingActivities

559000000

eur

CY2022

ifrs-full

Interest Paid Classified As Operating Activities

InterestPaidClassifiedAsOperatingActivities

380000000

eur

CY2021

ifrs-full

Interest Paid Classified As Operating Activities

InterestPaidClassifiedAsOperatingActivities

334000000

eur

CY2023

ifrs-full

Interest Received Classified As Operating Activities

InterestReceivedClassifiedAsOperatingActivities

547000000

eur

CY2022

ifrs-full

Interest Received Classified As Operating Activities

InterestReceivedClassifiedAsOperatingActivities

173000000

eur

CY2021

ifrs-full

Interest Received Classified As Operating Activities

InterestReceivedClassifiedAsOperatingActivities

3000000

eur

CY2023

sny

Dividends Received From Non Consolidated Entities Classified As Operating Activities

DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities

17000000

eur

CY2022

sny

Dividends Received From Non Consolidated Entities Classified As Operating Activities

DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities

1000000

eur

CY2021

sny

Dividends Received From Non Consolidated Entities Classified As Operating Activities

DividendsReceivedFromNonConsolidatedEntitiesClassifiedAsOperatingActivities

2000000

eur

CY2023

ifrs-full

Disclosure Of General Information About Financial Statements Explanatory

DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory

<div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:120%">Introduction</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi, together with its subsidiaries (collectively “Sanofi”, “the Group” or “the Company”), is a global healthcare leader engaged in the research, development and marketing of therapeutic solutions focused on patient needs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is listed in Paris (Euronext: SAN) and New York (Nasdaq: SNY).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The consolidated financial statements for the year ended December 31, 2023, and the notes thereto, were signed off by the Sanofi Board of Directors on</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> January 31, 2024.</span></div>

CY2023

ifrs-full

Disclosure Of Basis Of Preparation Of Financial Statements Explanatory

DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory

Basis of preparation<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.1. International financial reporting standards (IFRS)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The consolidated financial statements cover the twelve-month periods ended December 31, 2023, 2022 and 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with Regulation No. 1606/2002 of the European Parliament and Council of July 19, 2002 on the application of international accounting standards, Sanofi has presented its consolidated financial statements in accordance with IFRS since January 1, 2005. The term “IFRS” refers collectively to international accounting and financial reporting standards (IASs and IFRSs) and to interpretations of the interpretations committees (SIC and IFRIC) with mandatory application as of December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The consolidated financial statements of Sanofi as of December 31, 2023 have been prepared in compliance with IFRS as issued by the International Accounting Standards Board (IASB) and with IFRS as endorsed by the European Union as of December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">IFRS as endorsed by the European Union as of December 31, 2023 are available under the heading “IFRS Financial Statements” via the following web link:</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">https://www.efrag.org/Endorsement</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in accordance with the IFRS general principles of fair presentation, going concern, accrual basis of accounting, consistency of presentation, materiality, and aggregation.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.2. New standards, amendments and interpretations</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.2.1. New standards applicable from January 1, 2023</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following amendments are applicable from January 1, 2023, and have had no material impact: “Disclosure of Accounting Policies” (amendment to IAS 1); “Definition of Accounting Estimates” (amendment to IAS 8); and “Deferred Tax Assets and Liabilities Arising from a Single Transaction” (amendment to IAS 12).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 23, 2023, the IASB issued “International Tax Reform—Pillar Two Model Rules”, an immediately applicable amendment to IAS 12 that was endorsed on November 9, 2023. The amendment relates to the effects of the global minimum corporate income tax rate of 15% that will come into force in 2024, in accordance with the model framework of OECD Pillar Two.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The French Finance Bill for 2024 imposes a global minimum corporate income tax rate of 15% and introduces (i) a supplementary multinational tax and (ii) a supplementary national tax for annual accounting periods commencing on or after December 31, 2023. Given that the legislation had not come into force as of December 31, 2023, Sanofi is not liable for any current taxes in that respect. In addition, Sanofi has not recognized any deferred taxes associated with the minimum tax, in accordance with the temporary exemption available under the May 2023 amendment to IAS 12. At this stage, a material impact is expected in respect of Sanofi's operations in France and Singapore, because Sanofi’s average effective tax rate in those countries was less than 15% at the end of 2023. Other things being equal, applying the Pillar 2 rules in 2023 would have led to an increase of approximately 1.5 percentage points in the effective tax rate based on the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income before tax and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">IFRS 17 (Insurance Contracts), issued on May 18, 2017 and applicable on or after January 1, 2023, does not apply to the Sanofi consolidated financial statements because the insurance activities carried on by Sanofi’s captive insurance companies are internal within the Sanofi group (the sole policyholders being subsidiaries of Sanofi), and hence are eliminated on consolidation.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.2.2. New pronouncements issued by the IASB and applicable from 2024 or later</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This note describes standards, amendments and interpretations issued by the IASB that will have mandatory application in 2024 or subsequent years, and Sanofi’s position regarding future application.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On September 22, 2022, the IASB issued an amendment to IFRS 16 (Leases), relating to lease liabilities in a sale-and-leaseback arrangement, which is applicable at the earliest from January 1, 2024;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> it will not have a material impact on the Sanofi financial statements, and </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has not early adopted it.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On January 23, 2020, the IASB issued “Classification of Liabilities as Current or Non-current”, an amendment to IAS 1, and then on October 31, 2022 issued “Non-current Liabilities with Covenants”, a further amendment to IAS 1. The amendments are applicable at the earliest from January 1, 2024; they will not have a material impact on the Sanofi financial statements, and Sanofi has not early adopted them.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 25, 2023, the IASB issued "Supplier Finance Arrangements", an amendment to IAS 7 and IFRS 7, which is applicable at the earliest from January 1, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (subject to endorsement by the European Union) and which relates to disclosures of information about such arrangements. The amendment does not </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">have a material impact on the Sanofi financial statements, and Sanofi will not early adopt it</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On August 15, 2023, the IASB issued "Lack of Exchangeability", an amendment to IAS 21 (The Effect of Changes in Foreign Exchange Rates), relating to how to determine the exchange rate when a currency is not exchangeable. The amendment is applicable at the earliest from January 1, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (subject to endorsement by the European Union); it</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> will not have a material impact on the Sanofi financial statements, and Sanofi will not early adopt it</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.3. Use of estimates and judgments</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date of the finalization of the financial statements. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions (see Notes B.13. and D.23.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">impairment of property, plant and equipment and intangible assets (see Notes B.6. and D.5.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the valuation of goodwill and the valuation and estimated useful life of acquired intangible assets (see Notes B.3.2., B.4., D.4. and D.5.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the measurement of contingent consideration receivable in connection with asset divestments (see Notes B.8.5. and D.12.) and of contingent consideration payable (see Notes B.3. and D.18.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the measurement of financial assets and liabilities at amortized cost (see Note B.8.5.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of post-employment benefit obligations (see Notes B.23. and D.19.1.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of liabilities or provisions for restructuring, litigation, tax risks relating to corporate income taxes, and environmental risks (see Notes B.12., B.19., B.20., D.19. and D.22.); and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of deferred tax assets resulting from tax losses available for carry-forward and deductible temporary differences (see Notes B.22. and D.14.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actual results could differ from these estimates.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In preparing the consolidated financial statements, Sanofi has also taken account of risks related to the effects of climate change and energy transition.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As part of its Planet Care program, Sanofi has committed to move towards carbon neutrality by 2030 and net zero emissions by 2045 for its Scope 1, 2 and 3 emissions. That involves:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">aiming for a 55% reduction in greenhouse gas (GHG) emissions from Sanofi’s own activities (Scopes 1 & 2) and a 30% reduction in Scope 3 GHG emissions by 2030 (versus a 2019 baseline), and a 90% reduction in GHG emissions (all scopes) by 2045. These objectives have been validated by the Science Based Target initiative (STBi);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">supplying all our sites with 100% renewably-sourced electricity by 2030;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">promoting an eco-friendly vehicle fleet by 2030; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">engaging the Sanofi supply chain in reducing Scope 3 emissions.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The analysis of climate-related physical and transition risks facing Sanofi was updated in 2023 on the basis of three global warming scenarios out to 2030 and 2050. A number of assumptions – on issues such as carbon costs, natural disasters, water stress, raw material scarcity and logistics disruption – were built into this analysis, which also takes account of certain capital expenditures on mitigations derived from the Planet Care roadmap.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In preparing the consolidated financial statements, that analysis was taken into account as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the value of intangible assets and property, plant and equipment was subject to impairment testing conducted at CGU level, as described in Note D.5. Certain climate-related assumptions, such as the evolution of energy costs, transitioning to sustainable agriculture, and waste management, are already built into the forecast used for impairment testing purposes. For those assumptions not yet built into budgets, sensitivity analyses can be performed as needed;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the periodic reviews conducted on the useful lives of property, plant and equipment take account of environmental regulatory constraints, including not only GHG emissions but also physical risks;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">environmental risks are covered by provisions on the basis described in Note D.19.3.; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the credit facilities available to Sanofi as of December 31, 2023 incorporate performance objectives, including objectives related to cutting Sanofi’s carbon footprint, which could reduce the cost of debt if they are attained (see Note D.17.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is important to bear in mind that estimating climate change related risks involves an element of unpredictability. Uncertainties may arise from factors such as changes in government policy, rapid technological change, and varied responses from stakeholders. That high level of uncertainty adds complexity to assessment of the potential impacts on our operations, and to how those impacts are reflected in our budgets. Actual impacts on Sanofi’s profits and financial position could therefore differ from initial estimates.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, in line with its environmental protection objectives, Sanofi has initiated projects to build eco-design into its products so as to limit their environmental impacts over their entire life cycle. Those projects will require Sanofi to redefine all of its production methods, and as such have also been built into definitions of the useful lives of Sanofi production facilities.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.4. Hyperinflation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, Sanofi continued to account for subsidiaries based in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS 10 (Consolidated Financial Statements) are still met. The contribution of the Venezuelan subsidiaries to the consolidated financial statements is immaterial.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Argentina, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since July 1, 2018 treated Argentina as a hyperinflationary economy and has applied IAS 29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Turkey, the cumulative rate of inflation over the last three years is in excess of 100% based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since January 1, 2022 treated Turkey as a hyperinflationary economy and has applied IAS 29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.5. Agreements relating to the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On February 18, 2020, Sanofi and the US Department of Health and Human Services extended their research and development partnership to leverage Sanofi’s previous development work on a SARS vaccine to attempt to unlock a fast path forward for developing a COVID-19 vaccine. Under the terms of the collaboration, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the US Department of Health and Human Services, is helping to fund the research and development undertaken by Sanofi.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On April 14, 2020, Sanofi and GlaxoSmithKline (GSK) entered into a collaboration agreement to develop a recombinant COVID-19 vaccine candidate, with Sanofi contributing its S‑protein COVID-19 antigen (based on recombinant DNA technology) and GSK contributing its pandemic adjuvant technology. Sanofi is leading clinical development and the registration process for the vaccine.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On July 31, 2020, the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK was selected by the US government’s Operation Warp Speed (OWS) program. Under the OWS, the US government is providing funds to support further development of the vaccine, including clinical trials and scaling-up of manufacturing capacity. Initially, the agreement also provided for the supply of 100 million doses of the vaccine. In light of the evolving context of the pandemic (including variants of the virus) and the availability of vaccines on the market, the parties decided to review the initial supply contract. At the end of 2023, the agreement was amended in respect of the supply clause, confirming that Sanofi had fulfilled its contractual obligations and setting the amount of compensation paid to Sanofi. On the basis of that signed amendment, Sanofi recognized an amount of €411 million within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">; that amount was paid to Sanofi in December 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has recognized the funding received from the US government as a deduction from the development expenses incurred, in accordance with IAS 20 (Accounting for Government Grants and Disclosure of Government Assistance).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The amount of government aid received from the US federal government and BARDA and recognized </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">as a deduction from development expenses</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and other operating expenses was €59 million in 2023, compared with €265 million in 2022 and €147 million in 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In September 2020, Sanofi and GSK signed pre-order contracts with the Canadian and UK governments and with the European Union for doses of the vaccine candidate. During 2021, Sanofi and GSK contractualized with the Canadian and UK governments and with the European Union on the number of doses ordered.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On December 15, 2021, Sanofi and GSK announced positive preliminary data on their COVID-19 booster vaccine candidate and indicated that their Phase 3 trial was to continue, based on recommendations from an independent monitoring board.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On November 10, 2022, in line with the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, the European Commission approved VIDPREVTYN Beta vaccine as booster for the prevention of COVID-19 in adults aged 18 years and older. Designed to provide broad protection against multiple variants, this protein-based COVID-19 booster vaccine is based on the Beta variant antigen and includes GSK’s pandemic adjuvant. VIDPREVTYN</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Beta is indicated as a booster for active immunization against SARS-CoV-2 in adults who have previously received an mRNA or adenoviral COVID-19 vaccine.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On December 21, 2022, following the European Commission approval, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved VIDPREVTYN Beta vaccine for the prevention of COVID-19 in adults aged 18 and over within the UK.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 15 (see Note B.13.1.), Sanofi recognizes revenue when control over the product is transferred to the customer (for vaccines, transfer of control is determined by reference to the terms of release and acceptance of batches of vaccine). Payments received subsequent to signature of vaccine pre-order contracts relating to doses not yet delivered are customer contract liabilities (i.e. an obligation for the entity to supply goods to a customer, for which consideration has been received from the customer). They are presented within “Customer contract liabilities” in the balance sheet (see Note D.19.5.), and within “Net change in other current assets and other current liabilities” in the statement of cash flows.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The pre-order contracts for Canada, the United Kingdom and the European Union expired in 2023. The customer contract liabilities, which amounted to €269 million as of December 31, 2022 and €319 million as of December 31, 2021 (see Note D.19.5., “</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Current provisions and other current liabilities”</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">) were released to profit or loss in 2023, including an amount of €94 million classified in</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other revenue</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in respect of doses which there was no longer an obligation to deliver as of December 31, 2023.</span></div>

CY2023

ifrs-full

Statement Of Ifrs Compliance

StatementOfIFRSCompliance

International financial reporting standards (IFRS)<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The consolidated financial statements cover the twelve-month periods ended December 31, 2023, 2022 and 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with Regulation No. 1606/2002 of the European Parliament and Council of July 19, 2002 on the application of international accounting standards, Sanofi has presented its consolidated financial statements in accordance with IFRS since January 1, 2005. The term “IFRS” refers collectively to international accounting and financial reporting standards (IASs and IFRSs) and to interpretations of the interpretations committees (SIC and IFRIC) with mandatory application as of December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The consolidated financial statements of Sanofi as of December 31, 2023 have been prepared in compliance with IFRS as issued by the International Accounting Standards Board (IASB) and with IFRS as endorsed by the European Union as of December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">IFRS as endorsed by the European Union as of December 31, 2023 are available under the heading “IFRS Financial Statements” via the following web link:</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;text-decoration:underline">https://www.efrag.org/Endorsement</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in accordance with the IFRS general principles of fair presentation, going concern, accrual basis of accounting, consistency of presentation, materiality, and aggregation.</span></div>

CY2023

ifrs-full

Description Of Initial Application Of Standards Or Interpretations

DescriptionOfInitialApplicationOfStandardsOrInterpretations

New standards, amendments and interpretations<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">A.2.1. New standards applicable from January 1, 2023</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following amendments are applicable from January 1, 2023, and have had no material impact: “Disclosure of Accounting Policies” (amendment to IAS 1); “Definition of Accounting Estimates” (amendment to IAS 8); and “Deferred Tax Assets and Liabilities Arising from a Single Transaction” (amendment to IAS 12).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 23, 2023, the IASB issued “International Tax Reform—Pillar Two Model Rules”, an immediately applicable amendment to IAS 12 that was endorsed on November 9, 2023. The amendment relates to the effects of the global minimum corporate income tax rate of 15% that will come into force in 2024, in accordance with the model framework of OECD Pillar Two.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The French Finance Bill for 2024 imposes a global minimum corporate income tax rate of 15% and introduces (i) a supplementary multinational tax and (ii) a supplementary national tax for annual accounting periods commencing on or after December 31, 2023. Given that the legislation had not come into force as of December 31, 2023, Sanofi is not liable for any current taxes in that respect. In addition, Sanofi has not recognized any deferred taxes associated with the minimum tax, in accordance with the temporary exemption available under the May 2023 amendment to IAS 12. At this stage, a material impact is expected in respect of Sanofi's operations in France and Singapore, because Sanofi’s average effective tax rate in those countries was less than 15% at the end of 2023. Other things being equal, applying the Pillar 2 rules in 2023 would have led to an increase of approximately 1.5 percentage points in the effective tax rate based on the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income before tax and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">IFRS 17 (Insurance Contracts), issued on May 18, 2017 and applicable on or after January 1, 2023, does not apply to the Sanofi consolidated financial statements because the insurance activities carried on by Sanofi’s captive insurance companies are internal within the Sanofi group (the sole policyholders being subsidiaries of Sanofi), and hence are eliminated on consolidation.</span></div>

CY2023

sny

Increase Decrease In Effective Tax Rate

IncreaseDecreaseInEffectiveTaxRate

0.015

CY2023

ifrs-full

Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations

DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations

New pronouncements issued by the IASB and applicable from 2024 or later<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This note describes standards, amendments and interpretations issued by the IASB that will have mandatory application in 2024 or subsequent years, and Sanofi’s position regarding future application.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On September 22, 2022, the IASB issued an amendment to IFRS 16 (Leases), relating to lease liabilities in a sale-and-leaseback arrangement, which is applicable at the earliest from January 1, 2024;</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> it will not have a material impact on the Sanofi financial statements, and </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has not early adopted it.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On January 23, 2020, the IASB issued “Classification of Liabilities as Current or Non-current”, an amendment to IAS 1, and then on October 31, 2022 issued “Non-current Liabilities with Covenants”, a further amendment to IAS 1. The amendments are applicable at the earliest from January 1, 2024; they will not have a material impact on the Sanofi financial statements, and Sanofi has not early adopted them.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On May 25, 2023, the IASB issued "Supplier Finance Arrangements", an amendment to IAS 7 and IFRS 7, which is applicable at the earliest from January 1, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (subject to endorsement by the European Union) and which relates to disclosures of information about such arrangements. The amendment does not </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">have a material impact on the Sanofi financial statements, and Sanofi will not early adopt it</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On August 15, 2023, the IASB issued "Lack of Exchangeability", an amendment to IAS 21 (The Effect of Changes in Foreign Exchange Rates), relating to how to determine the exchange rate when a currency is not exchangeable. The amendment is applicable at the earliest from January 1, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (subject to endorsement by the European Union); it</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> will not have a material impact on the Sanofi financial statements, and Sanofi will not early adopt it</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div>

CY2023

ifrs-full

Disclosure Of Accounting Judgements And Estimates Explanatory

DisclosureOfAccountingJudgementsAndEstimatesExplanatory

Use of estimates and judgments<div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The preparation of financial statements requires management to make reasonable estimates and assumptions based on information available at the date of the finalization of the financial statements. Those estimates and assumptions may affect the reported amounts of assets, liabilities, revenues and expenses in the financial statements, and disclosures of contingent assets and contingent liabilities as of the date of the review of the financial statements. Examples of estimates and assumptions include:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">amounts deducted from sales for projected sales returns, chargeback incentives, rebates and price reductions (see Notes B.13. and D.23.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">impairment of property, plant and equipment and intangible assets (see Notes B.6. and D.5.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the valuation of goodwill and the valuation and estimated useful life of acquired intangible assets (see Notes B.3.2., B.4., D.4. and D.5.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the measurement of contingent consideration receivable in connection with asset divestments (see Notes B.8.5. and D.12.) and of contingent consideration payable (see Notes B.3. and D.18.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the measurement of financial assets and liabilities at amortized cost (see Note B.8.5.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of post-employment benefit obligations (see Notes B.23. and D.19.1.);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of liabilities or provisions for restructuring, litigation, tax risks relating to corporate income taxes, and environmental risks (see Notes B.12., B.19., B.20., D.19. and D.22.); and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of deferred tax assets resulting from tax losses available for carry-forward and deductible temporary differences (see Notes B.22. and D.14.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actual results could differ from these estimates.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In preparing the consolidated financial statements, Sanofi has also taken account of risks related to the effects of climate change and energy transition.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As part of its Planet Care program, Sanofi has committed to move towards carbon neutrality by 2030 and net zero emissions by 2045 for its Scope 1, 2 and 3 emissions. That involves:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">aiming for a 55% reduction in greenhouse gas (GHG) emissions from Sanofi’s own activities (Scopes 1 & 2) and a 30% reduction in Scope 3 GHG emissions by 2030 (versus a 2019 baseline), and a 90% reduction in GHG emissions (all scopes) by 2045. These objectives have been validated by the Science Based Target initiative (STBi);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">supplying all our sites with 100% renewably-sourced electricity by 2030;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">promoting an eco-friendly vehicle fleet by 2030; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">engaging the Sanofi supply chain in reducing Scope 3 emissions.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The analysis of climate-related physical and transition risks facing Sanofi was updated in 2023 on the basis of three global warming scenarios out to 2030 and 2050. A number of assumptions – on issues such as carbon costs, natural disasters, water stress, raw material scarcity and logistics disruption – were built into this analysis, which also takes account of certain capital expenditures on mitigations derived from the Planet Care roadmap.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In preparing the consolidated financial statements, that analysis was taken into account as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the value of intangible assets and property, plant and equipment was subject to impairment testing conducted at CGU level, as described in Note D.5. Certain climate-related assumptions, such as the evolution of energy costs, transitioning to sustainable agriculture, and waste management, are already built into the forecast used for impairment testing purposes. For those assumptions not yet built into budgets, sensitivity analyses can be performed as needed;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the periodic reviews conducted on the useful lives of property, plant and equipment take account of environmental regulatory constraints, including not only GHG emissions but also physical risks;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">environmental risks are covered by provisions on the basis described in Note D.19.3.; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the credit facilities available to Sanofi as of December 31, 2023 incorporate performance objectives, including objectives related to cutting Sanofi’s carbon footprint, which could reduce the cost of debt if they are attained (see Note D.17.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It is important to bear in mind that estimating climate change related risks involves an element of unpredictability. Uncertainties may arise from factors such as changes in government policy, rapid technological change, and varied responses from stakeholders. That high level of uncertainty adds complexity to assessment of the potential impacts on our operations, and to how those impacts are reflected in our budgets. Actual impacts on Sanofi’s profits and financial position could therefore differ from initial estimates.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, in line with its environmental protection objectives, Sanofi has initiated projects to build eco-design into its products so as to limit their environmental impacts over their entire life cycle. Those projects will require Sanofi to redefine all of its production methods, and as such have also been built into definitions of the useful lives of Sanofi production facilities.</span></div>

CY2023

sny

Planet Care Program Objectives Net Emissions By2045

PlanetCareProgramObjectivesNetEmissionsBy2045

0

emission

CY2023

sny

Planet Care Program Objectives Percentage Of Reduction In Scope1 And2 Greenhouse Gas By2030

PlanetCareProgramObjectivesPercentageOfReductionInScope1And2GreenhouseGasBy2030

0.55

CY2023

sny

Planet Care Program Objectives Percentage Of Reduction In Scope3 Greenhouse Gas By2030

PlanetCareProgramObjectivesPercentageOfReductionInScope3GreenhouseGasBy2030

0.30

CY2023

sny

Planet Care Program Objectives Percentage Of Reduction In All Scopes Greenhouse Gas By2030

PlanetCareProgramObjectivesPercentageOfReductionInAllScopesGreenhouseGasBy2030

0.90

CY2023

sny

Planet Care Program Objectives Percentage Of Renewably Sourced Energy In All Sites By2030

PlanetCareProgramObjectivesPercentageOfRenewablySourcedEnergyInAllSitesBy2030

1

CY2023

sny

Planet Care Program Objectives Number Of Global Warming Scenarios

PlanetCareProgramObjectivesNumberOfGlobalWarmingScenarios

3

scenario

CY2023

ifrs-full

Description Of Accounting Policy For Treasury Shares Explanatory

DescriptionOfAccountingPolicyForTreasurySharesExplanatory

Treasury shares<div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS 32, Sanofi treasury shares are deducted from equity, irrespective of the purpose for which they are held. No gain or loss is recognized in the income statement on the purchase, sale, impairment or cancellation of treasury shares.</span></div>

CY2023

ifrs-full

Disclosure Of Hyperinflationary Reporting Explanatory

DisclosureOfHyperinflationaryReportingExplanatory

Hyperinflation<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, Sanofi continued to account for subsidiaries based in Venezuela using the full consolidation method, on the basis that the criteria for control as specified in IFRS 10 (Consolidated Financial Statements) are still met. The contribution of the Venezuelan subsidiaries to the consolidated financial statements is immaterial.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Argentina, the cumulative rate of inflation over the last three years is in excess of 100%, based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since July 1, 2018 treated Argentina as a hyperinflationary economy and has applied IAS 29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In Turkey, the cumulative rate of inflation over the last three years is in excess of 100% based on a combination of indices used to measure inflation in that country. Consequently, Sanofi has since January 1, 2022 treated Turkey as a hyperinflationary economy and has applied IAS 29. The impact of the resulting restatements is immaterial at Sanofi group level.</span></div>

CY2023

ifrs-full

Disclosure Of Material Accounting Policy Information Explanatory

DisclosureOfMaterialAccountingPolicyInformationExplanatory

Summary of significant accounting policiesBasis of consolidation<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 10 (Consolidated Financial Statements), the consolidated financial statements of Sanofi include the financial statements of entities that Sanofi controls directly or indirectly, regardless of the level of the equity interest in those entities. An entity is controlled when Sanofi has power over the entity, exposure or rights to variable returns from its involvement with the entity, and the ability to affect those returns through its power over the entity. In determining whether control exists, potential voting rights must be taken into account if those rights are substantive, in other words they can be exercised on a timely basis when decisions about the relevant activities of the entity are to be taken.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Entities consolidated by Sanofi are referred to as “subsidiaries”. Entities that Sanofi controls by means other than voting rights are referred to as “consolidated structured entities”.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 11 (Joint Arrangements), Sanofi classifies its joint arrangements (i.e. arrangements in which Sanofi exercises joint control with one or more other parties) either as a joint operation (in which case, Sanofi recognizes the assets and liabilities of the operation in proportion to its rights and obligations relating to those assets and liabilities) or as a joint venture.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi exercises joint control over a joint arrangement when decisions relating to the relevant activities of the arrangement require the unanimous consent of Sanofi and the other parties with whom control is shared.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi exercises significant influence over an entity when it has the power to participate in the financial and operating policy decisions of that entity, but does not have the power to exercise control or joint control over those policies.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS 28 (Investments in Associates and Joint Ventures), the equity method is used to account for joint ventures (i.e. entities over which Sanofi exercises joint control) and for associates (i.e. entities over which Sanofi exercises significant influence).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under the equity method, the investment is initially recognized at cost, and subsequently adjusted to reflect changes in the net assets of the associate or joint venture. IAS 28 does not specify the treatment to be adopted on first-time application of the equity method to an investee following a step acquisition. Consequently, by reference to paragraph 10 of IAS 28, Sanofi has opted to apply the cost method, whereby the carrying amount of the investment represents the sum of the historical cost amounts for each step in the acquisition. As of the date on which the equity method is first applied, goodwill (which is included in the carrying amount of the investment) is determined for each acquisition step. The same applies to subsequent increases in the percentage interest in the equity-accounted investment.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When the criteria of IFRS 5 are met, Sanofi recognizes the equity interest within the balance sheet line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. The equity method is not applied to equity interests that are classified as held-for-sale assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Transactions between consolidated companies are eliminated, as are intragroup profits.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A list of the principal companies included in the consolidation in 2023 is presented in Note F.</span></div>Foreign currency translation<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.2.1. Accounting for foreign currency transactions in the financial statements of consolidated entities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Non-current assets (other than receivables) and inventories acquired in foreign currencies are translated into the functional currency using the exchange rate prevailing at the acquisition date.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the end of the reporting period. The gains and losses resulting from foreign currency translation are recorded in the income statement. However, foreign exchange gains and losses arising from the translation of advances between consolidated subsidiaries for which settlement is neither planned nor likely to occur in the foreseeable future are recognized in equity, in the line item</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Change in currency translation differences.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.2.2. Foreign currency translation of the financial statements of foreign entities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi presents its consolidated financial statements in euros (€). In accordance with IAS 21 (The Effects of Changes in Foreign Exchange Rates), each subsidiary accounts for its transactions in the currency that is most representative of its economic environment (the functional currency).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">All assets and liabilities are translated into euros using the exchange rate of the subsidiary’s functional currency prevailing at the end of the reporting period. Income statements are translated using a weighted average exchange rate for the period, except in the case of foreign subsidiaries in a hyperinflationary economy. The resulting currency translation difference is recognized as a separate component of equity in the consolidated statement of comprehensive income, and is recognized in the income statement only when the subsidiary is sold or is wholly or partially liquidated.</span></div>Business combinations and transactions with non-controlling interests<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.3.1. Accounting for business combinations, transactions with non-controlling interests and loss of control</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Business combinations are accounted for in accordance with IFRS 3 (Business Combinations) and IFRS 10 (Consolidated Financial Statements).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Business combinations are accounted for using the acquisition method. Under this method, the acquiree’s identifiable assets and liabilities that satisfy the recognition criteria of IFRS 3 (Business Combinations) are measured initially at their fair values at the date of acquisition, except for (i) non-current assets classified as held for sale (which are measured at fair value less costs to sell) and (ii) assets and liabilities that fall within the scope of IAS 12 (Income Taxes) and IAS 19 (Employee Benefits). Restructuring liabilities are recognized as a liability of the acquiree only if the acquiree has an obligation as of the acquisition date to carry out the restructuring.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal accounting rules applicable to business combinations and transactions with non-controlling interests include:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">acquisition-related costs are recognized as an expense, as a component of </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">contingent consideration is recognized in equity if the contingent payment is settled by delivery of a fixed number of the acquirer’s equity instruments; otherwise, it is recognized in liabilities related to business combinations. Contingent consideration is recognized at fair value at the acquisition date irrespective of the probability of payment. If the contingent consideration was originally recognized as a financial liability, subsequent adjustments to the liability are recognized in profit or loss in the line item</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Fair value remeasurement of contingent consideration</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, unless the adjustment is made within the 12 months following the acquisition date and relates to facts and circumstances existing as of that date;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">goodwill may be calculated on the basis of either (i) the entire fair value of the acquiree, or (ii) a share of the fair value of the acquiree proportionate to the interest acquired. This option is elected for each acquisition individually.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Purchase price allocations are performed under the responsibility of management, with assistance from an independent valuer in the case of major acquisitions. IFRS 3 does not specify an accounting treatment for contingent consideration arising from a business combination made by an entity prior to the acquisition of control in that entity and carried as a liability in the acquired entity’s balance sheet. The accounting treatment applied by Sanofi to such a liability is to measure it at fair value as of the acquisition date and to report it in the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, with subsequent remeasurements recognized in profit or loss. This treatment is consistent with the accounting applied to contingent consideration in the books of the acquirer.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, management may where it deems fit elect to apply the optional test to identify concentration of fair value permitted under IFRS 3 in order to determine whether a transaction is a business combination within the meaning of IFRS 3, or merely the acquisition of an asset or of a group of similar assets.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.3.2. Goodwill</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The excess of the cost of an acquisition over Sanofi’s interest in the fair value of the identifiable assets and liabilities of the acquiree is recognized as goodwill at the date of the business combination. Goodwill arising on the acquisition of subsidiaries is shown in a separate balance sheet line item, whereas goodwill arising on the acquisition of investments accounted for using the equity method is recorded in</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Investments accounted for using the equity method.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill arising on foreign operations is expressed in the functional currency of the country concerned and translated into euros using the exchange rate prevailing at the end of the reporting period.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS 36 (Impairment of Assets), goodwill is carried at cost less accumulated impairment (see Note B.6.).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill is tested for impairment annually and whenever events or circumstances indicate that impairment might exist. Such events or circumstances include significant changes more likely than not to have an other-than-temporary impact on the substance of the original investment.</span></div>Other intangible assets<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other intangible assets are initially measured at acquisition cost or production cost, including any directly attributable costs of preparing the asset for its intended use, or (in the case of assets acquired in a business combination) at fair value as of the date of the business combination. Intangible assets are amortized on a straight line basis over their useful lives.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The useful lives of other intangible assets are reviewed at the end of each reporting period. The effect of any adjustment to useful lives is recognized prospectively as a change in accounting estimate.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amortization of other intangible assets is recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Amortization of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> except for amortization charged against (i) acquired or internally-developed software and (ii) other rights of an industrial or operational nature, which is recognized in the relevant classification of expense by function.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi does not own any intangible assets with an indefinite useful life, other than goodwill.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Intangible assets (other than goodwill) are carried at cost less accumulated amortization and accumulated impairment, if any, in accordance with IAS 36 (see Note B.6.).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.4.1. Research and development not acquired in a business combination</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Internally generated research and development</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IAS 38, research expenses are recognized in profit or loss when incurred.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Internally generated development expenses are recognized as an intangible asset if, and only if, all the following six criteria can be demonstrated: (a) the technical feasibility of completing the development project; (b) Sanofi’s intention to complete the project; (c) Sanofi’s ability to use the project; (d) the probability that the project will generate future economic benefits; (e) the availability of adequate technical, financial and other resources to complete the project; and (f) the ability to measure the development expenditure reliably.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Due to the risks and uncertainties relating to regulatory approval and to the research and development process, the six criteria for capitalization are usually considered not to have been met until the product has obtained marketing approval from the regulatory authorities. Consequently, internally generated development expenses arising before marketing approval has been obtained, mainly the cost of clinical trials, are generally expensed as incurred within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Some industrial development expenses (such as those incurred in developing a second-generation synthesis process) are incurred after marketing approval has been obtained, in order to improve the industrial process for an active ingredient. To the extent that the six IAS 38 criteria are considered as having been met, such expenses are recognized as an asset in the balance sheet within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> as incurred. Similarly, some clinical trials, for example those undertaken to obtain a geographical extension for a molecule that has already obtained marketing approval in a major market, may in certain circumstances meet the six capitalization criteria under IAS 38, in which case the related expenses are recognized as an asset in the balance sheet within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separately acquired research and development</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Payments for separately acquired research and development are capitalized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> provided that they meet the definition of an intangible asset: a resource that is (i) controlled by Sanofi, (ii) expected to provide future economic benefits for Sanofi, and (iii) identifiable (i.e. it is either separable or arises from contractual or legal rights). Under paragraph 25 of IAS 38, the first condition for capitalization (the probability that the expected future economic benefits from the asset will flow to the entity) is considered to be satisfied for separately acquired research and development. Consequently, upfront and milestone payments to third parties related to pharmaceutical products for which marketing approval has not yet been obtained are recognized as intangible assets, and amortized on a straight line basis over their useful lives beginning when marketing approval is obtained.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Payments under research and development arrangements relating to access to technology or to databases, and payments made to purchase generics dossiers, are also capitalized, and amortized over the useful life of the intangible asset.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subcontracting arrangements, payments for research and development services, and continuous payments under research and development collaborations which are unrelated to the outcome of that collaboration, are expensed over the service term.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.4.2. Other intangible assets not acquired in a business combination</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Licenses other than those related to pharmaceutical products and research projects, in particular software licenses, are capitalized at acquisition cost, including any directly attributable cost of preparing the software for its intended use. Software licenses are amortized on a straight line basis over their useful lives for Sanofi (<span style="-sec-ix-hidden:f-646">three</span> to five years).</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Internally generated costs incurred to develop or upgrade software are capitalized if the IAS 38 recognition criteria are satisfied, and amortized on a straight line basis over the useful life of the software from the date on which the software is ready for use.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.4.3. Other intangible assets acquired in a business combination</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other intangible assets acquired in a business combination (in-process research and development, technology platforms, and currently marketed products) that are reliably measurable are identified separately from goodwill, measured at fair value, and capitalized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with IFRS 3 (Business Combinations) and IAS 38 (Intangible Assets). The related deferred tax liability is also recognized if a deductible or taxable temporary difference exists.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In-process research and development acquired in a business combination is amortized on a straight line basis over its useful life from the date of receipt of marketing approval.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Rights to technology platforms and to products currently marketed by Sanofi are amortized on a straight line basis over their useful lives, determined (in particular for marketed products) on the basis of cash flow forecasts which take into account the patent protection period of the marketed product.</span></div>Property, plant and equipment owned and leased<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.5.1. Property, plant and equipment owned</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Property, plant and equipment is initially measured and recognized at acquisition cost, including any directly attributable cost of preparing the asset for its intended use, or (in the case of assets acquired in a business combination) at fair value as of the date of the business combination. The component-based approach to accounting for property, plant and equipment is applied. Under this approach, each component of an item of property, plant and equipment with a cost which is significant in relation to the total cost of the item and which has a different useful life from the other components must be depreciated separately.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">After initial measurement, property, plant and equipment is carried at cost less accumulated depreciation and impairment, except for land which is carried at cost less impairment.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subsequent costs are not recognized as assets unless (i) it is probable that future economic benefits associated with those costs will flow to Sanofi and (ii) the costs can be measured reliably.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Borrowing costs attributable to the financing of items of property, plant and equipment, and incurred during the construction period, are capitalized as part of the acquisition cost of the item.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Government grants relating to property, plant and equipment are deducted from the acquisition cost of the asset to which they relate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The depreciable amount of items of property, plant and equipment, net of any residual value, is depreciated on a straight line basis over the useful life of the asset. The useful life of an asset is usually equivalent to its economic life.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The customary useful lives of property, plant and equipment are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:49.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.671%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15 to 40 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 to 20 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 to 15 years</span></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 to 15 years</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Useful lives and residual values of property, plant and equipment are reviewed annually. The effect of any adjustment to useful lives or residual values is recognized prospectively as a change in accounting estimate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Depreciation of property, plant and equipment is recognized as an expense in the income statement, in the relevant classification of expense by function.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.5.2. Property, plant and equipment leased</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Effective from January 1, 2019 leases contracted by Sanofi have been accounted for in accordance with IFRS 16 (Leases). Sanofi recognizes a right-of-use asset and a lease liability for all of its lease contracts, except for (i) leases relating to low-value assets and (ii) short-term leases (12 months or less). Payments made in respect of leases not recognized on the balance sheet are recognized as an operating expense on a straight line basis over the lease term.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On commencement of a lease, the liability for future lease payments is discounted at the incremental borrowing rate, which is a risk-free rate adjusted to reflect the specific risk profile of each Sanofi entity. Because lease payments are spread over the lease term, Sanofi applies a discount rate based on the duration of those payments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The payments used to determine the liability for future lease payments exclude non-lease components, but include fixed payments that Sanofi expects to make to the lessor over the estimated lease term.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">After commencement of the lease, the liability for future lease payments is reduced by the amount of the lease payments made, and increased to reflect interest on the liability. In the event of a reassessment or modification of future lease payments, the lease liability is remeasured. The right-of-use asset – which is initially measured at cost including direct costs of the lessee, prepayments made at or prior to the commencement date, less lease incentives received and restoration costs – is depreciated on a straight line basis over the lease term, and tested for impairment as required.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi recognizes deferred taxes in respect of right-of-use assets and lease liabilities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Leasehold improvements are depreciated over their economic life, which is capped at the lease term as determined under IFRS 16.</span></div>Impairment of property, plant and equipment, intangible assets, and investments accounted for using the equity method<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.6.1. Impairment of property, plant and equipment and intangible assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS 36 (Impairment of Assets), assets that generate separate cash flows and assets included in cash-generating units (CGUs) are assessed for impairment when events or changes in circumstances indicate that the asset or CGU may be impaired. A CGU is the smallest identifiable group of assets that generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IAS 36, each CGU or group of CGUs to which goodwill is allocated must (i) represent the lowest level within the entity at which the goodwill is monitored for internal management purposes, and (ii) not be larger than an operating segment determined in accordance with IFRS 8 (Operating Segments), before application of the IFRS 8 aggregation criteria (see Note B.26.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Quantitative and qualitative indications of impairment (primarily relating to the status of the research and development portfolio, pharmacovigilance, patent litigation, and the launch of competing products) are reviewed at the end of each reporting period. If there is any internal or external indication of impairment, Sanofi estimates the recoverable amount of the asset or CGU.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other intangible assets not yet available for use (such as capitalized in-process research and development), and CGUs or groups of CGUs that include goodwill, are tested for impairment annually whether or not there is any indication of impairment, and more frequently if any event or circumstance indicates that they might be impaired. Such assets are not amortized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When there is an internal or external indication of impairment, Sanofi estimates the recoverable amount of the asset and recognizes an impairment loss if the carrying amount of the asset exceeds its recoverable amount. The recoverable amount of the asset is the higher of its fair value less costs to sell or its value in use. To determine value in use, Sanofi uses estimates of future cash flows generated by the asset or CGU, prepared using the same methods as those used in the initial measurement of the asset or CGU on the basis of medium-term strategic plans.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of goodwill, estimates of future cash flows are based on a six-year strategic plan and a terminal value. In the case of other intrangible assets, the period used is based on the economic life of the asset.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Estimated cash flows are discounted at long-term market interest rates that reflect the best estimate by Sanofi of the time value of money, the risks specific to the asset or CGU, and economic conditions in the geographical regions in which the business activity associated with the asset or CGU is located.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Certain assets and liabilities that are not directly attributable to a specific CGU are allocated between CGUs on a basis that is reasonable, and consistent with the allocation of the corresponding goodwill.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Impairment losses arising on property, plant and equipment, software and certain rights, are recognized within the appropriate income statement line item according to the origin of the impairment.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Impairment losses arising on other intangible assets (products, trademarks, technology platforms, acquired R&D) are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Impairment of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.6.2. Impairment of investments accounted for using the equity method</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS 28 (Investments in Associates and Joint Ventures), Sanofi determines whether investments accounted for using the equity method may be impaired based on indicators such as default in contractual payments, significant financial difficulties, probability of bankruptcy, or a prolonged or significant decline in quoted market price. If an investment is impaired, the amount of the impairment loss is determined by applying IAS 36 (see Note B.6.1.) and recognized in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Share of profit/(loss) from investments accounted for using the equity method.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.6.3. Reversals of impairment losses charged against property, plant and equipment, intangible assets, and investments accounted for using the equity method</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">At the end of each reporting period, Sanofi assesses whether events or changes in circumstances indicate that an impairment loss recognized in a prior period in respect of an asset (other than goodwill) or an investment accounted for using the equity method can be reversed. If this is the case, and the recoverable amount as determined based on the revised estimates exceeds the carrying amount of the asset, Sanofi reverses the impairment loss only to the extent of the carrying amount that would have been determined had no impairment loss been recognized for the asset.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Reversals of impairment losses in respect of other intangible assets are recognized within the income statement line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Impairment of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, while reversals of impairment losses in respect of investments accounted for using the equity method are recognized within the income statement line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Share of profit/(loss) from investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Impairment losses taken against goodwill are never reversed, unless the goodwill is part of the carrying amount of an investment accounted for using the equity method.</span></div>Assets held for sale or exchange and liabilities related to assets held for sale or exchange<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations), non-current assets and groups of assets are classified as held for sale in the balance sheet if their carrying amount will be recovered principally through a sale transaction rather than through continuing use. Within the meaning of IFRS 5, the term “sale” also includes exchanges for other assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Non-current assets or asset groups held for sale must be available for immediate sale in their present condition, subject only to terms that are usual and customary for sales of such assets, and a sale must be highly probable. Criteria used to determine whether a sale is highly probable include:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the appropriate level of management must be committed to a plan to sell;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">an active program to locate a buyer and complete the plan must have been initiated;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the asset must be actively marketed for sale at a price that is reasonable in relation to its current fair value;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">completion of the sale should be foreseeable within the 12 months following the date of reclassification to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">actions required to complete the plan should indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Before initial reclassification of the non-current asset (or asset group) to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, the carrying amounts of the asset (or of all the assets and liabilities in the asset group) must be measured in accordance with the applicable standards.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subsequent to reclassification to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, the non-current asset (or asset group) is measured at the lower of carrying amount or fair value less costs to sell, with any write-down recognized by means of an impairment loss. Once a non-current asset has been reclassified as held for sale or exchange, it is no longer depreciated or amortized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In a disposal of an equity interest leading to loss of control, all the assets and liabilities of the entity involved are classified as held-for-sale assets or liabilities within the balance sheet line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">or</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Liabilities related to assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, provided that the disposal satisfies the IFRS 5 classification criteria.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The profit or loss generated by a held-for-sale asset group is reported in a separate line item in the income statement for the current period and for the comparative periods presented, provided that the asset group:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">represents a separate major line of business or geographical area of operations; or</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">is part of a single coordinated plan to dispose of a separate major line of business or geographical area of operations; or</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">is a subsidiary acquired exclusively with a view to resale.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 10, transactions between companies that are held for sale or treated as discontinued operations and other consolidated companies are eliminated.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Events or circumstances beyond Sanofi’s control may extend the period to complete the sale or exchange beyond one year without precluding classification of the asset (or disposal group) in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> provided that there is sufficient evidence that Sanofi remains committed to the planned sale or exchange. Finally, in the event of changes to a plan of sale that requires an asset no longer to be classified as held for sale, IFRS 5 specifies the following treatment:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the assets and liabilities previously classified as held for sale are reclassified to the appropriate balance sheet line items, with no restatement of comparative periods;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">each asset is measured at the lower of (a) its carrying amount before the asset was reclassified as held for sale, adjusted for any depreciation, amortization or revaluation that would have been recognized if the asset had not been reclassified as held for sale, or (b) its recoverable amount at the date of reclassification;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the backlog of depreciation, amortization and impairment not recognized while non-current assets were classified as held for sale must be reported in the same income statement line item that was used to report impairment losses arising on initial reclassification of assets as held for sale and gains or losses arising on the sale of such assets. In the consolidated income statement, those impacts are reported within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the net income of a business previously classified as discontinued or as held for sale or exchange and reported on a separate line in the income statement must be reclassified and included in net income from continuing operations, for all periods presented;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">in addition, segment information relating to the income statement and the statement of cash flows (acquisitions of non-current assets) must be disclosed in the notes to the financial statements in accordance with IFRS 8 (Operating Segments), and must also be restated for all prior periods presented.</span></div>Financial instruments<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.1. Non-derivative financial assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 9 (Financial Instruments) and IAS 32 (Financial Instruments: Presentation), Sanofi has adopted the classification of non-derivative financial assets described below. The classification used depends on (i) the characteristics of the contractual cash flows (i.e. whether they represent interest or principal) and (ii) the business model for managing the asset applied at the time of initial recognition.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial assets at fair value through other comprehensive income</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These mainly comprise:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">quoted and unquoted equity investments that Sanofi does not hold for trading purposes and that management has designated at “fair value through other comprehensive income” on initial recognition. Gains and losses arising from changes in fair value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such instruments are derecognized, the previously-recognized changes in fair value remain within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, as does the gain or loss on divestment. Dividends received are recognized in profit or loss for the period, within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">debt instruments whose contractual cash flows represent payments of interest or repayments of principal, and which are managed with a view to collecting cash flows and selling the asset. Gains and losses arising from changes in fair value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such assets are derecognized, the cumulative gains and losses previously recognized in equity are reclassified to profit or loss for the period within the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial assets at fair value through profit or loss</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These mainly comprise:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">contingent consideration already carried in the books of an acquired entity or granted in connection with a business combination;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">instruments whose contractual cash flows represent payments of interest and repayments of principal, which are managed with a view to selling the asset;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">instruments that management has designated at “fair value through profit or loss” on initial recognition; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">quoted and unquoted equity investments: equity instruments that are not held for trading and which management did not designate at “fair value through other comprehensive income” on initial recognition, and instruments that do not meet the IFRS definition of “equity instruments”.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Gains and losses arising from changes in fair value are recognized in profit or loss within the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Dividends received are recognized in profit or loss for the period, within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of equity investments in unquoted entities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On initial recognition of an equity investment in an entity not quoted in an active market, the fair value of the investment is the acquisition cost. Cost ceases to be a representative measure of the fair value of an unquoted equity investment when Sanofi identifies significant changes in the investee, or in the environment in which it operates. In such cases, an internal valuation is carried out, based mainly on growth forecasts or by reference to similar transactions contracted with third parties.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial assets measured at amortized cost</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Financial assets at amortized cost comprise instruments whose contractual cash flows represent payments of interest and repayments of principal and which are managed with a view to collecting cash flows. The main assets in this category are loans and receivables. They are presented within the line items</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other non-current assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Accounts receivable </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Cash and cash equivalents</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Loans with a maturity of more than 12 months are presented in “Long-term loans and advances” within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other non-current assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. These financial assets are measured at amortized cost using the effective interest method.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of financial assets measured at amortized cost</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The main assets involved are accounts receivable. Accounts receivable are initially recognized at the amount invoiced to the customer. Impairment losses on trade accounts receivable are estimated using the expected loss method, in order to take account of the risk of payment default throughout the lifetime of the receivables. The expected credit loss is estimated collectively for all accounts receivable at each reporting date using an average expected loss rate, determined primarily on the basis of historical credit loss rates. However, that average expected loss rate may be adjusted if there are indications of a likely significant increase in credit risk. If a receivable is subject to a known credit risk, a specific impairment loss is recognized for that receivable. The amount of expected losses is recognized in the balance sheet as a reduction in the gross amount of accounts receivable. Impairment losses on accounts receivable are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Selling and general expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.2. Derivative instruments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Derivative instruments that do not qualify for hedge accounting are initially and subsequently measured at fair value, with changes in fair value recognized in the income statement in</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, depending on the nature of the underlying economic item which is hedged.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Derivative instruments that qualify for hedge accounting are measured using the policies described in Note B.8.3. below.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">IFRS 13 (Fair Value Measurement) requires counterparty credit risk to be taken into account when measuring the fair value of financial instruments. That risk is estimated on the basis of observable, publicly-available statistical data.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Policy on offsetting</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In order for a financial asset and a financial liability to be presented as a net amount in the balance sheet under IAS 32, there must be:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(a) a legally enforceable right to offset; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(b) the intention either to settle on a net basis, or to realize the asset and settle the liability simultaneously.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.3. Hedging</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As part of its overall market risk management policy, Sanofi enters into various hedging transactions involving derivative or non-derivative instruments; these may include forward contracts, currency swaps or options, interest rate swaps or options, cross-currency swaps, and debt placings or issues.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Such financial instruments are designated as hedging instruments and recognized using the hedge accounting principles of IFRS 9 when (a) there is formal designation and documentation of the hedging relationship, of how the effectiveness of the hedging relationship will be assessed, and of the underlying market risk management objective and strategy; (b) the hedged item and the hedging instrument are eligible for hedge accounting; and (c) there is an economic relationship between the hedged item and the hedging instrument, defined on the basis of a hedge ratio that is consistent with the underlying market risk management strategy, and the residual credit risk does not dominate the value changes that result from that economic relationship.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value hedge</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A fair value hedge is a hedge of the exposure to changes in fair value of an asset, liability or firm commitment that is attributable to one or more risk components and could affect profit or loss.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in fair value of the hedging instrument and changes in fair value of the hedged item attributable to the hedged risk components are generally recognized in the income statement, within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to operating activities, or within</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to investing or financing activities.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash flow hedge</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A cash flow hedge is a hedge of the exposure to variability in cash flows from an asset, liability or highly probable forecast transaction that is attributable to one or more risk components and could affect profit or loss.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in fair value of the hedging instrument attributable to the effective portion of the hedge are recognized directly in equity in the consolidated statement of comprehensive income. Changes in fair value attributable to the ineffective portion of the hedge are recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">for hedges related to operating activities, and within</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to investing or financing activities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Cumulative changes in fair value of the hedging instrument previously recognized in equity are reclassified to the income statement when the hedged transaction affects profit or loss. Those reclassified gains and losses are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to operating activities, and within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to investing or financing activities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When a forecast transaction results in the recognition of a non-financial asset or liability, cumulative changes in the fair value of the hedging instrument previously recognized in equity are incorporated in the initial carrying amount of that asset or liability.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When the hedging instrument expires or is sold, terminated or exercised, the cumulative gain or loss previously recognized in equity remains separately recognized in equity and is not reclassified to the income statement, or recognized as an adjustment to the initial cost of the related non-financial asset or liability, until the forecast transaction occurs. However, if Sanofi no longer expects the forecast transaction to occur, the cumulative gain or loss previously recognized in equity is recognized immediately in profit or loss.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hedge of a net investment in a foreign operation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In a hedge of a net investment in a foreign operation, changes in the fair value of the hedging instrument attributable to the effective portion of the hedge are recognized directly in equity in the consolidated statement of comprehensive income. Changes in fair value attributable to the ineffective portion of the hedge are recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. When the investment in the foreign operation is sold, the changes in the fair value of the hedging instrument previously recognized in equity are reclassified to the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of hedging</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As part of its market risk management policy, Sanofi may designate currency options or interest rate options as hedging instruments, the effectiveness of which is measured on the basis of changes in intrinsic value. In such cases, the time value of the option is treated as a hedging cost and accounted for as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">if the option includes a component that is not aligned on the critical features of the hedged item, the corresponding change in the time value is taken to profit or loss;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">otherwise, the change in the time value is taken to equity within the statement of comprehensive income, and then:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">if the hedged item is linked to a transaction that results in the recognition of a financial asset or liability, the change in the time value is reclassified to profit or loss symmetrically with the hedged item, or</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">if the hedged item is linked to a transaction that results in the recognition of a non-financial asset or liability, the change in the time value is incorporated in the initial carrying amount of that asset or liability, or</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">if the hedged item is linked to a period of time, the change in time value is reclassified to profit or loss on a straight line basis over the life of the hedging relationship.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of forward contracts and foreign exchange swaps, and of cross-currency swaps that qualify for hedge accounting on the basis of changes in spot rates, Sanofi may elect for each transaction to use the option whereby the premium/discount or foreign currency basis spread are treated in the same way as the time value of an option.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discontinuation of hedge accounting</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Hedge accounting is discontinued when the eligibility criteria are no longer met (in particular, when the hedging instrument expires or is sold, terminated or exercised), or if there is a change in the market risk management objective of the hedging relationship.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.4. Non-derivative financial liabilities</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Borrowings and debt</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Bank borrowings and debt instruments are initially measured at fair value of the consideration received, net of directly attributable transaction costs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subsequently, they are measured at amortized cost using the effective interest method. All costs related to the issuance of borrowings or debt instruments, and all differences between the issue proceeds net of transaction costs and the value on redemption, are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement over the term of the debt using the effective interest method.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These line items record the fair value of (i) contingent consideration payable in connection with business combinations and (ii) commitments to buy out equity holders of subsidiaries, including put options granted to non-controlling interests.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Adjustments to the fair value of commitments to buy out equity holders of subsidiaries, including put options granted to non-controlling interests, are recognized in equity.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other non-derivative financial liabilities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other non-derivative financial liabilities include trade accounts payable, which are measured at fair value (which in most cases equates to face value) on initial recognition, and subsequently at amortized cost.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.5. Fair value of financial instruments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IFRS 13 (Fair Value Measurement) and IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.69pt">level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.08pt">level 2: quoted prices in active markets for similar assets and liabilities, or valuation techniques in which all important inputs are derived from observable market data; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.61pt">level 3: valuation techniques in which not all important inputs are derived from observable market data.</span></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:5.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.362%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Type of financial instrument</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Measurement<br/>principle</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in<br/>fair value<br/>hierarchy</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation<br/>technique</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Method used to determine fair value</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation<br/>model</span></td><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market data</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exchange rate</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest<br/>rate</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted equity instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted debt instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (unquoted equity instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cost/Approach based on comparables</span></div></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">If cost ceases to be a representative measure of fair value, an internal valuation is carried out, based mainly on comparables.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (contingent consideration receivable)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value held to meet obligations under <br/>post-employment benefit plans</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets designated at fair value held to meet obligations under deferred compensation plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.13.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Investments in mutual funds</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Net asset value</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.13.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Negotiable debt instruments, commercial paper, instant access deposits and term deposits</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Because these instruments have a maturity of less than three months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.17.1., D.19.</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">In the case of debt with a maturity of less than three months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">For debt with a maturity of more than three months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.17.2.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The liability for future lease payments is discounted using the incremental borrowing rate.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">< 1 year:</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Money Market</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">> 1 year: </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Zero Coupon</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market<br/>Spot</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">< 1 year:</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Money Market and LIFFE interest rate futures</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">> 1 year: </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Zero Coupon</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market<br/>Spot</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">< 1 year:<br/>Mid Money Market and LIFFE interest rate futures<br/>> 1 year: <br/>Mid Zero Coupon</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.18.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests (CVRs)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.18.</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests (other than CVRs)</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3 </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.8.4.</span></div></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.6. Derecognition of financial instruments</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Financial assets are derecognized when the contractual rights to cash flows from the asset have ended or have been transferred and when Sanofi has transferred substantially all the risks and rewards of ownership of the asset. If Sanofi has neither transferred nor retained substantially all the risks and rewards of ownership of a financial asset, it is derecognized if Sanofi does not retain control of the asset.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A financial liability is derecognized when Sanofi’s contractual obligations in respect of the liability are discharged, cancelled or extinguished.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.7. Risks relating to financial instruments</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Market risks in respect of non-current financial assets, cash equivalents, derivative instruments and debt are described in the discussions of risk factors presented in Item 3.D. and Item 11. of Sanofi’s annual report on Form 20-F for 2023.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Credit risk is the risk that customers may fail to pay their debts. For a description of credit risk, refer to “We are subject to the risk of non-payment by our customers” within Item 3.D. and Item 11. of Sanofi’s annual report on Form 20-F for 2023.</span></div>Inventories<div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Inventories are measured at the lower of cost or net realizable value. Cost is calculated using the weighted average cost method or the first-in, first-out method, depending on the nature of the inventory.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The cost of finished goods inventories includes costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the launch phase of a new product, any inventories of that product are written down to zero pending regulatory approval, other than in specific circumstances which make it possible to estimate that there is a high probability at the end of the reporting period that the carrying amount of the inventories will be recoverable. The write-down is reversed once it becomes highly probable that marketing approval will be obtained.</span></div>Cash and cash equivalents<div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Cash and cash equivalents as shown in the consolidated balance sheet and statement of cash flows comprise cash, plus liquid short-term investments that are readily convertible into cash and are subject to an insignificant risk of changes in value in the event of movements in interest rates.</span></div>Treasury shares<div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS 32, Sanofi treasury shares are deducted from equity, irrespective of the purpose for which they are held. No gain or loss is recognized in the income statement on the purchase, sale, impairment or cancellation of treasury shares.</span></div>Provisions for risks<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS 37 (Provisions, Contingent Liabilities and Contingent Assets), Sanofi records a provision when it has a present obligation, whether legal or constructive, as a result of a past event; it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and a reliable estimate can be made of the amount of the outflow of resources.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If the obligation is expected to be settled more than 12 months after the end of the reporting period, or has no definite settlement date, the provision is recorded within Non-current provisions and other non-current liabilities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Provisions relating to the insurance programs in which Sanofi’s captive insurance company participates are based on risk exposure estimates calculated by management, with assistance from independent actuaries, using IBNR (Incurred But Not Reported) techniques. Those techniques use past claims experience, within Sanofi and in the market, to estimate future trends in the cost of claims.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Contingent liabilities are not recognized, but are disclosed in the notes to the financial statements unless the possibility of an outflow of economic resources is remote.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi estimates provisions on the basis of events and circumstances related to present obligations at the end of the reporting period and of past experience, and to the best of management’s knowledge at the date of preparation of the financial statements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Reimbursements offsetting the probable outflow of resources are recognized as assets only if it is virtually certain that they will be received. Contingent assets are not recognized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restructuring provisions are recognized if Sanofi has a detailed, formal restructuring plan at the end of the reporting period and has announced its intention to implement this plan to those affected by it.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No provisions are recorded for future operating losses.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi records non-current provisions for certain obligations, such as legal or constructive obligations, where an outflow of resources is probable and the amount of the outflow can be reliably estimated.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of environmental risks, including at sites where operations are ongoing, Sanofi recognizes a provision where there is a violation of integrity in respect of human health or the environment resulting from past contamination at a site that requires remediation. The amount of the provision is a best estimate of the future expenditures to be incurred on the remediation plan.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Where the effect of the time value of money is material, those provisions are measured at the present value of the expenditures expected to be required to settle the obligation, calculated using a discount rate that reflects an estimate of the time value of money and the risks specific to the obligation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Increases in provisions to reflect the effects of the passage of time are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div>Revenue recognition<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.13.1. Net sales</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Revenue arising from the sale of goods is presented in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net sales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Net sales comprise revenue from sales of pharmaceutical products, consumer healthcare products, active ingredients and vaccines, net of sales returns, of customer incentives and discounts, and of certain sales-based payments paid or payable to the healthcare authorities. Analyses of net sales are provided in Note D.35.1. “Segment Information”.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 15 (Revenue from Contracts with Customers), such revenue is recognized when Sanofi transfers control over the product to the customer; control of an asset refers to the ability to direct the use of, and obtain substantially all of the remaining benefits from that asset. For the vast majority of contracts, revenue is recognized when the product is physically transferred, in accordance with the delivery and acceptance terms agreed with the customer.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For contracts entered into by Sanofi Pasteur, transfer of control is usually determined by reference to the terms of release (immediate or deferred) and acceptance of batches of vaccine.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of contracts with distributors, Sanofi does not recognize revenue when the product is physically transferred to the distributor if the products are sold on consignment, or if the distributor acts as agent. In such cases, revenue is recognized when control is transferred to the end customer, and the distributor’s commission is presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Selling and general expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The amount of revenue recognized reflects the various types of price reductions or rights of return offered by Sanofi to its customers on certain products. Such price reductions and rights of return qualify as variable consideration under IFRS 15.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In particular, products sold in the United States are covered by various Government and State programs (such as Medicare and Medicaid) under which products are sold at a discount. Rebates are granted to healthcare authorities, and under contractual arrangements with certain customers. Some wholesalers are entitled to chargeback incentives based on the selling price to the end customer, under specific contractual arrangements. Cash discounts may also be granted for prompt payment. Returns, discounts, incentives and rebates, as described above, are recognized in the period in which the underlying sales are recognized as a reduction of gross sales.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These amounts are calculated as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of chargeback incentives is estimated on the basis of the relevant subsidiary’s standard sales terms and conditions, and in certain cases on the basis of specific contractual arrangements with the customer;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of rebates based on attainment of sales targets is estimated and accrued as each of the underlying sales transactions is recognized;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of price reductions under Government and State programs, largely in the United States, is estimated on the basis of the specific terms of the relevant regulations or agreements, and accrued as each of the underlying sales transactions is recognized;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of sales returns is calculated on the basis of management’s best estimate of the amount of product that will ultimately be returned by customers. In countries where product returns are possible, Sanofi operates a returns policy that allows the customer to return products within a certain period either side of the expiry date (usually 12 months after the expiry date). The amount recognized for returns is estimated on the basis of past experience of sales returns. Sanofi also takes into account factors such as levels of inventory in its various distribution channels, product expiry dates, information about potential discontinuation of products, the entry of competing generics into the market, and the launch of over-the-counter medicines. Most product return clauses relate solely to date-expired products, which cannot be resold and are destroyed. Sanofi does not recognize a right of return asset in the balance sheet for contracts that allow for the return of time-expired products, since those products have no value.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The estimated amounts described above are recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net sales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">as a reduction of gross sales, and within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the balance sheet. They are subject to regular review and adjustment as appropriate based on the most recent data available to management. Sanofi believes that it has the ability to measure each of the above amounts reliably, using the following factors in developing its estimates:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the nature and patient profile of the underlying product;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the applicable regulations or the specific terms and conditions of contracts with governmental authorities, wholesalers and other customers;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">historical data relating to similar contracts, in the case of qualitative and quantitative rebates and chargeback incentives;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">past experience and sales growth trends for the same or similar products;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">actual inventory levels in distribution channels, monitored by Sanofi using internal sales data and externally provided data;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the shelf life of Sanofi products; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">market trends including competition, pricing and demand.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of provisions for discounts, rebates and sales returns is provided in Note D.23.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.13.2. Other revenues</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is used to recognize all revenue that falls within the scope of IFRS 15 but does not relate to sales of Sanofi products.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It mainly comprises (i) royalties received from licensing intellectual property rights to third parties; (ii) VaxServe sales of products sourced from third-party manufacturers; and (iii) revenue received under agreements for Sanofi to provide manufacturing services to third parties.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Royalties received under licensing arrangements are recognized over the period during which the underlying sales are recognized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">VaxServe is a Vaccines segment entity whose operations include the distribution within the United States of vaccines and other products manufactured by third parties. VaxServe sales of products sourced from third-party manufacturers are presented within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div>Cost of sales<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> consists primarily of the industrial cost of goods sold, payments made under licensing agreements, and distribution costs. The industrial cost of goods sold includes the cost of materials, depreciation of property, plant and equipment, amortization of software, personnel costs, and other expenses attributable to production.</span></div>Research and development<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Note B.4.1. “Research and development not acquired in a business combination” and Note B.4.3. “Other intangible assets acquired in a business combination” describe the principles applied to the recognition of research and development costs.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Contributions or reimbursements received from alliance partners are recorded as a reduction of </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div>Other operating income and expenses<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.16.1. Other operating income</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> includes the share of profits that Sanofi is entitled to receive from alliance partners in respect of product marketing agreements. It also includes revenues generated under certain agreements, which may include partnership, co-promotion arrangements and licenses not included in Other revenues.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This line item also includes realized and unrealized foreign exchange gains and losses on operating activities (see Note B.8.3.), and operating gains on disposals not regarded as major disposals (see Note B.20.).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.16.2. Other operating expenses</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> mainly comprise the share of profits that alliance partners are entitled to receive from Sanofi under product marketing agreements.</span></div>Amortization and impairment of intangible assets<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.17.1. Amortization of intangible assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The expenses recorded in this line item comprise amortization charged against intangible assets (products, trademarks and technology platforms, see Note D.4.) whose contribution to Sanofi’s commercial, industrial and development functions cannot be separately identified.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amortization of software, and of other rights of an industrial or operational nature, is recognized as an expense in the income statement, in the relevant line items of expense by function.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.17.2. Impairment of intangible assets</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This line item records impairment losses taken against intangible assets (products, trademarks, technology platforms and acquired research), and any reversals of such impairment losses.</span></div>Fair value remeasurement of contingent consideration<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in the fair value of contingent consideration that was (i) already carried in the books of an acquired entity, or (ii) granted in connection with a business combination and initially recognized as a liability in accordance with IFRS 3, are reported in profit or loss. Such adjustments are reported separately in the income statement, in the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Fair value remeasurement of contingent consideration</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This line item also includes changes in the fair value of contingent consideration receivable in connection with a divestment and classified as a financial asset at fair value through profit or loss.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, it includes the effect of the unwinding of discount, and of exchange rate movements where the asset or liability is expressed in a currency other than the functional currency of the reporting entity.</span></div>Restructuring costs and similar items<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restructuring costs are expenses incurred in connection with the transformation or reorganization of Sanofi’s operations or support functions. Such costs include collective redundancy plans, compensation to third parties for early termination of contracts, and commitments made in connection with transformation or reorganization decisions. They also include accelerated depreciation charges arising from site closures (including closures of leased sites), and losses on asset disposals resulting from such decisions.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, this line item includes expenses incurred in connection with programs implemented as part of the transformation strategy announced in December 2019 (and previously in November 2015), and intended primarily (i) to deliver a global information systems solution, further supported by the implementation from 2021 of Sanofi’s new digital strategy; and (ii) to create a standalone CHC entity and proceed to the proposed separation of the CHC business as announced when the new chapter in the Play to Win strategy was presented in October 2023.</span></div>Other gains and losses, and litigation<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> includes the impact of material transactions of an unusual nature or amount which Sanofi believes it necessary to report separately in the income statement in order to improve the relevance of the financial statements, such as:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">gains and losses on major disposals of property, plant and equipment, of intangible assets, of assets (or groups of assets and liabilities) held for sale, or of a business within the meaning of IFRS 3, other than those considered to be restructuring costs;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">impairment losses and reversals of impairment losses on assets (or groups of assets and liabilities) held for sale, other than those considered to be restructuring costs;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">gains on bargain purchases;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">costs relating to major litigation; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">pre-tax separation costs associated with the process of disinvesting from operations in the event of a major divestment.</span></div>Financial expenses and income<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.21.1. Financial expenses</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> mainly comprise interest charges on debt financing; negative changes in the fair value of certain financial instruments (where changes in fair value are recognized in profit or loss); realized and unrealized foreign exchange losses on financing and investing activities; impairment losses on financial instruments; and any reversals of impairment losses on financial instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> also include expenses arising from the unwinding of discount on long-term provisions, and the net interest cost related to employee benefits. This line item does not include commercial cash discounts, which are deducted from net sales.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.21.2. Financial income</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> includes interest and dividend income; positive changes in the fair value of certain financial instruments (where changes in fair value are recognized in profit or loss); realized and unrealized foreign exchange gains on financing and investing activities; and gains on disposals of financial assets at fair value through profit or loss.</span></div>Income tax expense<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income tax expense </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">includes all current and deferred taxes of consolidated companies.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi accounts for deferred taxes in accordance with IAS 12 (Income Taxes), using the methods described below:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">deferred tax assets and liabilities are recognized on taxable and deductible temporary differences, and on tax loss carry-forwards. Temporary differences are differences between the carrying amount of an asset or liability in the balance sheet and its tax base;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">French business taxes include a value added based component: “CVAE” </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Cotisation sur la Valeur Ajoutée des Entreprises)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Given that CVAE is (i) calculated as the amount by which certain revenues exceed certain expenses and (ii) borne primarily by companies that own intellectual property rights on income derived from those rights (royalties, and margin on sales to third parties and to Sanofi entities), it is regarded as meeting the definition of income taxes specified in IAS 12, paragraph 2 (“taxes which are based on taxable profits”);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">deferred tax assets and liabilities are calculated using the tax rate expected to apply in the period when the corresponding temporary differences are expected to reverse, based on tax rates enacted or substantively enacted at the end of the reporting period;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">deferred tax assets are recognized in respect of deductible temporary differences, tax losses available for carry-forward and unused tax credits to the extent that future recovery is regarded as probable. The recoverability of deferred tax assets is assessed on a case-by-case basis, taking into account the profit forecasts contained in Sanofi’s medium-term business plan;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a deferred tax liability is recognized for temporary differences relating to interests in subsidiaries, associates and joint ventures, except in cases where Sanofi is able to control the timing of the reversal of the temporary differences. This applies in particular when Sanofi is able to control dividend policy and it is probable that the temporary differences will not reverse in the foreseeable future;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">no deferred tax is recognized on eliminations of intragroup transfers of interests in subsidiaries, associates or joint ventures;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">each tax entity calculates its own net deferred tax position. All net deferred tax asset and liability positions are then aggregated and shown in separate line items on the relevant side of the consolidated balance sheet. Deferred tax assets and liabilities are offset only if (i) Sanofi has a legally enforceable right to offset current tax assets and current tax liabilities, and (ii) the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same taxation authority;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">deferred taxes are not discounted, except implicitly in the case of deferred taxes on assets and liabilities which are already impacted by discounting. In addition, Sanofi has elected not to discount current taxes payable or receivable where the amounts in question are payable or receivable in the long term;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">withholding taxes on intragroup royalties and dividends, and on royalties and dividends collected from third parties, are accounted for as current income taxes.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accounting for business combinations, Sanofi complies with IFRS 3 as regards the recognition of deferred tax assets after the initial accounting period. Consequently, any deferred tax assets recognized by the acquiree after the end of that period in respect of temporary differences or tax loss carry-forwards existing at the acquisition date are recognized in profit or loss.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The positions adopted by Sanofi in tax matters are based on its interpretation of tax laws and regulations. Some of those positions may be subject to uncertainty. In such cases, Sanofi assesses the amount of the tax liability on the basis of the following assumptions: that its position will be examined by one or more tax authorities on the basis of all relevant information; that a technical assessment is carried out with reference to legislation, case law, regulations, and established practice; and that each position is assessed individually (or collectively where appropriate), with no offset or aggregation between positions. Those assumptions are assessed on the basis of facts and circumstances existing at the end of the reporting period. When an uncertain tax liability is regarded as probable, it is measured on the basis of Sanofi’s best estimate and recognized as a liability; uncertain tax assets are not recognized. The amount of the liability includes any penalties and late payment interest. The line item</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Income tax expense</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> includes the effects of tax reassessments and tax disputes, and any penalties and late payment interest arising from such disputes that have the characteristics of income taxes within the meaning of paragraph 2 of IAS 12 (“taxes which are based on taxable profits”). Tax exposures relating to corporate income taxes are presented separately within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Non-current income tax liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (see Note D.19.4.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No deferred taxation is recognized on temporary differences that are liable to be subject to US global intangible low taxed income (GILTI) provisions. The related tax expense is recognized in the year in which it is declared in the tax return to the extent that it arises from the existence of non-US profits that exceed the theoretical return on investment specified in the GILTI provisions and are taxed at a rate lower than the applicable US tax rate.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS 1 (Presentation of Financial Statements), current income tax assets and liabilities are presented as separate line items in the consolidated balance sheet.</span></div>Employee benefit obligations<div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi offers retirement benefits to employees and retirees. Such benefits are accounted for in accordance with IAS 19 (Employee Benefits).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Benefits are provided in the form of either defined contribution plans or defined benefit plans. In the case of defined contribution plans, the cost is recognized immediately in the period in which it is incurred, and equates to the amount of the contributions paid by Sanofi. For defined benefit plans, Sanofi generally recognizes its obligations to pay pensions and similar benefits to employees as a liability, based on an actuarial estimate of the rights vested or currently vesting in employees and retirees, using the projected unit credit method. Estimates are performed at least once a year, and rely on financial assumptions (such as discount </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">rates) and demographic assumptions (such as life expectancy, retirement age, employee turnover, and the rate of salary increases).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Obligations relating to other post-employment benefits (healthcare and life insurance) offered by Sanofi companies to employees are also recognized as a liability based on an actuarial estimate of the rights vested or currently vesting in employees and retirees at the end of the reporting period.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Such liabilities are recognized net of the fair value of plan assets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of multi-employer defined benefit plans where plan assets cannot be allocated to each participating employer with sufficient reliability, the plan is accounted for as a defined contribution plan, in accordance with paragraph 34 of IAS 19.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The benefit cost for the period consists primarily of current service cost, past service cost, net interest cost, gains or losses arising from plan settlements not specified in the terms of the plan, and actuarial gains or losses arising from plan curtailments. Net interest cost for the period is determined by applying the discount rate specified in IAS 19 to the net liability (i.e. the amount of the obligation, net of plan assets) recognized in respect of defined benefit plans. Past service cost is recognized immediately in profit or loss in the period in which it is incurred, regardless of whether or not the rights have vested at the time of adoption (in the case of a new plan) or of amendment (in the case of an existing plan).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actuarial gains and losses on defined benefit plans (pensions and other post-employment benefits), also referred to as “Remeasurements of the net defined benefit liability (asset)”</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> arise as a result of changes in financial and demographic assumptions, experience adjustments, and the difference between the actual return and interest cost on plan assets. The impacts of those remeasurements are recognized in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, net of deferred taxes; they are not subsequently reclassifiable to profit or loss.</span></div>Share-based payment<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Share-based payment expense is recognized as a component of operating income, in the relevant classification of expense by function. In measuring the expense, the level of attainment of any performance conditions is taken into account.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.24.1. Stock option plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has granted a number of equity-settled share-based payment plans (stock option plans) to some of its employees. The terms of those plans may make the award contingent on the attainment of performance criteria for some of the grantees.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 2 (Share-Based Payment), services received from employees as consideration for stock options are recognized as an expense in the income statement, with the opposite entry recognized in equity. The expense corresponds to the fair value of the stock option plans, and is charged to income on a straight-line basis over the four-year vesting period of the plan.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The fair value of stock option plans is measured at the date of grant using the Black-Scholes valuation model, taking into account the expected life of the options. The resulting expense also takes into account the expected cancellation rate of the options. The expense is adjusted over the vesting period to reflect actual cancellation rates resulting from option-holders ceasing to be employed by Sanofi.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.24.2. Employee share ownership plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi may offer its employees the opportunity to subscribe to reserved share issues at a discount to the reference market price. Shares awarded to employees under such plans fall within the scope of IFRS 2. Consequently, an expense is recognized at the subscription date, based on the value of the discount offered to employees.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.24.3. Restricted share plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi may award restricted share plans to certain of its employees. The terms of those plans may make the award contingent on the attainment of performance criteria for some of the grantees.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 2, an expense equivalent to the fair value of such plans is recognized in profit or loss on a straight line basis over the vesting period of the plan, with the opposite entry recognized in equity. The vesting period is three years.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The fair value of restricted share plans is based on the quoted market price of Sanofi shares at the date of grant, adjusted for expected dividends during the vesting period; it also takes account of any vesting conditions contingent on stock market performance, measured using the Monte-Carlo valuation model. Other vesting conditions are taken into account in the estimate of the number of shares awarded during the vesting period; that number is then definitively adjusted based on the actual number of shares awarded on the vesting date.</span></div>Earnings per share<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Basic earnings per share is calculated using the weighted average number of shares outstanding during the reporting period, adjusted on a time-weighted basis from the acquisition date to reflect the number of own shares held by Sanofi. Diluted earnings per share is calculated on the basis of the weighted average number of ordinary shares, computed using the treasury stock method.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This method assumes that (i) all outstanding dilutive options and warrants are exercised, and (ii) Sanofi acquires its own shares at the quoted market price for an amount equivalent to the cash received as consideration for the exercise of the options or warrants, plus the expense arising on unamortized stock options.</span></div>Segment information<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 8 (Operating Segments), the segment information reported by Sanofi is prepared on the basis of internal management data provided to our Chief Executive Officer, who is the chief operating decision maker of Sanofi. The performance of those segments is monitored individually using internal reports and common indicators.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2022, Sanofi reported three operating segments (Pharmaceuticals, Vaccines and Consumer Healthcare). The costs of the global support functions (Corporate Affairs, Finance, People & Culture, Legal, Ethics, Business Integrity & Global Security, Information Solutions & Technology, Sanofi Business Services, etc.), which are mainly managed centrally at group-wide level, were presented within the “Other” category. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, Sanofi reviewed the presentation of its segment information following adjustments to its internal reporting systems in order to reflect (i) progress on the “Play to Win” strategy leading to the creation of the standalone Consumer Healthcare Global Business Unit (GBU) which, in addition to integrated research, development and production functions now also has its own dedicated global support functions (including Finance, People & Culture, Legal, Ethics, Business Integrity & Global Security, Information Solutions & Technology, Global Business Services, etc.); and (ii) organizational changes to Sanofi’s Manufacturing & Supply global function (previously known as Industrial Affairs). </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Consequently, with effect from January 1, 2023, Sanofi reports two operating segments: Biopharma and Consumer Healthcare.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Biopharma operating segment comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines and Vaccines franchises, for all geographical territories. The segment’s results include the costs of global support functions that are not within the managerial responsibility of the Consumer Healthcare GBU.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Consumer Healthcare operating segment comprises commercial operations relating to Consumer Healthcare products, and research, development and production activities and global support functions (as listed above) dedicated to the segment, for all geographical territories. The Consumer Healthcare GBU segment’s results reflect all incurred costs of global support functions attributable to its business.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The “Other” category comprises reconciling items, primarily but not limited to (i) gains and losses on centralized foreign exchange risk hedging transactions that cannot be allocated to the operating segments and (ii) gains and losses on retained commitments in respect of previously divested operations.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Information about operating segments for the years ended December 31, 2023, 2022 and 2021 is presented in Note D.35</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">., </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">“Segment information”.</span></div>Management of capital<div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In order to maintain or adjust the capital structure, Sanofi can adjust the amount of dividends paid to shareholders, repurchase its own shares, issue new shares, or issue securities giving access to its capital.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following objectives are defined under the terms of Sanofi’s share repurchase programs:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the implementation of any stock option plan giving entitlement to purchase shares in the Sanofi parent company;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the allotment or sale of shares to employees under statutory profit sharing schemes and employee savings plans;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the consideration-free allotment of shares (i.e. restricted share plans);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the cancellation of some or all of the repurchased shares;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">market-making in the secondary market by an investment services provider under a liquidity contract in compliance with the ethical code recognized by the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Autorité des marchés financiers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (AMF);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the delivery of shares on the exercise of rights attached to securities giving access to the capital by redemption, conversion, exchange, presentation of a warrant or any other means;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the delivery of shares (in exchange, as payment, or otherwise) in connection with mergers and acquisitions;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the execution by an investment services provider of purchases, sales or transfers by any means, in particular via off-market trading; or</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.1pt">any other purpose that is or may in the future be authorized under the applicable laws and regulations.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is not subject to any constraints on equity capital imposed by third parties.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total equity includes </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Equity attributable to equity holders of Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Equity attributable to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, as shown in the consolidated balance sheet.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi defines “Net debt” as (i) the sum of short-term debt, long-term debt and interest rate derivatives and currency derivatives used to hedge debt, minus (ii) the sum of cash and cash equivalents and interest rate derivatives and currency derivatives used to hedge cash and cash equivalents.</span></div>

CY2023

ifrs-full

Description Of Accounting Policy For Foreign Currency Translation Explanatory

DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory

Foreign currency translation<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.2.1. Accounting for foreign currency transactions in the financial statements of consolidated entities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Non-current assets (other than receivables) and inventories acquired in foreign currencies are translated into the functional currency using the exchange rate prevailing at the acquisition date.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Monetary assets and liabilities denominated in foreign currencies are translated using the exchange rate prevailing at the end of the reporting period. The gains and losses resulting from foreign currency translation are recorded in the income statement. However, foreign exchange gains and losses arising from the translation of advances between consolidated subsidiaries for which settlement is neither planned nor likely to occur in the foreseeable future are recognized in equity, in the line item</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Change in currency translation differences.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.2.2. Foreign currency translation of the financial statements of foreign entities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi presents its consolidated financial statements in euros (€). In accordance with IAS 21 (The Effects of Changes in Foreign Exchange Rates), each subsidiary accounts for its transactions in the currency that is most representative of its economic environment (the functional currency).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">All assets and liabilities are translated into euros using the exchange rate of the subsidiary’s functional currency prevailing at the end of the reporting period. Income statements are translated using a weighted average exchange rate for the period, except in the case of foreign subsidiaries in a hyperinflationary economy. The resulting currency translation difference is recognized as a separate component of equity in the consolidated statement of comprehensive income, and is recognized in the income statement only when the subsidiary is sold or is wholly or partially liquidated.</span></div>

CY2023

ifrs-full

Description Of Accounting Policy For Business Combinations And Goodwill Explanatory

DescriptionOfAccountingPolicyForBusinessCombinationsAndGoodwillExplanatory

Business combinations and transactions with non-controlling interests<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.3.1. Accounting for business combinations, transactions with non-controlling interests and loss of control</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Business combinations are accounted for in accordance with IFRS 3 (Business Combinations) and IFRS 10 (Consolidated Financial Statements).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Business combinations are accounted for using the acquisition method. Under this method, the acquiree’s identifiable assets and liabilities that satisfy the recognition criteria of IFRS 3 (Business Combinations) are measured initially at their fair values at the date of acquisition, except for (i) non-current assets classified as held for sale (which are measured at fair value less costs to sell) and (ii) assets and liabilities that fall within the scope of IAS 12 (Income Taxes) and IAS 19 (Employee Benefits). Restructuring liabilities are recognized as a liability of the acquiree only if the acquiree has an obligation as of the acquisition date to carry out the restructuring.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal accounting rules applicable to business combinations and transactions with non-controlling interests include:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">acquisition-related costs are recognized as an expense, as a component of </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">contingent consideration is recognized in equity if the contingent payment is settled by delivery of a fixed number of the acquirer’s equity instruments; otherwise, it is recognized in liabilities related to business combinations. Contingent consideration is recognized at fair value at the acquisition date irrespective of the probability of payment. If the contingent consideration was originally recognized as a financial liability, subsequent adjustments to the liability are recognized in profit or loss in the line item</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Fair value remeasurement of contingent consideration</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, unless the adjustment is made within the 12 months following the acquisition date and relates to facts and circumstances existing as of that date;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">goodwill may be calculated on the basis of either (i) the entire fair value of the acquiree, or (ii) a share of the fair value of the acquiree proportionate to the interest acquired. This option is elected for each acquisition individually.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Purchase price allocations are performed under the responsibility of management, with assistance from an independent valuer in the case of major acquisitions. IFRS 3 does not specify an accounting treatment for contingent consideration arising from a business combination made by an entity prior to the acquisition of control in that entity and carried as a liability in the acquired entity’s balance sheet. The accounting treatment applied by Sanofi to such a liability is to measure it at fair value as of the acquisition date and to report it in the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, with subsequent remeasurements recognized in profit or loss. This treatment is consistent with the accounting applied to contingent consideration in the books of the acquirer.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Finally, management may where it deems fit elect to apply the optional test to identify concentration of fair value permitted under IFRS 3 in order to determine whether a transaction is a business combination within the meaning of IFRS 3, or merely the acquisition of an asset or of a group of similar assets.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.3.2. Goodwill</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The excess of the cost of an acquisition over Sanofi’s interest in the fair value of the identifiable assets and liabilities of the acquiree is recognized as goodwill at the date of the business combination. Goodwill arising on the acquisition of subsidiaries is shown in a separate balance sheet line item, whereas goodwill arising on the acquisition of investments accounted for using the equity method is recorded in</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Investments accounted for using the equity method.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill arising on foreign operations is expressed in the functional currency of the country concerned and translated into euros using the exchange rate prevailing at the end of the reporting period.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS 36 (Impairment of Assets), goodwill is carried at cost less accumulated impairment (see Note B.6.).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Goodwill is tested for impairment annually and whenever events or circumstances indicate that impairment might exist. Such events or circumstances include significant changes more likely than not to have an other-than-temporary impact on the substance of the original investment.</span></div>

CY2023

ifrs-full

Description Of Accounting Policy For Intangible Assets Other Than Goodwill Explanatory

DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory

Other intangible assets<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other intangible assets are initially measured at acquisition cost or production cost, including any directly attributable costs of preparing the asset for its intended use, or (in the case of assets acquired in a business combination) at fair value as of the date of the business combination. Intangible assets are amortized on a straight line basis over their useful lives.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The useful lives of other intangible assets are reviewed at the end of each reporting period. The effect of any adjustment to useful lives is recognized prospectively as a change in accounting estimate.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amortization of other intangible assets is recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Amortization of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> except for amortization charged against (i) acquired or internally-developed software and (ii) other rights of an industrial or operational nature, which is recognized in the relevant classification of expense by function.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi does not own any intangible assets with an indefinite useful life, other than goodwill.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Intangible assets (other than goodwill) are carried at cost less accumulated amortization and accumulated impairment, if any, in accordance with IAS 36 (see Note B.6.).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.4.1. Research and development not acquired in a business combination</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Internally generated research and development</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IAS 38, research expenses are recognized in profit or loss when incurred.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Internally generated development expenses are recognized as an intangible asset if, and only if, all the following six criteria can be demonstrated: (a) the technical feasibility of completing the development project; (b) Sanofi’s intention to complete the project; (c) Sanofi’s ability to use the project; (d) the probability that the project will generate future economic benefits; (e) the availability of adequate technical, financial and other resources to complete the project; and (f) the ability to measure the development expenditure reliably.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Due to the risks and uncertainties relating to regulatory approval and to the research and development process, the six criteria for capitalization are usually considered not to have been met until the product has obtained marketing approval from the regulatory authorities. Consequently, internally generated development expenses arising before marketing approval has been obtained, mainly the cost of clinical trials, are generally expensed as incurred within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Some industrial development expenses (such as those incurred in developing a second-generation synthesis process) are incurred after marketing approval has been obtained, in order to improve the industrial process for an active ingredient. To the extent that the six IAS 38 criteria are considered as having been met, such expenses are recognized as an asset in the balance sheet within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> as incurred. Similarly, some clinical trials, for example those undertaken to obtain a geographical extension for a molecule that has already obtained marketing approval in a major market, may in certain circumstances meet the six capitalization criteria under IAS 38, in which case the related expenses are recognized as an asset in the balance sheet within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separately acquired research and development</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Payments for separately acquired research and development are capitalized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> provided that they meet the definition of an intangible asset: a resource that is (i) controlled by Sanofi, (ii) expected to provide future economic benefits for Sanofi, and (iii) identifiable (i.e. it is either separable or arises from contractual or legal rights). Under paragraph 25 of IAS 38, the first condition for capitalization (the probability that the expected future economic benefits from the asset will flow to the entity) is considered to be satisfied for separately acquired research and development. Consequently, upfront and milestone payments to third parties related to pharmaceutical products for which marketing approval has not yet been obtained are recognized as intangible assets, and amortized on a straight line basis over their useful lives beginning when marketing approval is obtained.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Payments under research and development arrangements relating to access to technology or to databases, and payments made to purchase generics dossiers, are also capitalized, and amortized over the useful life of the intangible asset.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subcontracting arrangements, payments for research and development services, and continuous payments under research and development collaborations which are unrelated to the outcome of that collaboration, are expensed over the service term.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.4.2. Other intangible assets not acquired in a business combination</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Licenses other than those related to pharmaceutical products and research projects, in particular software licenses, are capitalized at acquisition cost, including any directly attributable cost of preparing the software for its intended use. Software licenses are amortized on a straight line basis over their useful lives for Sanofi (<span style="-sec-ix-hidden:f-646">three</span> to five years).</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Internally generated costs incurred to develop or upgrade software are capitalized if the IAS 38 recognition criteria are satisfied, and amortized on a straight line basis over the useful life of the software from the date on which the software is ready for use.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.4.3. Other intangible assets acquired in a business combination</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other intangible assets acquired in a business combination (in-process research and development, technology platforms, and currently marketed products) that are reliably measurable are identified separately from goodwill, measured at fair value, and capitalized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in accordance with IFRS 3 (Business Combinations) and IAS 38 (Intangible Assets). The related deferred tax liability is also recognized if a deductible or taxable temporary difference exists.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In-process research and development acquired in a business combination is amortized on a straight line basis over its useful life from the date of receipt of marketing approval.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Rights to technology platforms and to products currently marketed by Sanofi are amortized on a straight line basis over their useful lives, determined (in particular for marketed products) on the basis of cash flow forecasts which take into account the patent protection period of the marketed product.</span></div>

CY2023

ifrs-full

Description Of Accounting Policy For Property Plant And Equipment Explanatory

DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory

Property, plant and equipment owned and leased<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.5.1. Property, plant and equipment owned</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Property, plant and equipment is initially measured and recognized at acquisition cost, including any directly attributable cost of preparing the asset for its intended use, or (in the case of assets acquired in a business combination) at fair value as of the date of the business combination. The component-based approach to accounting for property, plant and equipment is applied. Under this approach, each component of an item of property, plant and equipment with a cost which is significant in relation to the total cost of the item and which has a different useful life from the other components must be depreciated separately.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">After initial measurement, property, plant and equipment is carried at cost less accumulated depreciation and impairment, except for land which is carried at cost less impairment.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subsequent costs are not recognized as assets unless (i) it is probable that future economic benefits associated with those costs will flow to Sanofi and (ii) the costs can be measured reliably.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Borrowing costs attributable to the financing of items of property, plant and equipment, and incurred during the construction period, are capitalized as part of the acquisition cost of the item.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Government grants relating to property, plant and equipment are deducted from the acquisition cost of the asset to which they relate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The depreciable amount of items of property, plant and equipment, net of any residual value, is depreciated on a straight line basis over the useful life of the asset. The useful life of an asset is usually equivalent to its economic life.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The customary useful lives of property, plant and equipment are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:49.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.671%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15 to 40 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 to 20 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 to 15 years</span></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 to 15 years</span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Useful lives and residual values of property, plant and equipment are reviewed annually. The effect of any adjustment to useful lives or residual values is recognized prospectively as a change in accounting estimate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Depreciation of property, plant and equipment is recognized as an expense in the income statement, in the relevant classification of expense by function.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.5.2. Property, plant and equipment leased</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Effective from January 1, 2019 leases contracted by Sanofi have been accounted for in accordance with IFRS 16 (Leases). Sanofi recognizes a right-of-use asset and a lease liability for all of its lease contracts, except for (i) leases relating to low-value assets and (ii) short-term leases (12 months or less). Payments made in respect of leases not recognized on the balance sheet are recognized as an operating expense on a straight line basis over the lease term.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On commencement of a lease, the liability for future lease payments is discounted at the incremental borrowing rate, which is a risk-free rate adjusted to reflect the specific risk profile of each Sanofi entity. Because lease payments are spread over the lease term, Sanofi applies a discount rate based on the duration of those payments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The payments used to determine the liability for future lease payments exclude non-lease components, but include fixed payments that Sanofi expects to make to the lessor over the estimated lease term.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">After commencement of the lease, the liability for future lease payments is reduced by the amount of the lease payments made, and increased to reflect interest on the liability. In the event of a reassessment or modification of future lease payments, the lease liability is remeasured. The right-of-use asset – which is initially measured at cost including direct costs of the lessee, prepayments made at or prior to the commencement date, less lease incentives received and restoration costs – is depreciated on a straight line basis over the lease term, and tested for impairment as required.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi recognizes deferred taxes in respect of right-of-use assets and lease liabilities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Leasehold improvements are depreciated over their economic life, which is capped at the lease term as determined under IFRS 16.</span></div>

CY2023

ifrs-full

Description Of Accounting Policy For Impairment Of Assets Explanatory

DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory

Impairment of property, plant and equipment, intangible assets, and investments accounted for using the equity method<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.6.1. Impairment of property, plant and equipment and intangible assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS 36 (Impairment of Assets), assets that generate separate cash flows and assets included in cash-generating units (CGUs) are assessed for impairment when events or changes in circumstances indicate that the asset or CGU may be impaired. A CGU is the smallest identifiable group of assets that generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IAS 36, each CGU or group of CGUs to which goodwill is allocated must (i) represent the lowest level within the entity at which the goodwill is monitored for internal management purposes, and (ii) not be larger than an operating segment determined in accordance with IFRS 8 (Operating Segments), before application of the IFRS 8 aggregation criteria (see Note B.26.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Quantitative and qualitative indications of impairment (primarily relating to the status of the research and development portfolio, pharmacovigilance, patent litigation, and the launch of competing products) are reviewed at the end of each reporting period. If there is any internal or external indication of impairment, Sanofi estimates the recoverable amount of the asset or CGU.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other intangible assets not yet available for use (such as capitalized in-process research and development), and CGUs or groups of CGUs that include goodwill, are tested for impairment annually whether or not there is any indication of impairment, and more frequently if any event or circumstance indicates that they might be impaired. Such assets are not amortized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When there is an internal or external indication of impairment, Sanofi estimates the recoverable amount of the asset and recognizes an impairment loss if the carrying amount of the asset exceeds its recoverable amount. The recoverable amount of the asset is the higher of its fair value less costs to sell or its value in use. To determine value in use, Sanofi uses estimates of future cash flows generated by the asset or CGU, prepared using the same methods as those used in the initial measurement of the asset or CGU on the basis of medium-term strategic plans.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of goodwill, estimates of future cash flows are based on a six-year strategic plan and a terminal value. In the case of other intrangible assets, the period used is based on the economic life of the asset.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Estimated cash flows are discounted at long-term market interest rates that reflect the best estimate by Sanofi of the time value of money, the risks specific to the asset or CGU, and economic conditions in the geographical regions in which the business activity associated with the asset or CGU is located.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Certain assets and liabilities that are not directly attributable to a specific CGU are allocated between CGUs on a basis that is reasonable, and consistent with the allocation of the corresponding goodwill.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Impairment losses arising on property, plant and equipment, software and certain rights, are recognized within the appropriate income statement line item according to the origin of the impairment.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Impairment losses arising on other intangible assets (products, trademarks, technology platforms, acquired R&D) are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Impairment of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.6.2. Impairment of investments accounted for using the equity method</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS 28 (Investments in Associates and Joint Ventures), Sanofi determines whether investments accounted for using the equity method may be impaired based on indicators such as default in contractual payments, significant financial difficulties, probability of bankruptcy, or a prolonged or significant decline in quoted market price. If an investment is impaired, the amount of the impairment loss is determined by applying IAS 36 (see Note B.6.1.) and recognized in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Share of profit/(loss) from investments accounted for using the equity method.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.6.3. Reversals of impairment losses charged against property, plant and equipment, intangible assets, and investments accounted for using the equity method</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">At the end of each reporting period, Sanofi assesses whether events or changes in circumstances indicate that an impairment loss recognized in a prior period in respect of an asset (other than goodwill) or an investment accounted for using the equity method can be reversed. If this is the case, and the recoverable amount as determined based on the revised estimates exceeds the carrying amount of the asset, Sanofi reverses the impairment loss only to the extent of the carrying amount that would have been determined had no impairment loss been recognized for the asset.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Reversals of impairment losses in respect of other intangible assets are recognized within the income statement line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Impairment of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, while reversals of impairment losses in respect of investments accounted for using the equity method are recognized within the income statement line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Share of profit/(loss) from investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Impairment losses taken against goodwill are never reversed, unless the goodwill is part of the carrying amount of an investment accounted for using the equity method.</span></div>

CY2023

ifrs-full

Description Of Accounting Policy For Noncurrent Assets Or Disposal Groups Classified As Held For Sale And Discontinued Operations Explanatory

DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperationsExplanatory

Assets held for sale or exchange and liabilities related to assets held for sale or exchange<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations), non-current assets and groups of assets are classified as held for sale in the balance sheet if their carrying amount will be recovered principally through a sale transaction rather than through continuing use. Within the meaning of IFRS 5, the term “sale” also includes exchanges for other assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Non-current assets or asset groups held for sale must be available for immediate sale in their present condition, subject only to terms that are usual and customary for sales of such assets, and a sale must be highly probable. Criteria used to determine whether a sale is highly probable include:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the appropriate level of management must be committed to a plan to sell;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">an active program to locate a buyer and complete the plan must have been initiated;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the asset must be actively marketed for sale at a price that is reasonable in relation to its current fair value;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">completion of the sale should be foreseeable within the 12 months following the date of reclassification to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">actions required to complete the plan should indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Before initial reclassification of the non-current asset (or asset group) to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, the carrying amounts of the asset (or of all the assets and liabilities in the asset group) must be measured in accordance with the applicable standards.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subsequent to reclassification to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, the non-current asset (or asset group) is measured at the lower of carrying amount or fair value less costs to sell, with any write-down recognized by means of an impairment loss. Once a non-current asset has been reclassified as held for sale or exchange, it is no longer depreciated or amortized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In a disposal of an equity interest leading to loss of control, all the assets and liabilities of the entity involved are classified as held-for-sale assets or liabilities within the balance sheet line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">or</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Liabilities related to assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, provided that the disposal satisfies the IFRS 5 classification criteria.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The profit or loss generated by a held-for-sale asset group is reported in a separate line item in the income statement for the current period and for the comparative periods presented, provided that the asset group:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">represents a separate major line of business or geographical area of operations; or</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">is part of a single coordinated plan to dispose of a separate major line of business or geographical area of operations; or</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">is a subsidiary acquired exclusively with a view to resale.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 10, transactions between companies that are held for sale or treated as discontinued operations and other consolidated companies are eliminated.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Events or circumstances beyond Sanofi’s control may extend the period to complete the sale or exchange beyond one year without precluding classification of the asset (or disposal group) in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> provided that there is sufficient evidence that Sanofi remains committed to the planned sale or exchange. Finally, in the event of changes to a plan of sale that requires an asset no longer to be classified as held for sale, IFRS 5 specifies the following treatment:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the assets and liabilities previously classified as held for sale are reclassified to the appropriate balance sheet line items, with no restatement of comparative periods;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">each asset is measured at the lower of (a) its carrying amount before the asset was reclassified as held for sale, adjusted for any depreciation, amortization or revaluation that would have been recognized if the asset had not been reclassified as held for sale, or (b) its recoverable amount at the date of reclassification;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the backlog of depreciation, amortization and impairment not recognized while non-current assets were classified as held for sale must be reported in the same income statement line item that was used to report impairment losses arising on initial reclassification of assets as held for sale and gains or losses arising on the sale of such assets. In the consolidated income statement, those impacts are reported within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the net income of a business previously classified as discontinued or as held for sale or exchange and reported on a separate line in the income statement must be reclassified and included in net income from continuing operations, for all periods presented;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">in addition, segment information relating to the income statement and the statement of cash flows (acquisitions of non-current assets) must be disclosed in the notes to the financial statements in accordance with IFRS 8 (Operating Segments), and must also be restated for all prior periods presented.</span></div>

CY2023

ifrs-full

Description Of Accounting Policy For Financial Instruments Explanatory

DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory

Financial instruments<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.1. Non-derivative financial assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 9 (Financial Instruments) and IAS 32 (Financial Instruments: Presentation), Sanofi has adopted the classification of non-derivative financial assets described below. The classification used depends on (i) the characteristics of the contractual cash flows (i.e. whether they represent interest or principal) and (ii) the business model for managing the asset applied at the time of initial recognition.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial assets at fair value through other comprehensive income</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These mainly comprise:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">quoted and unquoted equity investments that Sanofi does not hold for trading purposes and that management has designated at “fair value through other comprehensive income” on initial recognition. Gains and losses arising from changes in fair value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such instruments are derecognized, the previously-recognized changes in fair value remain within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, as does the gain or loss on divestment. Dividends received are recognized in profit or loss for the period, within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">debt instruments whose contractual cash flows represent payments of interest or repayments of principal, and which are managed with a view to collecting cash flows and selling the asset. Gains and losses arising from changes in fair value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such assets are derecognized, the cumulative gains and losses previously recognized in equity are reclassified to profit or loss for the period within the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial assets at fair value through profit or loss</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These mainly comprise:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">contingent consideration already carried in the books of an acquired entity or granted in connection with a business combination;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">instruments whose contractual cash flows represent payments of interest and repayments of principal, which are managed with a view to selling the asset;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">instruments that management has designated at “fair value through profit or loss” on initial recognition; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">quoted and unquoted equity investments: equity instruments that are not held for trading and which management did not designate at “fair value through other comprehensive income” on initial recognition, and instruments that do not meet the IFRS definition of “equity instruments”.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Gains and losses arising from changes in fair value are recognized in profit or loss within the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Dividends received are recognized in profit or loss for the period, within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of equity investments in unquoted entities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On initial recognition of an equity investment in an entity not quoted in an active market, the fair value of the investment is the acquisition cost. Cost ceases to be a representative measure of the fair value of an unquoted equity investment when Sanofi identifies significant changes in the investee, or in the environment in which it operates. In such cases, an internal valuation is carried out, based mainly on growth forecasts or by reference to similar transactions contracted with third parties.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial assets measured at amortized cost</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Financial assets at amortized cost comprise instruments whose contractual cash flows represent payments of interest and repayments of principal and which are managed with a view to collecting cash flows. The main assets in this category are loans and receivables. They are presented within the line items</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other non-current assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Accounts receivable </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Cash and cash equivalents</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Loans with a maturity of more than 12 months are presented in “Long-term loans and advances” within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other non-current assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. These financial assets are measured at amortized cost using the effective interest method.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of financial assets measured at amortized cost</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The main assets involved are accounts receivable. Accounts receivable are initially recognized at the amount invoiced to the customer. Impairment losses on trade accounts receivable are estimated using the expected loss method, in order to take account of the risk of payment default throughout the lifetime of the receivables. The expected credit loss is estimated collectively for all accounts receivable at each reporting date using an average expected loss rate, determined primarily on the basis of historical credit loss rates. However, that average expected loss rate may be adjusted if there are indications of a likely significant increase in credit risk. If a receivable is subject to a known credit risk, a specific impairment loss is recognized for that receivable. The amount of expected losses is recognized in the balance sheet as a reduction in the gross amount of accounts receivable. Impairment losses on accounts receivable are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Selling and general expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.2. Derivative instruments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Derivative instruments that do not qualify for hedge accounting are initially and subsequently measured at fair value, with changes in fair value recognized in the income statement in</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, depending on the nature of the underlying economic item which is hedged.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Derivative instruments that qualify for hedge accounting are measured using the policies described in Note B.8.3. below.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">IFRS 13 (Fair Value Measurement) requires counterparty credit risk to be taken into account when measuring the fair value of financial instruments. That risk is estimated on the basis of observable, publicly-available statistical data.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Policy on offsetting</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In order for a financial asset and a financial liability to be presented as a net amount in the balance sheet under IAS 32, there must be:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(a) a legally enforceable right to offset; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(b) the intention either to settle on a net basis, or to realize the asset and settle the liability simultaneously.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.3. Hedging</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As part of its overall market risk management policy, Sanofi enters into various hedging transactions involving derivative or non-derivative instruments; these may include forward contracts, currency swaps or options, interest rate swaps or options, cross-currency swaps, and debt placings or issues.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Such financial instruments are designated as hedging instruments and recognized using the hedge accounting principles of IFRS 9 when (a) there is formal designation and documentation of the hedging relationship, of how the effectiveness of the hedging relationship will be assessed, and of the underlying market risk management objective and strategy; (b) the hedged item and the hedging instrument are eligible for hedge accounting; and (c) there is an economic relationship between the hedged item and the hedging instrument, defined on the basis of a hedge ratio that is consistent with the underlying market risk management strategy, and the residual credit risk does not dominate the value changes that result from that economic relationship.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value hedge</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A fair value hedge is a hedge of the exposure to changes in fair value of an asset, liability or firm commitment that is attributable to one or more risk components and could affect profit or loss.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in fair value of the hedging instrument and changes in fair value of the hedged item attributable to the hedged risk components are generally recognized in the income statement, within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to operating activities, or within</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to investing or financing activities.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash flow hedge</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A cash flow hedge is a hedge of the exposure to variability in cash flows from an asset, liability or highly probable forecast transaction that is attributable to one or more risk components and could affect profit or loss.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in fair value of the hedging instrument attributable to the effective portion of the hedge are recognized directly in equity in the consolidated statement of comprehensive income. Changes in fair value attributable to the ineffective portion of the hedge are recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">for hedges related to operating activities, and within</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to investing or financing activities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Cumulative changes in fair value of the hedging instrument previously recognized in equity are reclassified to the income statement when the hedged transaction affects profit or loss. Those reclassified gains and losses are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to operating activities, and within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> for hedges related to investing or financing activities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When a forecast transaction results in the recognition of a non-financial asset or liability, cumulative changes in the fair value of the hedging instrument previously recognized in equity are incorporated in the initial carrying amount of that asset or liability.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">When the hedging instrument expires or is sold, terminated or exercised, the cumulative gain or loss previously recognized in equity remains separately recognized in equity and is not reclassified to the income statement, or recognized as an adjustment to the initial cost of the related non-financial asset or liability, until the forecast transaction occurs. However, if Sanofi no longer expects the forecast transaction to occur, the cumulative gain or loss previously recognized in equity is recognized immediately in profit or loss.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hedge of a net investment in a foreign operation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In a hedge of a net investment in a foreign operation, changes in the fair value of the hedging instrument attributable to the effective portion of the hedge are recognized directly in equity in the consolidated statement of comprehensive income. Changes in fair value attributable to the ineffective portion of the hedge are recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. When the investment in the foreign operation is sold, the changes in the fair value of the hedging instrument previously recognized in equity are reclassified to the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of hedging</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As part of its market risk management policy, Sanofi may designate currency options or interest rate options as hedging instruments, the effectiveness of which is measured on the basis of changes in intrinsic value. In such cases, the time value of the option is treated as a hedging cost and accounted for as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">if the option includes a component that is not aligned on the critical features of the hedged item, the corresponding change in the time value is taken to profit or loss;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">otherwise, the change in the time value is taken to equity within the statement of comprehensive income, and then:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">if the hedged item is linked to a transaction that results in the recognition of a financial asset or liability, the change in the time value is reclassified to profit or loss symmetrically with the hedged item, or</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">if the hedged item is linked to a transaction that results in the recognition of a non-financial asset or liability, the change in the time value is incorporated in the initial carrying amount of that asset or liability, or</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">if the hedged item is linked to a period of time, the change in time value is reclassified to profit or loss on a straight line basis over the life of the hedging relationship.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of forward contracts and foreign exchange swaps, and of cross-currency swaps that qualify for hedge accounting on the basis of changes in spot rates, Sanofi may elect for each transaction to use the option whereby the premium/discount or foreign currency basis spread are treated in the same way as the time value of an option.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discontinuation of hedge accounting</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Hedge accounting is discontinued when the eligibility criteria are no longer met (in particular, when the hedging instrument expires or is sold, terminated or exercised), or if there is a change in the market risk management objective of the hedging relationship.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.4. Non-derivative financial liabilities</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Borrowings and debt</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Bank borrowings and debt instruments are initially measured at fair value of the consideration received, net of directly attributable transaction costs.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Subsequently, they are measured at amortized cost using the effective interest method. All costs related to the issuance of borrowings or debt instruments, and all differences between the issue proceeds net of transaction costs and the value on redemption, are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement over the term of the debt using the effective interest method.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities related to business combinations and to non-controlling interests</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These line items record the fair value of (i) contingent consideration payable in connection with business combinations and (ii) commitments to buy out equity holders of subsidiaries, including put options granted to non-controlling interests.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Adjustments to the fair value of commitments to buy out equity holders of subsidiaries, including put options granted to non-controlling interests, are recognized in equity.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other non-derivative financial liabilities</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other non-derivative financial liabilities include trade accounts payable, which are measured at fair value (which in most cases equates to face value) on initial recognition, and subsequently at amortized cost.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.5. Fair value of financial instruments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Under IFRS 13 (Fair Value Measurement) and IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a hierarchy based on the inputs used to measure the fair value of the instrument. This hierarchy has three levels:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.69pt">level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.08pt">level 2: quoted prices in active markets for similar assets and liabilities, or valuation techniques in which all important inputs are derived from observable market data; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:7.61pt">level 3: valuation techniques in which not all important inputs are derived from observable market data.</span></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:5.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.362%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Type of financial instrument</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Measurement<br/>principle</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in<br/>fair value<br/>hierarchy</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation<br/>technique</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Method used to determine fair value</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation<br/>model</span></td><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market data</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exchange rate</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest<br/>rate</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted equity instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted debt instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (unquoted equity instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cost/Approach based on comparables</span></div></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">If cost ceases to be a representative measure of fair value, an internal valuation is carried out, based mainly on comparables.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (contingent consideration receivable)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value held to meet obligations under <br/>post-employment benefit plans</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets designated at fair value held to meet obligations under deferred compensation plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.13.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Investments in mutual funds</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Net asset value</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.13.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Negotiable debt instruments, commercial paper, instant access deposits and term deposits</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Because these instruments have a maturity of less than three months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.17.1., D.19.</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">In the case of debt with a maturity of less than three months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">For debt with a maturity of more than three months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.17.2.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The liability for future lease payments is discounted using the incremental borrowing rate.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">< 1 year:</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Money Market</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">> 1 year: </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Zero Coupon</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market<br/>Spot</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">< 1 year:</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Money Market and LIFFE interest rate futures</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">> 1 year: </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Zero Coupon</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market<br/>Spot</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">< 1 year:<br/>Mid Money Market and LIFFE interest rate futures<br/>> 1 year: <br/>Mid Zero Coupon</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.18.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests (CVRs)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.18.</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests (other than CVRs)</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3 </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.8.4.</span></div></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.6. Derecognition of financial instruments</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Financial assets are derecognized when the contractual rights to cash flows from the asset have ended or have been transferred and when Sanofi has transferred substantially all the risks and rewards of ownership of the asset. If Sanofi has neither transferred nor retained substantially all the risks and rewards of ownership of a financial asset, it is derecognized if Sanofi does not retain control of the asset.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A financial liability is derecognized when Sanofi’s contractual obligations in respect of the liability are discharged, cancelled or extinguished.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.8.7. Risks relating to financial instruments</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Market risks in respect of non-current financial assets, cash equivalents, derivative instruments and debt are described in the discussions of risk factors presented in Item 3.D. and Item 11. of Sanofi’s annual report on Form 20-F for 2023.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Credit risk is the risk that customers may fail to pay their debts. For a description of credit risk, refer to “We are subject to the risk of non-payment by our customers” within Item 3.D. and Item 11. of Sanofi’s annual report on Form 20-F for 2023.</span></div>

CY2023

ifrs-full

Disclosure Of Detailed Information About Financial Instruments Explanatory

DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory

<div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the disclosures required under IFRS 7 relating to the measurement principles applied to financial instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:5.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.313%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.362%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Type of financial instrument</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Measurement<br/>principle</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level in<br/>fair value<br/>hierarchy</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation<br/>technique</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Method used to determine fair value</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation<br/>model</span></td><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market data</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exchange rate</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest<br/>rate</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted equity instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (quoted debt instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (unquoted equity instruments)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cost/Approach based on comparables</span></div></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">If cost ceases to be a representative measure of fair value, an internal valuation is carried out, based mainly on comparables.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value (contingent consideration receivable)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The fair value of contingent consideration receivable is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note D.7.3.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets measured at fair value held to meet obligations under <br/>post-employment benefit plans</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Financial assets designated at fair value held to meet obligations under deferred compensation plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.7.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The amortized cost of long-term loans and advances and other non-current receivables at the end of the reporting period is not materially different from their fair value.</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.13.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Investments in mutual funds</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Net asset value</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.13.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Negotiable debt instruments, commercial paper, instant access deposits and term deposits</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Because these instruments have a maturity of less than three months, amortized cost is regarded as an acceptable approximation of fair value as disclosed in the notes to the consolidated financial statements.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.17.1., D.19.</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">In the case of debt with a maturity of less than three months, amortized cost is regarded as an acceptable approximation of fair value as reported in the notes to the consolidated financial statements. </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">For debt with a maturity of more than three months, fair value as reported in the notes to the consolidated financial statements is determined either by reference to quoted market prices at the end of the reporting period (quoted instruments) or by discounting the future cash flows based on observable market data at the end of the reporting period (unquoted instruments).</span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">For financial liabilities based on variable payments such as royalties, fair value is determined on the basis of discounted cash flow projections.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.17.2.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized cost</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="9" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">The liability for future lease payments is discounted using the incremental borrowing rate.</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Forward currency contracts</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">< 1 year:</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Money Market</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">> 1 year: </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Zero Coupon</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market<br/>Spot</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">< 1 year:</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Money Market and LIFFE interest rate futures</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">> 1 year: </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid Zero Coupon</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.20.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Present value of future cash flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mid<br/>Market<br/>Spot</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">< 1 year:<br/>Mid Money Market and LIFFE interest rate futures<br/>> 1 year: <br/>Mid Zero Coupon</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.18.</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests (CVRs)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Market value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Quoted market price</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">D.18.</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Liabilities related to business combinations and to non-controlling interests (other than CVRs)</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair value</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3 </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Revenue-based approach</span></td><td colspan="9" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Under IAS 32, contingent consideration payable in a business combination is a financial liability. The fair value of such liabilities is determined by adjusting the contingent consideration at the end of the reporting period using the method described in Note B.8.4.</span></div></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) In the case of debt designated as a hedged item in a fair value hedging relationship, the carrying amount in the consolidated balance sheet includes changes in fair value attributable to the hedged risk(s).</span></div>

CY2023

ifrs-full

Description Of Accounting Policy For Measuring Inventories

DescriptionOfAccountingPolicyForMeasuringInventories

Inventories<div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Inventories are measured at the lower of cost or net realizable value. Cost is calculated using the weighted average cost method or the first-in, first-out method, depending on the nature of the inventory.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The cost of finished goods inventories includes costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition.</span></div><div style="margin-bottom:7pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During the launch phase of a new product, any inventories of that product are written down to zero pending regulatory approval, other than in specific circumstances which make it possible to estimate that there is a high probability at the end of the reporting period that the carrying amount of the inventories will be recoverable. The write-down is reversed once it becomes highly probable that marketing approval will be obtained.</span></div>

CY2023

ifrs-full

Description Of Accounting Policy To Determine Components Of Cash And Cash Equivalents

DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents

Cash and cash equivalents<div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Cash and cash equivalents as shown in the consolidated balance sheet and statement of cash flows comprise cash, plus liquid short-term investments that are readily convertible into cash and are subject to an insignificant risk of changes in value in the event of movements in interest rates.</span></div>

CY2023

sny

Gain Loss On Impairment Of Treasury Shares

GainLossOnImpairmentOfTreasuryShares

0

eur

CY2023

sny

Gain Loss On Purchase Of Treasury Shares

GainLossOnPurchaseOfTreasuryShares

0

eur

CY2023

sny

Gain Loss On Cancellation Of Treasury Shares

GainLossOnCancellationOfTreasuryShares

0

eur

CY2023

sny

Gain Loss On Sale Of Treasury Shares

GainLossOnSaleOfTreasuryShares

0

eur

CY2023

ifrs-full

Description Of Accounting Policy For Provisions Explanatory

DescriptionOfAccountingPolicyForProvisionsExplanatory

Provisions for risks<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS 37 (Provisions, Contingent Liabilities and Contingent Assets), Sanofi records a provision when it has a present obligation, whether legal or constructive, as a result of a past event; it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and a reliable estimate can be made of the amount of the outflow of resources.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If the obligation is expected to be settled more than 12 months after the end of the reporting period, or has no definite settlement date, the provision is recorded within Non-current provisions and other non-current liabilities.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Provisions relating to the insurance programs in which Sanofi’s captive insurance company participates are based on risk exposure estimates calculated by management, with assistance from independent actuaries, using IBNR (Incurred But Not Reported) techniques. Those techniques use past claims experience, within Sanofi and in the market, to estimate future trends in the cost of claims.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Contingent liabilities are not recognized, but are disclosed in the notes to the financial statements unless the possibility of an outflow of economic resources is remote.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi estimates provisions on the basis of events and circumstances related to present obligations at the end of the reporting period and of past experience, and to the best of management’s knowledge at the date of preparation of the financial statements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Reimbursements offsetting the probable outflow of resources are recognized as assets only if it is virtually certain that they will be received. Contingent assets are not recognized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restructuring provisions are recognized if Sanofi has a detailed, formal restructuring plan at the end of the reporting period and has announced its intention to implement this plan to those affected by it.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No provisions are recorded for future operating losses.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi records non-current provisions for certain obligations, such as legal or constructive obligations, where an outflow of resources is probable and the amount of the outflow can be reliably estimated.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of environmental risks, including at sites where operations are ongoing, Sanofi recognizes a provision where there is a violation of integrity in respect of human health or the environment resulting from past contamination at a site that requires remediation. The amount of the provision is a best estimate of the future expenditures to be incurred on the remediation plan.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Where the effect of the time value of money is material, those provisions are measured at the present value of the expenditures expected to be required to settle the obligation, calculated using a discount rate that reflects an estimate of the time value of money and the risks specific to the obligation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Increases in provisions to reflect the effects of the passage of time are recognized within </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div>

CY2023

sny

Provisions Recorded For Future Operating Losses

ProvisionsRecordedForFutureOperatingLosses

0

eur

CY2023

ifrs-full

Description Of Accounting Policy For Recognition Of Revenue

DescriptionOfAccountingPolicyForRecognitionOfRevenue

Revenue recognition<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.13.1. Net sales</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Revenue arising from the sale of goods is presented in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net sales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Net sales comprise revenue from sales of pharmaceutical products, consumer healthcare products, active ingredients and vaccines, net of sales returns, of customer incentives and discounts, and of certain sales-based payments paid or payable to the healthcare authorities. Analyses of net sales are provided in Note D.35.1. “Segment Information”.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 15 (Revenue from Contracts with Customers), such revenue is recognized when Sanofi transfers control over the product to the customer; control of an asset refers to the ability to direct the use of, and obtain substantially all of the remaining benefits from that asset. For the vast majority of contracts, revenue is recognized when the product is physically transferred, in accordance with the delivery and acceptance terms agreed with the customer.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For contracts entered into by Sanofi Pasteur, transfer of control is usually determined by reference to the terms of release (immediate or deferred) and acceptance of batches of vaccine.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of contracts with distributors, Sanofi does not recognize revenue when the product is physically transferred to the distributor if the products are sold on consignment, or if the distributor acts as agent. In such cases, revenue is recognized when control is transferred to the end customer, and the distributor’s commission is presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Selling and general expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the income statement.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The amount of revenue recognized reflects the various types of price reductions or rights of return offered by Sanofi to its customers on certain products. Such price reductions and rights of return qualify as variable consideration under IFRS 15.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In particular, products sold in the United States are covered by various Government and State programs (such as Medicare and Medicaid) under which products are sold at a discount. Rebates are granted to healthcare authorities, and under contractual arrangements with certain customers. Some wholesalers are entitled to chargeback incentives based on the selling price to the end customer, under specific contractual arrangements. Cash discounts may also be granted for prompt payment. Returns, discounts, incentives and rebates, as described above, are recognized in the period in which the underlying sales are recognized as a reduction of gross sales.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">These amounts are calculated as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of chargeback incentives is estimated on the basis of the relevant subsidiary’s standard sales terms and conditions, and in certain cases on the basis of specific contractual arrangements with the customer;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of rebates based on attainment of sales targets is estimated and accrued as each of the underlying sales transactions is recognized;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of price reductions under Government and State programs, largely in the United States, is estimated on the basis of the specific terms of the relevant regulations or agreements, and accrued as each of the underlying sales transactions is recognized;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the amount of sales returns is calculated on the basis of management’s best estimate of the amount of product that will ultimately be returned by customers. In countries where product returns are possible, Sanofi operates a returns policy that allows the customer to return products within a certain period either side of the expiry date (usually 12 months after the expiry date). The amount recognized for returns is estimated on the basis of past experience of sales returns. Sanofi also takes into account factors such as levels of inventory in its various distribution channels, product expiry dates, information about potential discontinuation of products, the entry of competing generics into the market, and the launch of over-the-counter medicines. Most product return clauses relate solely to date-expired products, which cannot be resold and are destroyed. Sanofi does not recognize a right of return asset in the balance sheet for contracts that allow for the return of time-expired products, since those products have no value.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The estimated amounts described above are recognized in the income statement within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Net sales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">as a reduction of gross sales, and within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in the balance sheet. They are subject to regular review and adjustment as appropriate based on the most recent data available to management. Sanofi believes that it has the ability to measure each of the above amounts reliably, using the following factors in developing its estimates:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the nature and patient profile of the underlying product;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the applicable regulations or the specific terms and conditions of contracts with governmental authorities, wholesalers and other customers;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">historical data relating to similar contracts, in the case of qualitative and quantitative rebates and chargeback incentives;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">past experience and sales growth trends for the same or similar products;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">actual inventory levels in distribution channels, monitored by Sanofi using internal sales data and externally provided data;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the shelf life of Sanofi products; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">market trends including competition, pricing and demand.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of provisions for discounts, rebates and sales returns is provided in Note D.23.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.13.2. Other revenues</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">The line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is used to recognize all revenue that falls within the scope of IFRS 15 but does not relate to sales of Sanofi products.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">It mainly comprises (i) royalties received from licensing intellectual property rights to third parties; (ii) VaxServe sales of products sourced from third-party manufacturers; and (iii) revenue received under agreements for Sanofi to provide manufacturing services to third parties.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Royalties received under licensing arrangements are recognized over the period during which the underlying sales are recognized.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">VaxServe is a Vaccines segment entity whose operations include the distribution within the United States of vaccines and other products manufactured by third parties. VaxServe sales of products sourced from third-party manufacturers are presented within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other revenues</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div>

CY2023

sny

Description Of Accounting Policy For Cost Of Sales Explanatory

DescriptionOfAccountingPolicyForCostOfSalesExplanatory

Cost of sales<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> consists primarily of the industrial cost of goods sold, payments made under licensing agreements, and distribution costs. The industrial cost of goods sold includes the cost of materials, depreciation of property, plant and equipment, amortization of software, personnel costs, and other expenses attributable to production.</span></div>

CY2023

ifrs-full

Description Of Accounting Policy For Research And Development Expense Explanatory

DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory

Research and development<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Note B.4.1. “Research and development not acquired in a business combination” and Note B.4.3. “Other intangible assets acquired in a business combination” describe the principles applied to the recognition of research and development costs.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Contributions or reimbursements received from alliance partners are recorded as a reduction of </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div>

CY2023

ifrs-full

Description Of Accounting Policy For Intangible Assets And Goodwill Explanatory

DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory

Amortization and impairment of intangible assets<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.17.1. Amortization of intangible assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The expenses recorded in this line item comprise amortization charged against intangible assets (products, trademarks and technology platforms, see Note D.4.) whose contribution to Sanofi’s commercial, industrial and development functions cannot be separately identified.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amortization of software, and of other rights of an industrial or operational nature, is recognized as an expense in the income statement, in the relevant line items of expense by function.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.17.2. Impairment of intangible assets</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This line item records impairment losses taken against intangible assets (products, trademarks, technology platforms and acquired research), and any reversals of such impairment losses.</span></div>

CY2022Q4

ifrs-full

Property Plant And Equipment

PropertyPlantAndEquipment

9869000000

eur

CY2023Q4

ifrs-full

Property Plant And Equipment

PropertyPlantAndEquipment

10160000000

eur

CY2023

ifrs-full

Description Of Accounting Policy For Finance Income And Costs Explanatory

DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory

Financial expenses and income<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.21.1. Financial expenses</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> mainly comprise interest charges on debt financing; negative changes in the fair value of certain financial instruments (where changes in fair value are recognized in profit or loss); realized and unrealized foreign exchange losses on financing and investing activities; impairment losses on financial instruments; and any reversals of impairment losses on financial instruments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> also include expenses arising from the unwinding of discount on long-term provisions, and the net interest cost related to employee benefits. This line item does not include commercial cash discounts, which are deducted from net sales.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.21.2. Financial income</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> includes interest and dividend income; positive changes in the fair value of certain financial instruments (where changes in fair value are recognized in profit or loss); realized and unrealized foreign exchange gains on financing and investing activities; and gains on disposals of financial assets at fair value through profit or loss.</span></div>

CY2023

ifrs-full

Description Of Accounting Policy For Income Tax Explanatory

DescriptionOfAccountingPolicyForIncomeTaxExplanatory

Income tax expense<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Income tax expense </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">includes all current and deferred taxes of consolidated companies.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi accounts for deferred taxes in accordance with IAS 12 (Income Taxes), using the methods described below:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">deferred tax assets and liabilities are recognized on taxable and deductible temporary differences, and on tax loss carry-forwards. Temporary differences are differences between the carrying amount of an asset or liability in the balance sheet and its tax base;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">French business taxes include a value added based component: “CVAE” </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">(Cotisation sur la Valeur Ajoutée des Entreprises)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. Given that CVAE is (i) calculated as the amount by which certain revenues exceed certain expenses and (ii) borne primarily by companies that own intellectual property rights on income derived from those rights (royalties, and margin on sales to third parties and to Sanofi entities), it is regarded as meeting the definition of income taxes specified in IAS 12, paragraph 2 (“taxes which are based on taxable profits”);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">deferred tax assets and liabilities are calculated using the tax rate expected to apply in the period when the corresponding temporary differences are expected to reverse, based on tax rates enacted or substantively enacted at the end of the reporting period;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">deferred tax assets are recognized in respect of deductible temporary differences, tax losses available for carry-forward and unused tax credits to the extent that future recovery is regarded as probable. The recoverability of deferred tax assets is assessed on a case-by-case basis, taking into account the profit forecasts contained in Sanofi’s medium-term business plan;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a deferred tax liability is recognized for temporary differences relating to interests in subsidiaries, associates and joint ventures, except in cases where Sanofi is able to control the timing of the reversal of the temporary differences. This applies in particular when Sanofi is able to control dividend policy and it is probable that the temporary differences will not reverse in the foreseeable future;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">no deferred tax is recognized on eliminations of intragroup transfers of interests in subsidiaries, associates or joint ventures;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">each tax entity calculates its own net deferred tax position. All net deferred tax asset and liability positions are then aggregated and shown in separate line items on the relevant side of the consolidated balance sheet. Deferred tax assets and liabilities are offset only if (i) Sanofi has a legally enforceable right to offset current tax assets and current tax liabilities, and (ii) the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same taxation authority;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">deferred taxes are not discounted, except implicitly in the case of deferred taxes on assets and liabilities which are already impacted by discounting. In addition, Sanofi has elected not to discount current taxes payable or receivable where the amounts in question are payable or receivable in the long term;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">withholding taxes on intragroup royalties and dividends, and on royalties and dividends collected from third parties, are accounted for as current income taxes.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accounting for business combinations, Sanofi complies with IFRS 3 as regards the recognition of deferred tax assets after the initial accounting period. Consequently, any deferred tax assets recognized by the acquiree after the end of that period in respect of temporary differences or tax loss carry-forwards existing at the acquisition date are recognized in profit or loss.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The positions adopted by Sanofi in tax matters are based on its interpretation of tax laws and regulations. Some of those positions may be subject to uncertainty. In such cases, Sanofi assesses the amount of the tax liability on the basis of the following assumptions: that its position will be examined by one or more tax authorities on the basis of all relevant information; that a technical assessment is carried out with reference to legislation, case law, regulations, and established practice; and that each position is assessed individually (or collectively where appropriate), with no offset or aggregation between positions. Those assumptions are assessed on the basis of facts and circumstances existing at the end of the reporting period. When an uncertain tax liability is regarded as probable, it is measured on the basis of Sanofi’s best estimate and recognized as a liability; uncertain tax assets are not recognized. The amount of the liability includes any penalties and late payment interest. The line item</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Income tax expense</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> includes the effects of tax reassessments and tax disputes, and any penalties and late payment interest arising from such disputes that have the characteristics of income taxes within the meaning of paragraph 2 of IAS 12 (“taxes which are based on taxable profits”). Tax exposures relating to corporate income taxes are presented separately within </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Non-current income tax liabilities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (see Note D.19.4.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No deferred taxation is recognized on temporary differences that are liable to be subject to US global intangible low taxed income (GILTI) provisions. The related tax expense is recognized in the year in which it is declared in the tax return to the extent that it arises from the existence of non-US profits that exceed the theoretical return on investment specified in the GILTI provisions and are taxed at a rate lower than the applicable US tax rate.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IAS 1 (Presentation of Financial Statements), current income tax assets and liabilities are presented as separate line items in the consolidated balance sheet.</span></div>

CY2023

ifrs-full

Description Of Accounting Policy For Employee Benefits Explanatory

DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory

Employee benefit obligations<div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi offers retirement benefits to employees and retirees. Such benefits are accounted for in accordance with IAS 19 (Employee Benefits).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Benefits are provided in the form of either defined contribution plans or defined benefit plans. In the case of defined contribution plans, the cost is recognized immediately in the period in which it is incurred, and equates to the amount of the contributions paid by Sanofi. For defined benefit plans, Sanofi generally recognizes its obligations to pay pensions and similar benefits to employees as a liability, based on an actuarial estimate of the rights vested or currently vesting in employees and retirees, using the projected unit credit method. Estimates are performed at least once a year, and rely on financial assumptions (such as discount </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">rates) and demographic assumptions (such as life expectancy, retirement age, employee turnover, and the rate of salary increases).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Obligations relating to other post-employment benefits (healthcare and life insurance) offered by Sanofi companies to employees are also recognized as a liability based on an actuarial estimate of the rights vested or currently vesting in employees and retirees at the end of the reporting period.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Such liabilities are recognized net of the fair value of plan assets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In the case of multi-employer defined benefit plans where plan assets cannot be allocated to each participating employer with sufficient reliability, the plan is accounted for as a defined contribution plan, in accordance with paragraph 34 of IAS 19.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The benefit cost for the period consists primarily of current service cost, past service cost, net interest cost, gains or losses arising from plan settlements not specified in the terms of the plan, and actuarial gains or losses arising from plan curtailments. Net interest cost for the period is determined by applying the discount rate specified in IAS 19 to the net liability (i.e. the amount of the obligation, net of plan assets) recognized in respect of defined benefit plans. Past service cost is recognized immediately in profit or loss in the period in which it is incurred, regardless of whether or not the rights have vested at the time of adoption (in the case of a new plan) or of amendment (in the case of an existing plan).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Actuarial gains and losses on defined benefit plans (pensions and other post-employment benefits), also referred to as “Remeasurements of the net defined benefit liability (asset)”</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> arise as a result of changes in financial and demographic assumptions, experience adjustments, and the difference between the actual return and interest cost on plan assets. The impacts of those remeasurements are recognized in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, net of deferred taxes; they are not subsequently reclassifiable to profit or loss.</span></div>

CY2023

ifrs-full

Description Of Accounting Policy For Sharebased Payment Transactions Explanatory

DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory

Share-based payment<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Share-based payment expense is recognized as a component of operating income, in the relevant classification of expense by function. In measuring the expense, the level of attainment of any performance conditions is taken into account.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.24.1. Stock option plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has granted a number of equity-settled share-based payment plans (stock option plans) to some of its employees. The terms of those plans may make the award contingent on the attainment of performance criteria for some of the grantees.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 2 (Share-Based Payment), services received from employees as consideration for stock options are recognized as an expense in the income statement, with the opposite entry recognized in equity. The expense corresponds to the fair value of the stock option plans, and is charged to income on a straight-line basis over the four-year vesting period of the plan.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The fair value of stock option plans is measured at the date of grant using the Black-Scholes valuation model, taking into account the expected life of the options. The resulting expense also takes into account the expected cancellation rate of the options. The expense is adjusted over the vesting period to reflect actual cancellation rates resulting from option-holders ceasing to be employed by Sanofi.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.24.2. Employee share ownership plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi may offer its employees the opportunity to subscribe to reserved share issues at a discount to the reference market price. Shares awarded to employees under such plans fall within the scope of IFRS 2. Consequently, an expense is recognized at the subscription date, based on the value of the discount offered to employees.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">B.24.3. Restricted share plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi may award restricted share plans to certain of its employees. The terms of those plans may make the award contingent on the attainment of performance criteria for some of the grantees.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 2, an expense equivalent to the fair value of such plans is recognized in profit or loss on a straight line basis over the vesting period of the plan, with the opposite entry recognized in equity. The vesting period is three years.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The fair value of restricted share plans is based on the quoted market price of Sanofi shares at the date of grant, adjusted for expected dividends during the vesting period; it also takes account of any vesting conditions contingent on stock market performance, measured using the Monte-Carlo valuation model. Other vesting conditions are taken into account in the estimate of the number of shares awarded during the vesting period; that number is then definitively adjusted based on the actual number of shares awarded on the vesting date.</span></div>

CY2023

ifrs-full

Description Of Accounting Policy For Earnings Per Share Explanatory

DescriptionOfAccountingPolicyForEarningsPerShareExplanatory

Earnings per share<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Basic earnings per share is calculated using the weighted average number of shares outstanding during the reporting period, adjusted on a time-weighted basis from the acquisition date to reflect the number of own shares held by Sanofi. Diluted earnings per share is calculated on the basis of the weighted average number of ordinary shares, computed using the treasury stock method.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">This method assumes that (i) all outstanding dilutive options and warrants are exercised, and (ii) Sanofi acquires its own shares at the quoted market price for an amount equivalent to the cash received as consideration for the exercise of the options or warrants, plus the expense arising on unamortized stock options.</span></div>

CY2023

ifrs-full

Description Of Accounting Policy For Segment Reporting Explanatory

DescriptionOfAccountingPolicyForSegmentReportingExplanatory

Segment information<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In accordance with IFRS 8 (Operating Segments), the segment information reported by Sanofi is prepared on the basis of internal management data provided to our Chief Executive Officer, who is the chief operating decision maker of Sanofi. The performance of those segments is monitored individually using internal reports and common indicators.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2022, Sanofi reported three operating segments (Pharmaceuticals, Vaccines and Consumer Healthcare). The costs of the global support functions (Corporate Affairs, Finance, People & Culture, Legal, Ethics, Business Integrity & Global Security, Information Solutions & Technology, Sanofi Business Services, etc.), which are mainly managed centrally at group-wide level, were presented within the “Other” category. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, Sanofi reviewed the presentation of its segment information following adjustments to its internal reporting systems in order to reflect (i) progress on the “Play to Win” strategy leading to the creation of the standalone Consumer Healthcare Global Business Unit (GBU) which, in addition to integrated research, development and production functions now also has its own dedicated global support functions (including Finance, People & Culture, Legal, Ethics, Business Integrity & Global Security, Information Solutions & Technology, Global Business Services, etc.); and (ii) organizational changes to Sanofi’s Manufacturing & Supply global function (previously known as Industrial Affairs). </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Consequently, with effect from January 1, 2023, Sanofi reports two operating segments: Biopharma and Consumer Healthcare.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Biopharma operating segment comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines and Vaccines franchises, for all geographical territories. The segment’s results include the costs of global support functions that are not within the managerial responsibility of the Consumer Healthcare GBU.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Consumer Healthcare operating segment comprises commercial operations relating to Consumer Healthcare products, and research, development and production activities and global support functions (as listed above) dedicated to the segment, for all geographical territories. The Consumer Healthcare GBU segment’s results reflect all incurred costs of global support functions attributable to its business.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The “Other” category comprises reconciling items, primarily but not limited to (i) gains and losses on centralized foreign exchange risk hedging transactions that cannot be allocated to the operating segments and (ii) gains and losses on retained commitments in respect of previously divested operations.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Information about operating segments for the years ended December 31, 2023, 2022 and 2021 is presented in Note D.35</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">., </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">“Segment information”.</span></div>

CY2022

sny

Number Of Operating Segments1

NumberOfOperatingSegments1

3

segment

CY2023

sny

Number Of Operating Segments1

NumberOfOperatingSegments1

2

segment

CY2023

ifrs-full

Description Of Accounting Policy For Issued Capital Explanatory

DescriptionOfAccountingPolicyForIssuedCapitalExplanatory

Management of capital<div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In order to maintain or adjust the capital structure, Sanofi can adjust the amount of dividends paid to shareholders, repurchase its own shares, issue new shares, or issue securities giving access to its capital.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The following objectives are defined under the terms of Sanofi’s share repurchase programs:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the implementation of any stock option plan giving entitlement to purchase shares in the Sanofi parent company;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the allotment or sale of shares to employees under statutory profit sharing schemes and employee savings plans;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the consideration-free allotment of shares (i.e. restricted share plans);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the cancellation of some or all of the repurchased shares;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">market-making in the secondary market by an investment services provider under a liquidity contract in compliance with the ethical code recognized by the </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Autorité des marchés financiers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> (AMF);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the delivery of shares on the exercise of rights attached to securities giving access to the capital by redemption, conversion, exchange, presentation of a warrant or any other means;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the delivery of shares (in exchange, as payment, or otherwise) in connection with mergers and acquisitions;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the execution by an investment services provider of purchases, sales or transfers by any means, in particular via off-market trading; or</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:6.1pt">any other purpose that is or may in the future be authorized under the applicable laws and regulations.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi is not subject to any constraints on equity capital imposed by third parties.</span></div><div style="margin-bottom:4pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total equity includes </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Equity attributable to equity holders of Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Equity attributable to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, as shown in the consolidated balance sheet.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi defines “Net debt” as (i) the sum of short-term debt, long-term debt and interest rate derivatives and currency derivatives used to hedge debt, minus (ii) the sum of cash and cash equivalents and interest rate derivatives and currency derivatives used to hedge cash and cash equivalents.</span></div>

CY2023

ifrs-full

Disclosure Of Detailed Information About Business Combinations Explanatory

DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory

<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The provisional purchase price allocation led to the recognition of goodwill of €475 million, determined as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:66.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value at acquisition date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">774</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current and non-current assets and liabilities</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes, net</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net assets of QRIB Intermediate Holdings, LLC</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">867</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">475</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Purchase price</span></div></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,342</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The final purchase price allocation led to the recognition of €609 million of goodwill, determined as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:72.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value at acquisition date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">493</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current and non-current assets and liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net assets of Amunix</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">517</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">609</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Purchase price</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,126</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The final purchase price allocation, as presented in the table below, led to the recognition of goodwill of €2,118 million:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:72.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value at acquisition date</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">396</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(93)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current and non-current assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">235</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shire contingent consideration liability (see Note D.18.)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(323)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net assets of Translate Bio</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">462</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,118</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Purchase price</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,580</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div>

CY2023

sny

Goodwill Tax Deductible Period

GoodwillTaxDeductiblePeriod

P15Y

CY2023

ifrs-full

Disclosure Of Property Plant And Equipment Explanatory

DisclosureOfPropertyPlantAndEquipmentExplanatory

Property, plant and equipment<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.3.1. Property, plant and equipment owned</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Property, plant and equipment owned by Sanofi is comprised of the following items:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:28.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Buildings</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Machinery<br/>and<br/>equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fixtures,<br/>fittings and<br/>other</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Property, plant<br/>and equipment<br/>in process</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">236</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,828</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,127</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,524</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,454</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">23,169</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,404 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,504 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(75)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(153)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(80)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(314)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">169 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">155 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">443 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">453 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(839)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">240</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,170</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,648</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,655</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,097</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24,810</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(294)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,480)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(163)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(150)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,104)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,642 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,748 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(161)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(240)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(155)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(559)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">122 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">144 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">347 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">480 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">722 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">108 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,626)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(318)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">237</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,328</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,848</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,515</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,996</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">23,924</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,583 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,693 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(340)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(502)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">481 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">457 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,071)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">228</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,681</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,912</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,500</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,449</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24,770</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation & impairment at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(10)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3,898)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(7,792)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,981)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(123)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(13,804)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(306)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(592)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(167)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,065)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">149 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">299 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(80)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(99)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(208)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation & impairment at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(9)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(4,190)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8,340)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,115)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(128)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(14,782)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,202 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">130 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,533 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(356)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(622)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(164)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,142)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(50)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(58)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(75)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(186)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">153 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">518 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(52)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(69)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(138)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation & impairment at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(10)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(4,225)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(7,637)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,015)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(168)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(14,055)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(321)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(620)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(139)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,080)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(130)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">488 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation & impairment at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(4,500)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(7,873)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,037)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(192)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(14,610)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carrying amount at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">231 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,980 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,308 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">540 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,969 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,028 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carrying amount at December 31, 2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,103 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,211 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">500 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,828 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,869 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">220</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,181</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,039</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">463</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,257</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,160</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) This line includes in particular property, plant and equipment in process brought into service during the period, but also the effect of the reclassification of assets to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth acquisitions and capitalized interest by operating segment for the years ended December 31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"></td><td style="width:57.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.188%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.188%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,693</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,748</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,504</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biopharma</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,592 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,678 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">of which Manufacturing & Supply</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,188 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,129 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceuticals</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,010 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vaccines</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">421 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consumer Healthcare</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">70 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">of which Manufacturing & Supply</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">63</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Of which capitalized interest</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) 2022 figures have been adjusted to take into account of the two new operating segments, Biopharma and Consumer Healthcare, effective January 1, 2023.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Off balance sheet commitments relating to property, plant and equipment as of December 31, 2023, 2022 and 2021 are set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Firm orders of property, plant and equipment</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">638 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">861 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">769 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Property, plant and equipment pledged as security for liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth the net impairment losses recognized in each of the last three financial periods:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net impairment losses on property, plant and equipment</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">130</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">186</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">39</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) These amounts mainly comprise impairment losses recognized as a result of decisions taken during the periods presented, relating primarily to shutdowns or changes in use of industrial sites.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.3.2. Property, plant and equipment leased – right-of-use assets</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Right-of-use assets relating to property, plant and equipment leased by Sanofi are analyzed in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:82.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Right-of-use assets</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,711</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">93 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">963 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(91)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,745</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(26)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">292 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(232)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,872</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,672</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation & impairment at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(513)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation and impairment charged in the period</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(315)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation & impairment at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(797)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation and impairment charged in the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(341)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation & impairment at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,057)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation and impairment charged in the period</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation & impairment at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,018)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,948</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,815</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,654</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) This line also includes the effect of the reclassification of assets to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) In December 2018, Sanofi signed two leases on real estate assets in the United States (at Cambridge, Massachusetts) for an initial lease term of 15 years. The first lease, relating to office space, began in April 2021; Sanofi recognized a right-of-use asset of €320 million, as well as the lease liability. The second lease, relating to laboratory facilities, began on July 1, 2021; Sanofi recognized a right-of-use asset of €424 million, as well as the lease liability.</span></div><div style="margin-top:1pt;padding-left:18pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Leased assets comprised offices and industrial premises (90%) and the vehicle fleet (10%) as of December 31, 2023.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Annual lease costs on short term leases and low value asset leases amounted to €19 million in the year ended December 31, 2023, €26 million in the year ended December 31, 2022, and €25 million in the year ended December 31, 2021. Variable lease payments, sub-leasing activities, and sale-and-leaseback transactions were immaterial.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total cash outflows on leases (excluding annual lease costs on short term leases and low value asset leases) were €315 million in the year ended December 31, 2023, €389 million in the year ended December 31, 2022, and €302 million in the year ended December 31, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A maturity analysis of the lease liability is disclosed in Note D.17.2.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Commitments related to short-term leases and low value asset leases, including future payments for lease contracts committed but not yet commenced, are disclosed in Note D.21.</span></div>

CY2021Q4

ifrs-full

Property Plant And Equipment

PropertyPlantAndEquipment

10028000000

eur

CY2023

ifrs-full

Additions Other Than Through Business Combinations Property Plant And Equipment

AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment

1693000000

eur

CY2022

ifrs-full

Additions Other Than Through Business Combinations Property Plant And Equipment

AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment

1748000000

eur

CY2021

ifrs-full

Additions Other Than Through Business Combinations Property Plant And Equipment

AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment

1504000000

eur

CY2023

ifrs-full

Interest Costs Capitalised

InterestCostsCapitalised

26000000

eur

CY2022

ifrs-full

Interest Costs Capitalised

InterestCostsCapitalised

17000000

eur

CY2021

ifrs-full

Interest Costs Capitalised

InterestCostsCapitalised

14000000

eur

CY2023

sny

Firm Orders Of Property Plant And Equipment

FirmOrdersOfPropertyPlantAndEquipment

638000000

eur

CY2022

sny

Firm Orders Of Property Plant And Equipment

FirmOrdersOfPropertyPlantAndEquipment

861000000

eur

CY2021

sny

Firm Orders Of Property Plant And Equipment

FirmOrdersOfPropertyPlantAndEquipment

769000000

eur

CY2023Q4

ifrs-full

Property Plant And Equipment Pledged As Security

PropertyPlantAndEquipmentPledgedAsSecurity

16000000

eur

CY2022Q4

ifrs-full

Property Plant And Equipment Pledged As Security

PropertyPlantAndEquipmentPledgedAsSecurity

0

eur

CY2021Q4

ifrs-full

Property Plant And Equipment Pledged As Security

PropertyPlantAndEquipmentPledgedAsSecurity

9000000

eur

CY2023

ifrs-full

Impairment Loss Recognised In Profit Or Loss Property Plant And Equipment

ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment

130000000

eur

CY2022

ifrs-full

Impairment Loss Recognised In Profit Or Loss Property Plant And Equipment

ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment

186000000

eur

CY2021

ifrs-full

Impairment Loss Recognised In Profit Or Loss Property Plant And Equipment

ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment

39000000

eur

CY2023

ifrs-full

Disclosure Of Quantitative Information About Rightofuse Assets Explanatory

DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory

<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Right-of-use assets relating to property, plant and equipment leased by Sanofi are analyzed in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:82.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Right-of-use assets</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,711</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">93 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">963 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(91)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,745</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(26)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">292 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(232)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,872</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,672</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation & impairment at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(513)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation and impairment charged in the period</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(315)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation & impairment at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(797)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation and impairment charged in the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(341)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation & impairment at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,057)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Depreciation and impairment charged in the period</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated depreciation & impairment at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,018)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,948</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,815</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,654</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) This line also includes the effect of the reclassification of assets to </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) In December 2018, Sanofi signed two leases on real estate assets in the United States (at Cambridge, Massachusetts) for an initial lease term of 15 years. The first lease, relating to office space, began in April 2021; Sanofi recognized a right-of-use asset of €320 million, as well as the lease liability. The second lease, relating to laboratory facilities, began on July 1, 2021; Sanofi recognized a right-of-use asset of €424 million, as well as the lease liability.</span></div>

CY2021Q4

ifrs-full

Rightofuse Assets

RightofuseAssets

1948000000

eur

CY2022Q4

ifrs-full

Rightofuse Assets

RightofuseAssets

1815000000

eur

CY2023Q4

ifrs-full

Rightofuse Assets

RightofuseAssets

1654000000

eur

CY2023

sny

Expense Relating To Short Term Leases And Low Value Assets For Which Recognition Exemption Has Been Used

ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed

19000000

eur

CY2022

sny

Expense Relating To Short Term Leases And Low Value Assets For Which Recognition Exemption Has Been Used

ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed

26000000

eur

CY2021

sny

Expense Relating To Short Term Leases And Low Value Assets For Which Recognition Exemption Has Been Used

ExpenseRelatingToShortTermLeasesAndLowValueAssetsForWhichRecognitionExemptionHasBeenUsed

25000000

eur

CY2023

ifrs-full

Cash Outflow For Leases

CashOutflowForLeases

315000000

eur

CY2022

ifrs-full

Cash Outflow For Leases

CashOutflowForLeases

389000000

eur

CY2021

ifrs-full

Cash Outflow For Leases

CashOutflowForLeases

302000000

eur

CY2023

ifrs-full

Disclosure Of Intangible Assets And Goodwill Explanatory

DisclosureOfIntangibleAssetsAndGoodwillExplanatory

Goodwill and other intangible assets<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in goodwill comprise:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:82.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">44,364</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions during the period</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,179 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other movements during the period</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(89)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,602 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">48,056</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions during the period</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">609 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other movements during the period</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(258)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,485 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">49,892</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions during the period</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">475 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other movements during the period</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(873)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">49,404</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) This line mainly comprises the amount of goodwill allocated to divested operations in accordance with paragraph 86 of IAS 36, and in 2022 the loss of control of EUROAPI (see note D.2.1.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><br/>In accordance with IAS 36, goodwill is allocated to groups of Cash Generating Units (CGUs) at a level corresponding to the Biopharma and Consumer Healthcare segments. When testing goodwill annually for impairment, the recoverable amount is determined for each of the two segments (Biopharma and Consumer Healthcare) on the basis of value in use, as derived from discounted estimates of the future cash flows in accordance with the policies described in Note B.6.1.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The allocation of goodwill by segment as of December 31, 2023 is as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.361%"><tr><td style="width:1.0%"></td><td style="width:55.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.078%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer Healthcare</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Goodwill</span></div></td><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">42,324</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,080</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">49,404</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;border-top:1pt solid #795c8c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition of QRIB Intermediate Holdings, LLC (2023)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The provisional purchase price allocation for QRIB Intermediate Holdings, LLC resulted in the recognition of intangible assets (other than goodwill) o</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">f €774 million as of the acquisition d</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ate (September 29, 2023), a</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">nd of goodwill provisionally measured at €475 million as of the acquisition date (see Note D.1.).</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition of Amunix Pharmaceuticals, Inc. (2022)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The final purchase price allocation for Amunix Pharmaceuticals, Inc. resulted in the recognition of intangible assets (other than goodwill) o</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">f €493 million as of the acquisition date (February 8, 2022), and of goodwill measured at €609 million as of the acquisition date (see Note D.2.1.).</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition of Translate Bio (2021)</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The final purchase price allocation for Translate Bio resulted in the recognition of intangible a</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ssets (other than goodwill) of €396 million as of the acquisition date (September 14, 2021), and of goodwill measured at €2,118 million as of the</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> acquisition date (see Note D.2.2.).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in other intangible assets comprise:</span></div><div style="margin-bottom:2pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:53.877%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquired R&D</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Products,<br/>trademarks and<br/>other rights</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total other<br/>intangible assets</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at January 1, 2021</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,600</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">61,074</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,633</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">72,307</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,805 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,821 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,626 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">339 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">159 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">616 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(313)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(173)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(16)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(502)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">560 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,234 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,818 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(784)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">791 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2021</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,207</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">65,906</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,752</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">78,865</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">499 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(35)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">464 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">277 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">195 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">571 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(72)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(423)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(543)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">518 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,994 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,533 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,576)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,408 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(174)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2022</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,354</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">69,579</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,783</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">81,716</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,287 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,401 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions and other increases</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,062 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,970 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,112 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(262)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(380)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(683)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(242)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,584)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,837)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,253)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">861 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(396)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross value at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,772</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">73,733</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,808</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">85,313</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated amortization & impairment at January 1, 2021</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3,508)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(49,345)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,113)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(53,966)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization expense</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,621)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(119)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,740)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(150)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(42)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(192)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">313 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">462 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(132)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,869)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,022)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated amortization & impairment at December 31, 2021</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3,477)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(52,744)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,237)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(57,458)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization expense</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,099)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(97)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,196)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,107)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,561 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">454 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">411 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">525 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,567)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,591)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">388 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(214)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">179 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated amortization & impairment at December 31, 2022</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(4,128)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(54,652)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,296)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(60,076)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Changes in scope of consolidation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization expense</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,225)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,345)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impairment losses, net of reversals</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(842)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(932)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Disposals and other decreases</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">262 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">629 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,184 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,287 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Transfers</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">268 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated amortization & impairment at December 31, 2023</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3,734)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(55,908)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,352)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(60,994)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carrying amount at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,730 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,162 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">515 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21,407 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carrying amount at December 31, 2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,226 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,927 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">487 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21,640 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,038</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,825</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">456</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24,319</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Includes the impact of the IFRIC agenda decision of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement (see Note A.2.1. to our 2021 consolidated financial statements, included in our annual report on Form 20-F for that year).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) The “Transfers” line mainly comprises (i) acquired R&D that came into commercial use during the period and (ii) reclassifications of assets as </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Assets held for sale or exchange</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) The “Changes in scope of consolidation” line mainly comprises the fair value of intangible assets recognized in connection with acquisitions made during the period (see Notes D.1. and D.2.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d) See Note D.5.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e) The amendment to the terms of the IO License and Collaboration Agreement resulted in the recognition of an amortization charge of €226 million in 2022 (see Note C.1.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(f) This line mainly comprises:</span></div><div style="margin-top:1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.59pt">the rights acquired as a result of the simplification agreed between Sanofi and AstraZeneca in April 2023 in respect of the agreements on BEYFORTUS (nirsevimab) (see Note C.2.);</span></div><div style="margin-top:1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.59pt">an upfront payment of $500 million relating to the rights acquired under the agreement with Teva Pharmaceuticals on the co-development and co-commercialization of TEV’574; and</span></div><div style="margin-top:1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.59pt">an upfront payment of $175 million for the rights acquired under the agreement with Janssen Pharmaceuticals, Inc. relating to a vaccine against extra-intestinal pathogenic strains of E-Coli.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">“Products, trademarks and other rights” mainly comprise:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">“marketed products”, with a carrying amount of €16.6 billion as of December 31, 2023 (versus €12.7 billion as of December 31, 2022 and €11.7 billion as of December 31, 2021) and a weighted average amortization period of approximately 11 years; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">“technology platforms”, with a carrying amount of €1.2 billion as of December 31, 2023 (versus €2.2 billion as of December 31, 2022 and €1.2 billion as of December 31, 2021) and a weighted average amortization period of approximately 18 years.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below provides information about the principal “marketed products”, which were recognized in connection with major acquisitions made by Sanofi and represented 96% of the carrying amount of that item as of December 31, 2023:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:20.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.081%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross<br/>value</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>amortization &<br/>impairment</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortization</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">period</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(years)</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Residual</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">amortization</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">period</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(years)</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying amount at December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,279 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10,071)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">621 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,032 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Boehringer Ingelheim </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Consumer Healthcare</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,504 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,698)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,806 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,037 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,213 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33,043 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(33,000)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chattem</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,319 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(818)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">501 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">574 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">593 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Protein Sciences</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(411)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">420 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">498 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">532 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ablynx</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,966 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(746)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,220 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,357 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,494 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bioverativ</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,798 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,646)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,152 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,836 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,065 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">REZUROCK</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,907 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(327)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,580 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,702 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,750 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TZIELD</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,546 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,405 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">BEYFORTUS</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,946 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,870 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">180 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">QUNOL</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">741 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">722 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total: principal marketed products</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">66,880</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(50,953)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15,927</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,863</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,752</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Weighted averages. The amortization periods for these products vary between 1 and 25 years.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Weighted averages.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) Commercialized products derived from the acquisition of these companies.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal intangible assets brought into service during 2023 were:</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">ALTUVIIIO (efanesoctocog alfa), which extends protection from bleeds and treats acute hemorrhages in people with hemophilia A. The asset came into service on the date of marketing approval (February 23, 2023), and has a gross value of €1,110 million.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">During 2022, some of the acquired research and development came into commercial use, and started being amortized from the date of marketing approval; the main item involved was ENJAYMO (sutimlimab-jome), a treatment for cold agglutinin disease.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The main asset brought into service during 2021 was the Translate Bio mRNA technology platform.</span></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Amortization of other intangible assets is recognized in the income statement within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Amortization of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, except for amortization of software and other rights of an industrial or operational nature which is recognized in the relevant classification of expense by function. An analysis of amortization of software is shown in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">120</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">97</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">119</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div>

CY2023

ifrs-full

Disclosure Of Reconciliation Of Changes In Goodwill Explanatory

DisclosureOfReconciliationOfChangesInGoodwillExplanatory

<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in goodwill comprise:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:82.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">44,364</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions during the period</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,179 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other movements during the period</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(89)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,602 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">48,056</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions during the period</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">609 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other movements during the period</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(258)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,485 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">49,892</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions during the period</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">475 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other movements during the period</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency translation differences</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(873)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">49,404</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) This line mainly comprises the amount of goodwill allocated to divested operations in accordance with paragraph 86 of IAS 36, and in 2022 the loss of control of EUROAPI (see note D.2.1.).</span></div>

CY2023

sny

Number Of Operating Segments1

NumberOfOperatingSegments1

2

segment

CY2023Q4

ifrs-full

Goodwill

49404000000

eur

CY2021Q4

ifrs-full

Other Intangible Assets

OtherIntangibleAssets

21407000000

eur

CY2022Q4

ifrs-full

Other Intangible Assets

OtherIntangibleAssets

21640000000

eur

CY2023Q4

ifrs-full

Other Intangible Assets

OtherIntangibleAssets

24319000000

eur

CY2023

sny

Number Of Operating Segments1

NumberOfOperatingSegments1

2

segment

CY2023

sny

Percentage Of Discount Rate Above Rate Actually Used Would Not Cause Impairment Loss

PercentageOfDiscountRateAboveRateActuallyUsedWouldNotCauseImpairmentLoss

2.8

CY2023

sny

Percentage Of Perpetuity Growth Rate Below The Rates Actually Used Would Not Cause Impairment Loss

PercentageOfPerpetuityGrowthRateBelowTheRatesActuallyUsedWouldNotCauseImpairmentLoss

4.9

CY2023

sny

Percentage Of Operating Margin Rate Below Rates Actually Used Would Not Cause Impairment Loss

PercentageOfOperatingMarginRateBelowRatesActuallyUsedWouldNotCauseImpairmentLoss

7.2

CY2022

ifrs-full

Impairment Loss Recognised In Profit Or Loss Goodwill

ImpairmentLossRecognisedInProfitOrLossGoodwill

0

eur

CY2021

ifrs-full

Impairment Loss Recognised In Profit Or Loss Goodwill

ImpairmentLossRecognisedInProfitOrLossGoodwill

0

eur

CY2023

ifrs-full

Impairment Loss Recognised In Profit Or Loss Goodwill

ImpairmentLossRecognisedInProfitOrLossGoodwill

0

eur

CY2023

ifrs-full

Disclosure Of Investments Accounted For Using Equity Method Explanatory

DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory

Investments accounted for using the equity method<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Investments accounted for using the equity method comprise associates and joint ventures (see Note B.1.), and are set forth below.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:49.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% interest</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EUROAPI</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29.8 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">392 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Infraserv GmbH & Co. Höchst KG</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">MSP Vaccine Company</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">104 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">84 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">424</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">677</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">250</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Following the distribution in kind and the acquisition of an equity interest by EPIC Bpifrance, Sanofi holds an equity interest in EUROAPI accounted for using the equity method in accordance with IAS 28 (see Note D.2.). As of December 31, 2023, an impairment loss of €231 million was recognized on the equity-accounted investment in EUROAPI in view of the fall in the share price since March 2023. The amount of the loss was determined on the basis of the share price as of December 31, 2023 (€5.73).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Joint venture.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Joint venture. MSP Vaccine Company owns 100% of MCM Vaccine BV.</span></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows Sanofi’s overall share of (i) profit or loss and (ii) other comprehensive income from investments accounted for using the equity method, showing the split between associates and joint ventures in accordance with IFRS 12 (the amounts for each individual associate or joint venture are not material):</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"></td><td style="width:28.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.881%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.881%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.425%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Joint ventures</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Associates</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Joint ventures</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Associates</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Joint ventures</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Associates</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of other comprehensive income from investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">94</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(208)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">72</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(9)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) An impairment loss of </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">€231 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> was recognized on the equity-accounted interest in EUROAPI as of December 31, 2023, to reflect the fall in the share price since March 2023. The amount of the loss was determined on the basis of the quoted market price as of December 31, 2023 (€5.73).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The financial statements include arm’s length transactions between Sanofi and some equity-accounted investments that are classified as related parties. The principal transactions and balances with related parties are summarized below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:58.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.998%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:2.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.998%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.999%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">131 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Royalties and other income</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">81 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">66 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts receivable and other receivables</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">249 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">330 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">269 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchases and other expenses (including research expenses)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">642 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">477 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">178 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts payable and other payables</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">132 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) In 2022, these items include Sanofi's transactions with EUROAPI from May 10, 2022 (see Note D.2.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Includes loans to joint ventures and associates.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">There were no funding commitments to associates and joint ventures as of December 31, 2023, December 31, 2022 or December 31, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For off balance sheet commitments of an operational nature involving joint ventures, see Note D.21.1.</span></div>

CY2023Q4

ifrs-full

Investments In Subsidiaries Joint Ventures And Associates

InvestmentsInSubsidiariesJointVenturesAndAssociates

424000000

eur

CY2022Q4

ifrs-full

Investments In Subsidiaries Joint Ventures And Associates

InvestmentsInSubsidiariesJointVenturesAndAssociates

677000000

eur

CY2021Q4

ifrs-full

Investments In Subsidiaries Joint Ventures And Associates

InvestmentsInSubsidiariesJointVenturesAndAssociates

250000000

eur

CY2023

ifrs-full

Disclosure Of Transactions Between Related Parties Explanatory

DisclosureOfTransactionsBetweenRelatedPartiesExplanatory

The principal transactions and balances with related parties are summarized below:<div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:58.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.998%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:2.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.998%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.999%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">131 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Royalties and other income</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">81 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">66 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts receivable and other receivables</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">249 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">330 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">269 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchases and other expenses (including research expenses)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">642 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">477 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">178 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accounts payable and other payables</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">132 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) In 2022, these items include Sanofi's transactions with EUROAPI from May 10, 2022 (see Note D.2.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Includes loans to joint ventures and associates.</span></div>

CY2023

ifrs-full

Disclosure Of Other Noncurrent Assets Explanatory

DisclosureOfOtherNoncurrentAssetsExplanatory

Other non-current assets<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other non-current assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> comprise:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:49.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.288%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments at fair value through other comprehensive income (D.7.1.)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,088 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">936 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">823 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt instruments at fair value through other comprehensive income (D.7.2.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">329 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">447 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other financial assets at fair value through profit or loss (D.7.3.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">808 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">823 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">902 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pre-funded pension obligations (Note D.19.1.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">269 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">408 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term prepaid expenses</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">286 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term loans and advances and other non-current receivables</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">591 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">452 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">485 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivative financial instruments (Note D.20.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,218</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,095</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,127</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) As of December 31, 2023, this line includes:</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- the renewal of a loan of €157 million to the BioAtrium joint venture which matures on December 1, 2031, of which €156 million was recognized in "Other current assets" as of December 31, 2022; and</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- a receivable under a sub-lease amounting to €132 million (€170 million before discounting), versus €164 million (or €201 million before discounting) as of December 31, 2022.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.7.1. Equity instruments at fair value through other comprehensive income</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quoted equity investments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The line “Equity instruments at fair value through other comprehensive income” includes equity investments quoted in an active market with a carrying amount of €470 million as of December 31, 2023, €387 million as of December 31, 2022 and €396 million as of December 31, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">There were no material movements in quoted equity investments during the year ended December 31, 2023.</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The main changes during previous years in quoted equity investments included in the “Equity instruments at fair value through other comprehensive income” category are described below:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">in 2022:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">the sale in June 2022 of the residual equity interest in Regeneron (see Note C.1.) for $174 million, the entire loss on which was recorded within Other comprehensive income, and </span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">the acquisition of an equity interest in Innovent Biologics, in connection with a strategic collaboration agreement to intensify development in oncology medicines signed in August 2022, which had a fair value of €250 million as of that date and €228 million as of December 31, 2022;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">in 2021:</span></div><div style="margin-bottom:3pt;padding-left:25.51pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">–</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:5.99pt">following completion of the acquisition of Translate Bio on September 14, 2021 (see Note D.2.2), the equity interest of approximately 5% in Translate Bio previously held by Sanofi ceased to be accounted for in the “Equity instruments at fair value through other comprehensive income” category.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A 10% decline in stock prices of the quoted equity investments included within “Equity instruments at fair value through other comprehensive income” would have had a pre-tax impact of €47 million on </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> as of December 31, 2023.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unquoted equity investments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The line item “Equity instruments at fair value through other comprehensive income” also includes equity investments not quoted in an active market with a carrying amount of €618 million as of December 31, 2023, €549 million as of December 31, 2022 and €427 million as of December 31, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The change in unquoted equity investments included in the “Equity instruments at fair value through other comprehensive income” category during the year ended December 31, 2023 was mainly due to various equity stakes acquired through the Sanofi Ventures fund.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In addition, commitments relating to equity investments classified in this asset category amount to €65 million as of December 31, 2023 (compared to €60 million as of December 31, 2022).</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.7.2. Debt instruments at fair value through other comprehensive income</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The “Debt instruments at fair value through other comprehensive income” category includes quoted euro-denominated senior bonds amounting to €346 million as of December 31, 2023, including €107 million of securities obtained in exchange for financial assets held to meet obligations to employees under post-employment benefit plans.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi held €329 million of quoted senior bonds as of December 31, 2022 and €447 million as of December 31, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As regards debt instruments held to meet obligations to employees under post-employment benefit plans, an increase of 10 basis points in market interest rates as of December 31, 2023 would have had a pre-tax impact of €1 million on </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As regards other quoted debt instruments, an increase of 10 basis points in market interest rates as of December 31, 2023 would have had a pre-tax impact of €1 million on </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Other comprehensive income recognized in respect of “Equity instruments at fair value through other comprehensive income” and “Debt instruments at fair value through other comprehensive income” represented unrealized after-tax gains of €349 million for the year ended December 31, 2023, versus unrealized after-tax gains of €256 million for the year ended December 31, 2022 and of €322 million for the year ended December 31, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of the change in gains and losses recognized in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, and of items reclassified to profit or loss, is presented in Note D.15.7.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.7.3. Other financial assets at fair value through profit or loss</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The “Other financial assets at fair value through profit or loss”</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">category includes:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">contingent consideration receivable by Sanofi following the dissolution of the Sanofi Pasteur MSD (SPMSD) joint venture, based on a percentage of MSD’s future sales during the 2017-2024 period of specified products previously distributed by SPMSD (see Note D.12.).</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The fair value of the MSD contingent consideration was determined by applying the royalty percentage stipulated in the contract to discounted sales projections. A reduction of one percentage point in the discount rate would increase the fair value of the MSD contingent consideration by approximately 1%.</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Changes in the fair value of this contingent consideration are recognized in the income statement within the line item</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Fair value remeasurement of contingent consideration </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">(see Note B.18.). As of December 31, 2023, the contingent consideration asset amounted to €214 million (including a non-current portion of €104 million), versus €303 million (non-current portion: €196 million) as of December 31, 2022 and €378 million (non current portion: €275 million) as of December 31, 2021;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">a portfolio of financial investments (amounting to €572 million as of December 31, 2023) held to fund a deferred compensation plan provided to certain employees (versus €512 million as of December 31, 2022 and €549 million as of December 31, 2021);</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">unquoted securities not meeting the definition of equity instruments amounting to €132 million as of December 31, 2023 (versus €115 million as of December 31, 2022 and €78 million as of December 31, 2021). In addition, commitments relating to unquoted securities classified in this asset category amount to €159 million as of December 31, 2023 (compared to €192 million as of December 31, 2022).</span></div>

CY2023Q4

ifrs-full

Noncurrent Financial Assets At Fair Value Through Profit Or Loss

NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss

808000000

eur

CY2022Q4

ifrs-full

Noncurrent Financial Assets At Fair Value Through Profit Or Loss

NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss

823000000

eur

CY2021Q4

ifrs-full

Noncurrent Financial Assets At Fair Value Through Profit Or Loss

NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss

902000000

eur

CY2023Q4

sny

Pre Funded Pension Obligations

PreFundedPensionObligations

271000000

eur

CY2022Q4

sny

Pre Funded Pension Obligations

PreFundedPensionObligations

269000000

eur

CY2021Q4

sny

Pre Funded Pension Obligations

PreFundedPensionObligations

408000000

eur

CY2023Q4

sny

Long Term Prepaid Expenses

LongTermPrepaidExpenses

114000000

eur

CY2022Q4

sny

Long Term Prepaid Expenses

LongTermPrepaidExpenses

286000000

eur

CY2021Q4

sny

Long Term Prepaid Expenses

LongTermPrepaidExpenses

59000000

eur

CY2023Q4

ifrs-full

Noncurrent Loans And Receivables

NoncurrentLoansAndReceivables

591000000

eur

CY2022Q4

ifrs-full

Noncurrent Loans And Receivables

NoncurrentLoansAndReceivables

452000000

eur

CY2021Q4

ifrs-full

Noncurrent Loans And Receivables

NoncurrentLoansAndReceivables

485000000

eur

CY2023Q4

ifrs-full

Noncurrent Derivative Financial Assets

NoncurrentDerivativeFinancialAssets

0

eur

CY2022Q4

ifrs-full

Noncurrent Derivative Financial Assets

NoncurrentDerivativeFinancialAssets

0

eur

CY2021Q4

ifrs-full

Noncurrent Derivative Financial Assets

NoncurrentDerivativeFinancialAssets

3000000

eur

CY2023Q4

ifrs-full

Other Noncurrent Assets

OtherNoncurrentAssets

3218000000

eur

CY2022Q4

ifrs-full

Other Noncurrent Assets

OtherNoncurrentAssets

3095000000

eur

CY2021Q4

ifrs-full

Other Noncurrent Assets

OtherNoncurrentAssets

3127000000

eur

CY2022Q4

ifrs-full

Inventories

8960000000

eur

CY2023Q4

ifrs-full

Noncurrent Finance Lease Receivables

NoncurrentFinanceLeaseReceivables

132000000

eur

CY2023Q4

sny

Non Current Finance Lease Receivables Gross

NonCurrentFinanceLeaseReceivablesGross

170000000

eur

CY2022Q4

ifrs-full

Noncurrent Finance Lease Receivables

NoncurrentFinanceLeaseReceivables

164000000

eur

CY2022Q4

sny

Non Current Finance Lease Receivables Gross

NonCurrentFinanceLeaseReceivablesGross

201000000

eur

CY2023

sny

Equity Instruments At Fair Value Through Other Comprehensive Income Loss10 Decline In Credit Prices Pre Tax Amount

EquityInstrumentsAtFairValueThroughOtherComprehensiveIncomeLoss10DeclineInCreditPricesPreTaxAmount

47000000

eur

CY2023

ifrs-full

Disclosure Of Noncurrent Assets Or Disposal Groups Classified As Held For Sale Explanatory

DisclosureOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory

Assets held for sale or exchange and liabilities related to assets held for sale or exchange<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Assets held for sale or exchange, and liabilities related to assets held for sale or exchange, comprise:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:52.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.216%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Assets held for sale or exchange</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">85</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">89</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Liabilities related to assets held for sale or exchange</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>

CY2023Q4

ifrs-full

Noncurrent Assets Or Disposal Groups Classified As Held For Sale

NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale

15000000

eur

CY2022Q4

ifrs-full

Noncurrent Assets Or Disposal Groups Classified As Held For Sale

NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale

85000000

eur

CY2021Q4

ifrs-full

Noncurrent Assets Or Disposal Groups Classified As Held For Sale

NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSale

89000000

eur

CY2023Q4

ifrs-full

Liabilities Included In Disposal Groups Classified As Held For Sale

LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale

13000000

eur

CY2022Q4

ifrs-full

Liabilities Included In Disposal Groups Classified As Held For Sale

LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale

10000000

eur

CY2021Q4

ifrs-full

Liabilities Included In Disposal Groups Classified As Held For Sale

LiabilitiesIncludedInDisposalGroupsClassifiedAsHeldForSale

0

eur

CY2023

ifrs-full

Disclosure Of Inventories Explanatory

DisclosureOfInventoriesExplanatory

Inventories<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Inventories comprise the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross<br/>value</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Allowances</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Allowances</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Allowances</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying<br/>amount</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,676 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,550 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,613 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(139)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,474 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,344 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(66)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,278 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,869 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(553)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,316 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,663 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(678)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,985 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,579 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(554)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,025 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,045 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(245)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,800 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,748 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(247)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,501 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,696 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(284)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,412 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,590</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(924)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,666</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,024</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,064)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,960</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,619</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(904)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,715</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Allowances include write-downs of products on hand pending marketing approval, except in specific circumstances where it is possible to estimate that recovery of the value of inventories as of the end of the reporting period is highly probable.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No inventories were pledged as security for liabilities as of December 31, 2023 (versus €3 million as of December 31, 2022 and €20 million as of December 31, 2021).</span></div>

CY2023Q4

ifrs-full

Raw Materials

RawMaterials

1550000000

eur

CY2022Q4

ifrs-full

Raw Materials

RawMaterials

1474000000

eur

CY2021Q4

ifrs-full

Raw Materials

RawMaterials

1278000000

eur

CY2023Q4

ifrs-full

Work In Progress

WorkInProgress

5316000000

eur

CY2022Q4

ifrs-full

Work In Progress

WorkInProgress

4985000000

eur

CY2021Q4

ifrs-full

Work In Progress

WorkInProgress

5025000000

eur

CY2023Q4

ifrs-full

Finished Goods

FinishedGoods

2800000000

eur

CY2022Q4

ifrs-full

Finished Goods

FinishedGoods

2501000000

eur

CY2021Q4

ifrs-full

Finished Goods

FinishedGoods

2412000000

eur

CY2023Q4

ifrs-full

Inventories

9666000000

eur

CY2021Q4

ifrs-full

Inventories

8715000000

eur

CY2023Q4

ifrs-full

Inventories Pledged As Security For Liabilities

InventoriesPledgedAsSecurityForLiabilities

0

eur

CY2022Q4

ifrs-full

Inventories Pledged As Security For Liabilities

InventoriesPledgedAsSecurityForLiabilities

3000000

eur

CY2021Q4

ifrs-full

Inventories Pledged As Security For Liabilities

InventoriesPledgedAsSecurityForLiabilities

20000000

eur

CY2023Q4

ifrs-full

Current Trade Receivables

CurrentTradeReceivables

8433000000

eur

CY2022Q4

ifrs-full

Current Trade Receivables

CurrentTradeReceivables

8424000000

eur

CY2021Q4

ifrs-full

Current Trade Receivables

CurrentTradeReceivables

7568000000

eur

CY2023

ifrs-full

Impairment Loss Recognised In Profit Or Loss Trade Receivables

ImpairmentLossRecognisedInProfitOrLossTradeReceivables

8000000

eur

CY2022

ifrs-full

Impairment Loss Recognised In Profit Or Loss Trade Receivables

ImpairmentLossRecognisedInProfitOrLossTradeReceivables

1000000

eur

CY2021

ifrs-full

Impairment Loss Recognised In Profit Or Loss Trade Receivables

ImpairmentLossRecognisedInProfitOrLossTradeReceivables

12000000

eur

CY2023Q4

sny

Overdue Receivables Gross Value

OverdueReceivablesGrossValue

689000000

eur

CY2022Q4

sny

Overdue Receivables Gross Value

OverdueReceivablesGrossValue

452000000

eur

CY2021Q4

sny

Overdue Receivables Gross Value

OverdueReceivablesGrossValue

455000000

eur

CY2023Q4

sny

Overdue Receivables Gross Value

OverdueReceivablesGrossValue

689000000

eur

CY2022Q4

sny

Overdue Receivables Gross Value

OverdueReceivablesGrossValue

452000000

eur

CY2021Q4

sny

Overdue Receivables Gross Value

OverdueReceivablesGrossValue

455000000

eur

CY2023Q4

sny

Derecognized Receivables

DerecognizedReceivables

761000000

eur

CY2022Q4

sny

Derecognized Receivables

DerecognizedReceivables

131000000

eur

CY2021Q4

sny

Derecognized Receivables

DerecognizedReceivables

3000000

eur

CY2023

ifrs-full

Disclosure Of Other Current Assets Explanatory

DisclosureOfOtherCurrentAssetsExplanatory

Other current assets<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Other current assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tax receivables, other than corporate income taxes</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">768 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">658 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">802 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">768 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">714 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">615 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other receivables</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,448 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,290 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">805 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate derivatives measured at fair value (see Note D.20.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency derivatives measured at fair value (see Note D.20.)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">284 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current financial assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">270 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">664 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,054 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,455</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,532</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,571</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) This line mainly comprises advance payments to suppliers, and receivables relating to Sanofi's activities as agent under a transitional services agreement.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) This item mainly comprises bank loans and receivables maturing in less than one year with high-grade counterparties. For 2021, this item also includes debt instruments derived from the acquisitions of Translate Bio and Kadmon (carried out in 2021) with maturities of more than three months at inception and less than 12 months at December 31, 2021.</span></div>

CY2023Q4

ifrs-full

Current Receivables From Taxes Other Than Income Tax

CurrentReceivablesFromTaxesOtherThanIncomeTax

768000000

eur

CY2022Q4

ifrs-full

Current Receivables From Taxes Other Than Income Tax

CurrentReceivablesFromTaxesOtherThanIncomeTax

658000000

eur

CY2021Q4

ifrs-full

Current Receivables From Taxes Other Than Income Tax

CurrentReceivablesFromTaxesOtherThanIncomeTax

802000000

eur

CY2023Q4

ifrs-full

Current Prepaid Expenses

CurrentPrepaidExpenses

768000000

eur

CY2022Q4

ifrs-full

Current Prepaid Expenses

CurrentPrepaidExpenses

714000000

eur

CY2021Q4

ifrs-full

Current Prepaid Expenses

CurrentPrepaidExpenses

615000000

eur

CY2023Q4

ifrs-full

Other Current Receivables

OtherCurrentReceivables

1448000000

eur

CY2022Q4

ifrs-full

Other Current Receivables

OtherCurrentReceivables

1290000000

eur

CY2021Q4

ifrs-full

Other Current Receivables

OtherCurrentReceivables

805000000

eur

CY2023Q4

sny

Interest Rate Derivatives Measured At Fair Value

InterestRateDerivativesMeasuredAtFairValue

0

eur

CY2022Q4

sny

Interest Rate Derivatives Measured At Fair Value

InterestRateDerivativesMeasuredAtFairValue

0

eur

CY2021Q4

sny

Interest Rate Derivatives Measured At Fair Value

InterestRateDerivativesMeasuredAtFairValue

11000000

eur

CY2023Q4

sny

Currency Derivatives Measured At Fair Value

CurrencyDerivativesMeasuredAtFairValue

201000000

eur

CY2022Q4

sny

Currency Derivatives Measured At Fair Value

CurrencyDerivativesMeasuredAtFairValue

206000000

eur

CY2021Q4

sny

Currency Derivatives Measured At Fair Value

CurrencyDerivativesMeasuredAtFairValue

284000000

eur

CY2023Q4

ifrs-full

Other Current Financial Assets

OtherCurrentFinancialAssets

270000000

eur

CY2022Q4

ifrs-full

Other Current Financial Assets

OtherCurrentFinancialAssets

664000000

eur

CY2021Q4

ifrs-full

Other Current Financial Assets

OtherCurrentFinancialAssets

1054000000

eur

CY2023Q4

ifrs-full

Other Current Assets

OtherCurrentAssets

3455000000

eur

CY2022Q4

ifrs-full

Other Current Assets

OtherCurrentAssets

3532000000

eur

CY2021Q4

ifrs-full

Other Current Assets

OtherCurrentAssets

3571000000

eur

CY2023

ifrs-full

Disclosure Of Cash And Cash Equivalents Explanatory

DisclosureOfCashAndCashEquivalentsExplanatory

Cash and cash equivalents<div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,461 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,385 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,358 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash equivalents</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,249 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,351 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,740 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,710</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,736</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,098</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) As of December 31, 2023, cash equivalents mainly comprised the following: (i) €5,349 million invested in euro and US dollar denominated money-market mutual funds (December 31, 2022: €9,537 million; December 31, 2021: €5,057 million); (ii) €1,191 million of term deposits (December 31, 2022: €1,167 million; December 31, 2021: €2,768 million) and (iii) zero commercial paper (December 31, 2022: zero; December 31, 2021: €179 million). Cash equivalents also include €476 million held by captive insurance and reinsurance companies in accordance with insurance regulations (December 31, 2022: €439 million; December 31, 2021: €427 million).</span></div>

CY2023Q4

ifrs-full

Cash

1461000000

eur

CY2022Q4

ifrs-full

Cash

1385000000

eur

CY2021Q4

ifrs-full

Cash

1358000000

eur

CY2023Q4

ifrs-full

Cash Equivalents

CashEquivalents

7249000000

eur

CY2022Q4

ifrs-full

Cash Equivalents

CashEquivalents

11351000000

eur

CY2021Q4

ifrs-full

Cash Equivalents

CashEquivalents

8740000000

eur

CY2023Q4

ifrs-full

Cash And Cash Equivalents

CashAndCashEquivalents

8710000000

eur

CY2022Q4

ifrs-full

Cash And Cash Equivalents

CashAndCashEquivalents

12736000000

eur

CY2021Q4

ifrs-full

Cash And Cash Equivalents

CashAndCashEquivalents

10098000000

eur

CY2023Q4

sny

Cash Equivalents Money Market Mutual Funds

CashEquivalentsMoneyMarketMutualFunds

5349000000

eur

CY2022Q4

sny

Cash Equivalents Money Market Mutual Funds

CashEquivalentsMoneyMarketMutualFunds

9537000000

eur

CY2021Q4

sny

Cash Equivalents Money Market Mutual Funds

CashEquivalentsMoneyMarketMutualFunds

5057000000

eur

CY2023Q4

ifrs-full

Shortterm Deposits Classified As Cash Equivalents

ShorttermDepositsClassifiedAsCashEquivalents

1191000000

eur

CY2022Q4

ifrs-full

Shortterm Deposits Classified As Cash Equivalents

ShorttermDepositsClassifiedAsCashEquivalents

1167000000

eur

CY2021Q4

ifrs-full

Shortterm Deposits Classified As Cash Equivalents

ShorttermDepositsClassifiedAsCashEquivalents

2768000000

eur

CY2023Q4

sny

Cash Equivalents Commercial Paper

CashEquivalentsCommercialPaper

0

eur

CY2022Q4

sny

Cash Equivalents Commercial Paper

CashEquivalentsCommercialPaper

0

eur

CY2021Q4

sny

Cash Equivalents Commercial Paper

CashEquivalentsCommercialPaper

179000000

eur

CY2023Q4

sny

Cash Equivalents Captive Insurance And Reinsurance Companies

CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies

476000000

eur

CY2022Q4

sny

Cash Equivalents Captive Insurance And Reinsurance Companies

CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies

439000000

eur

CY2021Q4

sny

Cash Equivalents Captive Insurance And Reinsurance Companies

CashEquivalentsCaptiveInsuranceAndReinsuranceCompanies

427000000

eur

CY2023

ifrs-full

Disclosure Of Deferred Taxes Explanatory

DisclosureOfDeferredTaxesExplanatory

Net deferred tax position<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of the net deferred tax position is set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.854%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Deferred taxes on:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Consolidation adjustments (intragroup margin in inventory)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,525 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,388 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,292 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provision for pensions and other employee benefits</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,117 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Remeasurement of other acquired intangible assets</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,904)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,269)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,079)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Recognition of acquired property, plant and equipment at fair value</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity interests in subsidiaries and investments in other entities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,023)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(617)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(590)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tax losses available for carry-forward</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,526 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,506 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,516 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock options and other share-based payments</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accrued expenses and provisions deductible at the time of payment</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,994 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,859 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,585 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,536 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,755 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,078 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net deferred tax asset/(liability)</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,570</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,540</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,981</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) As of December 31, 2023, includes remeasurements of the acquired intangible assets of Bioverativ (€1,241 million), Principia (€610 million), Ablynx (€204 million), Genzyme (€50 million) and Amunix (€109 million).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) In some countries, Sanofi is liable for withholding taxes and other tax charges when dividends are distributed. Consequently, Sanofi recognizes a deferred tax liability on the reserves of French and foreign subsidiaries (approximately €60.4 billion) which it regards as likely to be distributed in the foreseeable future. In determining the amount of the deferred tax liability as of December 31, 2023, Sanofi took into account changes in the ownership structure of certain subsidiaries, and the effects of changes in the taxation of dividends in France, following the ruling of the Court of Justice of the European Union in the Steria case and the resulting amendments to the 2015 Finance Act. As of December 31, 2023, this line includes a deferred tax liability arising from temporary differences on investments in subsidiaries which Sanofi expects will reverse in connection with the proposed separation of the Consumer Healthcare business, as announced in October 2023 (see Note D.30.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) Includes deferred tax assets related to restructuring provisions, amounting to €286 million as of December 31, 2023, €256 million as of December 31, 2022, and €226 million as of December 31, 2021.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d) Includes deferred taxes arising on the spread tax deduction of R&D expenses, amounting to €1,331 million as of December 31, 2023 and €742 million as of December 31, 2022.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The reserves of Sanofi subsidiaries that would be taxable if distributed but for which no distribution is planned, and for which no deferred tax liability has therefore been recognized, totaled €10.0 billion as of December 31, 2023, compared with €10.6 billion as of December 31, 2022 and €10.0 billion as of December 31, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Most of Sanofi’s tax loss carry-forwards are available indefinitely. For a description of policies on the recognition of deferred tax assets, refer to Note B.22. For each tax consolidation, the recognition of deferred tax assets is determined on the basis of profit forecasts that are consistent with Sanofi’s medium-term strategic plan, and taking into consideration the tax consequences of the strategic opportunities available to Sanofi within the period of availability of tax loss carry-forwards and the specific circumstances of each tax consolidation. Deferred tax assets relating to tax loss carry-forwards as of December 31, 2023 amounted to €2,729 million, of which €1,203 million were not recognized (including €473 million in respect of capital losses). This compares with €2,650 million as of December 31, 2022 (of which €1,144 million were not recognized) and €2,391 million as of December 31, 2021 (of which €875 million were not recognized).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows when tax losses available for carry-forward are due to expire:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:70.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Tax losses available for carry-forward</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">126 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2029 and later</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,737 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total as of December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,933</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total as of December 31, 2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,503</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total as of December 31, 2021</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,644</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Excluding tax loss carry-forwards on asset disposals. Such carry-forwards amounted to €5 million as of December 31, 2023, €5 million as of December 31, 2022 and €5 million as of December 31, 2021.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Use of tax loss carry-forwards is limited to the entity in which they arose. In jurisdictions where tax consolidations are in place, tax losses can be netted against taxable income generated by entities in the same tax consolidation.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Deferred tax assets not recognized (primarily because their future recovery was not regarded as probable given the expected results of the entities in question) amounted to €1,062 million in 2023, €995 million in 2022 and €615 million in 2021.</span></div>

CY2023

ifrs-full

Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits Explanatory

DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory

<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of the net deferred tax position is set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.854%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Deferred taxes on:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Consolidation adjustments (intragroup margin in inventory)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,525 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,388 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,292 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provision for pensions and other employee benefits</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,117 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Remeasurement of other acquired intangible assets</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,904)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,269)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,079)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Recognition of acquired property, plant and equipment at fair value</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity interests in subsidiaries and investments in other entities</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,023)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(617)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(590)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tax losses available for carry-forward</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,526 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,506 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,516 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock options and other share-based payments</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accrued expenses and provisions deductible at the time of payment</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,994 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,859 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,585 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,536 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,755 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,078 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net deferred tax asset/(liability)</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,570</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,540</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,981</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) As of December 31, 2023, includes remeasurements of the acquired intangible assets of Bioverativ (€1,241 million), Principia (€610 million), Ablynx (€204 million), Genzyme (€50 million) and Amunix (€109 million).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) In some countries, Sanofi is liable for withholding taxes and other tax charges when dividends are distributed. Consequently, Sanofi recognizes a deferred tax liability on the reserves of French and foreign subsidiaries (approximately €60.4 billion) which it regards as likely to be distributed in the foreseeable future. In determining the amount of the deferred tax liability as of December 31, 2023, Sanofi took into account changes in the ownership structure of certain subsidiaries, and the effects of changes in the taxation of dividends in France, following the ruling of the Court of Justice of the European Union in the Steria case and the resulting amendments to the 2015 Finance Act. As of December 31, 2023, this line includes a deferred tax liability arising from temporary differences on investments in subsidiaries which Sanofi expects will reverse in connection with the proposed separation of the Consumer Healthcare business, as announced in October 2023 (see Note D.30.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) Includes deferred tax assets related to restructuring provisions, amounting to €286 million as of December 31, 2023, €256 million as of December 31, 2022, and €226 million as of December 31, 2021.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d) Includes deferred taxes arising on the spread tax deduction of R&D expenses, amounting to €1,331 million as of December 31, 2023 and €742 million as of December 31, 2022.</span></div>

CY2023Q4

ifrs-full

Deferred Tax Liability Asset

DeferredTaxLiabilityAsset

-4570000000

eur

CY2022Q4

ifrs-full

Deferred Tax Liability Asset

DeferredTaxLiabilityAsset

-3540000000

eur

CY2021Q4

ifrs-full

Deferred Tax Liability Asset

DeferredTaxLiabilityAsset

-2981000000

eur

CY2023Q4

sny

Reserves Likely To Be Distributed In The Foreseeable Future

ReservesLikelyToBeDistributedInTheForeseeableFuture

60400000000

eur

CY2023Q4

ifrs-full

Temporary Differences Associated With Investments In Subsidiaries Branches And Associates And Interests In Joint Ventures

TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures

10000000000

eur

CY2022Q4

ifrs-full

Temporary Differences Associated With Investments In Subsidiaries Branches And Associates And Interests In Joint Ventures

TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures

10600000000

eur

CY2021Q4

ifrs-full

Temporary Differences Associated With Investments In Subsidiaries Branches And Associates And Interests In Joint Ventures

TemporaryDifferencesAssociatedWithInvestmentsInSubsidiariesBranchesAndAssociatesAndInterestsInJointVentures

10000000000

eur

CY2023Q4

sny

Total Deferred Tax Assets For Tax Loss Carryforwards

TotalDeferredTaxAssetsForTaxLossCarryforwards

2729000000

eur

CY2023Q4

ifrs-full

Unused Tax Losses For Which No Deferred Tax Asset Recognised

UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised

1203000000

eur

CY2023Q4

sny

Unused Capital Losses For Which No Deferred Tax Asset Recognised

UnusedCapitalLossesForWhichNoDeferredTaxAssetRecognised

473000000

eur

CY2022Q4

sny

Total Deferred Tax Assets For Tax Loss Carryforwards

TotalDeferredTaxAssetsForTaxLossCarryforwards

2650000000

eur

CY2022Q4

ifrs-full

Unused Tax Losses For Which No Deferred Tax Asset Recognised

UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised

1144000000

eur

CY2021Q4

sny

Total Deferred Tax Assets For Tax Loss Carryforwards

TotalDeferredTaxAssetsForTaxLossCarryforwards

2391000000

eur

CY2021Q4

ifrs-full

Unused Tax Losses For Which No Deferred Tax Asset Recognised

UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised

875000000

eur

CY2023

sny

Tax Losses Carryforwards

TaxLossesCarryforwards

8933000000

eur

CY2022

sny

Tax Losses Carryforwards

TaxLossesCarryforwards

8503000000

eur

CY2021

sny

Tax Losses Carryforwards

TaxLossesCarryforwards

7644000000

eur

CY2023Q4

sny

Tax Loss Carryforwards On Asset Disposals

TaxLossCarryforwardsOnAssetDisposals

5000000

eur

CY2022Q4

sny

Tax Loss Carryforwards On Asset Disposals

TaxLossCarryforwardsOnAssetDisposals

5000000

eur

CY2021Q4

sny

Tax Loss Carryforwards On Asset Disposals

TaxLossCarryforwardsOnAssetDisposals

5000000

eur

CY2023Q4

sny

Deferred Tax Assets Not Recognized As Future Recovery Not Probable

DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable

1062000000

eur

CY2022Q4

sny

Deferred Tax Assets Not Recognized As Future Recovery Not Probable

DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable

995000000

eur

CY2021Q4

sny

Deferred Tax Assets Not Recognized As Future Recovery Not Probable

DeferredTaxAssetsNotRecognizedAsFutureRecoveryNotProbable

615000000

eur

CY2023

ifrs-full

Disclosure Of Share Capital Reserves And Other Equity Interest Explanatory

DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory

Consolidated shareholders’ equity<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.15.1. Share capital</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of December 31, 2023, the share capital w</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">as €2,529,599,938, consisting of 1,264,799,969 shar</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">es with a par value of €2. Treasury shares held by Sanofi are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:49.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of shares </span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% of share capital <br/>for the period</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;border-top:0.25pt solid #0e32e1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13.45</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;border-top:0.25pt solid #0e32e1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-top:0.25pt solid #0e32e1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.063</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;border-top:0.25pt solid #0e32e1;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="2" style="border-top:0.25pt solid #0e32e1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8.20 </span></td><td style="border-top:0.25pt solid #0e32e1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #0e32e1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.650 </span></td><td style="border-top:0.25pt solid #0e32e1;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11.02 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.872 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">January 1, 2021</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8.28 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.658 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Treasury shares are deducted from shareholders’ equity. Gains and losses on disposals of treasury shares are recorded directly in equity and are not recognized in net income for the period.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements in the share capital of the Sanofi parent company over the last three years are set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:33.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Transaction</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of shares</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,258,971,738</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">During 2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase by exercise of stock subscription options</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">190,076 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">During 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase by issuance of restricted shares</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,836,179 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Board meeting of July 28, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase reserved for employees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,562,702 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,263,560,695</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">During 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase by exercise of stock subscription options</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">490,373 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">During 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase by issuance of restricted shares</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,499,987 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Board meeting of July 27, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase reserved for employees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,027,057 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Board meeting of December 14, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reduction in share capital by cancellation of </span></div><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">treasury shares</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,742,380)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,260,835,732</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">During 2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase by exercise of stock subscription options</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">504,956 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">During 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase by issuance of restricted shares</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,330,558 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Board meeting of July 27, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Capital increase reserved for employees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,128,723 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,264,799,969</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;border-top:0.5pt solid #21004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Shares issued on exercise of Sanofi stock subscription options.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Shares vesting under restricted share plans and issued in the period.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For the disclosures about the management of capital required under IFRS 7, refer to Note B.27.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.15.2. Restricted share plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restricted share plans are accounted for in accordance with the policies described in Note B.24.3. The principal characteristics of those plans are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:38.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Type of plan</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Date of Board meeting approving the plan</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">May 25, 2023</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 13, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">May 3, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 14, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">October 27, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Service period</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total number of shares awarded </span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,838,434 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65,129 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,344,432 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">109,981 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,484,420 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,521 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which with no market condition</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,425,047 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">944 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,000,627 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,335 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,209,901 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€87.69 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€77.42 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€91.19 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€79.17 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€77.27 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which with market condition</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,413,387 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64,185 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,343,805 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99,646 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,274,519 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,521 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded other than to the Chief Executive Officer</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€83.74 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€74.50 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€86.65 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€69.60 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€71.30 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€68.45 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded other than to the Chief Executive Officer - additional shares</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€43.60 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€34.90 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€49.00 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€54.70 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded to the Chief Executive Officer</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€82.17 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€84.46 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€71.30 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value of plan at the date of grant </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">326</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">294</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">262</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) Additional tranche subject to a higher level of market conditions: 121,097 additional shares were awarded in May 2023, and 5,838 additional shares were awarded in December 2023 (versus 114,874 additional shares awarded in May 2022, and 9,066 additional shares awarded in December 2022).</span></div><div style="margin-top:1pt;padding-left:18pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The total expense recognized for all restricted share plans, and the number of restricted shares not yet fully vested, are shown in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:58.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023 (a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022 (a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total expense for restricted share plans </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">193 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of shares not yet fully vested as of December 31</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,773,084 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,245,513 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,507,849 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2023 plans</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,780,513 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2022 plans</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,099,158 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,330,801 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2021 plans</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,893,413 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,097,531 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,364,895 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2020 plans</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,817,181 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,014,496 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Under 2019 plans</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,128,458 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Additional tranche subject to a higher level of market conditions: 126,935 additional shares were awarded in 2023, versus 123,940 additional shares awarded in 2022.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.15.3. Capital increases</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The characteristics of the employee share ownership plans awarded in the form of a capital increase reserved for employees in 2023, 2022 and 2021 are summarized in the table below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:58.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Date of Board meeting approving the plan</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">February 2, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">February 3, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">February 4, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Subscription price </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79.58 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80.21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">69.38 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Subscription period</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 5-23, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 9-29, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June 7-25, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of shares subscribed</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,009,306 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,909,008 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,438,590 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of shares issued immediately as employer’s contribution</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">119,417 </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118,049 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">124,112 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Subscription price representing 80% of the average of the opening quoted market prices of Sanofi shares during the 20 trading days preceding May 31, 2023, June 6, 2022 and June 3, 2021, respectively.</span></div><div style="margin-top:1pt;padding-left:18pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth the expense recognized for each plan:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:58.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expense recognized</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which employer’s contribution</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">11 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">11 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.15.4. Repurchase of Sanofi shares</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Annual General Meetings of Sanofi shareholders held on May 25, 2023, May 3, 2022 and April 30, 2021 each authorized a share repurchase program for a period of 18 months. The following repurchases have been made under those programs:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.185%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:29.25pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(in number of shares and € million)</span></div><div style="padding-right:29.25pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year of authorization</span></div></td><td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number <br/>of shares</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number <br/>of shares</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number <br/>of shares</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023 program</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,584,540 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022 program</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,000,204 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">363 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,510,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021 program</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,976,992 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">360 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,765,388 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">242 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020 program</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,758,569 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">140 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.15.5. Reductions in share capital</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Reductions in share capital for the accounting periods presented are described in the table included at Note D.15.1. above.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Those reductions have no impact on shareholders’ equity.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.15.6. Currency translation differences</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Currency translation differences comprise the following:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Attributable to equity holders of Sanofi</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,499 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(865)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(37)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(42)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(68)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,462</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(907)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The balance as of December 31, 2023 includes an after-tax amount of €(574) million relating to hedges of net investments in foreign operations (refer to Note B.8.3. for a description of the relevant accounting policy), compared with €(580) million as of December 31, 2022 and €(317) million as of December 31, 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The movement in </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Currency translation differences</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is mainly attributable to the US dollar.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.15.7. Other comprehensive income</span></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Movements within other comprehensive income are shown below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Actuarial gains/(losses):</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Actuarial gains/(losses) excluding investments accounted for using the equity method (see Note D.19.1.)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">685 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Actuarial gains/(losses) of investments accounted for using the equity method, net of taxes</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(212)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(36)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments included in financial assets and financial liabilities:</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;padding-right:29.25pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in fair value (excluding investments accounted for using the equity method)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">154 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Equity risk hedging instruments designated as fair value hedges</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Items not subsequently reclassifiable to profit or loss</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(77)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">451</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">797</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Debt instruments included in financial assets:</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in fair value (excluding investments accounted for using the equity method)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(77)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash flow and fair value hedges:</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in fair value (excluding investments accounted for using the equity method)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Change in fair value (investments accounted for using the equity method, net of taxes)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">▪</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:9.29pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Change in currency translation differences:</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Currency translation differences on foreign subsidiaries (excluding investments accounted for using the equity method)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,551)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,643 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,719 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Currency translation differences (investments accounted for using the equity method)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Hedges of net investments in foreign operations</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(354)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(254)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">Tax effects</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Items subsequently reclassifiable to profit or loss</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,526)</span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,313</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,510</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Amounts reclassified to profit or loss: immaterial amount in 2023, immaterial amount in 2022 and €4 million in 2021.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Amounts reclassified to profit or loss: €1 million in 2023, €2 million in 2022 and €12 million in 2021.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) Amounts reclassified to profit or loss: €(56) million in 2023, and €(40) million in 2022 (including €(35) million relating to the deconsolidation of EUROAPI). The amounts reclassified to profit and loss were immaterial in 2021. Currency translation differences arise from the translation into euros of the financial statements of foreign subsidiaries, and are mainly due to the appreciation of the dollar against the euro.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.15.8. Stock options</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock option plans awarded and measurement of stock option plans</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">No stock options were awarded during 2023, 2022 or 2021.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock subscription option plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Details of the terms of exercise of stock subscription options granted under the various plans are presented below in Sanofi share equivalents. These plans were awarded to certain corporate officers and employees of Sanofi companies.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table shows all Sanofi stock subscription option plans still outstanding or under which options were exercised in the year ended December 31, 2023:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:18.961%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Source</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Date of grant</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of<br/>options<br/>granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Start date of<br/>exercise<br/>period</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiry date</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">price </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of options outstanding as of 12/31/2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">03/05/2013</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">788,725 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">03/06/2017</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">03/05/2023</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72.19 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">03/05/2014</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,009,250 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">03/06/2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">03/05/2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73.48 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91,355 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">06/24/2015</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">435,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">06/25/2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">06/24/2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89.38 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">337,714 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/04/2016</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">402,750 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/05/2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/04/2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75.90 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">264,750 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/10/2017</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">378,040 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/11/2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/10/2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88.97 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">257,010 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/02/2018</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/03/2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/02/2028</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65.84 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168,784 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">04/30/2019</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">05/02/2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">04/30/2029</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76.71 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">213,400 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,333,013</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The exercise of all outstanding stock subscription options would increase shareholders’ equity by approximately €107 million. The exercise of each option results in the issuance of one share.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of stock option plans</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">A summary of stock options outstanding at each balance sheet date, and of movements during the relevant periods, is presented below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:58.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of<br/>options</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted average</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">exercise price</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">per share </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Options outstanding at January 1, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,579,270</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">75.61</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">195</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Options exercisable</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,845,050 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">74.51 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">137 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(190,076)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59.53 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Options cancelled</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a) </span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(51,216)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65.84 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50.48 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Options outstanding at December 31, 2021</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,337,968</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">77.13</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">180</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Options exercisable</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,949,184 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">78.15 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">152 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(490,373)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71.39 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(35)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Options cancelled</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a) </span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9,626)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80.56 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Options outstanding at December 31, 2022</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,837,969</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">78.64</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">145</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Options exercisable</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,624,569 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">78.89 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">128 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(504,956)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73.65 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(37)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Options outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,333,013</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">80.53</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">107</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Options exercisable</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,333,013 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">80.53 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">107 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Mainly due to the grantees leaving Sanofi.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below provides summary information about options outstanding and exercisable as of December 31, 2023:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Range of exercise prices per share</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of<br/>options</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">residual life</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(years)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">exercise</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">price per</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">share </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of<br/>options</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">exercise</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">price per</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">share </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From €60.00 to €70.00 per share</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168,784 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.34</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65.84 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168,784 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65.84 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From €70.00 to €80.00 per share</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">569,505 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.12</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75.82 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">569,505 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75.82 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">From €80.00 to €90.00 per share</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">594,724 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.29</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89.20 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">594,724 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89.20 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,333,013</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,333,013</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.15.9. Number of shares used to compute diluted earnings per share</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Diluted earnings per share is computed using the number of shares outstanding plus stock options with dilutive effect and restricted shares.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.991%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of shares outstanding</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,251.7 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,251.9 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,252.5 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustment for stock options with dilutive effect</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustment for restricted shares</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Average number of shares used to compute diluted earnings per share</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,256.4</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,256.9</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,257.9</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023 and 2022, all stock options were taken into account in computing diluted earnings per share because they all had a dilutive effect. In 2021, 0.6 million stock options were not taken into account in computing diluted earnings per share because they had no dilutive effect.</span></div>

CY2023Q4

ifrs-full

Issued Capital

IssuedCapital

2529599938

eur

CY2023Q4

ifrs-full

Number Of Shares Issued

NumberOfSharesIssued

1264799969

shares

CY2023Q4

ifrs-full

Par Value Per Share

ParValuePerShare

2

CY2023

ifrs-full

Disclosure Of Classes Of Share Capital Explanatory

DisclosureOfClassesOfShareCapitalExplanatory

Treasury shares held by Sanofi are as follows:<div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:49.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of shares </span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% of share capital <br/>for the period</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="2" style="background-color:#7802e6;border-top:0.25pt solid #0e32e1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13.45</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;border-top:0.25pt solid #0e32e1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-top:0.25pt solid #0e32e1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.063</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;border-top:0.25pt solid #0e32e1;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="2" style="border-top:0.25pt solid #0e32e1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8.20 </span></td><td style="border-top:0.25pt solid #0e32e1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.25pt solid #0e32e1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.650 </span></td><td style="border-top:0.25pt solid #0e32e1;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11.02 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.872 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">January 1, 2021</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8.28 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.658 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr></table></div>

CY2023Q4

sny

Number Of Shares Held

NumberOfSharesHeld

13450000

shares

CY2023Q4

sny

Percentage Of Share Capital For The Period

PercentageOfShareCapitalForThePeriod

0.01063

CY2022Q4

sny

Number Of Shares Held

NumberOfSharesHeld

8200000

shares

CY2022Q4

sny

Percentage Of Share Capital For The Period

PercentageOfShareCapitalForThePeriod

0.00650

CY2021Q4

sny

Number Of Shares Held

NumberOfSharesHeld

11020000.00

shares

CY2021Q4

sny

Percentage Of Share Capital For The Period

PercentageOfShareCapitalForThePeriod

0.00872

CY2020Q4

sny

Number Of Shares Held

NumberOfSharesHeld

8280000

shares

CY2020Q4

sny

Percentage Of Share Capital For The Period

PercentageOfShareCapitalForThePeriod

0.00658

CY2023

ifrs-full

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement Explanatory

DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory

<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Restricted share plans are accounted for in accordance with the policies described in Note B.24.3. The principal characteristics of those plans are as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:38.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Type of plan</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Performance<br/>share plans</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Date of Board meeting approving the plan</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">May 25, 2023</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 13, 2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">May 3, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 14, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April 30, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">October 27, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Service period</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 years</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total number of shares awarded </span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,838,434 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65,129 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,344,432 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">109,981 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,484,420 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,521 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which with no market condition</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,425,047 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">944 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,000,627 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,335 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,209,901 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€87.69 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€77.42 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€91.19 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€79.17 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€77.27 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Of which with market condition</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,413,387 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64,185 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,343,805 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99,646 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,274,519 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,521 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded other than to the Chief Executive Officer</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€83.74 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€74.50 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€86.65 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€69.60 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€71.30 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€68.45 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded other than to the Chief Executive Officer - additional shares</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€43.60 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€34.90 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€49.00 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€54.70 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value per share awarded to the Chief Executive Officer</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€82.17 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€84.46 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">€71.30 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value of plan at the date of grant </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">326</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">294</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">262</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Weighting between (i) fair value determined using the Monte Carlo model and (ii) market price of Sanofi shares at the date of grant, adjusted for dividends expected during the vesting period.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) Additional tranche subject to a higher level of market conditions: 121,097 additional shares were awarded in May 2023, and 5,838 additional shares were awarded in December 2023 (versus 114,874 additional shares awarded in May 2022, and 9,066 additional shares awarded in December 2022).</span></div>

CY2021

sny

Percentage Of Average Of Quoted Market Prices Of Shares

PercentageOfAverageOfQuotedMarketPricesOfShares

0.80

CY2023

sny

Percentage Of Average Of Quoted Market Prices Of Shares

PercentageOfAverageOfQuotedMarketPricesOfShares

0.80

CY2022

sny

Percentage Of Average Of Quoted Market Prices Of Shares

PercentageOfAverageOfQuotedMarketPricesOfShares

0.80

CY2023

sny

Number Of Trading Days Preceding Plan Approval

NumberOfTradingDaysPrecedingPlanApproval

P20D

CY2022

sny

Number Of Trading Days Preceding Plan Approval

NumberOfTradingDaysPrecedingPlanApproval

P20D

CY2021

sny

Number Of Trading Days Preceding Plan Approval

NumberOfTradingDaysPrecedingPlanApproval

P20D

CY2023

ifrs-full

Additional Information About Sharebased Payment Arrangements

AdditionalInformationAboutSharebasedPaymentArrangements

<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth the expense recognized for each plan:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:58.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expense recognized</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which employer’s contribution</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">11 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">11 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>

CY2023

sny

Hedges Of Net Investments In Foreign Operations After Tax

HedgesOfNetInvestmentsInForeignOperationsAfterTax

574000000

eur

CY2022

sny

Hedges Of Net Investments In Foreign Operations After Tax

HedgesOfNetInvestmentsInForeignOperationsAfterTax

580000000

eur

CY2021

sny

Hedges Of Net Investments In Foreign Operations After Tax

HedgesOfNetInvestmentsInForeignOperationsAfterTax

317000000

eur

CY2023

ifrs-full

Weighted Average Shares

WeightedAverageShares

1251700000

shares

CY2022

ifrs-full

Weighted Average Shares

WeightedAverageShares

1251900000

shares

CY2021

ifrs-full

Weighted Average Shares

WeightedAverageShares

1252500000

shares

CY2023

ifrs-full

Dilutive Effect Of Share Options On Number Of Ordinary Shares

DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares

200000

shares

CY2022

ifrs-full

Dilutive Effect Of Share Options On Number Of Ordinary Shares

DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares

300000

shares

CY2021

ifrs-full

Dilutive Effect Of Share Options On Number Of Ordinary Shares

DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares

300000

shares

CY2023

sny

Dilutive Effect Of Share Options On Number Of Restricted Shares

DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares

4500000

shares

CY2022

sny

Dilutive Effect Of Share Options On Number Of Restricted Shares

DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares

4700000

shares

CY2021

sny

Dilutive Effect Of Share Options On Number Of Restricted Shares

DilutiveEffectOfShareOptionsOnNumberOfRestrictedShares

5100000

shares

CY2023

ifrs-full

Adjusted Weighted Average Shares

AdjustedWeightedAverageShares

1256400000

shares

CY2022

ifrs-full

Adjusted Weighted Average Shares

AdjustedWeightedAverageShares

1256900000

shares

CY2021

ifrs-full

Adjusted Weighted Average Shares

AdjustedWeightedAverageShares

1257900000

shares

CY2021Q4

sny

Stock Options With No Dilutive Effect

StockOptionsWithNoDilutiveEffect

600000

shares

CY2023

ifrs-full

Disclosure Of Noncontrolling Interests Explanatory

DisclosureOfNoncontrollingInterestsExplanatory

Non-controlling interestsNon-controlling interests did not represent a material component of Sanofi’s consolidated financial statements in the years ended December 31, 2023, 2022 and 2021

CY2023Q4

ifrs-full

Longterm Borrowings

LongtermBorrowings

14347000000

eur

CY2022Q4

ifrs-full

Longterm Borrowings

LongtermBorrowings

14857000000

eur

CY2021Q4

ifrs-full

Longterm Borrowings

LongtermBorrowings

17123000000

eur

CY2023Q4

ifrs-full

Current Borrowings And Current Portion Of Noncurrent Borrowings

CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings

2045000000

eur

CY2022Q4

ifrs-full

Current Borrowings And Current Portion Of Noncurrent Borrowings

CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings

4174000000

eur

CY2021Q4

ifrs-full

Current Borrowings And Current Portion Of Noncurrent Borrowings

CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings

3183000000

eur

CY2023Q4

sny

Interest Rate And Currency Derivatives Used To Manage Debt

InterestRateAndCurrencyDerivativesUsedToManageDebt

-139000000

eur

CY2022Q4

sny

Interest Rate And Currency Derivatives Used To Manage Debt

InterestRateAndCurrencyDerivativesUsedToManageDebt

-187000000

eur

CY2021Q4

sny

Interest Rate And Currency Derivatives Used To Manage Debt

InterestRateAndCurrencyDerivativesUsedToManageDebt

56000000

eur

CY2023Q4

ifrs-full

Borrowings

16531000000

eur

CY2022Q4

ifrs-full

Borrowings

19218000000

eur

CY2021Q4

ifrs-full

Borrowings

20250000000

eur

CY2023Q4

ifrs-full

Cash And Cash Equivalents

CashAndCashEquivalents

8710000000

eur

CY2022Q4

ifrs-full

Cash And Cash Equivalents

CashAndCashEquivalents

12736000000

eur

CY2021Q4

ifrs-full

Cash And Cash Equivalents

CashAndCashEquivalents

10098000000

eur

CY2023Q4

sny

Interest Rate And Currency Derivatives Used To Manage Cash And Cash Equivalent

InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent

28000000

eur

CY2022Q4

sny

Interest Rate And Currency Derivatives Used To Manage Cash And Cash Equivalent

InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent

45000000

eur

CY2021Q4

sny

Interest Rate And Currency Derivatives Used To Manage Cash And Cash Equivalent

InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent

169000000

eur

CY2023Q4

sny

Debt Net Of Cash And Cash Equivalents

DebtNetOfCashAndCashEquivalents

7793000000

eur

CY2022Q4

sny

Debt Net Of Cash And Cash Equivalents

DebtNetOfCashAndCashEquivalents

6437000000

eur

CY2021Q4

sny

Debt Net Of Cash And Cash Equivalents

DebtNetOfCashAndCashEquivalents

9983000000

eur

CY2023Q4

ifrs-full

Lease Liabilities

LeaseLiabilities

2030000000

eur

CY2022Q4

ifrs-full

Lease Liabilities

LeaseLiabilities

2181000000

eur

CY2021Q4

ifrs-full

Lease Liabilities

LeaseLiabilities

2108000000

eur

CY2023Q4

ifrs-full

Longterm Borrowings

LongtermBorrowings

14347000000

eur

CY2023Q4

ifrs-full

Current Borrowings And Current Portion Of Noncurrent Borrowings

CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings

2045000000

eur

CY2023Q4

sny

Interest Rate And Currency Derivatives Used To Manage Debt

InterestRateAndCurrencyDerivativesUsedToManageDebt

-139000000

eur

CY2023Q4

ifrs-full

Borrowings

16531000000

eur

CY2023Q4

ifrs-full

Cash And Cash Equivalents

CashAndCashEquivalents

8710000000

eur

CY2023Q4

sny

Interest Rate And Currency Derivatives Used To Manage Cash And Cash Equivalent

InterestRateAndCurrencyDerivativesUsedToManageCashAndCashEquivalent

28000000

eur

CY2023Q4

sny

Debt Net Of Cash And Cash Equivalents

DebtNetOfCashAndCashEquivalents

7793000000

eur

CY2023

ifrs-full

Disclosure Of Detailed Information About Borrowings Explanatory

DisclosureOfDetailedInformationAboutBorrowingsExplanatory

<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the movement in total debt during the period:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:14.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.391%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash flows from<br/>financing activities</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-cash items</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Repayments</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">New<br/>borrowings</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">cash</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">flows </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Currency</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">translation</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">differences</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reclassification</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">from non-current to current</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">items</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,857 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(604)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,347 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,174 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,672)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">903 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">604 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,045 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(69)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,218</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3,684)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">48</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">895</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(22)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">76</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,531</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) These amounts mainly comprise €946 million related to the US commercial paper program.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the Euro zone.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) These amounts mainly comprise changes in accrued interest balances, and fair value adjustments.</span></div><div style="margin-bottom:5pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the movement in total debt during prior periods:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.391%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash flows from<br/>financing activities</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-cash items</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Repayments</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">New<br/>borrowings</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>cash<br/>flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Currency</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">translation</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">differences</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reclassification</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">from non-current to current</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">items</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,123 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,549 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,632)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(228)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,857 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,183 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,707)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,632 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,174 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(373)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">366 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">243 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,250</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,718)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,549</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(330)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">442</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,218</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the Euro zone.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) These amounts include movements in accrued interest and fair value remeasurements.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.391%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash flows from<br/>financing activities</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-cash items</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Repayments</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">New<br/>borrowings</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>cash<br/>flows</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Currency</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">translation</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">differences </span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reclassification</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">from non-current to current</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">items</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,745 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(38)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">124 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,704)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,123 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term debt and current portion of long-term debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,767 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,203)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(615)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">248 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,704 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">282 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,183 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate and currency derivatives used to manage debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">119 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(197)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22,631</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,241)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(812)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">381</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">291</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,250</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) These amounts include gains and losses, and the impact of foreign currency translation of the financial statements of subsidiaries outside the Euro zone.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) These amounts include (i) effects of changes in the scope of consolidation, amounting to €299 million; (ii) movements in accrued interest; and (iii) fair value remeasurements.</span></div>

CY2022Q4

ifrs-full

Borrowings

19218000000

eur

CY2023

ifrs-full

Repayments Of Borrowings Classified As Financing Activities

RepaymentsOfBorrowingsClassifiedAsFinancingActivities

3684000000

eur

CY2023

ifrs-full

Proceeds From Borrowings Classified As Financing Activities

ProceedsFromBorrowingsClassifiedAsFinancingActivities

48000000

eur

CY2023

ifrs-full

Other Inflows Outflows Of Cash Classified As Financing Activities

OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities

895000000

eur

CY2023

sny

Foreign Currency Translation Differences

ForeignCurrencyTranslationDifferences

-22000000

eur

CY2023Q4

sny

Reclassification From Non Current To Current

ReclassificationFromNonCurrentToCurrent

0

eur

CY2023

ifrs-full

Other Adjustments For Noncash Items

OtherAdjustmentsForNoncashItems

76000000

eur

CY2023Q4

ifrs-full

Borrowings

16531000000

eur

CY2023

sny

Number Of Bond Issues Redeemed

NumberOfBondIssuesRedeemed

3

bond

CY2023Q4

sny

Number Of Credit Facilities

NumberOfCreditFacilities

2

credit_facility

CY2023Q4

sny

Number Of Credit Facilities

NumberOfCreditFacilities

2

credit_facility

CY2023Q4

sny

Number Of Sustainable Development Performance Indicators

NumberOfSustainableDevelopmentPerformanceIndicators

2

performance_indicator

CY2021Q4

ifrs-full

Borrowings

20250000000

eur

CY2022

ifrs-full

Repayments Of Borrowings Classified As Financing Activities

RepaymentsOfBorrowingsClassifiedAsFinancingActivities

2718000000

eur

CY2022

ifrs-full

Proceeds From Borrowings Classified As Financing Activities

ProceedsFromBorrowingsClassifiedAsFinancingActivities

1549000000

eur

CY2022

ifrs-full

Other Inflows Outflows Of Cash Classified As Financing Activities

OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities

-330000000

eur

CY2022

sny

Foreign Currency Translation Differences

ForeignCurrencyTranslationDifferences

442000000

eur

CY2022Q4

sny

Reclassification From Non Current To Current

ReclassificationFromNonCurrentToCurrent

7000000

eur

CY2022

ifrs-full

Other Adjustments For Noncash Items

OtherAdjustmentsForNoncashItems

18000000

eur

CY2022Q4

ifrs-full

Borrowings

19218000000

eur

CY2020Q4

ifrs-full

Borrowings

22631000000

eur

CY2021

ifrs-full

Repayments Of Borrowings Classified As Financing Activities

RepaymentsOfBorrowingsClassifiedAsFinancingActivities

2241000000

eur

CY2021

ifrs-full

Proceeds From Borrowings Classified As Financing Activities

ProceedsFromBorrowingsClassifiedAsFinancingActivities

0

eur

CY2021

ifrs-full

Other Inflows Outflows Of Cash Classified As Financing Activities

OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities

-812000000

eur

CY2021

sny

Foreign Currency Translation Differences

ForeignCurrencyTranslationDifferences

381000000

eur

CY2021Q4

sny

Reclassification From Non Current To Current

ReclassificationFromNonCurrentToCurrent

0

eur

CY2021

ifrs-full

Other Adjustments For Noncash Items

OtherAdjustmentsForNoncashItems

291000000

eur

CY2021Q4

ifrs-full

Borrowings

20250000000

eur

CY2021

sny

Increase Decrease Through Change In Scope Of Consolidation Borrowings

IncreaseDecreaseThroughChangeInScopeOfConsolidationBorrowings

299000000

eur

CY2023Q4

sny

Number Of Commercial Paper Programs

NumberOfCommercialPaperPrograms

2

program

CY2023Q4

ifrs-full

Lease Liabilities

LeaseLiabilities

2030000000

eur

CY2022Q4

ifrs-full

Lease Liabilities

LeaseLiabilities

2181000000

eur

CY2021Q4

ifrs-full

Lease Liabilities

LeaseLiabilities

2108000000

eur

CY2023Q4

sny

Number Of Currencies Debt Is Issued In

NumberOfCurrenciesDebtIsIssuedIn

2

currency

CY2023Q4

ifrs-full

Nonderivative Financial Liabilities Undiscounted Cash Flows

NonderivativeFinancialLiabilitiesUndiscountedCashFlows

17710000000

eur

CY2023Q4

sny

Principal Undiscounted Cash Flow

PrincipalUndiscountedCashFlow

16468000000

eur

CY2023Q4

sny

Interest Undiscounted Cash Flow

InterestUndiscountedCashFlow

1242000000

eur

CY2023Q4

ifrs-full

Derivative Financial Liabilities Undiscounted Cash Flows

DerivativeFinancialLiabilitiesUndiscountedCashFlows

143000000

eur

CY2023Q4

sny

Total Undiscounted Cash Flow

TotalUndiscountedCashFlow

17853000000

eur

CY2022Q4

ifrs-full

Nonderivative Financial Liabilities Undiscounted Cash Flows

NonderivativeFinancialLiabilitiesUndiscountedCashFlows

20408000000

eur

CY2022Q4

sny

Principal Undiscounted Cash Flow

PrincipalUndiscountedCashFlow

18932000000

eur

CY2022Q4

sny

Interest Undiscounted Cash Flow

InterestUndiscountedCashFlow

1476000000

eur

CY2022Q4

ifrs-full

Derivative Financial Liabilities Undiscounted Cash Flows

DerivativeFinancialLiabilitiesUndiscountedCashFlows

209000000

eur

CY2022Q4

sny

Total Undiscounted Cash Flow

TotalUndiscountedCashFlow

20617000000

eur

CY2021Q4

ifrs-full

Nonderivative Financial Liabilities Undiscounted Cash Flows

NonderivativeFinancialLiabilitiesUndiscountedCashFlows

21728000000

eur

CY2021Q4

sny

Principal Undiscounted Cash Flow

PrincipalUndiscountedCashFlow

20086000000

eur

CY2021Q4

sny

Interest Undiscounted Cash Flow

InterestUndiscountedCashFlow

1642000000

eur

CY2021Q4

ifrs-full

Derivative Financial Liabilities Undiscounted Cash Flows

DerivativeFinancialLiabilitiesUndiscountedCashFlows

-51000000

eur

CY2021Q4

sny

Total Undiscounted Cash Flow

TotalUndiscountedCashFlow

21677000000

eur

CY2023Q4

ifrs-full

Lease Liabilities

LeaseLiabilities

2030000000

eur

CY2023Q4

sny

Lease Liabilities Effect Of Discounting

LeaseLiabilitiesEffectOfDiscounting

58000000

eur

CY2022Q4

ifrs-full

Lease Liabilities

LeaseLiabilities

2181000000

eur

CY2022Q4

sny

Lease Liabilities Effect Of Discounting

LeaseLiabilitiesEffectOfDiscounting

219000000

eur

CY2021Q4

ifrs-full

Lease Liabilities

LeaseLiabilities

2108000000

eur

CY2021Q4

sny

Lease Liabilities Effect Of Discounting

LeaseLiabilitiesEffectOfDiscounting

228000000

eur

CY2020Q4

ifrs-full

Contingent Liabilities Recognised In Business Combination

ContingentLiabilitiesRecognisedInBusinessCombination

605000000

eur

CY2021

ifrs-full

New Liabilities Contingent Liabilities Recognised In Business Combination

NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination

360000000

eur

CY2021

ifrs-full

Settled Liabilities Contingent Liabilities Recognised In Business Combination

SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination

258000000

eur

CY2021

ifrs-full

Gains Losses Recognised In Profit Or Loss Fair Value Measurement Liabilities

GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities

4000000

eur

CY2021

sny

Increase Decrease Through Other Movements Business Combinations And Non Controlling Interests

IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests

-14000000

eur

CY2021

sny

Increase Decrease Through Net Exchange Differences Business Combinations And Non Controlling Interests

IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests

25000000

eur

CY2021Q4

ifrs-full

Contingent Liabilities Recognised In Business Combination

ContingentLiabilitiesRecognisedInBusinessCombination

714000000

eur

CY2022

ifrs-full

New Liabilities Contingent Liabilities Recognised In Business Combination

NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination

156000000

eur

CY2022

ifrs-full

Settled Liabilities Contingent Liabilities Recognised In Business Combination

SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination

136000000

eur

CY2022

ifrs-full

Gains Losses Recognised In Profit Or Loss Fair Value Measurement Liabilities

GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities

-5000000

eur

CY2022

sny

Increase Decrease Through Other Movements Business Combinations And Non Controlling Interests

IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests

0

eur

CY2022

sny

Increase Decrease Through Net Exchange Differences Business Combinations And Non Controlling Interests

IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests

40000000

eur

CY2022Q4

ifrs-full

Contingent Liabilities Recognised In Business Combination

ContingentLiabilitiesRecognisedInBusinessCombination

779000000

eur

CY2023

ifrs-full

New Liabilities Contingent Liabilities Recognised In Business Combination

NewLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination

0

eur

CY2023

ifrs-full

Settled Liabilities Contingent Liabilities Recognised In Business Combination

SettledLiabilitiesContingentLiabilitiesRecognisedInBusinessCombination

167000000

eur

CY2023

ifrs-full

Gains Losses Recognised In Profit Or Loss Fair Value Measurement Liabilities

GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities

-114000000

eur

CY2023

sny

Increase Decrease Through Other Movements Business Combinations And Non Controlling Interests

IncreaseDecreaseThroughOtherMovementsBusinessCombinationsAndNonControllingInterests

0

eur

CY2023

sny

Increase Decrease Through Net Exchange Differences Business Combinations And Non Controlling Interests

IncreaseDecreaseThroughNetExchangeDifferencesBusinessCombinationsAndNonControllingInterests

-17000000

eur

CY2023Q4

ifrs-full

Contingent Liabilities Recognised In Business Combination

ContingentLiabilitiesRecognisedInBusinessCombination

709000000

eur

CY2023Q4

sny

Non Current Liabilities Related To Business Combinations And To Non Controlling Interests

NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests

501000000

eur

CY2022Q4

sny

Non Current Liabilities Related To Business Combinations And To Non Controlling Interests

NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests

674000000

eur

CY2021Q4

sny

Non Current Liabilities Related To Business Combinations And To Non Controlling Interests

NonCurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests

577000000

eur

CY2023Q4

sny

Current Liabilities Related To Business Combinations And To Non Controlling Interests

CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests

208000000

eur

CY2022Q4

sny

Current Liabilities Related To Business Combinations And To Non Controlling Interests

CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests

105000000

eur

CY2021Q4

sny

Current Liabilities Related To Business Combinations And To Non Controlling Interests

CurrentLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterests

137000000

eur

CY2023Q4

sny

Commitments Relating To Contingent Consideration In Connection With Business Combinations

CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations

133000000

eur

CY2022Q4

sny

Commitments Relating To Contingent Consideration In Connection With Business Combinations

CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations

604000000

eur

CY2021Q4

sny

Commitments Relating To Contingent Consideration In Connection With Business Combinations

CommitmentsRelatingToContingentConsiderationInConnectionWithBusinessCombinations

689000000

eur

CY2023Q4

ifrs-full

Noncurrent Provisions

NoncurrentProvisions

5262000000

eur

CY2022Q4

ifrs-full

Noncurrent Provisions

NoncurrentProvisions

5822000000

eur

CY2021Q4

ifrs-full

Noncurrent Provisions

NoncurrentProvisions

6430000000

eur

CY2023Q4

ifrs-full

Other Noncurrent Liabilities

OtherNoncurrentLiabilities

2340000000

eur

CY2022Q4

ifrs-full

Other Noncurrent Liabilities

OtherNoncurrentLiabilities

519000000

eur

CY2021Q4

ifrs-full

Other Noncurrent Liabilities

OtherNoncurrentLiabilities

291000000

eur

CY2023Q4

sny

Non Current Provisions And Other Non Current Liabilities

NonCurrentProvisionsAndOtherNonCurrentLiabilities

7602000000

eur

CY2022Q4

sny

Non Current Provisions And Other Non Current Liabilities

NonCurrentProvisionsAndOtherNonCurrentLiabilities

6341000000

eur

CY2021Q4

sny

Non Current Provisions And Other Non Current Liabilities

NonCurrentProvisionsAndOtherNonCurrentLiabilities

6721000000

eur

CY2023Q4

ifrs-full

Noncurrent Derivative Financial Liabilities

NoncurrentDerivativeFinancialLiabilities

164000000

eur

CY2022Q4

ifrs-full

Noncurrent Derivative Financial Liabilities

NoncurrentDerivativeFinancialLiabilities

232000000

eur

CY2021Q4

ifrs-full

Noncurrent Derivative Financial Liabilities

NoncurrentDerivativeFinancialLiabilities

6000000

eur

CY2020Q4

ifrs-full

Noncurrent Provisions

NoncurrentProvisions

6998000000

eur

CY2021

sny

Increase Decrease Through Changes In Scope Of Consolidation Other Provisions

IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions

35000000

eur

CY2021

ifrs-full

Changes In Other Provisions

ChangesInOtherProvisions

731000000

eur

CY2021

ifrs-full

Provision Used Other Provisions

ProvisionUsedOtherProvisions

459000000

eur

CY2021

sny

Increase Decrease Of Unused Provision Reversed Other Provisions

IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions

200000000

eur

CY2021

ifrs-full

Increase Decrease Through Transfers And Other Changes Other Provisions

IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions

-425000000

eur

CY2021

sny

Net Interest Related To Employees Benefits And Unwinding Of Discount

NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount

53000000

eur

CY2021

ifrs-full

Increase Decrease Through Net Exchange Differences Other Provisions

IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions

145000000

eur

CY2021

sny

Actuarial Gains And Losses On Defined Benefit Plans

ActuarialGainsAndLossesOnDefinedBenefitPlans

-448000000

eur

CY2021Q4

ifrs-full

Noncurrent Provisions

NoncurrentProvisions

6430000000

eur

CY2022

sny

Increase Decrease Through Changes In Scope Of Consolidation Other Provisions

IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions

-200000000

eur

CY2022

ifrs-full

Changes In Other Provisions

ChangesInOtherProvisions

1285000000

eur

CY2022

ifrs-full

Provision Used Other Provisions

ProvisionUsedOtherProvisions

528000000

eur

CY2022

sny

Increase Decrease Of Unused Provision Reversed Other Provisions

IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions

288000000

eur

CY2022

ifrs-full

Increase Decrease Through Transfers And Other Changes Other Provisions

IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions

-274000000

eur

CY2022

sny

Net Interest Related To Employees Benefits And Unwinding Of Discount

NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount

64000000

eur

CY2022

ifrs-full

Increase Decrease Through Net Exchange Differences Other Provisions

IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions

113000000

eur

CY2022

sny

Actuarial Gains And Losses On Defined Benefit Plans

ActuarialGainsAndLossesOnDefinedBenefitPlans

-780000000

eur

CY2022Q4

ifrs-full

Noncurrent Provisions

NoncurrentProvisions

5822000000

eur

CY2023

sny

Increase Decrease Through Changes In Scope Of Consolidation Other Provisions

IncreaseDecreaseThroughChangesInScopeOfConsolidationOtherProvisions

0

eur

CY2023

ifrs-full

Changes In Other Provisions

ChangesInOtherProvisions

952000000

eur

CY2023

ifrs-full

Provision Used Other Provisions

ProvisionUsedOtherProvisions

408000000

eur

CY2023

sny

Increase Decrease Of Unused Provision Reversed Other Provisions

IncreaseDecreaseOfUnusedProvisionReversedOtherProvisions

758000000

eur

CY2023

ifrs-full

Increase Decrease Through Transfers And Other Changes Other Provisions

IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions

-572000000

eur

CY2023

sny

Net Interest Related To Employees Benefits And Unwinding Of Discount

NetInterestRelatedToEmployeesBenefitsAndUnwindingOfDiscount

120000000

eur

CY2023

ifrs-full

Increase Decrease Through Net Exchange Differences Other Provisions

IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions

-65000000

eur

CY2023

sny

Actuarial Gains And Losses On Defined Benefit Plans

ActuarialGainsAndLossesOnDefinedBenefitPlans

171000000

eur

CY2023Q4

ifrs-full

Noncurrent Provisions

NoncurrentProvisions

5262000000

eur

CY2023

sny

Number Of Countries Included In Pension Plans

NumberOfCountriesIncludedInPensionPlans

4

country

CY2023Q4

sny

Pension Obligation Percentage To Defined Benefit Liability

PensionObligationPercentageToDefinedBenefitLiability

0.89

CY2023Q4

sny

Pension Obligation Percentage To Plan Assets

PensionObligationPercentageToPlanAssets

0.88

CY2023

ifrs-full

Weighted Average Duration Of Defined Benefit Obligation2019

WeightedAverageDurationOfDefinedBenefitObligation2019

P10Y

CY2023

ifrs-full

Disclosure Of Sensitivity Analysis For Actuarial Assumptions Explanatory

DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory

<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the sensitivity of Sanofi’s obligations for pensions and other post-employment benefits to changes in key actuarial assumptions:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:37.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pensions and other post-employment benefits, <br/>by principal country</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Measurement of defined-benefit obligation</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Change in<br/>assumption</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Germany</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">US</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">UK</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">-0.50 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+56 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+170 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+78 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+42 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">General inflation rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+0.50 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+40 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+220 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+43 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pension benefit indexation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+0.50 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+41 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+216 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+20 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Healthcare cost inflation rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+0.50 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+43 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortality table</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">+1 year</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+38 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+53 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+25 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">+19 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div>

CY2023

ifrs-full

Disclosure Of Fair Value Of Plan Assets Explanatory

DisclosureOfFairValueOfPlanAssetsExplanatory

<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the fair value of plan assets relating to Sanofi’s pension and other post-employment plans, split by asset category:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Securities quoted in an active market</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">84.9</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">84.4</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">86.9</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.7 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.7 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity instruments</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22.3 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bonds and similar instruments</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54.3 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Commodities</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other securities</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15.1</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15.6</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13.1</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hedge funds</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Insurance policies</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15.1 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100.0</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100.0</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100.0</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr></table></div>

CY2023Q4

sny

Percentage Contributed To Fair Value Of Plan Assets Securities Quoted In An Active Market

PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket

0.849

CY2022Q4

sny

Percentage Contributed To Fair Value Of Plan Assets Securities Quoted In An Active Market

PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket

0.844

CY2021Q4

sny

Percentage Contributed To Fair Value Of Plan Assets Securities Quoted In An Active Market

PercentageContributedToFairValueOfPlanAssetsSecuritiesQuotedInAnActiveMarket

0.869

CY2023Q4

sny

Percentage Contributed To Fair Value Of Plan Assets Other Securities

PercentageContributedToFairValueOfPlanAssetsOtherSecurities

0.151

CY2022Q4

sny

Percentage Contributed To Fair Value Of Plan Assets Other Securities

PercentageContributedToFairValueOfPlanAssetsOtherSecurities

0.156

CY2021Q4

sny

Percentage Contributed To Fair Value Of Plan Assets Other Securities

PercentageContributedToFairValueOfPlanAssetsOtherSecurities

0.131

CY2023Q4

sny

Percentage Contributed To Fair Value Of Plan Assets

PercentageContributedToFairValueOfPlanAssets

1.000

CY2022Q4

sny

Percentage Contributed To Fair Value Of Plan Assets

PercentageContributedToFairValueOfPlanAssets

1.000

CY2021Q4

sny

Percentage Contributed To Fair Value Of Plan Assets

PercentageContributedToFairValueOfPlanAssets

1.000

CY2023

sny

Net Pretax Actuarial Loss Excluding Associates And Joint Ventures Recognized Directly In Equity

NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity

-2259000000

eur

CY2022

sny

Net Pretax Actuarial Loss Excluding Associates And Joint Ventures Recognized Directly In Equity

NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity

-2090000000

eur

CY2021

sny

Net Pretax Actuarial Loss Excluding Associates And Joint Ventures Recognized Directly In Equity

NetPretaxActuarialLossExcludingAssociatesAndJointVenturesRecognizedDirectlyInEquity

-2738000000

eur

CY2023

sny

Expected Timing Of Payments In Respect Of Unfunded Pension And Other Post Employment Benefit Plans

ExpectedTimingOfPaymentsInRespectOfUnfundedPensionAndOtherPostEmploymentBenefitPlans

1238000000

eur

CY2023Q4

ifrs-full

Defined Benefit Obligation At Present Value

DefinedBenefitObligationAtPresentValue

968000000

eur

CY2022Q4

ifrs-full

Defined Benefit Obligation At Present Value

DefinedBenefitObligationAtPresentValue

1039000000

eur

CY2021Q4

ifrs-full

Defined Benefit Obligation At Present Value

DefinedBenefitObligationAtPresentValue

943000000

eur

CY2023

sny

Average Residual Holding Periods Under Various Early Retirement Plans

AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans

P2Y2M19D

CY2022

sny

Average Residual Holding Periods Under Various Early Retirement Plans

AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans

P2Y7M6D

CY2021

sny

Average Residual Holding Periods Under Various Early Retirement Plans

AverageResidualHoldingPeriodsUnderVariousEarlyRetirementPlans

P1Y11M8D

CY2023Q4

ifrs-full

Defined Benefit Obligation At Present Value

DefinedBenefitObligationAtPresentValue

968000000

eur

CY2022Q4

ifrs-full

Defined Benefit Obligation At Present Value

DefinedBenefitObligationAtPresentValue

1039000000

eur

CY2021Q4

ifrs-full

Defined Benefit Obligation At Present Value

DefinedBenefitObligationAtPresentValue

943000000

eur

CY2023Q4

sny

Non Current Provision For Environment Risks

NonCurrentProvisionForEnvironmentRisks

493000000

eur

CY2022Q4

sny

Non Current Provision For Environment Risks

NonCurrentProvisionForEnvironmentRisks

526000000

eur

CY2021Q4

sny

Non Current Provision For Environment Risks

NonCurrentProvisionForEnvironmentRisks

650000000

eur

CY2023Q4

sny

Non Current Provision For Product Liability Risks Litigation And Other

NonCurrentProvisionForProductLiabilityRisksLitigationAndOther

1283000000

eur

CY2022Q4

sny

Non Current Provision For Product Liability Risks Litigation And Other

NonCurrentProvisionForProductLiabilityRisksLitigationAndOther

1652000000

eur

CY2021Q4

sny

Non Current Provision For Product Liability Risks Litigation And Other

NonCurrentProvisionForProductLiabilityRisksLitigationAndOther

1374000000

eur

CY2023Q4

ifrs-full

Other Longterm Provisions

OtherLongtermProvisions

1776000000

eur

CY2022Q4

ifrs-full

Other Longterm Provisions

OtherLongtermProvisions

2178000000

eur

CY2021Q4

ifrs-full

Other Longterm Provisions

OtherLongtermProvisions

2024000000

eur

CY2023Q4

sny

Inventory Total Quotas Held

InventoryTotalQuotasHeld

3000000

eur

CY2023Q4

ifrs-full

Current Tax Liabilities Noncurrent

CurrentTaxLiabilitiesNoncurrent

1842000000

eur

CY2022Q4

ifrs-full

Current Tax Liabilities Noncurrent

CurrentTaxLiabilitiesNoncurrent

1979000000

eur

CY2021Q4

ifrs-full

Current Tax Liabilities Noncurrent

CurrentTaxLiabilitiesNoncurrent

2039000000

eur

CY2018

sny

Liability Recognized Representing Estimated Cost

LiabilityRecognizedRepresentingEstimatedCost

1092000000

usd

CY2023

sny

Tax Charge On Deemed Repatriation Attributable To Accumulated Earnings Payable Period

TaxChargeOnDeemedRepatriationAttributableToAccumulatedEarningsPayablePeriod

P8Y

CY2023Q4

ifrs-full

Current Payables On Social Security And Taxes Other Than Income Tax

CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax

395000000

eur

CY2022Q4

ifrs-full

Current Payables On Social Security And Taxes Other Than Income Tax

CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax

420000000

eur

CY2021Q4

ifrs-full

Current Payables On Social Security And Taxes Other Than Income Tax

CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax

428000000

eur

CY2023Q4

ifrs-full

Shortterm Employee Benefits Accruals

ShorttermEmployeeBenefitsAccruals

2106000000

eur

CY2022Q4

ifrs-full

Shortterm Employee Benefits Accruals

ShorttermEmployeeBenefitsAccruals

2158000000

eur

CY2021Q4

ifrs-full

Shortterm Employee Benefits Accruals

ShorttermEmployeeBenefitsAccruals

2126000000

eur

CY2023Q4

ifrs-full

Shortterm Restructuring Provision

ShorttermRestructuringProvision

578000000

eur

CY2022Q4

ifrs-full

Shortterm Restructuring Provision

ShorttermRestructuringProvision

472000000

eur

CY2021Q4

ifrs-full

Shortterm Restructuring Provision

ShorttermRestructuringProvision

594000000

eur

CY2023Q4

sny

Current Interest Rate Derivatives Payable

CurrentInterestRateDerivativesPayable

1000000

eur

CY2022Q4

sny

Current Interest Rate Derivatives Payable

CurrentInterestRateDerivativesPayable

0

eur

CY2021Q4

sny

Current Interest Rate Derivatives Payable

CurrentInterestRateDerivativesPayable

1000000

eur

CY2023Q4

sny

Current Currency Derivatives Payable

CurrentCurrencyDerivativesPayable

126000000

eur

CY2022Q4

sny

Current Currency Derivatives Payable

CurrentCurrencyDerivativesPayable

94000000

eur

CY2021Q4

sny

Current Currency Derivatives Payable

CurrentCurrencyDerivativesPayable

62000000

eur

CY2023Q4

sny

Current Equity Derivatives Payable

CurrentEquityDerivativesPayable

0

eur

CY2022Q4

sny

Current Equity Derivatives Payable

CurrentEquityDerivativesPayable

0

eur

CY2021Q4

sny

Current Equity Derivatives Payable

CurrentEquityDerivativesPayable

16000000

eur

CY2023Q4

sny

Amounts Payable For Acquisition Of Non Current Assets

AmountsPayableForAcquisitionOfNonCurrentAssets

945000000

eur

CY2022Q4

sny

Amounts Payable For Acquisition Of Non Current Assets

AmountsPayableForAcquisitionOfNonCurrentAssets

714000000

eur

CY2021Q4

sny

Amounts Payable For Acquisition Of Non Current Assets

AmountsPayableForAcquisitionOfNonCurrentAssets

559000000

eur

CY2023Q4

ifrs-full

Current Contract Liabilities

CurrentContractLiabilities

0

eur

CY2022Q4

ifrs-full

Current Contract Liabilities

CurrentContractLiabilities

269000000

eur

CY2021Q4

ifrs-full

Current Contract Liabilities

CurrentContractLiabilities

321000000

eur

CY2023Q4

ifrs-full

Other Current Liabilities

OtherCurrentLiabilities

9590000000

eur

CY2022Q4

ifrs-full

Other Current Liabilities

OtherCurrentLiabilities

7894000000

eur

CY2021Q4

ifrs-full

Other Current Liabilities

OtherCurrentLiabilities

7110000000

eur

CY2023Q4

sny

Current Provisions And Other Current Liabilities

CurrentProvisionsAndOtherCurrentLiabilities

13741000000

eur

CY2022Q4

sny

Current Provisions And Other Current Liabilities

CurrentProvisionsAndOtherCurrentLiabilities

12021000000

eur

CY2021Q4

sny

Current Provisions And Other Current Liabilities

CurrentProvisionsAndOtherCurrentLiabilities

11217000000

eur

CY2023

ifrs-full

Disclosure Of Derivative Financial Instruments Explanatory

DisclosureOfDerivativeFinancialInstrumentsExplanatory

Derivative financial instruments and market risks<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the fair value of derivative instruments as of December 31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.153%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current</span></div><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">assets</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current<br/>assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current<br/>liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Current<br/>liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>liabilities</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market value at December 31, 2023 (net)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market value at December 31, 2022 (net)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Market value at December 31, 2021 (net)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Currency derivatives</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(126)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(126)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">222 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">operating</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">financial</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(81)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(81)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">212 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate derivatives</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(164)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(165)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(232)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity derivatives</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(16)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">201</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">201</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(164)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(127)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(291)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(90)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">( 120)</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">213</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Objectives of the use of derivative financial instruments</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi uses derivative instruments to manage operating exposure to movements in exchange rates, and financial exposure to movements in interest rates and exchange rates (where the debt or receivable is not contracted in the functional currency of the borrower or lender entity). On occasion, Sanofi uses equity derivatives in connection with the management of its portfolio of equity investments.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi performs periodic reviews of its transactions and contractual agreements in order to identify any embedded derivatives, which are accounted for separately from the host contract in accordance with IFRS 9. Sanofi had no material embedded derivatives as of December 31, 2023, 2022 or 2021.</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Counterparty risk</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For a description of counterparty risk, refer to “Item 11. — Quantitative and Qualitative Disclosures about Market Risk”.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">a) Currency derivatives used to manage operating risk exposures</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For a description of Sanofi’s objectives, policies and procedures for the management of operating foreign exchange risk, refer to “Item 11. — Quantitative and Qualitative Disclosures about Market Risk”.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows operating currency hedging instruments in place as of December 31, 2023, with the notional amount translated into euros at the relevant closing exchange rate:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.615%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.615%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.982%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which derivatives designated as<br/>cash flow hedges</span></td><td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which derivatives not<br/>eligible for hedge accounting</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which<br/>recognized in equity</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,112</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">30</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,112</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">30</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,981 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,981 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">788 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">788 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">419 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">419 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Japanese yen</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">339 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">339 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Korean won</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,246</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,246</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,022 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,022 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">876 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">876 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">364 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">364 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Korean won</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Japanese yen</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,358</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,358</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows operating currency hedging instruments in place as of December 31, 2022, with the notional amount translated into euros at the relevant closing exchange rate:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.354%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which derivatives designated as<br/>cash flow hedges</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which derivatives not<br/>eligible for hedge accounting</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which<br/>recognized in equity</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,403</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">49</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,403</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">49</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,732 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">56 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,732 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">56 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">576 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">576 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Japanese yen</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">240 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">240 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">180 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">180 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Korean won</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">179 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">179 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,459</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(27)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,459</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(27)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,047 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(21)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,047 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(21)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">375 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">375 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">142 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">142 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Korean won</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">130 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">130 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Taiwan dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">84 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">84 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,862</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,862</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows operating currency hedging instruments in place as of December 31, 2021, with the notional amount translated into euros at the relevant closing exchange rate:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:20.339%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.921%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which derivatives<br/>designated as cash flow hedges</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which derivatives not</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">eligible for hedge accounting </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which<br/>recognized<br/>in equity</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,912</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">–</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">–</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">–</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,912</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,392 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">5 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,392 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">5 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">665 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">665 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">355 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">355 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Japanese yen</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">199 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">199 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Taiwan dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">122 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">122 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,374</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">–</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">–</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">–</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,374</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">833 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(2)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">833 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(2)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">696 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">696 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">255 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">255 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Hungarian forint</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">77 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">77 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Russian rouble</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">72 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">–</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">72 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,286</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">–</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">–</span></td><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">–</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,286</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">b) Currency and interest rate derivatives used to manage financial exposure</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For a description of Sanofi’s objectives, policies and procedures for the management of financial foreign exchange risk and interest rate risk, refer to “Item 11. — Quantitative and Qualitative Disclosures about Market Risk”.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows financial currency hedging instruments in place, with the notional amount translated into euros at the relevant closing exchange rate:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:22.942%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.187%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiry</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiry</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiry</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,279</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">111</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,559</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">66</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,655</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">6,628 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(a)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">6,114 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">59 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">5,384 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">23 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,556 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Chinese yuan renminbi</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">513 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">203 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">70 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forward currency purchases</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,055</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(58)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,997</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,293</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">197</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which US dollar</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3,073 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(b) (c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,011 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(4)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">4,816 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">128 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Singapore dollar</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,696 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,154 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">22 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2,910 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">75 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which Japanese yen</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">205 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">235 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,334</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">53</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,556</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">90</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,948</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">212</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#7802e6;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Includes forward sales with a notional amount of $3,615 million expiring in 2024, designated as a hedge of Sanofi’s net investment in Bioverativ. As of December 31, 2023, the fair value of these forward contracts represented an asset of €54 million; the opposite entry was recognized in "Other comprehensive income", with the impact on financial income and expense being immaterial.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.25pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Includes forward purchases with a notional amount of $1,000 million expiring in 2024, designated as a fair value hedge of the exposure of $1,000 million of bond issues to fluctuations in the EUR/USD spot rate. As of December 31, 2023, the fair value of the contracts was a liability of €31 million, the opposite entry for €2.7 million of which was credited to “Other comprehensive income” under the cost of hedging accounting treatment.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) Includes forward purchases with a notional amount of $1,044 million expiring in 2024, designated as a fair value hedge of the exposure of an equivalent amount of commercial paper. As of December 31, 2023, the fair value of the swaps was a liability of €3 million, the opposite entry for €0.7 million of which was credited to “Other comprehensive income” under the cost of hedging accounting treatment.</span></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows interest rate hedging instruments in place as of December 31, 2023:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:17.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#e3e3e3;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amounts by expiry date as of December 31, 2023</span></td><td colspan="3" style="background-color:#e3e3e3;padding:0 1pt"></td><td colspan="6" style="background-color:#e3e3e3;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">designated as</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">fair value hedges</span></div></td><td colspan="9" style="background-color:#e3e3e3;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which designated as<br/>cash flow hedges</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2029 and later</span></div></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which<br/>recognized<br/>in equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e3e3e3;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized SOFR USD/receive 1.03%</span></div></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">453 </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">453 </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">453 </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized SOFR USD/receive 1.32%</span></div></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">453 </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">453 </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">453 </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester/receive 0.69%</span></div></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850 </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850 </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850 </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester/receive 0.92%</span></div></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester / receive 3.43%</span></div></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">999 </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">999 </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">999 </span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e3e3e3;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e3e3e3;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#e3e3e3;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">999</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">850</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">906</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">650</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,405</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(165)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,405</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(165)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows interest rate hedging instruments in place as of December 31, 2022:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:17.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amounts by expiry date as of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">designated as</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">fair value hedges</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which designated as<br/>cash flow hedges</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2028 and later</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which<br/>recognized<br/>in equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate swaps</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized SOFR USD/receive 1.03%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(62)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(62)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized SOFR USD/receive 1.32%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester/receive 0.69%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(43)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">850 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(43)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized Ester/receive 0.92%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(71)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(71)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">850</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,584</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,434</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(232)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,434</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(232)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows interest rate hedging instruments in place as of December 31, 2021:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:17.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional amounts by expiry date as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">designated as</span></div><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">fair value hedges</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which designated as<br/>cash flow hedges</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2027 and later</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Notional<br/>amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>value</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Of which<br/>recognized<br/>in equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized EONIA/receive 0.06%</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay -0.57%/receive capitalized EONIA</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">600 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">600 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">600 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized USD SOFR/receive 1.03% </span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">440 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">440 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">440 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">pay capitalized USD SOFR/receive 1.32% </span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">440 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">440 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">440 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">receive capitalized Eonia/pay 1.48%</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,642</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">57</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">880</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,579</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,979</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">600</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) These interest rate swaps hedge fixed-rate bonds with a nominal of €99 million held in a Professional Specialized Investment Fund dedicated to Sanofi and recognized within “Long-term loans and advances and other non-current receivables” (see Note D.7.).</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Sanofi Serif',serif;font-size:10pt;font-weight:400;line-height:120%">c) Actual or potential effects of netting arrangements</span></div><div style="margin-bottom:11pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below is prepared in accordance with the accounting policies described in Note B.8.3.:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:31.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.081%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="6" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:26pt"><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivative<br/>financial<br/>assets</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivative<br/>financial<br/>liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivative<br/>financial<br/>assets</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivative<br/>financial<br/>liabilities</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivative<br/>financial<br/>assets</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Derivative<br/>financial<br/>liabilities</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross carrying amounts before offset (a)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">201 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(291)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(326)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">298 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(85)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross amounts offset (in accordance with IAS 32) (b)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net amounts as reported in the balance sheet (a) - (b) = (c)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">201</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(291)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">206</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(326)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">298</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(85)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effects of other netting arrangements (not fulfilling the IAS 32 criteria for offsetting) (d)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial instruments</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(160)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">160 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(67)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value of financial collateral</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net exposure (c) + (d)</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">30</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(120)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">46</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(166)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">231</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(18)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>

CY2023Q4

ifrs-full

Noncurrent Derivative Financial Assets

NoncurrentDerivativeFinancialAssets

0

eur

CY2023Q4

ifrs-full

Current Derivative Financial Assets

CurrentDerivativeFinancialAssets

201000000

eur

CY2023Q4

ifrs-full

Derivative Financial Assets

DerivativeFinancialAssets

201000000

eur

CY2023Q4

ifrs-full

Noncurrent Derivative Financial Liabilities

NoncurrentDerivativeFinancialLiabilities

164000000

eur

CY2023Q4

ifrs-full

Current Derivative Financial Liabilities

CurrentDerivativeFinancialLiabilities

127000000

eur

CY2023Q4

ifrs-full

Derivative Financial Liabilities

DerivativeFinancialLiabilities

291000000

eur

CY2023Q4

ifrs-full

Financial Instruments Designated As Hedging Instruments At Fair Value

FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue

-90000000

eur

CY2022Q4

ifrs-full

Financial Instruments Designated As Hedging Instruments At Fair Value

FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue

-120000000

eur

CY2021Q4

ifrs-full

Financial Instruments Designated As Hedging Instruments At Fair Value

FinancialInstrumentsDesignatedAsHedgingInstrumentsAtFairValue

213000000

eur

CY2023Q4

sny

Short Term Leases Low Value Asset Leases And Lease Contracts Committed But Not Started Yet

ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet

221000000

eur

CY2023Q4

sny

Irrevocable Purchase Commitments Given

IrrevocablePurchaseCommitmentsGiven

6141000000

eur

CY2023Q4

sny

Irrevocable Purchase Commitments Received

IrrevocablePurchaseCommitmentsReceived

550000000

eur

CY2023Q4

sny

Commitments Related To Research And Development License Agreements Other Commitments

CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments

381000000

eur

CY2023Q4

sny

CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress

4886000000

eur

CY2023Q4

sny

Total Off Balance Sheet Commitments

TotalOffBalanceSheetCommitments

11079000000

eur

CY2022Q4

sny

Short Term Leases Low Value Asset Leases And Lease Contracts Committed But Not Started Yet

ShortTermLeasesLowValueAssetLeasesAndLeaseContractsCommittedButNotStartedYet

38000000

eur

CY2023

sny

Lease Term

LeaseTerm

P15Y

sny

Lease Costs

LeaseCosts

200000000

usd

sny

Lease Extension Options Number

LeaseExtensionOptionsNumber

2

extension

sny

Lease Extension Options Term

LeaseExtensionOptionsTerm

P5Y

CY2022Q4

sny

Commitments Related To Research And Development License Agreements Other Commitments

CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsOtherCommitments

259000000

eur

CY2022Q4

sny

CommitmentsRelatedToResearchAndDevelopmentLicenseAgreementsContingentMilestonePaymentsInConnectionWithDevelopmentProgramsInProgress

2919000000

eur

CY2023Q4

sny

Commitments Related To Research And Development Relating To Projects In Research Phase

CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase

16800000000

eur

CY2022Q4

sny

Commitments Related To Research And Development Relating To Projects In Research Phase

CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase

18000000000

eur

CY2023Q4

sny

Commitments Related To Research And Development Payments Contingent Upon Attainment Of Sales Targets

CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets

17900000000

eur

CY2022Q4

sny

Commitments Related To Research And Development Payments Contingent Upon Attainment Of Sales Targets

CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets

18500000000

eur

CY2023Q4

sny

Commitments Related To Collaboration Discovery Development And Commercialization Agreements

CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements

10000000000

eur

CY2022Q4

sny

Commitments Related To Collaboration Discovery Development And Commercialization Agreements

CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements

8800000000

eur

CY2023Q4

sny

Commitments Related To Attainment Of Regulatory And Sales Milestones For Commercialized Products

CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts

8500000000

eur

CY2022Q4

sny

Commitments Related To Attainment Of Regulatory And Sales Milestones For Commercialized Products

CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts

7600000000

eur

CY2023Q4

sny

Cumulative Development Costs Incurred

CumulativeDevelopmentCostsIncurred

8600000000

eur

CY2023Q4

ifrs-full

Undrawn Borrowing Facilities

UndrawnBorrowingFacilities

8000000000

eur

CY2023Q4

ifrs-full

Undrawn Borrowing Facilities

UndrawnBorrowingFacilities

8000000000

eur

CY2022Q4

ifrs-full

Undrawn Borrowing Facilities

UndrawnBorrowingFacilities

8000000000

eur

CY2021Q4

ifrs-full

Undrawn Borrowing Facilities

UndrawnBorrowingFacilities

8000000000

eur

CY2022Q4

sny

Off Balance Sheet Commitments Received In Respect Of Disposals Proceeds Receivable And Contingent Consideration On Divestments

OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments

300000000

usd

CY2023Q4

sny

Non Current Provision For Product Liability Risks Litigation And Other

NonCurrentProvisionForProductLiabilityRisksLitigationAndOther

1283000000

eur

CY2023Q4

sny

Non Current Provision For Environment Risks

NonCurrentProvisionForEnvironmentRisks

493000000

eur

CY2020Q4

sny

Provisions For Discounts Rebates And Sales Returns

ProvisionsForDiscountsRebatesAndSalesReturns

6039000000

eur

CY2021

sny

Increase Decrease Through Changes In Scope Of Consolidation In Provision For Discounts Rebates And Sales Returns

IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns

2000000

eur

CY2021

sny

Increase Through New Provision Related To Current Period Sales

IncreaseThroughNewProvisionRelatedToCurrentPeriodSales

19714000000

eur

CY2021

sny

Increase Decrease In Provisions Related To Prior Period Sales

IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales

-242000000

eur

CY2021

sny

Decrease Through Payments Made Provisions For Discounts Rebates And Sales Returns

DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns

19461000000

eur

CY2021

sny

Increase Decrease Through Net Exchange Differences Provisions For Discounts Rebates And Sales Returns

IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns

-153000000

eur

CY2021Q4

sny

Provisions For Discounts Rebates And Sales Returns

ProvisionsForDiscountsRebatesAndSalesReturns

5899000000

eur

CY2022

sny

Increase Through New Provision Related To Current Period Sales

IncreaseThroughNewProvisionRelatedToCurrentPeriodSales

22141000000

eur

CY2022

sny

Increase Decrease In Provisions Related To Prior Period Sales

IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales

-315000000

eur

CY2022

sny

Decrease Through Payments Made Provisions For Discounts Rebates And Sales Returns

DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns

21699000000

eur

CY2022

sny

Increase Decrease Through Net Exchange Differences Provisions For Discounts Rebates And Sales Returns

IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns

464000000

eur

CY2022Q4

sny

Provisions For Discounts Rebates And Sales Returns

ProvisionsForDiscountsRebatesAndSalesReturns

6490000000

eur

CY2023

sny

Increase Decrease Through Changes In Scope Of Consolidation In Provision For Discounts Rebates And Sales Returns

IncreaseDecreaseThroughChangesInScopeOfConsolidationInProvisionForDiscountsRebatesAndSalesReturns

-3000000

eur

CY2023

sny

Increase Through New Provision Related To Current Period Sales

IncreaseThroughNewProvisionRelatedToCurrentPeriodSales

24296000000

eur

CY2023

sny

Increase Decrease In Provisions Related To Prior Period Sales

IncreaseDecreaseInProvisionsRelatedToPriorPeriodSales

-155000000

eur

CY2023

sny

Decrease Through Payments Made Provisions For Discounts Rebates And Sales Returns

DecreaseThroughPaymentsMadeProvisionsForDiscountsRebatesAndSalesReturns

22653000000

eur

CY2023

sny

Increase Decrease Through Net Exchange Differences Provisions For Discounts Rebates And Sales Returns

IncreaseDecreaseThroughNetExchangeDifferencesProvisionsForDiscountsRebatesAndSalesReturns

-213000000

eur

CY2023Q4

sny

Provisions For Discounts Rebates And Sales Returns

ProvisionsForDiscountsRebatesAndSalesReturns

7762000000

eur

CY2023

ifrs-full

Disclosure Of Information About Employees Explanatory

DisclosureOfInformationAboutEmployeesExplanatory

Personnel costs<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Total personnel costs (other than termination benefits, presented in Note D.27.) include the following items:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Salaries</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,183 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,145 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,625 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Social security charges (including defined-contribution pension plans)</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,100 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,098 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,929 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other employee benefits</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:3.9pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.1pt;vertical-align:baseline">(</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">a)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">531 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">748 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">786 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,814</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,991</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,340</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Includes expenses related to share-based payments and defined-benefit plans.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The total number of registered employees was 87,994 as of December 31, 2023, compared with 91,573 as of December 31, 2022 and 95,442 as of December 31, 2021.</span></div>

CY2023

ifrs-full

Wages And Salaries

WagesAndSalaries

7183000000

eur

CY2022

ifrs-full

Wages And Salaries

WagesAndSalaries

7145000000

eur

CY2021

ifrs-full

Wages And Salaries

WagesAndSalaries

6625000000

eur

CY2023

ifrs-full

Social Security Contributions

SocialSecurityContributions

2100000000

eur

CY2022

ifrs-full

Social Security Contributions

SocialSecurityContributions

2098000000

eur

CY2021

ifrs-full

Social Security Contributions

SocialSecurityContributions

1929000000

eur

CY2023

ifrs-full

Other Employee Expense

OtherEmployeeExpense

531000000

eur

CY2022

ifrs-full

Other Employee Expense

OtherEmployeeExpense

748000000

eur

CY2021

ifrs-full

Other Employee Expense

OtherEmployeeExpense

786000000

eur

CY2023

ifrs-full

Employee Benefits Expense

EmployeeBenefitsExpense

9814000000

eur

CY2022

ifrs-full

Employee Benefits Expense

EmployeeBenefitsExpense

9991000000

eur

CY2021

ifrs-full

Employee Benefits Expense

EmployeeBenefitsExpense

9340000000

eur

CY2023Q4

ifrs-full

Number Of Employees

NumberOfEmployees

87994

employee

CY2022Q4

ifrs-full

Number Of Employees

NumberOfEmployees

91573

employee

CY2021Q4

ifrs-full

Number Of Employees

NumberOfEmployees

95442

employee

CY2023

ifrs-full

Disclosure Of Other Operating Income Explanatory

DisclosureOfOtherOperatingIncomeExplanatory

Other operating income<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">totaled €1,292 million in 2023, versus €1,969 million in 2022 and €859 million in 2021.</span></div>Other operating income includes (i) gains from asset divestments, amounting to €688 million in 2023 (versus €655 million in 2022 and €418 million in 2021); and (ii) income from Sanofi’s pharmaceutical partners, amounting to €290 million in 2023 (including €227 million from Regeneron, see Note D.26. below and Note C.1.), compared with €1,178 million in 2022 (including €1,147 million from Regeneron), and €245 million in 2021. For 2021, it includes a payment of €119 million from Daiichi Sankyo relating to the termination of a vaccines collaboration agreement in Japan

CY2023

ifrs-full

Miscellaneous Other Operating Income

MiscellaneousOtherOperatingIncome

1292000000

eur

CY2022

ifrs-full

Miscellaneous Other Operating Income

MiscellaneousOtherOperatingIncome

1969000000

eur

CY2021

ifrs-full

Miscellaneous Other Operating Income

MiscellaneousOtherOperatingIncome

859000000

eur

CY2023

ifrs-full

Disclosure Of Other Operating Expense Explanatory

DisclosureOfOtherOperatingExpenseExplanatory

Other operating expenses<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> totaled €3,516 million in 2023, compared with €2,531 million in 2022 and €1,805 million in 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For 2023, this line item includes €3,206 million of expenses related to Regeneron (see Note C.1.), compared with €2,378 million for 2022 and €1,568 million for 2021 (as shown in the table below):</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income & expense related to sharing of (profits)/losses under the Monoclonal Antibody Alliance</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,321)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,325)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,253)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Additional share of profit paid by Regeneron towards development costs</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">434 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">127 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reimbursement to Regeneron of selling expenses incurred</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(543)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(476)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(303)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total - Monoclonal Antibody Alliance</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(3,196)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,367)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,429)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Immuno-Oncology Alliance</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">68</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other (mainly ZALTRAP and LIBTAYO)</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">217</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,120</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(12)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other operating income/(expenses), net related to Regeneron</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,979)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,231)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,373)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">of which amount presented in</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"> Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"> (Note D.25.)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">1,147 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">195 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Following the restructuring of the Immuno-Oncology agreement between Sanofi and Regeneron, applicable from July 1, 2022 (see Note C.1.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) As of December 31, 2023, the commitment received by Sanofi in respect of the additional profit share payable by Regeneron towards development costs amounted to €2.1 billion, compared with €2.7 billion as of December 31, 2022 (see note D.21.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Charges to provisions for litigation and environmental risks are also recorded within this line item.</span></div>

CY2023

ifrs-full

Miscellaneous Other Operating Expense

MiscellaneousOtherOperatingExpense

3516000000

eur

CY2022

ifrs-full

Miscellaneous Other Operating Expense

MiscellaneousOtherOperatingExpense

2531000000

eur

CY2021

ifrs-full

Miscellaneous Other Operating Expense

MiscellaneousOtherOperatingExpense

1805000000

eur

CY2023

ifrs-full

Other Operating Income Expense

OtherOperatingIncomeExpense

-2979000000

eur

CY2022

ifrs-full

Other Operating Income Expense

OtherOperatingIncomeExpense

-1231000000

eur

CY2021

ifrs-full

Other Operating Income Expense

OtherOperatingIncomeExpense

-1373000000

eur

CY2023

ifrs-full

Expense Of Restructuring Activities

ExpenseOfRestructuringActivities

1490000000

eur

CY2022

ifrs-full

Expense Of Restructuring Activities

ExpenseOfRestructuringActivities

1336000000

eur

CY2021

ifrs-full

Expense Of Restructuring Activities

ExpenseOfRestructuringActivities

820000000

eur

CY2023

sny

Expense Of Restructuring Activities Employee Related Expenses

ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses

489000000

eur

CY2022

sny

Expense Of Restructuring Activities Employee Related Expenses

ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses

507000000

eur

CY2021

sny

Expense Of Restructuring Activities Employee Related Expenses

ExpenseOfRestructuringActivitiesEmployeeRelatedExpenses

193000000

eur

CY2023

sny

Expense Of Restructuring Activities Related To Property Plant And Equipment And To Inventories

ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories

293000000

eur

CY2022

sny

Expense Of Restructuring Activities Related To Property Plant And Equipment And To Inventories

ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories

261000000

eur

CY2021

sny

Expense Of Restructuring Activities Related To Property Plant And Equipment And To Inventories

ExpenseOfRestructuringActivitiesRelatedToPropertyPlantAndEquipmentAndToInventories

110000000

eur

CY2023

sny

Expense Of Restructuring Activities Transformation Programs Costs

ExpenseOfRestructuringActivitiesTransformationProgramsCosts

676000000

eur

CY2022

sny

Expense Of Restructuring Activities Transformation Programs Costs

ExpenseOfRestructuringActivitiesTransformationProgramsCosts

547000000

eur

CY2021

sny

Expense Of Restructuring Activities Transformation Programs Costs

ExpenseOfRestructuringActivitiesTransformationProgramsCosts

463000000

eur

CY2023

sny

Other Restructuring Cost

OtherRestructuringCost

32000000

eur

CY2022

sny

Other Restructuring Cost

OtherRestructuringCost

21000000

eur

CY2021

sny

Other Restructuring Cost

OtherRestructuringCost

54000000

eur

CY2023

ifrs-full

Expense Of Restructuring Activities

ExpenseOfRestructuringActivities

1490000000

eur

CY2022

ifrs-full

Expense Of Restructuring Activities

ExpenseOfRestructuringActivities

1336000000

eur

CY2021

ifrs-full

Expense Of Restructuring Activities

ExpenseOfRestructuringActivities

820000000

eur

CY2023

sny

Increase Decrease In Expense Of Restructuring Activities

IncreaseDecreaseInExpenseOfRestructuringActivities

154000000

eur

CY2023

sny

Other Gains Losses And Litigation

OtherGainsLossesAndLitigation

-38000000

eur

CY2022

sny

Other Gains Losses And Litigation

OtherGainsLossesAndLitigation

-370000000

eur

CY2021

sny

Other Gains Losses And Litigation

OtherGainsLossesAndLitigation

-5000000

eur

CY2023

ifrs-full

Disclosure Of Finance Income Expense Explanatory

DisclosureOfFinanceIncomeExpenseExplanatory

Financial expenses and income<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">An analysis of </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial expenses</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Financial income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> is set forth below:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of debt</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(555)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(365)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(313)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">533 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cost of net debt</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(22)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(124)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(259)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-operating foreign exchange gains/(losses)</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unwinding of discounting of provisions</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest cost related to employee benefits</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(47)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(44)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains/(losses) on disposals of financial assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(40)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(35)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(526)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net financial income/(expenses)</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(722)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(234)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(328)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">comprising: Financial expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,313)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(440)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(368)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> Financial income</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">591</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">206</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">40</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Includes net gains/(losses) on interest rate and currency derivatives used to manage debt: €(67) million in 2023, €(11) million in 2022, €14 million in 2021.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Includes net gains on interest rate and currency derivatives used to manage cash and cash equivalents: €(13) million in 2023, €68 million in 2022, €51 million in 2021.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) Primarily on provisions for environmental risks, restructuring provisions, and provisions for product-related risks (see Note D.19.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d) Includes a financial expense of €541 million (zero in 2022 and 2021) in respect of the liability recognized in the balance sheet for estimated future royalties on US sales of BEYFORTUS, which was remeasured as of December 31, 2023 to reflect the very successful US launch of the product (see Note C.2.).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, 2022 and 2021, the impact of the ineffective portion of hedging relationships was not material.</span></div>

CY2023

ifrs-full

Interest Expense On Borrowings

InterestExpenseOnBorrowings

555000000

eur

CY2022

ifrs-full

Interest Expense On Borrowings

InterestExpenseOnBorrowings

365000000

eur

CY2021

ifrs-full

Interest Expense On Borrowings

InterestExpenseOnBorrowings

313000000

eur

CY2023

sny

Interest Income

InterestIncome

533000000

eur

CY2022

sny

Interest Income

InterestIncome

241000000

eur

CY2021

sny

Interest Income

InterestIncome

54000000

eur

CY2023

sny

Cost Of Debt Net

CostOfDebtNet

22000000

eur

CY2022

sny

Cost Of Debt Net

CostOfDebtNet

124000000

eur

CY2021

sny

Cost Of Debt Net

CostOfDebtNet

259000000

eur

CY2023

sny

Non Operating Foreign Exchange Gains Losses

NonOperatingForeignExchangeGainsLosses

-2000000

eur

CY2022

sny

Non Operating Foreign Exchange Gains Losses

NonOperatingForeignExchangeGainsLosses

-4000000

eur

CY2021

sny

Non Operating Foreign Exchange Gains Losses

NonOperatingForeignExchangeGainsLosses

2000000

eur

CY2023

ifrs-full

Expense Due To Unwinding Of Discount On Provisions

ExpenseDueToUnwindingOfDiscountOnProvisions

59000000

eur

CY2022

ifrs-full

Expense Due To Unwinding Of Discount On Provisions

ExpenseDueToUnwindingOfDiscountOnProvisions

20000000

eur

CY2021

ifrs-full

Expense Due To Unwinding Of Discount On Provisions

ExpenseDueToUnwindingOfDiscountOnProvisions

11000000

eur

CY2023

sny

Net Interest Cost Related To Employee Benefits

NetInterestCostRelatedToEmployeeBenefits

73000000

eur

CY2022

sny

Net Interest Cost Related To Employee Benefits

NetInterestCostRelatedToEmployeeBenefits

47000000

eur

CY2021

sny

Net Interest Cost Related To Employee Benefits

NetInterestCostRelatedToEmployeeBenefits

44000000

eur

CY2023

ifrs-full

Gains Losses On Availableforsale Financial Assets

GainsLossesOnAvailableforsaleFinancialAssets

-1000000

eur

CY2022

ifrs-full

Gains Losses On Availableforsale Financial Assets

GainsLossesOnAvailableforsaleFinancialAssets

1000000

eur

CY2021

ifrs-full

Gains Losses On Availableforsale Financial Assets

GainsLossesOnAvailableforsaleFinancialAssets

3000000

eur

CY2023

ifrs-full

Interest Expense On Lease Liabilities

InterestExpenseOnLeaseLiabilities

39000000

eur

CY2022

ifrs-full

Interest Expense On Lease Liabilities

InterestExpenseOnLeaseLiabilities

40000000

eur

CY2021

ifrs-full

Interest Expense On Lease Liabilities

InterestExpenseOnLeaseLiabilities

35000000

eur

CY2023

ifrs-full

Other Finance Income Cost

OtherFinanceIncomeCost

-526000000

eur

CY2022

ifrs-full

Other Finance Income Cost

OtherFinanceIncomeCost

0

eur

CY2021

ifrs-full

Other Finance Income Cost

OtherFinanceIncomeCost

16000000

eur

CY2023

ifrs-full

Finance Income Cost

FinanceIncomeCost

-722000000

eur

CY2022

ifrs-full

Finance Income Cost

FinanceIncomeCost

-234000000

eur

CY2021

ifrs-full

Finance Income Cost

FinanceIncomeCost

-328000000

eur

CY2023

ifrs-full

Finance Costs

FinanceCosts

1313000000

eur

CY2022

ifrs-full

Finance Costs

FinanceCosts

440000000

eur

CY2021

ifrs-full

Finance Costs

FinanceCosts

368000000

eur

CY2023

ifrs-full

Finance Income

FinanceIncome

591000000

eur

CY2022

ifrs-full

Finance Income

FinanceIncome

206000000

eur

CY2021

ifrs-full

Finance Income

FinanceIncome

40000000

eur

CY2023

sny

Liability Recognised For Estimated Future Royalties

LiabilityRecognisedForEstimatedFutureRoyalties

541000000

eur

CY2021

sny

Liability Recognised For Estimated Future Royalties

LiabilityRecognisedForEstimatedFutureRoyalties

0

eur

CY2022

sny

Liability Recognised For Estimated Future Royalties

LiabilityRecognisedForEstimatedFutureRoyalties

0

eur

CY2023

ifrs-full

Disclosure Of Income Tax Explanatory

DisclosureOfIncomeTaxExplanatory

Income tax expense<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has elected for tax consolidations in a number of countries, principally France, Germany, the United Kingdom and the United States.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the allocation of income tax expense between current and deferred taxes:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Current taxes</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,560)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,774)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,908)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">958 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">768 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">350 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,602)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,006)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,558)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,153</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,422</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,798</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The difference between the effective tax rate and the standard corporate income tax rate applicable in France is explained as follows:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(%)</span></div></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Standard tax rate applicable in France</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25.8 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25.8 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28.4 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Difference between the standard French tax rate and the rates applicable to Sanofi</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revisions to tax exposures and settlements of tax disputes</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Probable reversal of temporary differences on investments in Consumer Healthcare subsidiaries</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other items</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22.4</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19.2</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20.0</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) The difference between the French tax rate and tax rates applicable to foreign subsidiaries reflects the fact that Sanofi has operations in many countries, most of which have lower tax rates than France.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) In accordance with IAS 12, a deferred tax liability was recognized in 2023 on the temporary differences arising on investments in subsidiaries which Sanofi expects will reverse in connection with the proposed separation of the Consumer Healthcare business, as announced in October 2023.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) In determining the amount of the deferred tax liability for 2023, 2022 and 2021, Sanofi took into account changes in the ownership structure of certain subsidiaries.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">For the periods presented, the amount of deferred tax assets recognized in profit or loss that were initially subject to impairment losses at the time of a business combination is immaterial.</span></div>

CY2023

ifrs-full

Current Tax Expense Income

CurrentTaxExpenseIncome

2560000000

eur

CY2022

ifrs-full

Current Tax Expense Income

CurrentTaxExpenseIncome

2774000000

eur

CY2021

ifrs-full

Current Tax Expense Income

CurrentTaxExpenseIncome

1908000000

eur

CY2023

ifrs-full

Deferred Tax Expense Income

DeferredTaxExpenseIncome

-958000000

eur

CY2022

ifrs-full

Deferred Tax Expense Income

DeferredTaxExpenseIncome

-768000000

eur

CY2021

ifrs-full

Deferred Tax Expense Income

DeferredTaxExpenseIncome

-350000000

eur

CY2023

ifrs-full

Income Tax Expense Continuing Operations

IncomeTaxExpenseContinuingOperations

1602000000

eur

CY2022

ifrs-full

Income Tax Expense Continuing Operations

IncomeTaxExpenseContinuingOperations

2006000000

eur

CY2021

ifrs-full

Income Tax Expense Continuing Operations

IncomeTaxExpenseContinuingOperations

1558000000

eur

CY2023

sny

Income Before Tax And Investments Accounted For Equity Method Investments

IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments

7153000000

eur

CY2022

sny

Income Before Tax And Investments Accounted For Equity Method Investments

IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments

10422000000

eur

CY2021

sny

Income Before Tax And Investments Accounted For Equity Method Investments

IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments

7798000000

eur

CY2023

ifrs-full

Applicable Tax Rate

ApplicableTaxRate

0.258

CY2022

ifrs-full

Applicable Tax Rate

ApplicableTaxRate

0.258

CY2021

ifrs-full

Applicable Tax Rate

ApplicableTaxRate

0.284

CY2023

ifrs-full

Tax Rate Effect Of Foreign Tax Rates

TaxRateEffectOfForeignTaxRates

-0.136

CY2022

ifrs-full

Tax Rate Effect Of Foreign Tax Rates

TaxRateEffectOfForeignTaxRates

-0.065

CY2021

ifrs-full

Tax Rate Effect Of Foreign Tax Rates

TaxRateEffectOfForeignTaxRates

-0.095

CY2023

sny

Tax Rate Effect Of Revisions To Tax Exposures And Settlements Of Tax Disputes

TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes

0.027

CY2022

sny

Tax Rate Effect Of Revisions To Tax Exposures And Settlements Of Tax Disputes

TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes

-0.008

CY2021

sny

Tax Rate Effect Of Revisions To Tax Exposures And Settlements Of Tax Disputes

TaxRateEffectOfRevisionsToTaxExposuresAndSettlementsOfTaxDisputes

0.010

CY2023

sny

Tax Rate Effect Of Reversal Of Temporary Difference On Investments

TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments

0.051

CY2022

sny

Tax Rate Effect Of Reversal Of Temporary Difference On Investments

TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments

0

CY2021

sny

Tax Rate Effect Of Reversal Of Temporary Difference On Investments

TaxRateEffectOfReversalOfTemporaryDifferenceOnInvestments

0

CY2023

sny

Tax Rate Effect Of Fair Value Remeasurement Of Contingent Considerations

TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations

0.001

CY2022

sny

Tax Rate Effect Of Fair Value Remeasurement Of Contingent Considerations

TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations

-0.002

CY2021

sny

Tax Rate Effect Of Fair Value Remeasurement Of Contingent Considerations

TaxRateEffectOfFairValueRemeasurementOfContingentConsiderations

0

CY2023

ifrs-full

Other Tax Rate Effects For Reconciliation Between Accounting Profit And Tax Expense Income

OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome

0.023

CY2022

ifrs-full

Other Tax Rate Effects For Reconciliation Between Accounting Profit And Tax Expense Income

OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome

0.009

CY2021

ifrs-full

Other Tax Rate Effects For Reconciliation Between Accounting Profit And Tax Expense Income

OtherTaxRateEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome

0.001

CY2023

ifrs-full

Average Effective Tax Rate

AverageEffectiveTaxRate

0.224

CY2022

ifrs-full

Average Effective Tax Rate

AverageEffectiveTaxRate

0.192

CY2021

ifrs-full

Average Effective Tax Rate

AverageEffectiveTaxRate

0.200

CY2023

ifrs-full

Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method

ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod

-115000000

eur

CY2022

ifrs-full

Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method

ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod

68000000

eur

CY2021

ifrs-full

Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method

ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod

39000000

eur

CY2023

ifrs-full

Profit Loss Attributable To Noncontrolling Interests

ProfitLossAttributableToNoncontrollingInterests

36000000

eur

CY2022

ifrs-full

Profit Loss Attributable To Noncontrolling Interests

ProfitLossAttributableToNoncontrollingInterests

113000000

eur

CY2021

ifrs-full

Profit Loss Attributable To Noncontrolling Interests

ProfitLossAttributableToNoncontrollingInterests

56000000

eur

CY2023

ifrs-full

Disclosure Of Related Party Explanatory

DisclosureOfRelatedPartyExplanatory

Related party transactions<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal related parties are companies over which Sanofi has control or significant influence, joint ventures, key management personnel, and principal shareholders.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi has not entered into any material transactions with any key management personnel. Financial relations with Sanofi’s principal shareholders fall within the ordinary course of business and were immaterial in the years ended December 31, 2023, 2022 and 2021.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Note F.1. lists the principal companies controlled by Sanofi; those companies are fully consolidated, as described in Note B.1. Transactions between those companies, and between the parent company and its subsidiaries, are eliminated when preparing the consolidated financial statements.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Transactions with companies over which Sanofi has significant influence, and with joint ventures, are presented in Note D.6.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Key management personnel include corporate officers and the members of the Executive Committee (an a</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">verage of 10 members</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> in 2023, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">11 </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">in 2022 and in 2021).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows, by type, the compensation paid to key management personnel:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Short-term benefits</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Post-employment benefits</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based payment</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total recognized in profit or loss</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">46</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">52</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">55</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Compensation, employer’s social security contributions, directors’ compensation, and any termination benefits (net of reversals of termination benefit obligations).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the aggregate obligation as of December 31 for each period presented for individuals who hold or have held executive positions within Sanofi during that period.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate top-up pension obligation in favor of certain corporate officers and of Executive Committee members</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate termination benefits and lump-sum retirement benefits in favor of key management personnel</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div>

CY2023

sny

Number Of Executive Committee Members

NumberOfExecutiveCommitteeMembers

10

executives

CY2021

sny

Number Of Executive Committee Members

NumberOfExecutiveCommitteeMembers

11

executives

CY2022

sny

Number Of Executive Committee Members

NumberOfExecutiveCommitteeMembers

11

executives

CY2023

ifrs-full

Key Management Personnel Compensation Shortterm Employee Benefits

KeyManagementPersonnelCompensationShorttermEmployeeBenefits

36000000

eur

CY2022

ifrs-full

Key Management Personnel Compensation Shortterm Employee Benefits

KeyManagementPersonnelCompensationShorttermEmployeeBenefits

31000000

eur

CY2021

ifrs-full

Key Management Personnel Compensation Shortterm Employee Benefits

KeyManagementPersonnelCompensationShorttermEmployeeBenefits

33000000

eur

CY2023

ifrs-full

Key Management Personnel Compensation Postemployment Benefits

KeyManagementPersonnelCompensationPostemploymentBenefits

2000000

eur

CY2022

ifrs-full

Key Management Personnel Compensation Postemployment Benefits

KeyManagementPersonnelCompensationPostemploymentBenefits

2000000

eur

CY2021

ifrs-full

Key Management Personnel Compensation Postemployment Benefits

KeyManagementPersonnelCompensationPostemploymentBenefits

2000000

eur

CY2023

ifrs-full

Key Management Personnel Compensation Sharebased Payment

KeyManagementPersonnelCompensationSharebasedPayment

8000000

eur

CY2022

ifrs-full

Key Management Personnel Compensation Sharebased Payment

KeyManagementPersonnelCompensationSharebasedPayment

19000000

eur

CY2021

ifrs-full

Key Management Personnel Compensation Sharebased Payment

KeyManagementPersonnelCompensationSharebasedPayment

20000000

eur

CY2023

ifrs-full

Key Management Personnel Compensation

KeyManagementPersonnelCompensation

46000000

eur

CY2022

ifrs-full

Key Management Personnel Compensation

KeyManagementPersonnelCompensation

52000000

eur

CY2021

ifrs-full

Key Management Personnel Compensation

KeyManagementPersonnelCompensation

55000000

eur

CY2023

ifrs-full

Disclosure Of Amounts Incurred By Entity For Provision Of Key Management Personnel Services Provided By Separate Management Entities Explanatory

DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory

<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows the aggregate obligation as of December 31 for each period presented for individuals who hold or have held executive positions within Sanofi during that period.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:62.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.151%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.152%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate top-up pension obligation in favor of certain corporate officers and of Executive Committee members</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate termination benefits and lump-sum retirement benefits in favor of key management personnel</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div>

CY2023

sny

Aggregate Pension Obligation In Favor Of Certain Corporate Officers And Of Members Of The Executive Committee

AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee

10000000

eur

CY2022

sny

Aggregate Pension Obligation In Favor Of Certain Corporate Officers And Of Members Of The Executive Committee

AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee

10000000

eur

CY2021

sny

Aggregate Pension Obligation In Favor Of Certain Corporate Officers And Of Members Of The Executive Committee

AggregatePensionObligationInFavorOfCertainCorporateOfficersAndOfMembersOfTheExecutiveCommittee

28000000

eur

CY2023

sny

Key Management Personnel Compensation Termination Benefits And Lump Sum Retirement Benefits

KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits

6000000

eur

CY2022

sny

Key Management Personnel Compensation Termination Benefits And Lump Sum Retirement Benefits

KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits

5000000

eur

CY2021

sny

Key Management Personnel Compensation Termination Benefits And Lump Sum Retirement Benefits

KeyManagementPersonnelCompensationTerminationBenefitsAndLumpSumRetirementBenefits

7000000

eur

CY2023

ifrs-full

Disclosure Of Credit Risk Explanatory

DisclosureOfCreditRiskExplanatory

Disclosures about major customers and credit risk<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Credit risk is the risk that customers (wholesalers, distributors, pharmacies, hospitals, clinics or government agencies) may fail to pay their debts; for Sanofi, that risk is mainly concentrated on amounts receivable from wholesalers in the United States. Sanofi manages credit risk by vetting customers in order to set credit limits and risk levels, and asking for guarantees or insurance where necessary; performing controls; and monitoring qualitative and quantitative indicators of accounts receivable balances, such as the period of credit taken and overdue payments.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sales generated by Sanofi with its biggest customers, in particular certain wholesalers in the United States, represented </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">27% of net sales in </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The three largest customers respectively accounted for approximately 11%, 9% and 7% of Sanofi's net sales in 2023 (12%, 8% and 7% in 2022; 10%, 7% and 6% in 2021).</span></div>

CY2021

ifrs-full

Percentage Of Entitys Revenue

PercentageOfEntitysRevenue

0.06

CY2023

ifrs-full

Disclosure Of Entitys Reportable Segments Explanatory

DisclosureOfEntitysReportableSegmentsExplanatory

Segment information<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As indicated in Note B.26., Sanofi has two operating segments with effect from January 1, 2023: Biopharma and Consumer Healthcare.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2022, Sanofi reported three operating segments (Pharmaceuticals, Vaccines and Consumer Healthcare). The costs of the global support functions (Corporate Affairs, Finance, People & Culture, Legal, Ethics, Business Integrity & Global Security, Information Solutions & Technology, Sanofi Business Services, etc.), which are mainly managed centrally at group-wide level, were presented within the “Other” category. </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In 2023, Sanofi reviewed the presentation of its segment information following adjustments to its internal reporting systems in order to reflect (i) progress on the “Play to Win” strategy leading to the creation of the standalone Consumer Healthcare Global Business Unit (GBU) which, in addition to integrated research, development and production functions now also has its own dedicated global support functions (including Finance, People & Culture, Legal, Ethics, Business Integrity & Global Security, Information Solutions & Technology, Global Business Services, etc.); and (ii) organizational changes to Sanofi’s Manufacturing & Supply global function (previously known as Industrial Affairs). </span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Consequently, with effect from January 1, 2023, Sanofi reports two operating segments: Biopharma and Consumer Healthcare.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Biopharma operating segment comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines and Vaccines franchises, for all geographical territories. The segment’s results include the costs of global support functions that are not within the managerial responsibility of the Consumer Healthcare GBU.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The Consumer Healthcare operating segment comprises commercial operations relating to Consumer Healthcare products, and research, development and production activities and global support functions (as listed above) dedicated to the segment, for all geographical territories. The Consumer Healthcare GBU segment’s results reflect all incurred costs of global support functions attributable to its business.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The “Other” category comprises reconciling items, primarily but not limited to (i) gains and losses on centralized foreign exchange risk hedging transactions that cannot be allocated to the operating segments and (ii) gains and losses on retained commitments in respect of previously divested operations.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.35.1. Segment results</span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.35.1.1. Analysis of net sales</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below sets forth Sanofi’s net sales for the years ended December 31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:7.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.491%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="6" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:5.5pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" rowspan="2" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" rowspan="2" style="border-right:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2022</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" rowspan="2" style="border-left:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other<br/>countries</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2021</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(b)</span></div></td></tr><tr style="height:9pt"><td colspan="42" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,835</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17,265</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,790</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37,890</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,498</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,985</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,329</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37,812</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-left:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,426</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,246</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,621</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">33,293</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Specialty Care</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,206</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,917</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,917</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,040</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,016</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,848</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,593</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,457</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,764</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,847</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,141</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,752</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">of which</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">DUPIXENT</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,224 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">8,145 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,346 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10,715 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">940 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">6,346 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,007 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">8,293 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">649 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3,971 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">629 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5,249 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">AUBAGIO</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">437 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">460 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">955 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">511 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,420 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">100 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,031 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">512 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,312 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">131 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,955 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">CEREZYME</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">269 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">687 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">239 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">194 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">274 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">707 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">244 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">173 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">266 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">683 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">FABRAZYME</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">503 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">991 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">228 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">471 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">239 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">938 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">223 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">395 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">226 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">844 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">MYOZYME/<br/>LUMIZYME</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">783 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">408 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">318 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">232 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">958 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">410 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">373 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">220 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,003 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">JEVTANA</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">230 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">320 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">33 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">275 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">83 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">391 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">112 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">253 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">90 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">455 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">ALPROLIX</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">540 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">406 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">98 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">504 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">332 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">82 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">414 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">ELOCTATE</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">341 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">471 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">450 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">130 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">580 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">429 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">134 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">563 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">General Medicines</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,932</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,084</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,360</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,376</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,141</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,846</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,140</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,127</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,437</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,637</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,144</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,218</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Core Assets</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,988</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,485</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,797</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,270</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,917</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,653</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,819</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,389</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,868</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,315</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,585</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,768</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">LOVENOX</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">622 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">496 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,125 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">658 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">17 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">635 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,310 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">703 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">29 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">754 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,486 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">TOUJEO</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">441 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,123 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">421 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">283 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">413 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,117 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">394 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">259 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">316 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">969 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">PLAVIX</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">844 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">948 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">101 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">873 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">983 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">115 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">805 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">929 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Non-Core Assets</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,396</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">592</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,536</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,524</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,637</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,176</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,305</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,118</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,846</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,281</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,515</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,642</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">LANTUS</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">782 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,420 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">426 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">757 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,076 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,259 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">474 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">861 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,159 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,494 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Other non-core assets</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">961 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">302 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,424 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3,687 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,129 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">412 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,840 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,381 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,285 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">410 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3,034 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,729 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Industrial sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">548</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">27</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">582</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">587</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">17</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">620</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">723</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">41</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">44</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">808</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,697</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,264</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,513</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,474</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,341</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,291</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,596</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,228</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,225</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,762</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,336</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,323</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Polio/Pertussis/<br/>Hib Vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">398 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,470 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,165 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">325 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">456 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,504 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,285 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">306 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">470 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,383 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,159 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Influenza Vaccines</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">694 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,406 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">569 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,669 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">681 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,737 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">559 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,977 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">729 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,366 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">533 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,628 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer Healthcare</span></div></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,557</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,247</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,376</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,180</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,501</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,290</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,394</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,185</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-left:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,333</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,139</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,996</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,468</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">of which</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Allergy</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">769 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">55 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">439 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">276 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">770 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">49 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">371 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">192 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">612 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Pain Care</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">502 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">424 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,106 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">555 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">212 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">424 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,140 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">515 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">196 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">382 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,093 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Digestive Wellness</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">520 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">844 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,502 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">432 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">144 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">822 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,449 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">389 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">124 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">618 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,131 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total net sales</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,392</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,512</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,166</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43,070</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,999</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,275</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,723</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">42,997</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;border-left:0.5pt solid #21004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,759</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,385</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,617</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37,761</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) 2022 figures have been adjusted to take account of the two new operating segments, Biopharma and Consumer Healthcare, effective January 1, 2023.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:9pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.35.1.2. Business operating income</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Sanofi reports segment results on the basis of “Business operating income”. This indicator is used internally by Sanofi’s chief operating decision maker to measure the performance of each operating segment and to allocate resources.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">“Business operating income” is derived from </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, adjusted as follows:</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">amortization and impairment losses charged against intangible assets (other than software and other rights of an industrial or operational nature), are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">fair value remeasurements of contingent consideration relating to business combinations (IFRS 3) or business divestments, and presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Fair value remeasurement of contingent consideration</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">expenses arising from the remeasurement of inventories following business combinations (IFRS 3) or acquisitions of groups of assets that do not constitute a business within the meaning of paragraph 2b of IFRS 3, are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">amounts reported within the line items </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs and similar items </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">other gains and losses including gains and losses on major divestments, presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">other costs and provisions related to litigation, presented within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other gains and losses, and litigation</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">, are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">upfront payments and regulatory milestone payments recognized within the line item </span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">Other operating income</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">and related to transactions outside the ordinary activities of Sanofi are eliminated;</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">the share of profits/losses from investments accounted for using the equity method is added, to the extent that this relates to joint ventures and associates with which Sanofi has a strategic alliance; and</span></div><div style="margin-bottom:2pt;padding-left:14.17pt;text-align:justify;text-indent:-14.17pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:11.27pt">net income attributable to non-controlling interests is deducted.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows Sanofi’s segment results for the years ended December 31, 2023, December 31, 2022 and December 31, 2021:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:38.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer<br/>Healthcare</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Sanofi</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37,890</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,180</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43,070</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,322 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,374 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12,282)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,933)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(14,216)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,509)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,728)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,868)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,828)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10,692)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,387)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,224)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,247</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,438</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,670</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) This caption reconciles segment financial information to total consolidated financial information.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:38.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer<br/>Healthcare</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Sanofi</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37,812</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,185</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">42,997</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,330 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,392 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11,793)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,903)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13,692)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,503)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(205)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,706)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,736)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,761)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10,492)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,679)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">148 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,514)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(16)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(33)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,490</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,522</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">28</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,040</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) 2022 figures have been adjusted to take account of the two new operating segments, Biopharma and Consumer Healthcare, effective from January 1, 2023.</span></div><div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">This caption reconciles segment financial information to total consolidated financial information.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:39.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceuticals</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer<br/>Healthcare</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Sanofi</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26,970</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,323</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,468</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37,761</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">264 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,095 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,414 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,965)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,430)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,606)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(250)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12,251)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,330)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(712)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(153)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(497)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,692)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,326)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(805)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,388)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,036)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9,555)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,172)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">128 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(946)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(49)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,409</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,609</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,493</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,797)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,714</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure.</span></div><div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) This caption reconciles segment financial information to total consolidated financial information.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below, presented in compliance with IFRS 8, shows a reconciliation between aggregated “Business operating income” for the segments and</span><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%"> Income before tax and investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:57.552%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.684%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,670</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,040</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,714</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(88)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(39)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">33 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortization and impairment of intangible assets</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,068)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,599)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,772)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expenses arising from the impact of acquisitions on inventories</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Restructuring costs and similar items</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,490)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,336)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(820)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other gains and losses, and litigation</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(370)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income from out-licensing</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">952 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,875</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,656</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,126</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial expenses</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,313)</span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(440)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(368)</span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">591 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income before tax and investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,153</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,422</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7,798</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:0.5pt solid #23004c;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Joint ventures and associates with which Sanofi has entered into a strategic alliance.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Excludes (i) restructuring costs and (ii) other adjustments attributable to non-controlling interests.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) For 2023, this amount mainly comprises an impairment loss of €833 million, reflecting the impact of the strategic decision to de-prioritize certain R&D programs, in particular those related to the NK Cell and PRO-XTEN technology platforms. For 2022, this line includes a reversal of €2,154 million on ELOCTATE franchise products following FDA approval of ALTUVIIIO</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">dated February 22, 2023, partially offset by an impairment loss of €1,586 million on intangible assets relating to SAR444245 (non-alpha interleukin-2).</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d) This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(e) </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">For 2022, this line includes an upfront payment of $900 million and a regulatory milestone payment of $100 million related to the out-licensing of LIBTAYO following the restructuring of the Immuno-Oncology Collaboration and License Agreement with Regeneron (see Note C.1.).</span></div><div style="margin-bottom:5pt;padding-left:14.17pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.35.2. Other segment information</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The tables below show the split by operating segment of (i) the carrying amount of investments accounted for using the equity method with which Sanofi has entered into a strategic alliance, (ii) acquisitions of property, plant and equipment, and (iii) acquisitions of intangible assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The principal investments accounted for using the equity method in the Biopharma segment are the interests in MSP Vaccine Company, and Infraserv GmbH & Co. Höchst KG (see Note D.6.).</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"></td><td style="width:48.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.798%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer<br/>Healthcare</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">262 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,619 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,719 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other intangible assets</span></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,287 </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,305 </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.667%"><tr><td style="width:1.0%"></td><td style="width:48.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.798%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer<br/>Healthcare</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">248 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">285 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,529 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,606 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other intangible assets</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">574 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">595 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) 2022 figures have been adjusted to take account of the two new operating segments, Biopharma and Consumer Healthcare, effective from January 1, 2023.</span></div><div style="margin-top:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:48.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.613%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceuticals</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer<br/>Healthcare</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investments accounted for using the equity method</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">159 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">250 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,024 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">382 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,479 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisitions of other intangible assets</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">451 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">108 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">565 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure.</span></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#7802e6;font-family:'Sanofi Serif',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">D.35.3. Information by geographical region</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The geographical information on net sales provided below is based on the geographical location of the customer. In accordance with IFRS 8, the non-current assets reported below exclude right-of-use assets relating to leases as determined under IFRS 16, investments accounted for using the equity method, other non-current assets, non-current income tax assets, and deferred tax assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:28.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of which<br/>France</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">North<br/>America</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of which<br/>United States</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>countries</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43,070</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,392</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,379</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,216</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,512</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,462</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">property, plant and equipment owned</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,160 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,659 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,085 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,316 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,322 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,185 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">goodwill</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49,404 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">▪</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:9.29pt">other intangible assets</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24,319 </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,566 </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,852 </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">901 </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:28.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.696%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of which<br/>France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">North<br/>America</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of which<br/>United States</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>countries</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">42,997</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,999</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,296</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,984</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,275</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,014</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">property, plant and equipment owned</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,869 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,365 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,875 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,284 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,457 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,220 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">goodwill</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49,892 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">other intangible assets</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21,640 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,257 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,178 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,205 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:28.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.696%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of which<br/>France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">North<br/>America</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of which<br/>United States</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>countries</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37,761</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,759</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,256</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15,075</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,385</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,927</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">property, plant and equipment owned</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,028 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,959 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,253 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,998 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,234 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,071 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">goodwill</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48,056 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">other intangible assets</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21,407 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,059 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,187 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,161 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As stated in Note D.5., goodwill is not allocated by geographical region.</span></div>

CY2023

sny

Number Of Operating Segments1

NumberOfOperatingSegments1

2

segment

CY2022

sny

Number Of Operating Segments1

NumberOfOperatingSegments1

3

segment

CY2023

sny

Number Of Operating Segments1

NumberOfOperatingSegments1

2

segment

CY2023

ifrs-full

Revenue From Sale Of Goods

RevenueFromSaleOfGoods

43070000000

eur

CY2022

ifrs-full

Revenue From Sale Of Goods

RevenueFromSaleOfGoods

42997000000

eur

CY2021

ifrs-full

Revenue From Sale Of Goods

RevenueFromSaleOfGoods

37761000000

eur

CY2023

sny

Number Of Operating Segments1

NumberOfOperatingSegments1

2

segment

CY2023

ifrs-full

Disclosure Of Operating Segments Explanatory

DisclosureOfOperatingSegmentsExplanatory

<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows Sanofi’s segment results for the years ended December 31, 2023, December 31, 2022 and December 31, 2021:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:38.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#e7e7e8;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer<br/>Healthcare</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Sanofi</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37,890</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,180</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43,070</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,322 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,374 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12,282)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,933)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(14,216)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,509)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,728)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,868)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,828)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10,692)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,387)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,224)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,247</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,438</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,670</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) This caption reconciles segment financial information to total consolidated financial information.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:38.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Biopharma</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer<br/>Healthcare</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Sanofi</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37,812</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,185</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">42,997</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,330 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,392 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11,793)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,903)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13,692)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,503)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(205)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,706)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8,736)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,761)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10,492)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,679)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">148 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,514)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(16)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(33)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11,490</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,522</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">28</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,040</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) 2022 figures have been adjusted to take account of the two new operating segments, Biopharma and Consumer Healthcare, effective from January 1, 2023.</span></div><div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">This caption reconciles segment financial information to total consolidated financial information.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:39.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceuticals</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Consumer<br/>Healthcare</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Sanofi</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26,970</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,323</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,468</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37,761</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">264 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,095 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,414 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6,965)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,430)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,606)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(250)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12,251)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4,330)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(712)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(153)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(497)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,692)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,326)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(805)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,388)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,036)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9,555)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other operating income and expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,172)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">128 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(946)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit/(loss) from investments accounted for using the equity method</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(49)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Business operating income</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,409</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,609</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,493</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(2,797)</span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,714</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Due to a lack of available data and the complex adjustments that would be required (particularly for our reporting tools), the 2021 figures have not been restated to reflect changes arising from our new organizational structure.</span></div><div style="margin-top:1pt;padding-left:14.17pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) This caption reconciles segment financial information to total consolidated financial information.</span></div>

CY2023

sny

Number Of Operating Segments1

NumberOfOperatingSegments1

2

segment

CY2023

ifrs-full

Profit Loss From Operating Activities

ProfitLossFromOperatingActivities

7875000000

eur

CY2022

ifrs-full

Profit Loss From Operating Activities

ProfitLossFromOperatingActivities

10656000000

eur

CY2021

ifrs-full

Profit Loss From Operating Activities

ProfitLossFromOperatingActivities

8126000000

eur

CY2023

ifrs-full

Finance Costs

FinanceCosts

1313000000

eur

CY2022

ifrs-full

Finance Costs

FinanceCosts

440000000

eur

CY2021

ifrs-full

Finance Costs

FinanceCosts

368000000

eur

CY2023

ifrs-full

Finance Income

FinanceIncome

591000000

eur

CY2022

ifrs-full

Finance Income

FinanceIncome

206000000

eur

CY2021

ifrs-full

Finance Income

FinanceIncome

40000000

eur

CY2023

sny

Income Before Tax And Investments Accounted For Equity Method Investments

IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments

7153000000

eur

CY2022

sny

Income Before Tax And Investments Accounted For Equity Method Investments

IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments

10422000000

eur

CY2021

sny

Income Before Tax And Investments Accounted For Equity Method Investments

IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments

7798000000

eur

CY2023

sny

Number Of Operating Segments1

NumberOfOperatingSegments1

2

segment

CY2023

ifrs-full

Disclosure Of Geographical Areas Explanatory

DisclosureOfGeographicalAreasExplanatory

<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The geographical information on net sales provided below is based on the geographical location of the customer. In accordance with IFRS 8, the non-current assets reported below exclude right-of-use assets relating to leases as determined under IFRS 16, investments accounted for using the equity method, other non-current assets, non-current income tax assets, and deferred tax assets.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:28.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="background-color:#e7e7e8;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of which<br/>France</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">North<br/>America</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of which<br/>United States</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>countries</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43,070</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,392</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,379</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">19,216</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,512</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13,462</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">property, plant and equipment owned</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,160 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,659 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,085 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,316 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,322 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,185 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">goodwill</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49,404 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">▪</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:9.29pt">other intangible assets</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24,319 </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,566 </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,852 </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">901 </span></td><td style="background-color:#e7e7e8;border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:28.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.696%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of which<br/>France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">North<br/>America</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of which<br/>United States</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>countries</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">42,997</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,999</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,296</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,984</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18,275</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,014</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">property, plant and equipment owned</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,869 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,365 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,875 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,284 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,457 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,220 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">goodwill</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49,892 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">other intangible assets</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21,640 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,257 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,178 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,205 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:28.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.696%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of which<br/>France</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">North<br/>America</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">of which<br/>United States</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other<br/>countries</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net sales</span></div></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">37,761</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,759</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,256</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15,075</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14,385</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,927</span><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-current assets:</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">property, plant and equipment owned</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,028 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,959 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,253 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,998 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,234 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,071 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">goodwill</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48,056 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.34pt;text-indent:-11.34pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:700;line-height:100%">•</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%;padding-left:8.95pt">other intangible assets</span></div></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21,407 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,059 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,187 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,161 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>

CY2023

ifrs-full

Disclosure Of Auditors Remuneration Explanatory

DisclosureOfAuditorsRemunerationExplanatory

Principal accountants’ fees and services<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">PricewaterhouseCoopers Audit and Ernst & Young et Autres served as independent auditors of Sanofi for the year ended December 31, 2023 and for all other reporting periods presented. The table below shows fees charged by those firms and member firms of their networks to Sanofi and consolidated subsidiaries in the years ended December 31, 2023 and 2022.</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.973%"><tr><td style="width:1.0%"></td><td style="width:29.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.019%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ernst & Young</span></td><td colspan="12" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">PricewaterhouseCoopers</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="6" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="6" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(€ million)</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Audit:</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> Statutory audit of separate and consolidated financial statements</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15.1 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14.2 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14.7 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#e7e7e8;border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14.1 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Services other than statutory audit</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Audit-related services</span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)(d)</span></div></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e7e8;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e7e7e8;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7e7e8;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#7802e6;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20.5</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16.0</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20.5</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14.6</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#7802e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#7802e6;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(a) Includes services provided by the independent auditors of the parent company and French subsidiaries: Ernst & Young €7.9 million in 2023, €7.3 million in 2022; PricewaterhouseCoopers Audit €8.3 million in 2023, €7.7 million in 2022.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(b) Services other than statutory audit provided by Ernst & Young during 2023 comprised:</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- contractual audits, including on the combined financial statements of the Consumer Healthcare business;</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- additional procedures to enable reports previously signed by the firm to be incorporated by reference;</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- assurance engagements, agreed-upon procedures, tax compliance work and technical consultancy; and</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- issuance of the Independent Third Party’s report on the consolidated statement of extra-financial performance.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Services other than statutory audit provided by PricewaterhouseCoopers during 2023 comprised:</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- contractual audits, including on the combined financial statements of the Consumer Healthcare business;</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- additional procedures to enable reports previously signed by the firm to be incorporated by reference; and</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">- assurance engagements, agreed-upon procedures, tax compliance work and technical consultancy.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(c) Includes services provided by the independent auditors of the parent company and French subsidiaries: Ernst & Young: €5.2 million in 2023, €1.4 million in 2022; PricewaterhouseCoopers Audit €5.3 million in 2023, €0.3 million in 2022.</span></div><div style="margin-top:1pt;padding-left:11.34pt;text-align:justify;text-indent:-11.34pt"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(d) Includes €0.5 million for services that can only be provided by the statutory auditors, such as comfort letters, attestation services required by regulation (which qualify as audit fees under SEC rules).</span></div>

CY2023

sny

Auditors Remuneration For Audit Related Services Comfort Letters And Attestation Services

AuditorsRemunerationForAuditRelatedServicesComfortLettersAndAttestationServices

500000

eur

CY2023

ifrs-full

Disclosure Of Significant Investments In Subsidiaries Explanatory

DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory

List of principal companies included in the scope of consolidation during 2023<div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">F.1. Principal fully consolidated companies</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows Sanofi’s principal subsidiaries and their country of incorporation:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"></td><td style="width:60.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial interest (%) as of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hoechst GmbH</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Deutschland GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">A. Nattermann & Cie. GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Austria</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Belgium</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Belgium</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ablynx NV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Belgium</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Flanders BV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Belgium</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi A/S</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Denmark</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Spain, SL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Oy</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Finland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis France</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Winthrop Industrie</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Recherche & Développement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Groupe</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Chimie</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Participations</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis Pharma S.A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Biotechnology</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Mature IP</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur NVL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Europe</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SECIPE SAS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Merieux SAS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare International SAS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare France SAS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Group SAS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Polyclonals SAS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis A.E.B.E.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Greece</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Private Co, Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hungary</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chinoin Private Co. Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hungary</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Hungary Commercial K.F.T</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hungary</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Hungary K.F.T</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hungary</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carraig Insurance DAC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Ireland Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Holdings (Ireland) Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi SRL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Italy SRL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Global Sarl</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Luxembourg</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Luxembourg Sarl</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Luxembourg</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Norge AS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Norway</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi BV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Netherlands</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Foreign Participations BV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Netherlands</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Sp. z.o.o.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Poland sp.z.o.o.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Sp. z.o.o.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Produtos Farmaceuticos Lda</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Portugal</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis, s.r.o.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Czech Republic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Czech s.r.o</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Czech Republic</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"></td><td style="width:60.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial interest (%) as of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Romania SRL</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Romania</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Romania SRL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Romania</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis UK Holdings Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis Pharma Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Synthelabo UK Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis Pharma Holdings Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare UK Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">AO Sanofi Russia</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi AB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sweden</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis (Suisse) SA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Global Sarl Baar Intellectual Property Branch</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Ilac Sanayi ve Ticaret AS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Turkey</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Asi Ticaret AS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Turkey</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Tüketici Sağlığı Anonim Şirketi</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Turkey</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Saglik Urunleri Limited Sirketi</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Turkey</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"></td><td style="width:60.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial interest (%) as of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Therapeutic Products Limited Partnership</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi US Services Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis U.S. LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chattem, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventisub LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Corporation</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">VaxServe, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bioverativ Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bioverativ U.S. LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bioverativ Therapeutics Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Principia Biopharma Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Research Invest LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Bioverativ Holdings LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RPR US Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Kadmon Corporation, LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amunix</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Synthorx, Inc</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provention Bio</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">QRIB Intermediate Holding</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">QRI</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TargeGen Inc.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chattem (GB) Holding</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Translate Bio, Inc.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"></td><td style="width:57.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.311%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other Countries</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial interest (%) as of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis South Africa (Pty) Ltd</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">South Africa</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Algérie</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Algeria</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Arabia Trading Company Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Saudi Arabia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Argentina SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Argentina</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Healthcare Pty Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Australia Pty Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Medley Farmaceutica Ltda</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Brazil</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Brazil Ltda.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Brazil</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Canada Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Merieux Canada Holdings ULC (Canada)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi (Hangzhou) Pharmaceuticals Co., Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi (China) Investment Co., Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi (Beijing) Pharmaceuticals Co.Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Biologies Co., Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shenzhen Sanofi pasteur Biological Products Co, Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shanghai Rongheng Pharmaceutical Co, Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis de Colombia SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Colombia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Korea Co. Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella healthcare Korea Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Gulf FZE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Arab Emirates</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Egypt</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Egypt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Hong-Kong Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hong Kong</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi India Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">India</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Healthcare India Private Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">India</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Israël Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Israel</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi K.K.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SSP Co.,Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis (Malaysia) SDN. BHD.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Malaysia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Maroc</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Morocco</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis de Mexico SA de CV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur SA de CV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Azteca Vacunas, SA de CV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis de Panama SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Panama</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Panama SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Panama</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Puerto Rico Inc</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Puerto Rico</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Philippines Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Philippines</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Philippines Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Philippines</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Singapore Pte. Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis Pharma (Manufacturing) Pte. Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Manufacturing Pte Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Taiwan Co., Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Taiwan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis (Thailand) Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Thailand</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Thailand</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis de Venezuela SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Venezuela</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Vietnam Company Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vietnam</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Vietnam Shareholding Company Limited</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vietnam</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">85.0 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:12pt"><span style="color:#000000;font-family:'Sanofi Sans',sans-serif;font-size:12pt;font-weight:700;line-height:120%">F.2. Principal investments accounted for using the equity method</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"></td><td style="width:62.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.214%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial interest (%) as of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Haleon US, LP</span></div></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11.7 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Infraserv GmbH & Co. Höchst KG</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Maphar</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Morocco</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">MCM Vaccine BV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Netherlands</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">MSP Vaccine Company (formerly MCM company)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EUROAPI</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29.8 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>

CY2023

ifrs-full

Disclosure Of Interests In Subsidiaries Explanatory

DisclosureOfInterestsInSubsidiariesExplanatory

<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The table below shows Sanofi’s principal subsidiaries and their country of incorporation:</span></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"></td><td style="width:60.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial interest (%) as of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hoechst GmbH</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Deutschland GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">A. Nattermann & Cie. GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis GmbH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Austria</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Belgium</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Belgium</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ablynx NV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Belgium</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Flanders BV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Belgium</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi A/S</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Denmark</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Spain, SL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Oy</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Finland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis France</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Winthrop Industrie</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Recherche & Développement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Groupe</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Chimie</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Participations</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis Pharma S.A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Biotechnology</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Mature IP</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur NVL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Europe</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SECIPE SAS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Merieux SAS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare International SAS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare France SAS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Group SAS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Polyclonals SAS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">France</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis A.E.B.E.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Greece</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Private Co, Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hungary</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chinoin Private Co. Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hungary</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Hungary Commercial K.F.T</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hungary</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Hungary K.F.T</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hungary</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Carraig Insurance DAC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Ireland Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Holdings (Ireland) Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi SRL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Italy SRL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Global Sarl</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Luxembourg</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Luxembourg Sarl</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Luxembourg</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Norge AS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Norway</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi BV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Netherlands</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Foreign Participations BV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Netherlands</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Sp. z.o.o.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Poland sp.z.o.o.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Sp. z.o.o.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Produtos Farmaceuticos Lda</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Portugal</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis, s.r.o.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Czech Republic</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Czech s.r.o</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Czech Republic</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"></td><td style="width:60.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial interest (%) as of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Romania SRL</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Romania</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Romania SRL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Romania</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis UK Holdings Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis Pharma Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Synthelabo UK Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis Pharma Holdings Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare UK Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">AO Sanofi Russia</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi AB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sweden</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis (Suisse) SA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Global Sarl Baar Intellectual Property Branch</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Ilac Sanayi ve Ticaret AS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Turkey</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Asi Ticaret AS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Turkey</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Tüketici Sağlığı Anonim Şirketi</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Turkey</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Saglik Urunleri Limited Sirketi</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Turkey</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"></td><td style="width:60.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial interest (%) as of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Therapeutic Products Limited Partnership</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi US Services Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis U.S. LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chattem, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventisub LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Genzyme Corporation</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">VaxServe, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bioverativ Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bioverativ U.S. LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Bioverativ Therapeutics Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Principia Biopharma Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Research Invest LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Bioverativ Holdings LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RPR US Ltd.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#4c4d4f;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Kadmon Corporation, LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amunix</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Synthorx, Inc</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Provention Bio</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">QRIB Intermediate Holding</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">QRI</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">TargeGen Inc.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Chattem (GB) Holding</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Translate Bio, Inc.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.820%"><tr><td style="width:1.0%"></td><td style="width:57.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.311%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Other Countries</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#21004c;font-family:'Sanofi Sans',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial interest (%) as of December 31, 2023</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis South Africa (Pty) Ltd</span></td><td colspan="3" style="border-top:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">South Africa</span></td><td colspan="2" style="border-top:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="border-top:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Algérie</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Algeria</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Arabia Trading Company Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Saudi Arabia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Argentina SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Argentina</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Healthcare Pty Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Australia Pty Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Medley Farmaceutica Ltda</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Brazil</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Brazil Ltda.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Brazil</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Canada Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Merieux Canada Holdings ULC (Canada)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi (Hangzhou) Pharmaceuticals Co., Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi (China) Investment Co., Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi (Beijing) Pharmaceuticals Co.Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Biologies Co., Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shenzhen Sanofi pasteur Biological Products Co, Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shanghai Rongheng Pharmaceutical Co, Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis de Colombia SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Colombia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Korea Co. Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella healthcare Korea Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Gulf FZE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">United Arab Emirates</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Egypt</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Egypt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Hong-Kong Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hong Kong</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi India Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">India</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Healthcare India Private Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">India</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Israël Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Israel</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi K.K.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">SSP Co.,Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis (Malaysia) SDN. BHD.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Malaysia</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Maroc</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Morocco</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis de Mexico SA de CV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur SA de CV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Azteca Vacunas, SA de CV</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis de Panama SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Panama</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Panama SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Panama</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Puerto Rico Inc</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Puerto Rico</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Philippines Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Philippines</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Opella Healthcare Philippines Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Philippines</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Singapore Pte. Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aventis Pharma (Manufacturing) Pte. Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Manufacturing Pte Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Taiwan Co., Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Taiwan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis (Thailand) Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Thailand</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Pasteur Ltd</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Thailand</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis de Venezuela SA</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Venezuela</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi-Aventis Vietnam Company Limited</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vietnam</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sanofi Vietnam Shareholding Company Limited</span></td><td colspan="3" style="border-bottom:0.5pt solid #23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vietnam</span></td><td colspan="2" style="border-bottom:0.5pt solid #23004c;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#262626;font-family:'Sanofi Sans Light',sans-serif;font-size:7pt;font-weight:400;line-height:100%">85.0 </span></td><td style="border-bottom:0.5pt solid #23004c;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>

CY2023

ifrs-full

Disclosure Of Events After Reporting Period Explanatory

DisclosureOfEventsAfterReportingPeriodExplanatory

Event subsequent to December 31, 2023<div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On January 23, 2024 Sanofi announced the entry into a merger agreement with Inhibrx, Inc. (Inhibrx), a publicly traded, clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases (the Merger Agreement), pursuant to which Sanofi has agreed to acquire Inhibrx following the spin-off of Inhibrx's non-INBRX-101 assets and liabilities into a new publicly traded company ("New Inhibrx"). Under the terms of the Merger Agreement, Sanofi has agreed to: (i) provide Inhibrx's stockholders with consideration of $30 per share of Inhibrx common stock at the closing of the merger (approximately $1.7 billion), and to additionally issue one non-transferable contingent value right per share of Inhibrx common stock, which will entitle its holder to receive a deferred cash payment of $5, conditioned upon the achievement of a regulatory milestone (approximately $0.3 billion, if the regulatory milestone is achieved); (ii) pay off Inhibrx’s outstanding third-party debt (approximately $0.2 billion); and (iii) provide a capital contribution to New Inhibrx (up to $0.2 billion). At the closing of the merger, Sanofi will acquire 100% of the equity interests in Inhibrx, which will become a 100% wholly owned subsidiary of Sanofi. In addition, Inhibrx will retain a minority stake (approximately 8% equity interest) in New Inhibrx. INBRX-101 is a human recombinant protein that holds the promise of allowing Alpha-1 Antitrypsin Deficiency (AATD) patients to achieve normalization of serum AAT levels with less frequent (monthly vs. weekly) dosing. </span><span style="background-color:#ffffff;color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">AATD is an inherited rare disease characterized by low levels of AAT protein, predominantly affecting the lung with progressive deterioration of the tissue. INBRX-101 may help to reduce inflammation and prevent further deterioration of lung function in affected individuals. INBRX-101 acquisition is expected to </span><span style="color:#000000;font-family:'Sanofi Sans Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">support Sanofi’s portfolio growth strategy and complements the Company’s 30-year heritage in rare diseases and track record in immunology and inflammation. The transaction is subject to various closing conditions, including the receipt of regulatory approvals and completion of the spin-off of New Inhibrx. Assuming satisfaction of those closing conditions, Sanofi currently anticipates that the transaction will close in the second quarter of 2024.</span></div>

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SNY
Sanofi Stock $sny

2023 Q4 Form 20-F Financial Statement

#000112140424000009 Filed on February 23, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

Name	View Source	Status
0001121404-24-000009-index-headers.html	Edgar Link	pending
0001121404-24-000009-index.html	Edgar Link	pending
0001121404-24-000009.txt	Edgar Link	pending
0001121404-24-000009-xbrl.zip	Edgar Link	pending
a2023-exhibit11.htm	Edgar Link	pending
a2023-exhibit12.htm	Edgar Link	pending
a2023-exhibit121.htm	Edgar Link	pending
a2023-exhibit122.htm	Edgar Link	pending
a2023-exhibit131.htm	Edgar Link	pending
a2023-exhibit132.htm	Edgar Link	pending
a2023-exhibit151.htm	Edgar Link	pending
a2023-exhibit152.htm	Edgar Link	pending
a2023-exhibit153.htm	Edgar Link	pending
a2023-exhibit22.htm	Edgar Link	pending
a2023-exhibit97.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R120.htm	Edgar Link	pending
R121.htm	Edgar Link	pending
R122.htm	Edgar Link	pending
R123.htm	Edgar Link	pending
R124.htm	Edgar Link	pending
R125.htm	Edgar Link	pending
R126.htm	Edgar Link	pending
R127.htm	Edgar Link	pending
R128.htm	Edgar Link	pending
R129.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R130.htm	Edgar Link	pending
R131.htm	Edgar Link	pending
R132.htm	Edgar Link	pending
R133.htm	Edgar Link	pending
R134.htm	Edgar Link	pending
R135.htm	Edgar Link	pending
R136.htm	Edgar Link	pending
R137.htm	Edgar Link	pending
R138.htm	Edgar Link	pending
R139.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R140.htm	Edgar Link	pending
R141.htm	Edgar Link	pending
R142.htm	Edgar Link	pending
R143.htm	Edgar Link	pending
R144.htm	Edgar Link	pending
R145.htm	Edgar Link	pending
R146.htm	Edgar Link	pending
R147.htm	Edgar Link	pending
R148.htm	Edgar Link	pending
R149.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R150.htm	Edgar Link	pending
R151.htm	Edgar Link	pending
R152.htm	Edgar Link	pending
R153.htm	Edgar Link	pending
R154.htm	Edgar Link	pending
R155.htm	Edgar Link	pending
R156.htm	Edgar Link	pending
R157.htm	Edgar Link	pending
R158.htm	Edgar Link	pending
R159.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R160.htm	Edgar Link	pending
R161.htm	Edgar Link	pending
R162.htm	Edgar Link	pending
R163.htm	Edgar Link	pending
R164.htm	Edgar Link	pending
R165.htm	Edgar Link	pending
R166.htm	Edgar Link	pending
R167.htm	Edgar Link	pending
R168.htm	Edgar Link	pending
R169.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R170.htm	Edgar Link	pending
R171.htm	Edgar Link	pending
R172.htm	Edgar Link	pending
R173.htm	Edgar Link	pending
R174.htm	Edgar Link	pending
R175.htm	Edgar Link	pending
R176.htm	Edgar Link	pending
R177.htm	Edgar Link	pending
R178.htm	Edgar Link	pending
R179.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R180.htm	Edgar Link	pending
R181.htm	Edgar Link	pending
R182.htm	Edgar Link	pending
R183.htm	Edgar Link	pending
R184.htm	Edgar Link	pending
R185.htm	Edgar Link	pending
R186.htm	Edgar Link	pending
R187.htm	Edgar Link	pending
R188.htm	Edgar Link	pending
R189.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R190.htm	Edgar Link	pending
R191.htm	Edgar Link	pending
R192.htm	Edgar Link	pending
R193.htm	Edgar Link	pending
R194.htm	Edgar Link	pending
R195.htm	Edgar Link	pending
R196.htm	Edgar Link	pending
R197.htm	Edgar Link	pending
R198.htm	Edgar Link	pending
R199.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R200.htm	Edgar Link	pending
R201.htm	Edgar Link	pending
R202.htm	Edgar Link	pending
R203.htm	Edgar Link	pending
R204.htm	Edgar Link	pending
R205.htm	Edgar Link	pending
R206.htm	Edgar Link	pending
R207.htm	Edgar Link	pending
R208.htm	Edgar Link	pending
R209.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R210.htm	Edgar Link	pending
R211.htm	Edgar Link	pending
R212.htm	Edgar Link	pending
R213.htm	Edgar Link	pending
R214.htm	Edgar Link	pending
R215.htm	Edgar Link	pending
R216.htm	Edgar Link	pending
R217.htm	Edgar Link	pending
R218.htm	Edgar Link	pending
R219.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R220.htm	Edgar Link	pending
R221.htm	Edgar Link	pending
R222.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
sny-20231231.htm	Edgar Link	pending
sny-20231231.xsd	Edgar Link	pending
sny-20231231_g1.jpg	Edgar Link	pending
sny-20231231_g10.gif	Edgar Link	pending
sny-20231231_g11.gif	Edgar Link	pending
sny-20231231_g12.jpg	Edgar Link	pending
sny-20231231_g13.jpg	Edgar Link	pending
sny-20231231_g14.jpg	Edgar Link	pending
sny-20231231_g15.jpg	Edgar Link	pending
sny-20231231_g16.jpg	Edgar Link	pending
sny-20231231_def.xml	Edgar Link	unprocessable
sny-20231231_g17.jpg	Edgar Link	pending
sny-20231231_g18.jpg	Edgar Link	pending
sny-20231231_g19.jpg	Edgar Link	pending
sny-20231231_g2.jpg	Edgar Link	pending
sny-20231231_g20.jpg	Edgar Link	pending
sny-20231231_g21.jpg	Edgar Link	pending
sny-20231231_g22.jpg	Edgar Link	pending
sny-20231231_g23.jpg	Edgar Link	pending
sny-20231231_g24.jpg	Edgar Link	pending
sny-20231231_g25.jpg	Edgar Link	pending
sny-20231231_g26.jpg	Edgar Link	pending
sny-20231231_g27.jpg	Edgar Link	pending
sny-20231231_g28.jpg	Edgar Link	pending
sny-20231231_g29.jpg	Edgar Link	pending
sny-20231231_g3.jpg	Edgar Link	pending
sny-20231231_g4.jpg	Edgar Link	pending
sny-20231231_g5.gif	Edgar Link	pending
sny-20231231_g6.gif	Edgar Link	pending
sny-20231231_g7.gif	Edgar Link	pending
sny-20231231_g8.gif	Edgar Link	pending
sny-20231231_g9.gif	Edgar Link	pending
sny-20231231_pre.xml	Edgar Link	unprocessable
sny-20231231_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
sny-20231231_cal.xml	Edgar Link	unprocessable
sny-20231231_lab.xml	Edgar Link	unprocessable

$SNY Sanofi Stock $sny

2023 Q4 Form 20-F Financial Statement

#000112140424000009 Filed on February 23, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SNY
Sanofi Stock $sny